WorldWideScience

Sample records for advancing drug innovation

  1. Protein Innovations Advance Drug Treatments, Skin Care

    Science.gov (United States)

    2012-01-01

    Dan Carter carefully layered the sheets of tracing paper on the light box. On each sheet were renderings of the atomic components of an essential human protein, one whose structure had long been a mystery. With each layer Carter laid down, a never-before-seen image became clearer. Carter joined NASA s Marshall Space Flight Center in 1985 and began exploring processes of protein crystal growth in space. By bouncing intense X-rays off the crystals, researchers can determine the electron densities around the thousands of atoms forming the protein molecules, unveiling their atomic structures. Cultivating crystals of sufficient quality on Earth was problematic; the microgravity conditions of space were far more accommodating. At the time, only a few hundred protein structures had been mapped, and the methods were time consuming and tedious. Carter hoped his work would help reveal the structure of human serum albumin, a major protein in the human circulatory system responsible for ferrying numerous small molecules in the blood. More was at stake than scientific curiosity. Albumin has a high affinity for most of the world s pharmaceuticals, Carter explains, and its interaction with drugs can change their safety and efficacy. When a medication enters the bloodstream a cancer chemotherapy drug, for example a majority of it can bind with albumin, leaving only a small percentage active for treatment. How a drug interacts with albumin can influence considerations like the necessary effective dosage, playing a significant role in the design and application of therapeutic measures. In spite of numerous difficulties, including having no access to microgravity following the 1986 Space Shuttle Challenger disaster, the image Carter had hoped to see was finally clarifying. In 1988, his lab had acquired specialized X-ray and detection equipment a tipping point. Carter and his colleagues began to piece together albumin s portrait, the formation of its electron densities coalescing on

  2. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Innovations in care that advance Alzheimer's disease drug development.

    Science.gov (United States)

    Foster, Norman L; Andersen, Troy C; Zamrini, Edward Y

    2009-03-01

    Advancing the development of drugs for the prevention and treatment of Alzheimer's disease (AD) is dependent on the ability of investigators to identify, recruit, and retain appropriate subjects in clinical trials. Innovations in care that link primary-care providers with AD researchers can help overcome barriers to early, specific diagnosis and access to research studies. Collaborative care provides a new paradigm for the mutual benefit of patients, providers, and AD research. Recommendations to achieve this goal include funding clinical centers of excellence in AD, linked with community physicians to utilize clinical care and initial evaluations as early entry points for patients into AD research, and funding mini-fellowships for community physicians. Reimbursement for dementia care should be expanded to include periodic cognitive assessments for at-risk individuals, medically directed dementia education, and diagnostic imaging and biomarkers. These innovations can simultaneously improve the translation of research advances, and benefit AD research. PMID:19328451

  3. Drug innovation, prices and health

    OpenAIRE

    Ort??n, Vicente; Puig, Jaume; Callej??n, Mar??a

    2005-01-01

    This article tries to reconcile economic-industrial policy with health policy when dealing with biomedical innovation and welfare state sustainability. Better health accounts for an increasingly large proportion of welfare improvements. Explanation is given to the welfare losses coming from the fact than industrial and health policy tend to ignore each other. Drug?s prices reflecting their relative relative effectiveness send the right signal to the industry ?rewarding innovation with imp...

  4. Market Structure and Drug Innovation

    OpenAIRE

    Pammolli, Fabio; Riccaboni, Massimo

    2004-01-01

    An explosion of knowledge and a growing array of tools and technologies have transformed modern drug R&D, while its cost has risen by a sizable amount. At the same time, the unchecked increase in health care and prescription drug spending has spawned cost containment policies that are restricting the demand for drugs in all major markets. This Perspective explores the interplay between technological advances and regulatory policies and their likely impact on the dynamics of the ph...

  5. [Innovation in Surgery for Advanced Lung Cancer].

    Science.gov (United States)

    Nakano, Tomoyuki; Yasunori, Sohara; Endo, Shunsuke

    2016-07-01

    Thoracoscopic surgery can be one of less invasive surgical interventions for early stage lung cancer. Locally advanced lung cancer, however, cannot avoid aggressive procedures including pneumonectomy and/or extended combined resection of chest wall, aorta, esophagus, etc. for complete resection. Surgical approach even for advanced lung cancer can be less invasive by benefit from new anti-cancer treatment, innovated manipulations of bronchoplasty and angioplasty, and bench surgery( lung autotransplantation technique). We herein reviewed the strategy to minimize invasive interventions for locally advanced lung cancer, introducing 2 successful cases with advanced lung cancer. The 1st patient is a 62-year old man with centrally advanced lung cancer invading to mediastinum. Right upper sleeve lobectomy with one-stoma carinoplasty following induction chemoradiation therapy was successful. The operation time was 241 minutes. The performance status is good with no recurrence for 60 months after surgery. The 2nd is a 79-year old man with advanced lung cancer invading to the distal aortic arch. Left upper segmentectomy following thoracic endovascular aortic repair with stentgraft was successful with no extracorporeal circulation. The operation time was 170 minutes. The performance status is good with no recurrence for 30 months after surgery. The invasiveness of surgical interventions for local advanced lung cancer can be minimized by innovated device and new anti-cancer drugs. PMID:27440037

  6. A new prize system for drug innovation.

    Science.gov (United States)

    Gandjour, Afschin; Chernyak, Nadja

    2011-10-01

    We propose a new prize (reward) system for drug innovation which pays a price based on the value of health benefits accrued over time. Willingness to pay for a unit of health benefit is determined based on the cost-effectiveness ratio of palliative/nursing care. We solve the problem of limited information on the value of health benefits by mathematically relating reward size to the uncertainty of information including information on potential drug overuse. The proposed prize system offers optimal incentives to invest in research and development because it rewards the innovator for the social value of drug innovation. The proposal is envisaged as a non-voluntary alternative to the current patent system and reduces excessive marketing of innovators and generic drug producers. PMID:21724290

  7. Advances and challenges in innovation studies

    OpenAIRE

    Castellacci, F.; Grodal, S.; Mendonça, S; Wibe, M.

    2005-01-01

    The article discusses recent advances and future challenges in innovation studies. First, it separately considers four main strands of research, studying innovation at the organizational, systemic, sectoral and macroeconomic levels. Then, considering the field as a whole, the article points to the existence of important neglected topics and methodological challenges for future research. In fact, several fundamental issues are still unexplored, such as the co-evolution betwee...

  8. International Conference on Advanced Computing for Innovation

    CERN Document Server

    Angelova, Galia; Agre, Gennady

    2016-01-01

    This volume is a selected collection of papers presented and discussed at the International Conference “Advanced Computing for Innovation (AComIn 2015)”. The Conference was held at 10th -11th of November, 2015 in Sofia, Bulgaria and was aimed at providing a forum for international scientific exchange between Central/Eastern Europe and the rest of the world on several fundamental topics of computational intelligence. The papers report innovative approaches and solutions in hot topics of computational intelligence – advanced computing, language and semantic technologies, signal and image processing, as well as optimization and intelligent control.

  9. 78 FR 36711 - Food and Drug Administration Safety and Innovation Act Title VII-Drug Supply Chain; Standards for...

    Science.gov (United States)

    2013-06-19

    ... Innovation Act Title VII--Drug Supply Chain; Standards for Admission of Imported Drugs, Registration of... quality throughout the supply chain. Implementation of these authorities will significantly advance the... provides FDA with important new authorities to help it better protect the integrity of the drug...

  10. Advancing global health through innovation

    International Nuclear Information System (INIS)

    Canada's role in the supply of radioisotopes for healthcare applications is unparalleled anywhere else in the world. The NRU reactor, owned and operated by AECL, is the world's major manufacturer of reactor based isotopes. Our cyclotron facilities at the University of British Columbia, TRIUMF facilities, produce unique isotopes for medical research and treatment. CANDU power reactors operated by Hydro Quebec, Bruce Power and Ontario Power Generation are a key source of cobalt-60 production for use in the sterilization of single use medical products. Most of the innovation today is in medical applications of radioisotope technology. Every day, some 34,000 medical procedures take place using medical isotopes supplied by MDS Nordion. Sustaining this daily supply stream of medical isotopes around the world requires a complex combination of production, processing, and timely delivery of high quality isotopes. The NRU reactor, which has played a key role in supplying medical isotopes to date, has been in operation for over 40 years. Replacing this aging reactor has been a priority for MDS Nordion in order to assure the global nuclear medicine community that Canada can continue to be a dependable supplier of medical isotopes. MDS Nordion commissioned AECL to construct two MAPLE reactors dedicated to the production of medical isotopes. The MDS Nordion Medical Isotope Reactor (MMIR) project started in September 1996. This paper provides an update on the MAPLE reactors that AECL has built at its CRL site and will operate for MDS Nordion. (author)

  11. Alarm system advances and innovations

    International Nuclear Information System (INIS)

    Alarm: 'a signal (as a loud noise or flashing light) that warns or alerts; also: a device that signals... '. This statement, this definition as simple as it is sums up every alarm system for every control system that has ever existed, but what it's missing from it is the complexity and uniqueness required by a Nuclear Power Plant. With advances in computerized control and engineering technologies within these plants, the need for more comprehensive alarm control and monitoring systems is as critical as the operation itself. (authors)

  12. OPEN INNOVATION OF DRUG DEVELOPMENT WITHIN PHARMACEUTICAL INDUSTRY

    OpenAIRE

    Waltemath, Ursula; Jensen, Minna

    2015-01-01

    The pharmaceutical industry is a growing environment which seems to expand alongside globalization. External sources of ideas support open innovation for the initiation of the drug development process. Open innovation has shown to distinguish a firm from competitors. Further exploration of the methods involved in managing drug research and development provides insight into the success of modern innovative approaches for developing drugs.

  13. Medical innovation prize fund: new idea in drug development.

    Science.gov (United States)

    James, John S

    2005-05-27

    This proposal, now introduced in Congress as HR 417, would replace current drug marketing with system better designed to reward effective innovation. All drugs would be treated as generics immediately when approved by the FDA, and patent holders would be rewarded from a $60 billion a year award fund for innovations that actually led to better health. PMID:16047411

  14. Jiangsu Innovative New Drug Research Center (BPW CHINA)

    Institute of Scientific and Technical Information of China (English)

    2003-01-01

    @@ Jiangsu Innovative New Drug Research Center Co., Ltd. (BPW CHINA), established on August 8th, 2002, is the first research institute in China which is keeping pace with other international research institutes in the innovative new drugs development. Its sole investor is Basilea Pharmaceutica Ltd.

  15. Advanced CANDU reactor, evolution and innovation

    International Nuclear Information System (INIS)

    Atomic Energy of Canada Limited (AECL) has developed the ACRTM (Advanced CANDU(1) ReactorTM) to meet today's market challenges. It is a light water tube type pressurized water reactor and is the latest evolution of CANDU technology. The design was launched to be cost-competitive with other generating sources, while building on the unique safety and operational advantages of the CANDU design. The ACR is an evolutionary design that retains the proven CANDU features delivered at Qinshan Phase III, while incorporating a set of innovative features and proven state-of-the-art technologies that have emerged from AECL's ongoing Research, Development and Demonstration programs. This approach ensures that key design parameters are well supported by existing reactor experience and R and D. The result is a design that delivers a new threshold in safety, performance and economics while retaining ample design margin. AECL has developed the enabling technologies and components for the ACR design, and has applied them to two plant sizes, ACR-700 and ACR-1000. The ACR integrates hallmark characteristics of traditional CANDU plants (e.g. horizontal pressure tubes, on power fuelling, automated reactor control systems, and dual independent shutdown systems), new innovations (e.g. state-of-the- art control room, extensive use of modular construction techniques, smaller reactor core, enriched uranium fuel), and certain PWR features (e.g. light water coolant, negative void reactivity). The ACR is designed for a high capacity factor and low operation and maintenance costs. It fully exploits the construction techniques that contributed to the impressive schedule accomplishments at Qinshan Phase III and therefore features a very short construction schedule, 40 months construction schedule (First Concrete to Fuel Loading ) for the first unit with improvements to 36 months for later units. The ACR is a true Gen-III plus product with a broad application. It has been proven to be an ideal

  16. Advanced Materials and Processing for Drug Delivery: The Past and the Future

    OpenAIRE

    Zhang, Ying; Chan, Hon Fai; Leong, Kam W.

    2012-01-01

    Design and synthesis of efficient drug delivery systems are of vital importance for medicine and healthcare. Materials innovation and nanotechnology have synergistically fueled the advancement of drug delivery. Innovation in material chemistry allows the generation of biodegradable, biocompatible, environment-responsive, and targeted delivery systems. Nanotechnology enables control over size, shape and multi-functionality of particulate drug delivery systems. In this review, we focus on the m...

  17. Innovation and The Welfare Effects of Public Drug Insurance*

    OpenAIRE

    Lakdawalla, Darius; Sood, Neeraj

    2009-01-01

    Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation. Prescription drug insurance escapes that trade-off and achieves an elusive goal: lowering static deadweight loss, without reducing incentives for innovation. As a result of this feature, the public provision of drug insurance can be welfare-improving, even for risk-neutral and purely self-interested consumers. The design of insurers’ cost-sharing schedules can either reinforce or...

  18. Modern advances in heterocyclic chemistry in drug discovery.

    Science.gov (United States)

    Taylor, Alexandria P; Robinson, Ralph P; Fobian, Yvette M; Blakemore, David C; Jones, Lyn H; Fadeyi, Olugbeminiyi

    2016-07-12

    New advances in synthetic methodologies that allow rapid access to a wide variety of functionalized heterocyclic compounds are of critical importance to the medicinal chemist as it provides the ability to expand the available drug-like chemical space and drive more efficient delivery of drug discovery programs. Furthermore, the development of robust synthetic routes that can readily generate bulk quantities of a desired compound help to accelerate the drug development process. While established synthetic methodologies are commonly utilized during the course of a drug discovery program, the development of innovative heterocyclic syntheses that allow for different bond forming strategies are having a significant impact in the pharmaceutical industry. This review will focus on recent applications of new methodologies in C-H activation, photoredox chemistry, borrowing hydrogen catalysis, multicomponent reactions, regio- and stereoselective syntheses, as well as other new, innovative general syntheses for the formation and functionalization of heterocycles that have helped drive project delivery. Additionally, the importance and value of collaborations between industry and academia in shaping the development of innovative synthetic approaches to functionalized heterocycles that are of greatest interest to the pharmaceutical industry will be highlighted. PMID:27282396

  19. Open Innovation at NASA: A New Business Model for Advancing Human Health and Performance Innovations

    Science.gov (United States)

    Davis, Jeffrey R.; Richard, Elizabeth E.; Keeton, Kathryn E.

    2014-01-01

    This paper describes a new business model for advancing NASA human health and performance innovations and demonstrates how open innovation shaped its development. A 45 percent research and technology development budget reduction drove formulation of a strategic plan grounded in collaboration. We describe the strategy execution, including adoption and results of open innovation initiatives, the challenges of cultural change, and the development of virtual centers and a knowledge management tool to educate and engage the workforce and promote cultural change.

  20. Advancing Fusion by Innovations: Smaller, Quicker, Cheaper

    DEFF Research Database (Denmark)

    Gryaznevich, Mikhail; Chuyanov, V. A.; Kingham, D.;

    2015-01-01

    On the path to Fusion power, the construction of ITER is on-going, however there is not much progress in performance improvements of tokamaks in the last 15 years, Fig.1. One possible reason for this stagnation is the lack of innovations in physics and technology that could be implemented...... with this approach in which progress is expected mainly from the increase in the size of a Fusion device. Such innovations could be easier to test and use in much smaller (and so cheaper and quicker to build) compact Fusion devices. In this paper we propose a new path to Fusion energy based on a compact high field...

  1. Role of microemuslsions in advanced drug delivery.

    Science.gov (United States)

    Sharma, Aman Kumar; Garg, Tarun; Goyal, Amit K; Rath, Goutam

    2016-06-01

    Microemulsions have gained significant attention from formulation scientists since the time they have been discovered, because of their excellent properties related to their stability, solubility, simplicity, and formulation aspects. The application of microemulsions is not limited to drug delivery via the oral, topical or ocular routes, but may also be seen in cosmetics, immunology, sensor devices, coating, textiles, analytical chemistry, and spermicide. Finally, the objective of this review is to discuss briefly the applications of microemulsions in advanced drug delivery. PMID:25711493

  2. Antiangiogenic drugs and advanced proliferative diabetic retinopathy

    OpenAIRE

    Jefferson Augusto Santana Ribeiro; André Messias; Rodrigo Jorge

    2011-01-01

    Advanced diabetic retinopathy with tractional retinal detachment or persistent vitreous hemorrhage often requires surgical treatment with pars plana vitrectomy. Despite advances in vitrectomy, surgery for complications of diabetic retinopathy can be a challenge and may be impaired by intense fibrovascular proliferation. Antiangiogenic drugs have been used for the treatment of diabetic retinopathy because of their inhibitory action on vascular endothelial growth factor. In this review, we disc...

  3. Innovative Drug Injection via Laser Induced Plasma

    Science.gov (United States)

    Han, Tae-hee; Yoh, Jack J.

    2010-10-01

    A laser based needle-free liquid drug injection device has been developed. A laser beam is focused inside the liquid contained in the rubber chamber of micro scale. The focused laser beam causes explosive bubble growth and the sudden volume increase in a sealed chamber drives a microjet of liquid drug through the micronozzle. The exit diameter of the nozzle is 125 um and the injected microjet reaches an average velocity of 264 m/s. This device adds the time-varying feature of microjet to the current state of liquid injection for drug delivery.

  4. Something new every day: defining innovation and innovativeness in drug therapy.

    Science.gov (United States)

    Aronson, Jeffrey K

    2008-01-01

    The word "innovation" comes from the Latin noun innovatio, derived from the verb innovare, to introduce [something] new. It can refer either to the act of introducing something new or to the thing itself that is introduced. In terms of commerce, it is defined in the Oxford English Dictionary as "the action of introducing a new product into the market; a product newly brought on to the market," a definition that illustrates both aspects of the word's meaning. "Innovativeness" is the property of being an innovation. Here I identify several different types of innovativeness in drug therapy, including structural, pharmacological or pharmacodynamic, pharmaceutical, and pharmacokinetic innovativeness, and I stress the over-riding importance of clinical innovativeness, which should result in a better benefit to harm balance at an affordable cost. PMID:18162799

  5. Medical innovation, unmet medical needs, and the drug pipeline.

    Science.gov (United States)

    Mather, Charles M

    2006-01-01

    This paper outlines and illustrates the working of a theoretical approach from the social sciences for analyzing medical innovation, unmet medical need, and the drug pipeline. Using the social history of three drugs made from recombinant DNA (insulin, human growth hormone, and tissue-plasminogen activator) the paper shows how drugs can be both technically and organizationally efficient while the needs they satisfy can be created or identified. The paper posits that drugs that require more organizational efficiency tend to satisfy identified, rather then created needs. Key words: Recombinant DNA, technical efficiency, organizational efficiency, anthropology. PMID:16493177

  6. Exhibition design: hybrid space of advanced design innovation

    OpenAIRE

    Bollini, L; Borsotti, M

    2014-01-01

    The exhibition design has always been – among other design disciplines – one of the most innovative field of experimentation both for languages and projects improvement. Moreover in the recent years the use of digital technologies, on one hand, and the further more active participation of the public – or, better to say, of the user – on the other hand, are making exhibition design a promising and rising laboratory of advanced innovation. This evolution is shaping itself around the co-particip...

  7. Innovative Experimental Particle Physics through Technological Advances

    OpenAIRE

    Cheung, Harry W. K.

    2005-01-01

    This mini-course gives an introduction to the techniques used in experimental particle physics with an emphasis on the impact of technological advances. The basic detector types and particle accelerator facilities will be briefly covered with examples of their use and with comparisons. The mini-course ends with what can be expected in the near future from current technology advances. The mini-course is intended for graduate students and post-docs and as an introduction to experimental techniq...

  8. Innovation strategies for generic drug companies: moving into supergenerics.

    Science.gov (United States)

    Ross, Malcolm S F

    2010-04-01

    Pharmaceutical companies that market generic products generally are not regarded as innovators, but rather as companies that produce copies of originator products to be launched at patent expiration. However, many generics companies have developed excellent scientific innovative skills in an effort to circumvent the defense patents of originator companies. More patents per product, in terms of both drug substances (process patents and polymorph patents) and formulations, are issued to generics companies than to companies that are traditionally considered to be 'innovators'. This quantity of issued patents highlights the technical knowledge and skill sets that are available in generics companies. In order to adopt a completely innovative model (ie, the development of NCEs), a generics company would require a completely new set of skills in several fields, including a sufficient knowledge base, project and risk management experience, and capability for clinical data evaluation. However, with relatively little investment, generics companies should be able to progress into the so-called 'supergeneric' drug space - an area of innovation that reflects the existing competencies of both innovative and generics companies. PMID:20373253

  9. Advanced Polymeric Materials for High-tech Innovations

    Institute of Scientific and Technical Information of China (English)

    TANG BenZhong

    2001-01-01

    @@ High technology is advancing our society and modernizing our life and advanced materials play an important role in the technological innovations. My research group has been working on the development of advanced polymeric materials and in this talk I will report our recent work on the creation of new conjugated polymers with novel molecular structures and unique materials properties.1-18 Our work include the design of molecular structures of monomeric building blocks, development of stable, effective and environmentally benign "green” polymerization catalysts, discovery of new polymerization reactions, synthesis of functional macromolecules, fabrication of nanodimensional composites, assembly and control of hierarchical structures, and construction of electrooptical devices. We have revealed the liquid crystallinity, light emission, photoconductivity, optical limiting, nano-hybridization, solvatochromism, optical activity, self-organization, and biological activity of the linear polyacetylenes and hyperbranched polyarylenes. The utilization of the advanced polymers and their interesting materials properties for high-tech innovations will be discussed.

  10. Advanced Polymeric Materials for High-tech Innovations

    Institute of Scientific and Technical Information of China (English)

    TANG; BenZhong

    2001-01-01

    High technology is advancing our society and modernizing our life and advanced materials play an important role in the technological innovations. My research group has been working on the development of advanced polymeric materials and in this talk I will report our recent work on the creation of new conjugated polymers with novel molecular structures and unique materials properties.1-18 Our work include the design of molecular structures of monomeric building blocks, development of stable, effective and environmentally benign "green” polymerization catalysts, discovery of new polymerization reactions, synthesis of functional macromolecules, fabrication of nanodimensional composites, assembly and control of hierarchical structures, and construction of electrooptical devices. We have revealed the liquid crystallinity, light emission, photoconductivity, optical limiting, nano-hybridization, solvatochromism, optical activity, self-organization, and biological activity of the linear polyacetylenes and hyperbranched polyarylenes. The utilization of the advanced polymers and their interesting materials properties for high-tech innovations will be discussed.  ……

  11. Innovative Tools Advance Revolutionary Weld Technique

    Science.gov (United States)

    2009-01-01

    The iconic, orange external tank of the space shuttle launch system not only contains the fuel used by the shuttle s main engines during liftoff but also comprises the shuttle s backbone, supporting the space shuttle orbiter and solid rocket boosters. Given the tank s structural importance and the extreme forces (7.8 million pounds of thrust load) and temperatures it encounters during launch, the welds used to construct the tank must be highly reliable. Variable polarity plasma arc welding, developed for manufacturing the external tank and later employed for building the International Space Station, was until 1994 the best process for joining the aluminum alloys used during construction. That year, Marshall Space Flight Center engineers began experimenting with a relatively new welding technique called friction stir welding (FSW), developed in 1991 by The Welding Institute, of Cambridge, England. FSW differs from traditional fusion welding in that it is a solid-state welding technique, using frictional heat and motion to join structural components without actually melting any of the material. The weld is created by a shouldered pin tool that is plunged into the seam of the materials to be joined. The tool traverses the line while rotating at high speeds, generating friction that heats and softens but does not melt the metal. (The heat produced approaches about 80 percent of the metal s melting temperature.) The pin tool s rotation crushes and stirs the plasticized metal, extruding it along the seam as the tool moves forward. The material cools and consolidates, resulting in a weld with superior mechanical properties as compared to those weld properties of fusion welds. The innovative FSW technology promises a number of attractive benefits. Because the welded materials are not melted, many of the undesirables associated with fusion welding porosity, cracking, shrinkage, and distortion of the weld are minimized or avoided. The process is more energy efficient, safe

  12. Important drugs for cough in advanced cancer.

    Science.gov (United States)

    Homsi, J; Walsh, D; Nelson, K A

    2001-11-01

    Cough is a defense mechanism that prevents the entry of noxious materials into the respiratory system and clears foreign materials and excess secretions from the lungs and respiratory tract. In advanced cancer, it is a common symptom that interferes with the patient's daily activity and quality of life. Empiric treatment with antitussive agents is often needed. Two classes of antitussive drugs are available: (1) centrally acting: (a) opioids and (b) non-opioids; (2) peripherally acting: (a) directly and (b) indirectly. Antitussive availability varies widely around the world. Many antitussives, such as benzonatate, codeine, hydrocodone, and dextromethorphan, were extensively studied in the acute and chronic cough settings and showed relatively high efficacy and safety profiles. Benzonatate, clobutinol, dihydrocodeine, hydrocodone, and levodropropizine were the only antitussives specifically studied in cancer and advanced cancer cough. They all have shown to be effective and safe in recommended daily dose for cough. In advanced cancer the patient's current medications, previous antitussive use, the availability of routes of administration, any history of drug abuse, the presence of other symptoms and other factors, all have a role in the selection of antitussives for prescription. A good knowledge of the pharmacokinetics, dosage, efficacy, and side effects of the available antitussives provides for better management. PMID:11762966

  13. Impact of recent innovations in the use of mass cytometry in support of drug development.

    Science.gov (United States)

    Nassar, Ala F; Ogura, Hideki; Wisnewski, Adam V

    2015-10-01

    Cytometry by time-of-flight (CyTOF) is a novel technology for the real-time analysis of single cells. CyTOF is a significant advance in fields including immunology, hematology, and oncology. It resolves multiple metal-conjugated probes per cell with minimal signal overlap, which maximizes the information obtained from each individual sample. CyTOF provides the ability to phenotypically and functionally profile cells from normal and diseased states. Single cell technologies enable researchers to measure the effects of a drug at the single cell level and better understand its mechanism of action. Here, we discuss novel instruments for the analysis of individual biological cells, the impact of recent innovations in support of drug development, and the important roles of CyTOF in drug profiling. PMID:26092491

  14. Innovations and Advances in Computer, Information, Systems Sciences, and Engineering

    CERN Document Server

    Sobh, Tarek

    2013-01-01

    Innovations and Advances in Computer, Information, Systems Sciences, and Engineering includes the proceedings of the International Joint Conferences on Computer, Information, and Systems Sciences, and Engineering (CISSE 2011). The contents of this book are a set of rigorously reviewed, world-class manuscripts addressing and detailing state-of-the-art research projects in the areas of  Industrial Electronics, Technology and Automation, Telecommunications and Networking, Systems, Computing Sciences and Software Engineering, Engineering Education, Instructional Technology, Assessment, and E-learning.

  15. Industry perspectives on market access of innovative drugs

    Directory of Open Access Journals (Sweden)

    Kim ePauwels

    2016-06-01

    Full Text Available This study presents industry perspectives on the challenges related to market access of innovative drugs in general and oncology drugs in specific. Fifteen interviews were conducted with representatives of pharmaceutical companies and industry associations. Interviewees call for a broader recognition of value within the assessment and appraisal of drugs. According to interviewees, focus on value is jeopardized by the lack of a common value definition across Europe, poor availability and validity of value measures and cost-saving measures such as external reference price setting and cost-effectiveness analysis at the side of the payers. Centralized assessment of relative-effectiveness at European level would provide a common value estimate across member states, independent of financial drivers. Empirical evidence on patient reported outcomes and societal preferences is however essential in the development of a value definition. Furthermore, value-based pricing would imply a dynamic approach where the price is differentiated across indications and across the lifecycle of the drug, especially in fields such as oncology. Financial drivers however also threat the application of value-based pricing at the side of the industry, making value-based profitability a more appropriate term.

  16. Advanced design cultures long-term perspective and continuous innovation

    CERN Document Server

    2015-01-01

    This book describes new thinking and practice in Advanced Design (ADD) – design that is not merely highly developed but anticipates the future by envisioning novel products and processes. The focus is especially on the front end of innovation and the search for solutions in complex pioneering processes using design-related tools and practices. The book opens by describing these tools, the approaches that characterize ADD, and its historical dimension. Specific fields in which ADD has flourished are then examined, exploring the dynamics between research and design. The coverage ranges from transportation, lighting, and electrical appliances through to business networks, technology parks, and the development of ground-breaking materials. AdvanceDesign is the name of the research group at the Politecnico di Milano (Italy’s largest technical university) of which the authors are members. It was chosen to reflect both the “advanced”, tangible dimension of design in terms of modern product development, mater...

  17. Advances in anti-epileptic drug testing.

    Science.gov (United States)

    Krasowski, Matthew D; McMillin, Gwendolyn A

    2014-09-25

    In the past twenty-one years, 17 new antiepileptic drugs have been approved for use in the United States and/or Europe. These drugs are clobazam, ezogabine (retigabine), eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. Therapeutic drug monitoring is often used in the clinical dosing of the newer anti-epileptic drugs. The drugs with the best justifications for drug monitoring are lamotrigine, levetiracetam, oxcarbazepine, stiripentol, and zonisamide. Perampanel, stiripentol and tiagabine are strongly bound to serum proteins and are candidates for monitoring of the free drug fractions. Alternative specimens for therapeutic drug monitoring are saliva and dried blood spots. Therapeutic drug monitoring of the new antiepileptic drugs is discussed here for managing patients with epilepsy. PMID:24925169

  18. Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products.

    Science.gov (United States)

    Stegemann, Sven; Klebovich, Imre; Antal, István; Blume, Henning H; Magyar, Kálmán; Németh, György; Paál, Tamás L; Stumptner, Willibald; Thaler, György; Van de Putte, Armand; Shah, Vinod P

    2011-11-20

    With a New Drug Application (NDA) innovative drug therapies are reaching the market in a specific dosage form for one or more clinically proven indications of which after expiration of the patent or the data exclusivity copies are launched using Abbreviated New Drug Applications (ANDA). Advanced therapies that emerged from launched molecules during their product life-cycle have gained considerable attention as clinical practice provides evidence for additional therapeutic values, patient centric delivery systems show improved therapeutic outcomes or emerging technologies offer efficiency gains in manufacturing or access to emerging markets. The USA and European regulatory framework has set reasonable regulations in place for these "Supergenerics" or "hybrid" applications. While these regulations are relatively recent the pharmaceutical industry is just starting to use this route for their product development and life-cycle management. From a clinical perspective the potential for advanced product development have been demonstrated. Yet, there is still a lag of common understanding between the different stakeholders regarding the development, application process and commercial incentive in developing enhanced therapeutic entities based on existing drug products for the market. PMID:21968337

  19. Current therapies and technological advances in aqueous aerosol drug delivery.

    Science.gov (United States)

    Watts, Alan B; McConville, Jason T; Williams, Robert O

    2008-09-01

    Recent advances in aerosolization technology have led to renewed interest in pulmonary delivery of a variety of drugs. Pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs) have experienced success in recent years; however, many limitations are presented by formulation difficulties, inefficient delivery, and complex device designs. Simplification of the formulation process as well as adaptability of new devices has led many in the pharmaceutical industry to reconsider aerosolization in an aqueous carrier. In the acute care setting, breath-enhanced air-jet nebulizers are controlling and minimizing the amount of wasted medication, while producing a high percentage of respirable droplets. Vibrating mesh nebulizers offer advantages in higher respirable fractions (RFs) and slower velocity aerosols when compared with air-jet nebulizers. Vibrating mesh nebulizers incorporating formulation and patient adaptive components provide improvements to continuous nebulization technology by generating aerosol only when it is most likely to reach the deep lung. Novel innovations in generation of liquid aerosols are now being adapted for propellant-free pulmonary drug delivery to achieve unprecedented control over dose delivered and are leading the way for the adaptation of systemic drugs for delivery via the pulmonary route. Devices designed for the metered dose delivery of insulin, morphine, sildenafil, triptans, and various peptides are all currently under investigation for pulmonary delivery to treat nonrespiratory diseases. Although these devices are currently still in clinical testing (with the exception of the Respimat), metered dose liquid inhalers (MDLIs) have already shown superior outcomes to current pulmonary and systemic delivery methods. PMID:18663654

  20. Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs

    Science.gov (United States)

    Pauwels, Kim; Huys, Isabelle; Casteels, Minne; Simoens, Steven

    2016-01-01

    Key Points - Representatives of the pharmaceutical industry call for a broader recognition of value within the assessment and appraisal of innovative drugs- Focus on value within the assessment and appraisal of drugs is jeopardized by financial drives as the side of industry and at the side of the payers- A well–considered value-framework, with attention for patient reported outcomes, societal preferences and dynamic approach on the drug life cycle, needs to be incorporated in assessment and appraisal at national and European level in order to coordinate the views of different stakeholders and allow efficient resource allocation This study presents industry perspectives on the challenges related to market access of innovative drugs in general and oncology drugs in specific. Fifteen interviews were conducted with representatives of pharmaceutical companies and industry associations. Interviewees call for a broader recognition of value within the assessment and appraisal of drugs. According to interviewees, focus on value is jeopardized by the lack of a common value definition across Europe, poor availability and validity of value measures and cost-saving measures such as external reference price setting and cost-effectiveness analysis at the side of the payers. Centralized assessment of relative-effectiveness at European level would provide a common value estimate across member states, independent of financial drivers. Empirical evidence on PRO and societal preferences is however essential in the development of a value definition. Furthermore, value-based pricing would imply a dynamic approach where the price is differentiated across indications and across the lifecycle of the drug, especially in fields such as oncology. Financial drivers however also threat the application of value-based pricing at the side of the industry, making value-based profitability a more appropriate term. PMID:27313529

  1. Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs.

    Science.gov (United States)

    Pauwels, Kim; Huys, Isabelle; Casteels, Minne; Simoens, Steven

    2016-01-01

    Key Points - Representatives of the pharmaceutical industry call for a broader recognition of value within the assessment and appraisal of innovative drugs- Focus on value within the assessment and appraisal of drugs is jeopardized by financial drives as the side of industry and at the side of the payers- A well-considered value-framework, with attention for patient reported outcomes, societal preferences and dynamic approach on the drug life cycle, needs to be incorporated in assessment and appraisal at national and European level in order to coordinate the views of different stakeholders and allow efficient resource allocation This study presents industry perspectives on the challenges related to market access of innovative drugs in general and oncology drugs in specific. Fifteen interviews were conducted with representatives of pharmaceutical companies and industry associations. Interviewees call for a broader recognition of value within the assessment and appraisal of drugs. According to interviewees, focus on value is jeopardized by the lack of a common value definition across Europe, poor availability and validity of value measures and cost-saving measures such as external reference price setting and cost-effectiveness analysis at the side of the payers. Centralized assessment of relative-effectiveness at European level would provide a common value estimate across member states, independent of financial drivers. Empirical evidence on PRO and societal preferences is however essential in the development of a value definition. Furthermore, value-based pricing would imply a dynamic approach where the price is differentiated across indications and across the lifecycle of the drug, especially in fields such as oncology. Financial drivers however also threat the application of value-based pricing at the side of the industry, making value-based profitability a more appropriate term. PMID:27313529

  2. International conference on Advances in Intelligent Control and Innovative Computing

    CERN Document Server

    Castillo, Oscar; Huang, Xu; Intelligent Control and Innovative Computing

    2012-01-01

    In the lightning-fast world of intelligent control and cutting-edge computing, it is vitally important to stay abreast of developments that seem to follow each other without pause. This publication features the very latest and some of the very best current research in the field, with 32 revised and extended research articles written by prominent researchers in the field. Culled from contributions to the key 2011 conference Advances in Intelligent Control and Innovative Computing, held in Hong Kong, the articles deal with a wealth of relevant topics, from the most recent work in artificial intelligence and decision-supporting systems, to automated planning, modelling and simulation, signal processing, and industrial applications. Not only does this work communicate the current state of the art in intelligent control and innovative computing, it is also an illuminating guide to up-to-date topics for researchers and graduate students in the field. The quality of the contents is absolutely assured by the high pro...

  3. RECENT ADVANCES IN NOVEL DRUG DELIVERY SYSTEMS

    Directory of Open Access Journals (Sweden)

    Manivannan Rangasamy

    2010-12-01

    Full Text Available Drug delivered can have significant effect on its efficacy. Some drugs have an optimum concentration range with in which maximum benefit is derived and concentrations above (or below the range can be toxic or produce no therapeutic effect. Various drug delivery and drug targeting systems are currently under development. The main goal for developing such delivery systems is to minimize drug degradation and loss, to prevent harmful side effects and to increase bioavailability. Targeting is the ability to direct the drug loaded system to the site of interest. Among drug carrier one can name soluble polymers, microparticles made of insoluble (or biodegradable natural and synthetic polymers, microcapsules, cells, cell ghosts, lipoproteins, liposomes and micelles. Two major mechanisms can be distinguished for addressing the desired sites for drug release, (a Passive and (b Active targeting. Controlled drug carrier systems such as micellar solutions, vescicles and liquid crystal dispersions, as well as nanoparticle dispersions consisting of small particles of 10 – 400 nm show great promise as drug delivery systems. Hydrogels are three dimensional, hydrophilic, polymer networks capable of imbibing large amounts of water or biological fluids. Buckyballs, a novel delivery system with 60 carbon atoms formed in the shape of hollow ball. They are other type’s namely bucky babies, fuzzy balls, gadofullereness, and giant fullerenes. Nanoparticles can be classified as nano tubes, nano wires, nano cantilever, nanoshells, quantum dots, nano pores. Researchers at north western university using gold particles to develop ultra sensitive detection systems for DNA and protein markers associated with many forms of cancer, including breast and prostrate cancer. Drug loaded erythrocytes is one of the growing and potential systems for delivery of drugs and enzymes.

  4. Recent advancements in the cardiovascular drug carriers.

    Science.gov (United States)

    Singh, Baljeet; Garg, Tarun; Goyal, Amit K; Rath, Goutam

    2016-01-01

    Cardiovascular disease is the disease that affects the cardiovascular system, vascular diseases of the brain and kidney, and peripheral arterial disease. Despite of all advances in pharmacological and clinical treatment, heart failure is a leading cause of morbidness and mortality worldwide. Many new therapeutic advance strategies, including cell transplantation, gene delivery or therapy, and cytokines or other small molecules, have been research to treat heart failure. The main aim of this review article is to focus on nano carriers advancement and addressing the problems associated with old and modern therapeutics such as nonspecific effects and poor stability. PMID:25046615

  5. State of an innovation system: theoretical and empirical advance towards an innovation efficiency index

    OpenAIRE

    Montalvo, Carlos; Moghayer, Saeed

    2011-01-01

    Innovation is currently seen as a cornerstone not only for economic development but also as an intrinsic human activity that could help to face the great challenges of human kind. Given the importance of innovation in the new European 2020 Strategy, measuring progress but also monitoring what drives innovation becomes crucial for policy development. Following upon this strategy the new European flag initiative “Innovation Union” called for a new “single” indicator on innovation. Currently the...

  6. Innovation Training within the Australian Advanced Manufacturing Industry

    Science.gov (United States)

    Donovan, Jerome Denis; Maritz, Alex; McLellan, Andrew

    2013-01-01

    Innovation has emerged as a core driver for the future profitability and success of the manufacturing sector, and increasingly both governments and the private sector are examining ways to support the development of innovation capabilities within organisations. In this research, we have evaluated a government-funded innovation training course…

  7. Advancing drug availability-experiences from Africa.

    Science.gov (United States)

    Powell, Richard A; Kaye, Richard Mugula; Ddungu, Henry; Mwangi-Powell, Faith

    2010-07-01

    International health and drug regulatory authorities acknowledge that analgesics (especially opioids) are insufficiently available for pain management in many countries. In Africa, reported morphine consumption is far below the global mean, with multiple factors hampering opioid supply. Since 2006, the African Palliative Care Association has hosted three regional drug availability workshops across the continent to address this issue. Using an interactive format, the workshops have identified country-specific barriers to opioid and other essential medication accessibility before supporting participants to develop action plans to address recognized impediments. Despite multiple challenges, a number of successes have arisen from the implementation of the plans. However, key issues remain, including the introduction of supportive policy environments, effective educational initiatives, and measures to address supply-chain obstacles impeding drug availability. PMID:20619205

  8. Antiepileptic Drugs 2012: Recent Advances and Trends

    OpenAIRE

    Sirven, Joseph I.; Noe, Katherine; Hoerth, Matthew; Drazkowski, Joseph

    2012-01-01

    There are now 24 antiepileptic drugs (AEDs) approved for use in epilepsy in the United States by the Food and Drug Administration. A literature search was conducted using PubMed, MEDLINE, and Google for all English-language articles that discuss newly approved AEDs and the use of AEDs in epilepsy in the United States from January 1, 2008, through December 31, 2011. Five new agents were identified that have come onto the market within the past 2 years. Moreover, 3 trends involving AEDs have be...

  9. Advanced Analyses of Technology Innovations, Patents, and Intellectual Property

    Directory of Open Access Journals (Sweden)

    Amy J. C. Trappey

    2013-08-01

    Full Text Available A good indicator of the technical competitiveness of a country or an enterprise is the number of high quality international patents it owns. The latest statistics from the World Intellectual Property Organization (WIPO showed that USA, Japan, Germany, China, and South Korea are among the top patent filing countries [1]. WIPO data indicate that these countries and their global companies are directing significant resources toward engineering innovations, design inventions, and technology R&D. The end result will be to capitalize their intellectual assets for competitive advantage. The huge and ever growing data and knowledge content of international patent (cyber- depositories creates great challenges for engineers, researchers, and technology strategists to fully utilize the wealth of knowledge [2]. Most critically, engineers must make correct R&D decisions based on the complex sets of patent information. This special issue features research papers focusing on the advances of representing, modeling, reasoning, analyzing, and synthesizing knowledge related to innovations, intellectual property (IP, patents, and technology adoptions. For industries with short life cycles and technical products (e.g., semiconductor, LED, and consumer electronics, state-of-the-art knowledge engineering approaches for IP and patent analysis are essential for sustaining competitive advantage. We have accepted five articles in this special issue and each has developed methodologies using industrial cases for verification. The papers are highlighted briefly as follows. The article “Applying Hybrid-Quantity Analysis in the Asia Semiconductor Industry,” co-authored by Chin-yuan Fan, Ming-Fong Lai, and Shu-Hao Chang, provides an integrated approach to explore competing technological and strategic-group relationships within the semiconductor industry in the Asia-Pacific region. They use a combination of patents, multidimensional scaling, and K-means clustering to

  10. Recent advances in chitosan-based nanoparticulate pulmonary drug delivery.

    Science.gov (United States)

    Islam, Nazrul; Ferro, Vito

    2016-08-14

    The advent of biodegradable polymer-encapsulated drug nanoparticles has made the pulmonary route of administration an exciting area of drug delivery research. Chitosan, a natural biodegradable and biocompatible polysaccharide has received enormous attention as a carrier for drug delivery. Recently, nanoparticles of chitosan (CS) and its synthetic derivatives have been investigated for the encapsulation and delivery of many drugs with improved targeting and controlled release. Herein, recent advances in the preparation and use of micro-/nanoparticles of chitosan and its derivatives for pulmonary delivery of various therapeutic agents (drugs, genes, vaccines) are reviewed. Although chitosan has wide applications in terms of formulations and routes of drug delivery, this review is focused on pulmonary delivery of drug-encapsulated nanoparticles of chitosan and its derivatives. In addition, the controversial toxicological effects of chitosan nanoparticles for lung delivery will also be discussed. PMID:27439116

  11. Antiepileptic drugs 2012: recent advances and trends.

    Science.gov (United States)

    Sirven, Joseph I; Noe, Katherine; Hoerth, Matthew; Drazkowski, Joseph

    2012-09-01

    There are now 24 antiepileptic drugs (AEDs) approved for use in epilepsy in the United States by the Food and Drug Administration. A literature search was conducted using PubMed, MEDLINE, and Google for all English-language articles that discuss newly approved AEDs and the use of AEDs in epilepsy in the United States from January 1, 2008, through December 31, 2011. Five new agents were identified that have come onto the market within the past 2 years. Moreover, 3 trends involving AEDs have become clinically important and must be considered by all who treat patients with epilepsy. These trends include issues of generic substitution of AEDs, pharmacogenomics predicting serious adverse events in certain ethnic populations, and the issue of the suicide risk involving the entire class of AEDs. This article discusses the most recent AEDs approved for use in the United States and the 3 important trends shaping the modern medical management of epilepsy. PMID:22958992

  12. Advances in Lymphatic Imaging and Drug Delivery

    Energy Technology Data Exchange (ETDEWEB)

    Nune, Satish K.; Gunda, Padmaja; Majeti, Bharat K.; Thallapally, Praveen K.; Laird, Forrest M.

    2011-09-10

    Cancer remains the second leading cause of death after heart disease in the US. While metastasized cancers such as breast, prostate, and colon are incurable, before their distant spread, these diseases will have invaded the lymphatic system as a first step in their progression. Hence, proper evaluation of the disease state of the lymphatics which drain a tumor site is crucial to staging and the formation of a treatment plan. Current lymphatic imaging modalities with visible dyes and radionucleotide tracers offer limited sensitivity and poor resolution; however, newer tools using nanocarriers, quantum dots, and magnetic resonance imaging promise to vastly improve the staging of lymphatic spread without needless biopsies. Concurrent with the improvement of lymphatic imaging agents, has been the development of drug carriers that can localize chemotherapy to the lymphatic system, thus improving the treatment of localized disease while minimizing the exposure of healthy organs to cytotoxic drugs. This review will focus on polymeric systems that have been developed for imaging and drug delivery to the lymph system, how these new devices improve upon current technologies, and where further improvement is needed.

  13. PROMOTING BREAKTHROUGH MEDICAL INNOVATION: INSIGHTS FROM AN ANALYSIS OF RECENT TRANSFORMATIVE DRUGS, BIOLOGICS AND MEDICAL DEVICES

    OpenAIRE

    Xu, Shuai

    2014-01-01

    Given the recent concern from multiple healthcare stakeholders that the pipeline of medical innovation is slowing, this thesis provides insights on how to spur breakthrough medical innovation in present day. The findings and recommendations are derived from one of the largest collections of interview transcripts from biomedical innovators (n=143) responsible for developing critical devices, drugs and diagnostics used in medicine today. An exemplary case (coronary artery stent) was selected ...

  14. From generic to biosimilar drugs: why take an innovative pace?

    Directory of Open Access Journals (Sweden)

    Fereshteh Barei

    2012-12-01

    Full Text Available BACKGROUND: The transition of the generic/biotechnology industry to innovation by investing in innovative R&D will enhance business expertise in biopharmaceutical development and manufacturing. The major impact of this evolution is on patient access to treatment and savings for the health care systems. OBJECTIVES: The aim of this paper is to investigate the innovative aspect of biosimilar and biobetter products, manufactured by some big generic companies. We will also try to explore the innovative business strategy, implementing this high risk product differentiation policy. METHODS: This qualitative research is conducted by a series of interviews with CEOs, physicians, and academics in different countries. The qualitative data obtained were analyzed by Nvivo9.2 software. A literature review has also contributed to our key findings. RESULTS: The results show that switching into biosimilars/biobetters is an innovative strategic choice, approved by some big generic pharmaceutical companies. The biosimilar/biobetter products can be considered innovative because of their value added quality. CONCLUSION: Expanding the product portfolio to biosimilars/biobetter can be considered as a long run strategy in the innovative business plans aiming to ensure the market access. Patients and their access to better treatments are major components of these innovative business models.

  15. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.

    Science.gov (United States)

    Wallis, Robert S; Maeurer, Markus; Mwaba, Peter; Chakaya, Jeremiah; Rustomjee, Roxana; Migliori, Giovanni Battista; Marais, Ben; Schito, Marco; Churchyard, Gavin; Swaminathan, Soumya; Hoelscher, Michael; Zumla, Alimuddin

    2016-04-01

    Tuberculosis is the leading infectious cause of death worldwide, with 9·6 million cases and 1·5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug resistant (MDR). Less than half of patients who entered into treatment for MDR tuberculosis successfully completed that treatment, mainly due to high mortality and loss to follow-up. These in turn illustrate weaknesses in current treatment regimens and national tuberculosis programmes, coupled with operational treatment challenges. In this Review we provide an update on recent developments in the tuberculosis drug-development pipeline (including new and repurposed antimicrobials and host-directed drugs) as they are applied to new regimens to shorten and improve outcomes of tuberculosis treatment. Several new or repurposed antimicrobial drugs are in advanced trial stages for MDR tuberculosis, and two new antimicrobial drug candidates are in early-stage trials. Several trials to reduce the duration of therapy in MDR and drug-susceptible tuberculosis are ongoing. A wide range of candidate host-directed therapies are being developed to accelerate eradication of infection, prevent new drug resistance, and prevent permanent lung injury. As these drugs have been approved for other clinical indications, they are now ready for repurposing for tuberculosis in phase 2 clinical trials. We assess risks associated with evaluation of new treatment regimens, and highlight opportunities to advance tuberculosis research generally through regulatory innovation in MDR tuberculosis. Progress in tuberculosis-specific biomarkers (including culture conversion, PET and CT imaging, and gene expression profiles) can support this innovation. Several global initiatives now provide unique opportunities to tackle the tuberculosis epidemic through collaborative partnerships between high-income countries and middle-income and low-income countries for clinical trials training and research, allowing funders to

  16. To Establish a National Technical Platform of Molecular Nuclear Medicine for Innovative Drug Development

    Institute of Scientific and Technical Information of China (English)

    2004-01-01

    @@ The development of innovative drugs is no doubt the "top priority" in the fulfillment of the medical and pharmaceutical research task of our country.Previously, the development of drugs was mainly performed by imitation,and expense for importing drugs amounted to more than US$ 1 billion per year. After joining the WTO, we fully realize the urgency and seriousness of the country's situation in the drug development.

  17. Diterpenes: Advances in Neurobiological Drug Research.

    Science.gov (United States)

    Islam, Md Torequl; da Silva, Claucenira Bandeira; de Alencar, Marcus Vinícius Oliveira Barros; Paz, Márcia Fernanda Correia Jardim; Almeida, Fernanda Regina de Castro; Melo-Cavalcante, Ana Amélia de Carvalho

    2016-06-01

    A significant number of studies have been performed with diterpene effect on the brain. Our study aims to make a systematic revision on them. The initial purpose of this review was to screen diterpenes with neurological activity, in particular those that have already been studied and published in different journals (databases until August 2015). The second purpose was to make an action-wise discussion as results viewed on them by taking into drug discovery and development account. Diterpenes considered in this review were selected on the basis of updated information on them and having sufficient information on their screenings. We identified several examples of diterpenes having an interest in further study. We have included the possible sources of them as observed in evidence, their known molecular neurobiological mechanisms, and the active constituents responsible for such activities with the doses and test systems. Results suggest diterpenes to have neurobiological activities like neuro-protection, anti-epileptic, anxiolytic, anti-Alzheimer's disease, anti-Parkinson's disease, anti-cerebral ischemia, anti-neuropathic pain, anti-neuro-inflammatory, and many more. In conclusion, diterpenes may be the prominent candidates in neurobiological drug research. Copyright © 2016 John Wiley & Sons, Ltd. PMID:27020718

  18. Low-Cost Innovative Hi-Temp Fiber Coating Process for Advanced Ceramic Matrix Composites Project

    Data.gov (United States)

    National Aeronautics and Space Administration — MATECH GSM (MG) proposes 1) to demonstrate a low-cost innovative Hi-Temp Si-doped in-situ BN fiber coating process for advanced ceramic matrix composites in order...

  19. Open innovation in early drug discovery: roadmaps and roadblocks.

    Science.gov (United States)

    Reichman, Melvin; Simpson, Peter B

    2016-05-01

    Open innovation in pharmaceutical R&D evolved from a triple helix of convergent paradigm shifts in academic, industrial and government research sectors. The birth of the biotechnology sector catalyzed shifts in location dynamics that led to the first wave of open innovation in pharmaceutical R&D between big pharma and startup companies. The National Institutes of Health (NIH) Roadmap was a crucial inflection point that set the stage for a new wave of open innovation models between pharmaceutical companies and universities that have the potential to transform the pharmaceutical R&D landscape. We highlight the attributes of leading protected open innovation models that foster the sharing of proprietary small molecule collections by lowering the risk of premature escape of intellectual property, particularly structure-activity data. PMID:26743597

  20. Recent advances in gastric floating drug delivery technology: a review.

    Science.gov (United States)

    Pahwa, Rakesh; Bisht, Seema; Kumar, Vipin; Kohli, Kanchan

    2013-06-01

    Gastric floating drug delivery systems have been an avenue of considerable interest in terms of their immense potential for better pharmacotherapeutic interventions along with site-specific absorption. These buoyant systems significantly enhance the bioavailability and controlled delivery of several drug molecules. Scientific investigators have also carried out substantial research endeavours worldwide in order to design a more systematic and intellectual floating systems. The present manuscript is an attempt to highlight numerous recent advancements in the design of gastric floating drug delivery systems along with various available commercial preparations. Salient applications, characterization aspects and future perspectives of these multifarious systems have also been addressed. PMID:23808593

  1. Reply to "transforming oncology care": advancing value, accessing innovation.

    Science.gov (United States)

    Paradis, Rebecca

    2015-09-01

    Alternative payment models in oncology are already successfully standardizing care, curbing costs, and improving the patient experience. Yet, it is unclear whether decision makers are adequately considering patient access to innovation when creating these models, which could have severe consequences for a robust innovation ecosystem and the lives of afflicted patients. The suggested chart includes recommendations on: Allowing for the adoption of new, promising therapies; Promoting the measurement of patient-centered outcomes; and Providing support for personalized medicine. PMID:26618436

  2. Advanced and sustainable fuel cycles for innovative reactor systems

    International Nuclear Information System (INIS)

    The key objective of nuclear energy systems of the future as defined by the Generation IV road map is to provide a sustainable energy generation for the future. It includes the requirement to minimize the nuclear waste produced and thereby notably reduce the long term stewardship burden in the future. It is therefore evident that the corresponding fuel cycles will play a central role in trying to achieve these goals by creating clean waste streams which contain almost exclusively the fission products. A new concept based on a grouped separation of actinides is widely discussed in this context, but it is of course a real challenge to achieve this type of separation since technologies available today have been developed to separate actinides from each other. In France, the CEA has launched extensive research programs in the ATALANTE facility in Marcoule to develop the advanced fuel cycles for new generation reactor systems. In this so called global actinide management (GAM) concept, the actinides are extracted in a sequence of chemical reactions (grouped actinide extraction (GANEX)) and immediately reintroduced in the fuel fabrication process is to use all actinides in the energy production process. The new group separation processes can be derived as in this case from aqueous techniques but also from so-called pyrochemical partitioning processes. Significant progress was made in recent years for both routes in the frame of the European research projects PARTNEW, PYROREP and EUROPART, mainly devoted to the separation of minor actinides in the frame of partitioning and transmutation (P and T) studies. The fuels used in the new generation reactors will be significantly different from the commercial fuels of today. Because of the fuel type and the very high burn-ups reached, pyrometallurgical reprocessing could be the preferred method. The limited solubility of some of the fuel materials in acidic aqueous solutions, the possibility to have an integrated irradiation and

  3. Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry.

    Science.gov (United States)

    Kinch, Michael S; Moore, Ryan

    2016-06-23

    The way new medicines are discovered and brought to market has fundamentally changed over the last 30 years. Our previous analysis showed that biotechnology companies had contributed significantly to the US Food and Drug Administration approval of new molecular entities up to the mid-1980s, when the trends started to decline. Although intriguing, the focus on biotechnology necessarily precluded the wider question of how the biopharmaceutical industry has been delivering on its goals to develop new drugs. Here, we present a comprehensive analysis of all biopharmaceutical innovators and uncover unexpected findings. The present biopharmaceutical industry grew steadily from 1800 to 1950 and then stagnated for two decades, before a burst of growth attributable to the biotechnology revolution took place; but consolidation has reduced the number of active and independent innovators to a level not experienced since 1945. The trajectories and trends we observe raise fundamental questions about biopharmaceutical innovators and the sustainability of the drug-development enterprise. PMID:27341432

  4. Breaking the Bank: Three Financing Models for Addressing the Drug Innovation Cost Crisis

    Science.gov (United States)

    Kleinke, J.D.; McGee, Nancy

    2015-01-01

    Background The introduction of innovative specialty pharmaceuticals with high prices has renewed efforts by public and private healthcare payers to constrain their utilization, increase patient cost-sharing, and compel government intervention on pricing. These efforts, although rational for individual payers, have the potential to undermine the public health impact and overall economic value of these innovations for society. The emerging archetypal example is the outcry over the cost of sofosbuvir, a drug proved to cure hepatitis C infection at a cost of $84,000 per person for a course of treatment (or $1000 per tablet). This represents a radical medical breakthrough for public health, with great promise for the long-term costs associated with this disease, but with major short-term cost implications for the budgets of healthcare payers. Objectives To propose potential financing models to provide a workable and lasting solution that directly addresses the misalignment of incentives between healthcare payers confronted with the high upfront costs of innovative specialty drugs and the rest of the US healthcare system, and to articulate these in the context of the historic struggle over paying for innovation. Discussion We describe 3 innovative financing models to manage expensive specialty drugs that will significantly reduce the direct, immediate cost burden of these drugs to public and private healthcare payers. The 3 financing models include high-cost drug mortgages, high-cost drugs reinsurance, and high-cost drug patient rebates. These models have been proved successful in other areas and should be adopted into healthcare to mitigate the high-cost of specialty drugs. We discuss the distribution of this burden over time and across the healthcare system, and we match the financial burden of medical innovations to the healthcare stakeholders who capture their overall value. All 3 models work within or replicate the current healthcare marketplace mechanisms for

  5. Advanced Analyses of Technology Innovations, Patents, and Intellectual Property

    OpenAIRE

    Trappey, Amy J. C.

    2013-01-01

    A good indicator of the technical competitiveness of a country or an enterprise is the number of high quality international patents it owns. The latest statistics from the World Intellectual Property Organization (WIPO) showed that USA, Japan, Germany, China, and South Korea are among the top patent filing countries [1]. WIPO data indicate that these countries and their global companies are directing significant resources toward engineering innovations, design inventions, and technology R&...

  6. Innovations in building regulation and control for advancing sustainability in buildings (I)

    OpenAIRE

    Meacham, B.; Visscher, H.J.; Meijer, F.M.; Chan, C.; Chan, E; Laubscher, J.; Neng Kwei Sung, J.; Dodds, B.; J. Serra; Tenorio, J.A.; Echeverria, J.B.; Sanches-Ostiz, A.

    2014-01-01

    This session brings together policy-makers, government officials, researchers and others to present perspectives on how innovation in building regulation and control, such as performancebased approaches, are currently being used to advance sustainability concepts in buildings, and where and how we might see further innovation in the coming years. In this grouping of session papers, representatives of the Inter-jurisdictional Regulatory Collaboration Committee (IRCC) and the International Coun...

  7. Open Innovation Drug Discovery (OIDD): a potential path to novel therapeutic chemical space.

    Science.gov (United States)

    Alvim-Gaston, Maria; Grese, Timothy; Mahoui, Abdelaziz; Palkowitz, Alan D; Pineiro-Nunez, Marta; Watson, Ian

    2014-01-01

    The continued development of computational and synthetic methods has enabled the enumeration or preparation of a nearly endless universe of chemical structures. Nevertheless, the ability of this chemical universe to deliver small molecules that can both modulate biological targets and have drug-like physicochemical properties continues to be a topic of interest to the pharmaceutical industry and academic researchers alike. The chemical space described by public, commercial, in-house and virtual compound collections has been interrogated by multiple approaches including biochemical, cellular and virtual screening, diversity analysis, and in-silico profiling. However, current drugs and known chemical probes derived from these efforts are contained within a remarkably small volume of the predicted chemical space. Access to more diverse classes of chemical scaffolds that maintain the properties relevant for drug discovery is certainly needed to meet the increasing demands for pharmaceutical innovation. The Lilly Open Innovation Drug Discovery platform (OIDD) was designed to tackle barriers to innovation through the identification of novel molecules active in relevant disease biology models. In this article we will discuss several computational approaches towards describing novel, biologically active, drug-like chemical space and illustrate how the OIDD program may facilitate access to previously untapped molecules that may aid in the search for innovative pharmaceuticals. PMID:24283973

  8. Fast dissolving oral films technology: A recent trend for an innovative oral drug delivery system

    Directory of Open Access Journals (Sweden)

    Deepak Sharma

    2015-10-01

    Full Text Available Over the past few decades, there has been increased interest for innovative drug delivery system to improve the safety, efficacy and patient compliance, thereby increasing the product patent life cycle. In  the  recent  years,  many of  the  pharmaceutical  groups  are  focusing  their  research  on  rapid dissolving  technology. Fast dissolving oral films are the most advanced form of oral solid dosage form due to more flexibility and comfort. It improve the efficacy of APIs by dissolving within minute in oral cavity after the contact with less saliva as compared to fast dissolving tablets, without chewing and no need of water for administration. These films have a potential to deliver the drug systemically through intra-gastric, sublingual or buccal route of administration and also has been used for local action. This type of technology offer a convenient way of dosing medication, not to special population groups like pediatric, geriatric, bedridden patients, mentally ill patients, but also to the general population. Fast dissolving oral films are found to be satisfactory in many situations like allergic conditions, cold and cough, sore throat, nausea, pain, mouth ulcers, CNS disorders and CVS disorders. Oral film includes various ingredients for its formulation which includes polymers, active pharmaceutical ingredient, film stabilizing agents, plasticizers, sweeteners, flavours, colors, saliva stimulating agents, surfactants etc. The present review reflects  information regarding  formulation  ingredients,  technologies  and  evaluation  tests  employed  in  the  preparation  of  fast dissolving oral films. However, for future growth point of view the fast dissolving oral films sector is well-positioned. It seems that the value of the overall oral thin films market will grow significantly.

  9. SELF EMULSIFYING DRUG DELIVERY SYSTEM: HITHERTO AND RECENT ADVANCES

    Directory of Open Access Journals (Sweden)

    Taksande Jayshree B

    2011-04-01

    Full Text Available Oral delivery of poorly water-soluble drugs creates critical problem for their formulation as 35- 40% of new active pharmaceutical ingredients have poor water solubility and frequently associated with low bioavailability. Recently much attention has been given to lipid-based formulation with particular emphasis on self emulsifying drug delivery system (SEDDS to improve the oral bioavailability. These can exist in either liquid or solid states. Self-emulsifying system formulation mainly depends on the nature of oil/lipid excipients, surfactants, their concentration and temperature at which emulsification occurs. As advancement or substitute of conventional liquid SEDDS, Solid SEDDS are better in minimizing manufacturing cost, makes simpler industrial manufacture, enhancing stability, patient compliance and most prominently these are very flexible to develop different solid dosage forms for oral and parentral administration. In addition, such formulation prevents GI irritation and able to control drug release. Recently self emulsifying drug delivery system is used as an efficient approach for the formulation of drugs that are beneficial in the diseases such as hypertension and congestive heart failure, HIV infections, cancer etc. The main difficulty in the development of SEDDS and other lipid-based formulations is the lack of high-quality in vitro models for their evaluation. Finally, the existing problems and the possible future research directions in this field are pointed out.

  10. Material Innovation in Advancing Organometal Halide Perovskite Functionality.

    Science.gov (United States)

    Zheng, Fan; Saldana-Greco, Diomedes; Liu, Shi; Rappe, Andrew M

    2015-12-01

    Organometal halide perovskites (OMHPs) have garnered much attention recently for their unprecedented rate of increasing power conversion efficiency (PCE), positioning them as a promising basis for the next-generation photovoltaic devices. However, the gap between the rapid increasing PCE and the incomplete understanding of the structure-property-performance relationship prevents the realization of the true potential of OMHPs. This Perspective aims to provide a concise overview of the current status of OMHP research, highlighting the unique properties of OMHPs that are critical for solar applications but still not adequately explained. Stability and performance challenges of OMHP solar cells are discussed, calling upon combined experimental and theoretical efforts to address these challenges for pioneering commercialization of OMHP solar cells. Various material innovation strategies for improving the performance and stability of OMHPs are surveyed, showing that the OMHP architecture can serve as a promising and robust platform for the design and optimization of materials with desired functionalities. PMID:26631361

  11. Mapping knowledge translation and innovation processes in Cancer Drug Development: the case of liposomal doxorubicin.

    Science.gov (United States)

    Fajardo-Ortiz, David; Duran, Luis; Moreno, Laura; Ochoa, Hector; Castaño, Victor M

    2014-01-01

    We explored how the knowledge translation and innovation processes are structured when theyresult in innovations, as in the case of liposomal doxorubicin research. In order to map the processes, a literature network analysis was made through Cytoscape and semantic analysis was performed by GOPubmed which is based in the controlled vocabularies MeSH (Medical Subject Headings) and GO (Gene Ontology). We found clusters related to different stages of the technological development (invention, innovation and imitation) and the knowledge translation process (preclinical, translational and clinical research), and we were able to map the historic emergence of Doxil as a paradigmatic nanodrug. This research could be a powerful methodological tool for decision-making and innovation management in drug delivery research. PMID:25182125

  12. Drug therapy for advanced-stage liver cancer.

    Science.gov (United States)

    Peck-Radosavljevic, Markus

    2014-05-01

    Liver cancer was traditionally treated by surgery or interventional ablative treatments, or, if these options were not feasible, by best supportive care. Since 2008, systemic therapy with the multikinase inhibitor sorafenib has become available worldwide and has become the standard of care for unresectable/non-ablatable or advanced-stage hepatocellular carcinoma (HCC). Sorafenib is able to improve the median overall survival by approximately 3 months. Despite this significant advance in the non-surgical/non-interventional management of liver cancer, this improvement in overall survival is only a first step toward more potent, more targeted, and better tolerated oral antitumor treatments. Since the introduction of sorafenib into clinical practice, several attempts have been made to develop even more effective first-line treatments as well as an effective second-line treatment for HCC. None of these endeavors has been successful so far. The development of drug treatments for HCC has been particularly hampered by the unfortunate push to establish the diagnosis of liver cancer by non-invasive imaging alone, without requiring a liver biopsy for histologic confirmation: this precluded the very necessary search for informative biomarkers and the search for molecular targets for drug development in HCC. This important drawback is being increasingly recognized and corrected. Despite several obstacles remaining to be overcome, it seems reasonable to assume that using a rational, data-driven approach, we will be able to develop better drug treatments for liver cancer in the coming years. PMID:24945003

  13. Advanced pasture management through innovative robotic pasture maintenance

    OpenAIRE

    Gobor, Z.; Cariou, C.; Seiferth, B.; Thurner, S; Feucker, W.; Tessier, C.; Tekin, B.; Berducat, M.

    2015-01-01

    The results of the i-LEED project should demonstrate an advanced pasture management combining a pasture care and management robot with the i-LEED software in order to provide significantly improved pasture regrowth, biomass quality and consequently better feeding of the grazing cattle. The information from the barn and the pasture complementing one another will lead to a more balanced and demand driven feed supply to the cattle, particularly affecting the improved amount of valuable milk comp...

  14. Innovative powder production and granulation for advanced MOX fuel forming

    International Nuclear Information System (INIS)

    In accordance with a long ranged research and development plan on the MOX fuel production for future FBR, we have been investigating the innovative MOX processing. Along with this plan, a new idea for realizing the serial processing, (1) crushing the solidified solute, and (2) granulation, in one vessel, are being proposed. An innovative design of a new system and the granulation examination were attempted. In order to establish the granulation technology, JAEA selected a candidate of machine, which has a rotating three lobes impeller (the crusher) driven from top outside of the casing, so as to fit our new system. This machine is mounted on a circular pan which sustains the evaporation dish, forming a vessel. The evaporation dish filled by solidified solute is moved from the Microwave oven into this vessel after the de-nitration. The rotary impeller is inserted on the solidified solute and crushes it until a reasonable powder state is obtained. The impeller is also utilized as the granulator after completion of the crushing. Namely, giving a slow rotation under showering, those powder changes into particles. Thus, the crushing and granulation are combined through the rotary impeller. As a result, the air flow assisted transfer of powder from the crusher to the granulator becomes unnecessary. According to the cold testing employing WO3 powder, the practical granulation was successfully carried out. The size of formed particle was larger than 100 m, and the flow-ability was ranged 80-90, being better than averaged value of conventional MOX particles produced by microwave direct heating method. The merits of the new granulation system are, (1) dispersion, scatter, and deposit of MOX powder which appear in the conventional transfer route are easy to prevent, and (2) running and control of job are easy. Due to the establishment of granulation technology by the system, it contributes the improvement of processing efficiency, lowering the construction and maintenance

  15. Advanced and Innovative Reactor Concept Designs, Associated Objectives and Driving Forces

    International Nuclear Information System (INIS)

    Advanced and innovative options for fast reactors are presented through a short selection of recent publications at international conferences. Driving forces and major trends are analysed to give a comprehensive overview of the various existing projects and supportive R and D. (author)

  16. Integrating Social Neuroscience and Social Work: Innovations for Advancing Practice-Based Research

    Science.gov (United States)

    Matto, Holly C.; Strolin-Goltzman, Jessica

    2010-01-01

    Throughout the social work profession, there is ongoing interest in building a social science agenda that can address the complex practice-based questions faced by social work professionals today. Methodological innovations and unique funding opportunities have already significantly advanced research on social work practice. Still, there is…

  17. Advance of technological innovations of electric power in 2012

    International Nuclear Information System (INIS)

    Twelve companies in Japan reported on the technological innovations in 2012. The Japan Atomic Power Company mainly studied five projects; (1) control of wall thinning of the secondary system in PWR by injection of molybdic acid, (2) application of pipe test method using electromagnetic acoustic resonance to existing equipment, (3) developed high performance Co-60 crud removal resin for Tsuruga Power Station Unit 2, (4) improvement of technology for safety of core in FBR, and (5) improvement of technology for coolant of FBR by dispersing nano-particles in liquid sodium metal. Tokyo Electric Power Company developed mainly three projects; (1) the support for the mental health care activities by industry protection staff at the Fukushima Daiichi and Daini Nuclear Power Plant, (2) laboratory test method using non-radioactive cesium for performance of decontamination reagent, and (3) decontamination effects estimation code (DeConEP). Hokuriku Electric Power Company reported the operations management measures in accordance with the safety enhancement measures to Shika nuclear power station. Other nine reports are published by Hokkaido Electric Power Co., Inc. Tohoku Electric Power Co., Inc. Chubu Electric Power Co., Inc., The Kansai Electric Power Co., Inc., The Chugoku Electric Power Co., Inc., Shikoku Electric Power Co., Inc., Kyushu Electric Power Co., Inc., Okinawa Electric Power Company Inc. and J-Power. (S.Y.)

  18. Unsteady jet in designing innovative drug delivery system

    Science.gov (United States)

    Wang, Cong; Mazur, Paul; Cosse, Julia; Rider, Stephanie; Gharib, Morteza

    2014-11-01

    Micro-needle injections, a promising pain-free drug delivery method, is constrained by its limited penetration depth. This deficiency can be overcome by implementing fast unsteady jet that can penetrate sub-dermally. The development of a faster liquid jet would increase the penetration depth and delivery volume of micro-needles. In this preliminary work, the nonlinear transient behavior of an elastic tube balloon in providing fast discharge is analyzed. A physical model that combines the Mooney Rivlin Material model and Young-Lapalce's Law was developed and used to investigate the fast discharging dynamic phenomenon. A proof of concept prototype was constructed to demonstrate the feasibility of a simple thumb-sized delivery system to generate liquid jet with desired speed in the range of 5-10 m/s. This work is supported by ZCUBE Corporation.

  19. Innovation Meets Performance Demands of Advanced Lithium-ion Batteries

    Energy Technology Data Exchange (ETDEWEB)

    2016-06-01

    Advancements in high capacity and low density battery technologies have led to a growing need for battery materials with greater charge capacity and therefore stability. NREL's developments in ALD and molecular layer MLD allow for thin film coatings to battery composite electrodes, which can improve battery lifespan, high charge capacity, and stability. Silicon, one of the best high-energy anode materials for Li-ion batteries, can experience capacity fade from volumetric expansion. Using MLD to examine how surface modification could stabilize silicon anode material in Li-ion batteries, researchers discovered a new reaction precursor that leads to a flexible surface coating that accommodates volumetric expansion of silicon electrodes.

  20. Advanced Waste Retrieval System. Innovative Technology Summary Report

    International Nuclear Information System (INIS)

    At West Valley, following the baseline removal operations, bulk waste retrieval methods may be augmented if required, with the deployment of the Advanced Waste Retrieval System (AWRS). The AWRS is a hydraulic boom mounted on a trolley on the Mast-Mounted Tool Delivery System. The boom is about 15 ft long with a pan and tilt mechanism at the end. On the end is a steam jet with a suction tool that can reach down around the tank internal structure and vacuum up zeolite or sludge off the bottom of the tank from a thirty-foot diameter reach. A grinder is included topside in the discharge path to pulverize the zeolite so it can be readily retrieved from the destination tank

  1. Locally advanced cervix carcinoma - innovation in combined modality therapy

    International Nuclear Information System (INIS)

    Locally advanced cervical carcinoma continues to be a challenge to the clinician due to local failure as well as systemic metastases. Standard intracavitary and external beam techniques result in local control rates of only 35-65%, with long term survival rates of 25-60% in patients with state IIIA-IVA disease, indicating the need to identify new treatment strategies. Optimization programs for remote-afterloading interstitial brachytherapy allow the delivery of higher local doses of radiation to volumes that more closely approximate tumor target volumes as identified on MR scans, leading to improved therapeutic ratios. Identification of subsets of patients more likely to fail standard therapy, either locally or systemically, may be possible through such techniques as in vivo measurements of hypoxia with Eppendorf oxygen electrodes, interstitial fluid pressure measurements, the Comet assay, and nitroimidazole binding methods. Traditional chemotherapies, administered in either a neoadjuvant role or concomitantly with radiation have been disappointing in prospective trials. A variety of new agents are being investigated to determine if they can increase the frequency or duration of complete response. The taxanes, with response rates of 17-23% by themselves, are being assessed as potential radiosensitizers. The camptotheicin CRT-11 (Irinotecan) has demonstrated activity in platinum resistant cervix cancer, with response rates of 24%. Bioradiotherapeutic approaches, using 13-cis-retinoic acid and interferon-2a, are undergoing phase II studies. Neoangiogenesis inhibitors and vaccines against HPV are also being examined. The aggressive pursuit of techniques that help identify those patients most likely to fail, that allow the delivery of higher radiation doses more safely to the target volume, and that incorporate the use of more effective systemic therapies is necessary to improve the outcome for this disease

  2. Innovation

    DEFF Research Database (Denmark)

    Nielsen, Janni; Yaganeh, Suzanne; Bloch Rasmussen, Leif;

    2013-01-01

    This paper contributes to a theoretical discussion of creation of innovation with participants in, or outside, organisations. We address the creation of innovation with a complex theoretical understanding drawing on the Scandinavian and the Participatory Design tradition introducing two approaches...... to the processes of innovation. We ask if innovation can be initiated and enhanced looking at two collaborative approaches; participatory innovation (PIN) and cooperative innovation (COIN). We invite to dialogue and reflections on PIN’s conflict and creative frictions on one side and COIN’s complexity......, complementarity in diversity and the didactic scaffolding of the innovation process on the other side. Our contribution focuses on the methods and practices for facilitation of co-creating activities between different groups leading to cooperation, and innovation in thinking....

  3. Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-Cholesterol Drugs

    OpenAIRE

    Abe Dunn

    2010-01-01

    The pharmaceutical industry is characterized as having substantial investment in R&D and a large number of new product introductions, which poses special problems for price measurement caused by the quality of drug products changing over time. This paper applies recent demand estimation techniques to construct a constant- quality price index for anti-cholesterol drugs. Demand is estimated using a nationally representative sample of individuals over the period 1996 to 2007 that includes detail...

  4. Advancing the practice of online psychotherapy: An application of Rogers' diffusion of innovations theory.

    Science.gov (United States)

    Lovejoy, Travis I; Demireva, Petya D; Grayson, Jessica L; McNamara, John R

    2009-03-01

    With the advancements of technology and its increasing use in all spheres of life, clinicians too are faced with the decision of whether to adopt or refrain from adopting certain innovations in their practice. This article discusses the process of adopting clinical innovations within a theoretical framework, namely diffusion of innovations theory (DIT; Rogers, 2003). DIT constructs are applied to the example of online therapy adoption into clinical practice. Nine adoption barriers are identified, including issues of dehumanizing the therapeutic environment, start-up cost and reimbursement, infrastructure and training, licensure and jurisdiction concerns, ethical guidelines, both client and clinician suitability factors, and professional reputation and acceptance within the field. The authors conclude with a theory-based discussion of activities that may help to accelerate the adoption of online therapy among professional psychologists. (PsycINFO Database Record (c) 2010 APA, all rights reserved). PMID:22122574

  5. Nota Lepidopterologica combines tradition and innovation through open access and advanced publishing model

    Directory of Open Access Journals (Sweden)

    Jadranka Rota

    2014-06-01

    Full Text Available The Societas Europaea Lepidopterologica (SEL has joined forces with Pensoft as our new publisher to bring the Society’s journal Nota Lepidopterologica on the way to open access and innovation. Our intentions were first announced at the SEL congress in Bulgaria in 2013 and now we are pleased to announce the first issue of the journal published in an advanced open access format at the brand new editorial platform of Pensoft (http://nl.pensoft.net.

  6. Advanced technologies in plastic surgery: how new innovations can improve our training and practice.

    Science.gov (United States)

    Grunwald, Tiffany; Krummel, Thomas; Sherman, Randy

    2004-11-01

    Over the last two decades, virtual reality, haptics, simulators, robotics, and other "advanced technologies" have emerged as important innovations in medical learning and practice. Reports on simulator applications in medicine now appear regularly in the medical, computer science, engineering, and popular literature. The goal of this article is to review the emerging intersection between advanced technologies and surgery and how new technology is being utilized in several surgical fields, particularly plastic surgery. The authors also discuss how plastic and reconstructive surgeons can benefit by working to further the development of multimedia and simulated environment technologies in surgical practice and training. PMID:15509950

  7. Innovative grinding wheel design for cost-effective machining of advanced ceramics

    Energy Technology Data Exchange (ETDEWEB)

    Licht, R.H.; Kuo, P.; Liu, S.; Murphy, D.; Picone, J.W.; Ramanath, S.

    2000-05-01

    This Final Report covers the Phase II Innovative Grinding Wheel (IGW) program in which Norton Company successfully developed a novel grinding wheel for cost-effective cylindrical grinding of advanced ceramics. In 1995, Norton Company successfully completed the 16-month Phase I technical effort to define requirements, design, develop, and evaluate a next-generation grinding wheel for cost-effective cylindrical grinding of advanced ceramics using small prototype wheels. The Phase II program was initiated to scale-up the new superabrasive wheel specification to larger diameters, 305-mm to 406-mm, required for most production grinding of cylindrical ceramic parts, and to perform in-house and independent validation grinding tests.

  8. Drug delivery system innovation and Health Technology Assessment: Upgrading from Clinical to Technological Assessment.

    Science.gov (United States)

    Panzitta, Michele; Bruno, Giorgio; Giovagnoli, Stefano; Mendicino, Francesca R; Ricci, Maurizio

    2015-11-30

    Health Technology Assessment (HTA) is a multidisciplinary health political instrument that evaluates the consequences, mainly clinical and economical, of a health care technology; the HTA aim is to produce and spread information on scientific and technological innovation for health political decision making process. Drug delivery systems (DDS), such as nanocarriers, are technologically complex but they have pivotal relevance in therapeutic innovation. The HTA process, as commonly applied to conventional drug evaluation, should upgrade to a full pharmaceutical assessment, considering the DDS complexity. This is useful to study more in depth the clinical outcome and to broaden its critical assessment toward pharmaceutical issues affecting the patient and not measured by the current clinical evidence approach. We draw out the expertise necessary to perform the pharmaceutical assessment and we propose a format to evaluate the DDS technological topics such as formulation and mechanism of action, physicochemical characteristics, manufacturing process. We integrated the above-mentioned three points in the Evidence Based Medicine approach, which is data source for any HTA process. In this regard, the introduction of a Pharmaceutics Expert figure in the HTA could be fundamental to grant a more detailed evaluation of medicine product characteristics and performances and to help optimizing DDS features to overcome R&D drawbacks. Some aspects of product development, such as manufacturing processes, should be part of the HTA as innovative manufacturing processes allow new products to reach more effectively patient bedside. HTA so upgraded may encourage resource allocating payers to invest in innovative technologies and providers to focus on innovative material properties and manufacturing processes, thus contributing to bring more medicines in therapy in a sustainable manner. PMID:26399633

  9. Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs.

    Science.gov (United States)

    Lessl, Monika; Schoepe, Stefanie; Sommer, Anette; Schneider, Martin; Asadullah, Khusru

    2011-04-01

    Collaborations between industry and academia are steadily gaining importance. To combine expertises Bayer Healthcare has set up a novel open innovation approach called Grants4Targets. Ideas on novel drug targets can easily be submitted to http://www.grants4targets.com. After a review process, grants are provided to perform focused experiments to further validate the proposed targets. In addition to financial support specific know-how on target validation and drug discovery is provided. Experienced scientists are nominated as project partners and, depending on the project, tools or specific models are provided. Around 280 applications have been received and 41 projects granted. According to our experience, this type of bridging fund combined with joint efforts provides a valuable tool to foster drug discovery collaborations. PMID:21129498

  10. Advanced stent coating for drug delivery and in vivo biocompatibility

    Energy Technology Data Exchange (ETDEWEB)

    Liu, Yi; Wang, Wuchen; Acharya, Gayathri [University of Missouri at Kansas City, Division of Pharmaceutical Sciences, School of Pharmacy (United States); Shim, Yoon-Bo [Pusan National University, Departments of Chemistry (Korea, Republic of); Choe, Eun Sang [Pusan National University, Departments of Biological Sciences (Korea, Republic of); Lee, Chi H., E-mail: leech@umkc.edu [University of Missouri at Kansas City, Division of Pharmaceutical Sciences, School of Pharmacy (United States)

    2013-10-15

    As an effort to alleviate stent-induced cardiovascular injury including restenosis and thrombosis, advanced drug-eluting stent (ADES) with a bilayer construct composed of a top-coat made of collagen and a base-coat incorporated with N-nitrosomelatonin (NOMela)-loaded PLGA nanoparticles has been developed. NOMela is a hydrophobic prodrug of nitric oxide (NO) that is an endogenous anti-platelet compound. ADES was coated with PLGA nanoparticles via either electrophoretic deposition (EPD) technique or dip-coating technique, and their coating characteristics and efficacies were compared. The drug-loading efficacy and in vitro drug-release profiles from ADES were expressed with various variables including the additives to the collagen layer, the number of layers of the collagen top-coat, the hydrophobicity/hydrophilicity of the loaded drug, the coating technique of nanoparticles, and the concentration of coating emulsions in the EPD method. The morphological status of cross-section and surface of ADES was evaluated by laser scanning confocal microscope and scanning electronic microscope. The real-time release profiles of NO were assessed using the NO-microbiosensor. The anti-platelet activity of ADES was evaluated on the rabbit whole blood using an aggregometer. The intima formation and protein expression in aorta were examined using an in vivo rat model. Both collagen and PLGA used in ADES are biodegradable polymers that fully degrade and consequently produce less inflammation responses. NO released from ADES significantly reduced platelet aggregation in the rabbit blood as compared with those exposed to the control stents. ADES coated with a double layer consisted of collagen and PLGA and containing NOMela was less antigenic at the implanted sites and alleviating intima formation and thrombosis. An external exposure of aorta to NO elicits distinct and specific effects on mitogen-activated protein kinase (MAPK) and Ca{sup 2+}/calmodulin-dependent protein kinase II (Ca

  11. Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation.

    Science.gov (United States)

    Shi, Yun-Zhen; Hu, Hao; Wang, Chunming

    2014-01-01

    The significance of R&D capabilities of China has become increasingly important as an emerging force in the context of globalization of pharmaceutical research and development (R&D). While China has prospered in its R&D capability in the past decade, how to integrate the rising pharmaceutical R&D capability of China into the global development chain for innovative drugs remains challenging. For many multinational corporations and research organizations overseas, their attempt to integrate China's pharmaceutical R&D capabilities into their own is always hindered by policy constraints and reluctance of local universities and pharmaceutical firms. In light of the situation, contract research organizations (CROs) in China have made great innovation in value proposition, value chain and value networking to be at a unique position to facilitate global and local R&D integration. Chinese CROs are now being considered as the essentially important and highly versatile integrator of local R&D capability for global drug discovery and innovation. PMID:25406839

  12. State-of-the-art Report on Innovative Fuels for Advanced Nuclear Systems

    International Nuclear Information System (INIS)

    Development of innovative fuels such as homogeneous and heterogeneous fuels, ADS fuels, and oxide, metal, nitride and carbide fuels is an important stage in the implementation process of advanced nuclear systems. Several national and international R and D programmes are investigating minor actinide-bearing fuels due to their ability to help reduce the radiotoxicity of spent fuel and therefore decrease the burden on geological repositories. Minor actinides can be converted into a suitable fuel form for irradiation in reactor systems where they are transmuted into fission products with a significantly shorter half-life. This report compares recent studies of fuels containing minor actinides for use in advanced nuclear systems. The studies review different fuels for several types of advanced reactors by examining various technical issues associated with fabrication, characterisation, irradiation performance, design and safety criteria, as well as technical maturity. (authors)

  13. RECENT ADVANCES IN GASTRO RETENTIVE DRUG DELIVERY SYSTEM: A REVIEW

    OpenAIRE

    DASH ALOK KUMAR; MISHRA JHANSEE

    2013-01-01

    Several controlled oral drug delivery systems with prolonged gastric residence time have been reported recently. Gastro retentive drug delivery system is an approach to prolong gastric residence time, thereby targeting site-specific drug release in upper gastro intestinal tract improving the oral sustained delivery of drug that have an absorption window in a particular region of the gastrointestinal tract. These systems help in continuously releasing the drug before it reaches the absorption ...

  14. The Advanced Exploration Systems Water Recovery Project: Innovation on 2 Fronts

    Science.gov (United States)

    Sarguisingh, Miriam M.; Neumeyer, Derek; Shull, Sarah

    2012-01-01

    As NASA looks forward to sending humans farther away from Earth, we will have to develop a transportation architecture that is highly reliable and that can sustain life for long durations without the benefit of Earth s proximity for continuous resupply or even operational guidance. NASA has consistently been challenged with performing great feats of innovation, but particularly in this time of economic stress, we are challenged to go farther with less. The Advanced Exploration Systems (AES) projects were implemented to address both of these needs by not only developing innovative technologies, but by incorporating innovative management styles and processes that foster the needed technical innovation given a small amount of resources. This presentation explains how the AES Water Recovery Project is exhibiting innovation on both fronts; technical and process. The AES Water Recovery Project (WRP) is actively engineering innovative technologies in order to maximize the efficiency of water recovery. The development of reliable, energy-efficient, and low-mass spacecraft systems to provide environmental control and life support (ECLS) is critical to enable long-duration human missions outside of low-Earth orbit. Recycling of life support consumables is necessary to reduce resupply mass and provide for vehicle autonomy. To address this, the WRP is working on a rotary distiller that has shown enhanced performance over the state-of-the-art (SOA). Additionally, the WRP is looking at innovative ways to address issues present in the state-of-the-art (SOA) systems pertaining to toxicity and calcium scale buildup. As an AES project, the WRP has a more streamlined Skunk Works like approach to technology development intended to reduce overhead but achieve a more refined end product. The project has incorporated key partnerships between NASA centers as well as between NASA and industry. A minimal project management style has been implemented such that risks are managed and

  15. State of an innovation system: theoretical and empirical advance towards an innovation efficiency index. Or: Walking between ridicule and praise: measuring innovation systems effieciency with a single indicator

    OpenAIRE

    Montalvo Corral, C.; Mohammadian Moghayer, S.

    2011-01-01

    Innovation is currently seen as a cornerstone not only for economic development but also as an intrinsic human activity that could help to face the great challenges of human kind. Given the importance of innovation in the new European 2020 Strategy, measuring progress but also monitoring what drives innovation becomes crucial for policy development. Following upon this strategy the new European flag initiative “Innovation Union” called for a new “single” indicator on innovation. Currently the...

  16. Drug discovery in jeopardy

    OpenAIRE

    Cuatrecasas, Pedro

    2006-01-01

    Despite striking advances in the biomedical sciences, the flow of new drugs has slowed to a trickle, impairing therapeutic advances as well as the commercial success of drug companies. Reduced productivity in the drug industry is caused mainly by corporate policies that discourage innovation. This is compounded by various consequences of mega-mergers, the obsession for blockbuster drugs, the shift of control of research from scientists to marketers, the need for fast sales growth, and the dis...

  17. Innovation

    DEFF Research Database (Denmark)

    Helms, Niels Henrik

    2012-01-01

    Kravet om innovation og kreativitet er på flere måder en stor og en ny udfordring for voksenuddannelserne. Det udfordrer det didaktiske dilemma, det at vi skal gøres til kompetente og frie mennesker gennem pædagogiske handlinger, som netop pålægger os en ufrihed. – Men hvor denne ufrihed...... innovative, netop er det, vi endnu ikke kender...

  18. RECENT ADVANCES IN GASTRO RETENTIVE DRUG DELIVERY SYSTEM: A REVIEW

    Directory of Open Access Journals (Sweden)

    DASH ALOK KUMAR

    2013-01-01

    Full Text Available Several controlled oral drug delivery systems with prolonged gastric residence time have been reported recently. Gastro retentive drug delivery system is an approach to prolong gastric residence time, thereby targeting site-specific drug release in upper gastro intestinal tract improving the oral sustained delivery of drug that have an absorption window in a particular region of the gastrointestinal tract. These systems help in continuously releasing the drug before it reaches the absorption window, thus ensuring optimal bioavailability. Various approaches for gastric retention are Floating system, Swelling and expanding system, Bioadhesive systems, Modified-shape systems, High density systems etc.

  19. Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials

    Science.gov (United States)

    Shimizu-Motohashi, Yuko; Miyatake, Shouta; Komaki, Hirofumi; Takeda, Shin’ichi; Aoki, Yoshitsugu

    2016-01-01

    Duchenne muscular dystrophy (DMD) is an X-linked progressive degenerative muscle disorder caused by the absence of dystrophin. There is no curative therapy, although innovative therapeutic approaches have been aggressively investigated over recent years. Currently, the international clinical trial registry platform for this disease has been constructed and clinical trials for innovative therapeutic approaches are underway. Among these, exon skipping and read-through of nonsense mutations are in the most advanced stages, with exon skipping theoretically applicable to a larger number of patients. To date, exon skipping that targets exons 51, 44, 45, and 53 is being globally investigated including in USA, EU, and Japan. The latest announcement from Japan was made, demonstrating successful dystrophin production in muscles of patients with DMD after treating with exon 53 skipping antisense oligonucleotides (ASOs). However, the innovative therapeutic approaches have demonstrated limited efficacy. To address this issue in exon skipping, studies to unveil the mechanism underlying gymnotic delivery of ASO uptake in living cells have been conducted in an effort to improve in vivo delivery. Further, establishing the infrastructures to integrate multi-institutional clinical trials are needed to facilitate the development of successful therapies for DMD, which ultimately is applicable to other myopathies and neurodegenerative diseases, including spinal muscular atrophy and motor neuron diseases. PMID:27398133

  20. Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances.

    Science.gov (United States)

    Savaliya, Reema; Singh, Poornima; Singh, Sanjay

    2016-01-01

    The latest pharmacologic research has resulted number of new molecules with the potential to modernize the prevention or treatment of different complex diseases, including cancer. The therapeutics generally include moieties such as proteins, drugs and genes, etc. Current activities in the pharmacological field include the development of novel drug-delivery systems to overcome pharmacokinetic glitches such as limited bioavailability, unwanted distribution, drug resistant, and stability, etc. Therefore, to address these issues various biotechnological and pharmacological techniques has been introduced. However, effective drug delivery with improved efficacy remains challenging. This review is focused towards different strategies such as physical and biological methods for efficacious delivery at desired tissues and even sub-cellular targeting. Emphasis is also given about nanotechnology based drug or gene delivery strategies and co-delivery of drug-drug; gene-gene or combinations of drug-gene, etc. are the current cuttingedge methods, which are under clinical or pre-clinical stage of research. Uses of biodegradable materials, such as liposomes and polymeric particles are another class of drug delivery vehicles, which have shown tremendous success, are also discussed. Towards the end, future directions of pharmacological drug delivery methods have also been summarized. PMID:26654439

  1. A REVIEW ON ADVANCES OF SUSTAINED RELEASE DRUG DELIVERY SYSTEM

    Directory of Open Access Journals (Sweden)

    Sujit Bose

    2013-06-01

    Full Text Available Sustained release matrix tablets facilitate prolonged and continuous drug release and improve the bioavailability of drugs while avoiding unwanted side effects. Ofloxacin is a broad spectrum antibacterial agent used for treating wide range of gram positive and gram negative infections. The goal in designing sustained or controlled delivery systems is to reduce frequency of dosing or to increase the effectiveness of the drug by localization at the site of action, reducing the dose required, providing uniform drug delivery. Sustained release drug administration means not only prolongation of duration of drug delivery, but the term also implies the predictability and reproducibility of drug release kinetics. The controlled release of drug substances and their effective transport to sites of action can be exploited to maximize the beneficial clinical response and to minimize the incidence of unbeneficial adverse reactions and side effects. Oral ingestion has long been the most convenient and commonly employed route of drug delivery. Indeed, for sustained release systems, oral route of administration has received most of the attention with respect to research on physiological and drug constraints as well as design and testing of products.

  2. A REVIEW ON ADVANCES OF SUSTAINED RELEASE DRUG DELIVERY SYSTEM

    OpenAIRE

    Sujit Bose; Amandeep Kaur; Sharma, S K

    2013-01-01

    Sustained release matrix tablets facilitate prolonged and continuous drug release and improve the bioavailability of drugs while avoiding unwanted side effects. Ofloxacin is a broad spectrum antibacterial agent used for treating wide range of gram positive and gram negative infections. The goal in designing sustained or controlled delivery systems is to reduce frequency of dosing or to increase the effectiveness of the drug by localization at the site of action, reducing the dose required, pr...

  3. Recent advances in tuberculosis: New drugs and treatment regimens

    OpenAIRE

    Sloan, Derek J; Davies, Geraint R.; Khoo, Saye H.

    2013-01-01

    The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR−) forms of TB have presented new challenges for therapeutic research. Priority goals include shortening DS-TB treatment, improving DR-TB treatment and making combined TB-HIV therapy easier. To help achieve these goals, a range of new drugs and treatment strategies are currently being evaluated. Phase ...

  4. Exploring open innovation with a patient focus in drug discovery: an evolving paradigm of patient engagement.

    Science.gov (United States)

    Allarakhia, Minna

    2015-06-01

    It is suggested in this article that patient engagement should occur further upstream during the drug discovery stage. 'Lead patients', namely those patients who are proactive with respect to their health, possess knowledge of their disease and resulting symptoms. They are also well informed about the conventional as well as non-conventional treatments for disease management; and so can provide a nuanced perspective to drug design. Understanding how patients view the management of their diseases and how they view the use of conventional versus non-conventional interventions is of imperative importance to researchers. Indeed, this can provide insight into how conventional treatments might be designed from the outset to encourage compliance and positive health outcomes. Consequently, a continuum of lead patient engagement is employed that focuses on drug discovery processes ranging from participative, informative to collaborative engagement. This article looks at a variety of open innovation models that are currently employed across this engagement spectrum. It is no longer sufficient for industry stakeholders to consider conventional therapies as the only mechanisms being sought after by patients. Without patient engagement, the industry risks being re-prioritized in terms of its role in the patient journey towards not only recovery of health, but also sustained health and wellness before disease onset. PMID:25872566

  5. REVIEW ON ADVANCES IN COLON TARGETED DRUG DELIVERY SYSTEM

    Directory of Open Access Journals (Sweden)

    Sunena Sethi, SL Harikumar* and Nirmala

    2012-09-01

    Full Text Available The colon is the terminal part of the GIT which has gained in recent years as a potential site for delivery of various novel therapeutic drugs, i.e. peptides. However, colon is rich in microflora which can be used to target the drug release in the colon. Colon is a site where both local and systemic drug delivery can take place. Local delivery allows the topical treatment of inflammatory bowel disease. If drug can be targeted directly into the colon, treatment can become more effective and side effects can be minimized. These systemic side effects can be minimized by primary approaches for CDDS (Colon specific drug delivery namely prodrugs, pH and time dependent systems and microbially triggered system which gained limited success and have limitations as compared with recently new CDDS namely pressure controlled colon delivery capsules (PCDCS, CODESTM (Novel colon targeted delivery system osmotic controlled drug delivery system, Pulsincap system, time clock system, chronotropic system. This review is to understand the pharmaceutical approaches to colon targeted drug delivery systems for better therapeutic action without compromising on drug degradation (or its low bioavailability.

  6. Albumin-based nanocomposite spheres for advanced drug delivery systems.

    Science.gov (United States)

    Misak, Heath E; Asmatulu, Ramazan; Gopu, Janani S; Man, Ka-Poh; Zacharias, Nora M; Wooley, Paul H; Yang, Shang-You

    2014-01-01

    A novel drug delivery system incorporating human serum albumin, poly(lactic-co-glycolic acid, magnetite nanoparticles, and therapeutic agent(s) was developed for potential application in the treatment of diseases such as rheumatoid arthritis and skin cancer. An oil-in-oil emulsion/solvent evaporation (O/OSE) method was modified to produce a drug delivery system with a diameter of 0.5–2 μm. The diameter was mainly controlled by adjusting the viscosity of albumin in the discontinuous phase of the O/OSE method. The drug-release study showed that the release of drug and albumin was mostly dependent on the albumin content of the drug delivery system, which is very similar to the drug occlusion-mesopore model. Cytotoxicity tests indicated that increasing the albumin content in the drug delivery system increased cell viability, possibly due to the improved biocompatibility of the system. Overall, these studies show that the proposed system could be a viable option as a drug delivery system in the treatment of many illnesses, such as rheumatoid arthritis, and skin and breast cancers. PMID:24106002

  7. Assimilation Patterns in the Use of Advanced Manufacturing Technologies in SMEs: Exploring their Effects on Product Innovation Performance

    OpenAIRE

    Sylvestre Uwizeyemungu; Placide Poba-Nzaou; Josée St-Pierre

    2015-01-01

    Manufacturing small and medium-sized enterprises (SMEs) are more and more adopting advanced manufacturing technologies (AMT) aimed at fostering product innovation process, improving product quality, streamlining the production process, and gaining productivity. In this study, we analyze the relationship between AMT proficiency levels in manufacturing SMEs and product innovation performance. Using data from 616 manufacturing SMEs, and considering a wide range of various AMT (20 different types...

  8. Recent advances in the construction of antibody-drug conjugates

    Science.gov (United States)

    Chudasama, Vijay; Maruani, Antoine; Caddick, Stephen

    2016-02-01

    Antibody-drug conjugates (ADCs) comprise antibodies covalently attached to highly potent drugs using a variety of conjugation technologies. As therapeutics, they combine the exquisite specificity of antibodies, enabling discrimination between healthy and diseased tissue, with the cell-killing ability of cytotoxic drugs. This powerful and exciting class of targeted therapy has shown considerable promise in the treatment of various cancers with two US Food and Drug Administration approved ADCs currently on the market (Adcetris and Kadcyla) and approximately 40 currently undergoing clinical evaluation. However, most of these ADCs exist as heterogeneous mixtures, which can result in a narrow therapeutic window and have major pharmacokinetic implications. In order for ADCs to deliver their full potential, sophisticated site-specific conjugation technologies to connect the drug to the antibody are vital. This Perspective discusses the strategies currently used for the site-specific construction of ADCs and appraises their merits and disadvantages.

  9. INNOVATION

    DEFF Research Database (Denmark)

    Helms, Niels Henrik

    2012-01-01

    Kravet om innovation og kreativitet er på flere måder en stor og en ny udfordring for voksenuddannelserne. Det udfordrer det didaktiske dilemma, det at vi skal gøres til kompetente og frie mennesker gennem pædagogiske handlinger, som netop pålægger os en ufrihed. – Men hvor denne ufrihed tidligere...... kunne begrundes med, at skolen eller uddannelsen vidste bedre, så er det ikke længere tilfældet. Skolen skal sørge for, at vi lærer noget – og ikke noget andet. Men det kan ikke længere med bestemthed afgøres, hvad det er vi skal lære i skolen, fordi det nye, det kreative og ikke mindst innovative...

  10. Diabetes Drug Victoza Might Not Help Advanced Heart Failure Patients

    Science.gov (United States)

    ... liraglutide (Victoza) doesn't appear to improve heart function in patients with advanced heart failure, a new study finds. The theory ... even been slightly harmful in some patients with advanced heart failure, ... function. But, patients using Victoza who develop heart failure ...

  11. Advanced Drug Delivery Systems - a Synthetic and Biological Applied Evaluation

    DEFF Research Database (Denmark)

    Bjerg, Lise Nørkjær

    Specific delivery of drugs to diseased sites in the body is a major topic in the development of drug delivery system today. Especially, the field of cancer treatment needs improved drug delivery systems as the strong dose-limiting side effects of chemotherapy today often present a barrier for an...... unloading of the encapsulated drug have been tried optimized in a variety of ways. Many propose the use of small molecules, such as vitamins and peptides, for active targeting of the liposomes to overexpressed receptors on the cancerous tissue. Once located close to the diseased site a trigger mechanism for...... function as the targeting moiety on the surface of the liposomes. Several examples of synthetic procedures known from the literature are presented. The chapter is completed with a study covering the conjugation efficiencies of a variety of chemical functionalities. Large differences are revealed between...

  12. A Nanodroplet Processor for Advanced Microencapsulated Drug Formulations Project

    Data.gov (United States)

    National Aeronautics and Space Administration — The objective of this proposal is to provide a demonstration of a nanodroplet synthesis of multifunctional liposomes for drug delivery based on immiscible...

  13. SELF EMULSIFYING DRUG DELIVERY SYSTEM: HITHERTO AND RECENT ADVANCES

    OpenAIRE

    Taksande Jayshree B; Trivedi Rashmi V; Mahore Jayashri G; Wadher Kamlesh J; Umekar Milind J.

    2011-01-01

    Oral delivery of poorly water-soluble drugs creates critical problem for their formulation as 35- 40% of new active pharmaceutical ingredients have poor water solubility and frequently associated with low bioavailability. Recently much attention has been given to lipid-based formulation with particular emphasis on self emulsifying drug delivery system (SEDDS) to improve the oral bioavailability. These can exist in either liquid or solid states. Self-emulsifying system formulation mainly depen...

  14. Innovations and advances in computing, informatics, systems sciences, networking and engineering

    CERN Document Server

    Elleithy, Khaled

    2015-01-01

    Innovations and Advances in Computing, Informatics, Systems Sciences, Networking and Engineering  This book includes a set of rigorously reviewed world-class manuscripts addressing and detailing state-of-the-art research projects in the areas of Computer Science, Informatics, and Systems Sciences, and Engineering. It includes selected papers from the conference proceedings of the Eighth and some selected papers of the Ninth International Joint Conferences on Computer, Information, and Systems Sciences, and Engineering (CISSE 2012 & CISSE 2013). Coverage includes topics in: Industrial Electronics, Technology & Automation, Telecommunications and Networking, Systems, Computing Sciences and Software Engineering, Engineering Education, Instructional Technology, Assessment, and E-learning.  ·       Provides the latest in a series of books growing out of the International Joint Conferences on Computer, Information, and Systems Sciences, and Engineering; ·       Includes chapters in the most a...

  15. State of an innovation system: theoretical and empirical advance towards an innovation efficiency index. Or: Walking between ridicule and praise: measuring innovation systems effieciency with a single indicator

    NARCIS (Netherlands)

    Montalvo Corral, C.; Mohammadian Moghayer, S.

    2011-01-01

    Innovation is currently seen as a cornerstone not only for economic development but also as an intrinsic human activity that could help to face the great challenges of human kind. Given the importance of innovation in the new European 2020 Strategy, measuring progress but also monitoring what drives

  16. Insoluble drug delivery strategies: review of recent advances and business prospects.

    Science.gov (United States)

    Kalepu, Sandeep; Nekkanti, Vijaykumar

    2015-09-01

    The emerging trends in the combinatorial chemistry and drug design have led to the development of drug candidates with greater lipophilicity, high molecular weight and poor water solubility. Majority of the failures in new drug development have been attributed to poor water solubility of the drug. Issues associated with poor solubility can lead to low bioavailability resulting in suboptimal drug delivery. About 40% of drugs with market approval and nearly 90% of molecules in the discovery pipeline are poorly water-soluble. With the advent of various insoluble drug delivery technologies, the challenge to formulate poorly water soluble drugs could be achieved. Numerous drugs associated with poor solubility and low bioavailabilities have been formulated into successful drug products. Several marketed drugs were reformulated to improve efficacy, safety and patient compliance. In order to gain marketing exclusivity and patent protection for such products, revitalization of poorly soluble drugs using insoluble drug delivery technologies have been successfully adopted by many pharmaceutical companies. This review covers the recent advances in the field of insoluble drug delivery and business prospects. PMID:26579474

  17. Insoluble drug delivery strategies: review of recent advances and business prospects

    Directory of Open Access Journals (Sweden)

    Sandeep Kalepu

    2015-09-01

    Full Text Available The emerging trends in the combinatorial chemistry and drug design have led to the development of drug candidates with greater lipophilicity, high molecular weight and poor water solubility. Majority of the failures in new drug development have been attributed to poor water solubility of the drug. Issues associated with poor solubility can lead to low bioavailability resulting in suboptimal drug delivery. About 40% of drugs with market approval and nearly 90% of molecules in the discovery pipeline are poorly water-soluble. With the advent of various insoluble drug delivery technologies, the challenge to formulate poorly water soluble drugs could be achieved. Numerous drugs associated with poor solubility and low bioavailabilities have been formulated into successful drug products. Several marketed drugs were reformulated to improve efficacy, safety and patient compliance. In order to gain marketing exclusivity and patent protection for such products, revitalization of poorly soluble drugs using insoluble drug delivery technologies have been successfully adopted by many pharmaceutical companies. This review covers the recent advances in the field of insoluble drug delivery and business prospects.

  18. Fast Dissolving Oral Film: A Novel and Innovative Drug Delivery system

    Directory of Open Access Journals (Sweden)

    Ankita Keshari

    2014-03-01

    Full Text Available The oral route is more suitable than other route of administration of therapeutic agents due to low cost of therapy and ease of administration and of patient compliance. This is noninvasive method and produce less side effect. There are some oral solid dosage forms like capsules and tablets. In geriatric, pediatric and dysphagia like patients find it difficult to swallow capsules and tablets and cannot take their medicines as prescribed manner. In some condition such as, sudden allergic attack, coughing, motion sickness, fear of choking and an unavailability of water, the swallowing of capsules or tablet or may become difficult. To overcome from these types of problem, the pharmaceutical industries are design and develop the new type of drug delivery system such as fast dissolving drug delivery systems. This innovative Oral fast dissolving film is a new dosage form in which a thin film is prepared by using hydrophilic polymers with suitable excipients. The film dissolved quickly in mouth without taking of water. The oral films are prepared by the solvent casting method or hot melt extrusion.

  19. Methodical approaches to the choice of strategies of advancement of innovations on the market

    Directory of Open Access Journals (Sweden)

    O.M. Derikolenko

    2010-06-01

    Full Text Available It is offered to formulate the complex strategy which considers: risk kinds, types of innovations, requirements of the concrete innovation, the degree of novelty of themarket/goods/technology and activity scales on the basis of allocation of strategic advantages of the enterprise-innovator, risks of its innovative projects and market "signals".

  20. Recent Advances In Ndds (Nov el Drug Delivery System For Delivery Of Anti- Hypertensive Drugs

    Directory of Open Access Journals (Sweden)

    Kumar Vikas

    2011-03-01

    Full Text Available Novel drug delivery systems present an opportunity for formulation scientists to overcome the many challenges associated with antihypertensive drug therapy, thereby improving the management of patients with hypertension. Currently available Anti-hypertensive drugs can be classified into these categories: ACE inhibitors, angiotensin antagonist, calcium channel blocker, diuretics, central sympathomimetics, á- adernergic blocker, vasodilator, â-adernergic blocker. Most of these drugs bear some significant drawbacks such as relatively short half-life, low bioavailability, poor permeability and undesirable side effects. Efforts have been made to design drug delivery systems for anti hypertensive drugs to: a reduce the dosing frequency, b increase the bioavailability, c deliver them to the target cells selectively with minimal side effects. This paper provides a comprehensive review of the various anti hypertensive drug delivery systems that have been developed for achieving sustained drug release kinetics, and for addressing formulation difficulties such as poor solubility, stability and drug entrapment. The physicochemical properties and the in vitro/in vivo performances of various system such as such as sustained release tablets, ceramic implants, nanoparticles, nanocontainers, liposomes, emulsomes, aspasomes, microemulsions, nanopowders and PheroidTM are summarised. This review highlights the significant potential that novel drug delivery systems have for the future effective treatment of hypertensive patients on anti-hypertensive drug therapy.

  1. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.

    Science.gov (United States)

    Haggarty, Stephen J; Silva, M Catarina; Cross, Alan; Brandon, Nicholas J; Perlis, Roy H

    2016-06-01

    Compelling clinical, social, and economic reasons exist to innovate in the process of drug discovery for neuropsychiatric disorders. The use of patient-specific, induced pluripotent stem cells (iPSCs) now affords the ability to generate neuronal cell-based models that recapitulate key aspects of human disease. In the context of neuropsychiatric disorders, where access to physiologically active and relevant cell types of the central nervous system for research is extremely limiting, iPSC-derived in vitro culture of human neurons and glial cells is transformative. Potential applications relevant to early stage drug discovery, include support of quantitative biochemistry, functional genomics, proteomics, and perhaps most notably, high-throughput and high-content chemical screening. While many phenotypes in human iPSC-derived culture systems may prove adaptable to screening formats, addressing the question of which in vitro phenotypes are ultimately relevant to disease pathophysiology and therefore more likely to yield effective pharmacological agents that are disease-modifying treatments requires careful consideration. Here, we review recent examples of studies of neuropsychiatric disorders using human stem cell models where cellular phenotypes linked to disease and functional assays have been reported. We also highlight technical advances using genome-editing technologies in iPSCs to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays. Additionally, we evaluate the potential of in vitro stem cell models to investigate early events of disease pathogenesis, in an effort to understand the underlying molecular mechanism, including the basis of selective cell-type vulnerability, and the potential to create new cell-based diagnostics to aid in the classification of patients and subsequent

  2. Advances in polyelectrolyte multilayer nanofilms as tunable drug delivery systems

    Directory of Open Access Journals (Sweden)

    Bingbing Jiang

    2009-08-01

    Full Text Available Bingbing Jiang1, John B Barnett2,3, Bingyun Li1,4,5#1Biomaterials, Bioengineering and Nanotechnology Laboratory, Department of Orthopaedics, School of Medicine, 2Department of Microbiology, Immunology, and Cell Biology, 3Center for Immunopathology and Microbial Pathogenesis, School of Medicine, 5Department of Chemical Engineering, College of Engineering and Mineral Resources, West Virginia University, Morgantown, WV, USA; 4WVNano Initiative, Morgantown, WV, USA; #Aided by a grant from Osteosynthesis and Trauma Care (OTC FoundationAbstract: There has been considerable interest in polyelectrolyte multilayer nanofilms, which have a variety of applications ranging from optical and electrochemical materials to biomedical devices. Polyelectrolyte multilayer nanofilms are constructed from aqueous solutions using electrostatic layer-by-layer self-assembly of oppositely-charged polyelectrolytes on a solid substrate. Multifunctional polyelectrolyte multilayer nanofilms have been studied using charged dyes, metal and inorganic nanoparticles, DNA, proteins, and viruses. In the past few years, there has been increasing attention to developing polyelectrolyte multilayer nanofilms as drug delivery vehicles. In this mini-review, we present recent developments in polyelectrolyte multilayer nanofilms with tunable drug delivery properties, with particular emphasis on the strategies in tuning the loading and release of drugs in polyelectrolyte multilayer nanofilms as well as their applications.Keywords: nanofilm, polyelectrolyte multilayer, drug delivery, electrostatic layer-by-layer self-assembly, biomedical device, surface modification

  3. SOLID LIPID NANOPARTICLES: AN ADVANCED DRUG DELIVERY SYSTEM

    Directory of Open Access Journals (Sweden)

    Raghu Nandan Reddy* and Arshia Shariff

    2013-01-01

    Full Text Available Solid lipid nanoparticles are at the forefront of the rapidly developing field of nanotechnology with several potential applications in drug delivery, research and clinical medicine, as well as in other varied sciences. Solid lipid nanoparticle (SLN dispersions have been proposed as a new type of colloidal drug carrier system suitable for intravenous administration. Solid lipid nanoparticles (SLNs technology represents a promising new approach to lipophilic drug delivery. Solid lipid nanoparticles are spherical lipid particles ranging in size from 1 to 1000 nm and are dispersed in water or in aqueous surfactant solution. It is identical to an oil-in-water emulsion, but the liquid lipid (oil of the emulsion has been replaced by a solid lipid, i.e., yielding Solid Lipid Nanoparticles. SLN are particles made from solid lipid or lipid blends produced by high pressure homogenization. The biodegradable and bioacceptable nature of SLNs makes them less toxic as compared to polymeric nanoparticles. SLNs can also be used to improve the bioavailability of drugs. In this present review this new approach is discussed in terms of their advantages, disadvantages, methods, characterization, pharmacokinetic studies, in-vivo studies, in-vitro studies, and special features

  4. Advanced Recyclable Media System reg-sign. Innovative technology summary report

    International Nuclear Information System (INIS)

    The objective of the Large-Scale Demonstration Project (LSDP) is to select and demonstrate potentially beneficial technologies at the Argonne National Laboratory East's (ANL) Chicago Pile-5 (CP-5) Research Reactor. The purpose of the LSDP is to demonstrate that using innovative and improved deactivation and decommissioning (D and D) technologies from various sources can result in significant benefits, such as decreased cost and increased health and safety, as compared with baseline D and D technologies. This report describes a demonstration of the Advanced Recyclable Media System reg-sign technology which was employed by Surface Technology Systems, Inc. to remove coatings from a concrete floor. This demonstration is part of the CP-5 LSDP sponsored by the US Department of Energy (DOE) Office of Science and Technology Deactivation and Decommissioning Focus Area (DDFA). The Advanced Recyclable Media System reg-sign (ARMS) technology is an open blast technology which uses a soft recyclable media. The patented ARMS Engineered Blast Media consists of a fiber-reinforced polymer matrix which can be manufactured in various grades of abrasiveness. The fiber media can be remade and/or reused up to 20 times and can clean almost any surface (e.g., metal, wood, concrete, lead) and geometry including corners and the inside of air ducts

  5. China's new drug R&D is steadily advancing.

    Science.gov (United States)

    Xu, W F

    2007-08-01

    China appears to consistently lag behind developed countries like the US, Japan, and the nations of Europe in the development of pharmaceuticals, putting China in an embarrassing situation. In fact, China is still dependent on foreign imports for most highly effective cures to major diseases such as cancer, diabetes, hepatitis, and neurodegenerative disease. There is no denying the fact that governmental support, and especially a signifi cant amount of fi nancial support and political assistance to include government restructuring, is needed for the establishment of new drug Research and Development (R&D). Fortunately, China's authorities have recently recognized the importance of new drug development and have committed to implementing strong measures to help establish new drug R&D. This improvement in the government's status is showing immediate and substantial promise in the field of pharmaceuticals. On January 4, 2007, a research group directed by Wang Ming-Wei, Head of the National Center for Drug Screening, Shanghai Institute of Materia Medica (SIMM), made a breakthrough in the development of novel category I anti-diabetes drugs with the support of the Ministry of Science & Technology of China, the National Natural Science Foundation (NSFC) of China, and the Shanghai municipal government. Taking almost four years, the group finally developed a nonpeptide agonist of small molecule glucagon-like peptide 1 receptors with effi cacy in diabetic db/db mice (Proc Natl Acad Sci U S A 2007;104:943-948). As an antidiabetes drug, a peptide hormone traditionally had to be taken as an injection, which greatly limited its clinical application. In contrast, the new compound can be taken orally. This offers hope for the development of a new field of peptidomimetics for orally-available nonpeptide small molecules. Today, the ever-growing prevalence of major diseases worldwide is driving growth in new drug spending, encouraging the marketing of newly developed and effi cacious

  6. Grand Challenges of Advanced Computing for Energy Innovation Report from the Workshop Held July 31-August 2, 2012

    Energy Technology Data Exchange (ETDEWEB)

    Larzelere, Alex R.; Ashby, Steven F.; Christensen, Dana C.; Crawford, Dona L.; Khaleel, Mohammad A.; John, Grosh; Stults, B. Ray; Lee, Steven L.; Hammond, Steven W.; Grover, Benjamin T.; Neely, Rob; Dudney, Lee Ann; Goldstein, Noah C.; Wells, Jack; Peltz, Jim

    2013-03-06

    On July 31-August 2 of 2012, the U.S. Department of Energy (DOE) held a workshop entitled Grand Challenges of Advanced Computing for Energy Innovation. This workshop built on three earlier workshops that clearly identified the potential for the Department and its national laboratories to enable energy innovation. The specific goal of the workshop was to identify the key challenges that the nation must overcome to apply the full benefit of taxpayer-funded advanced computing technologies to U.S. energy innovation in the ways that the country produces, moves, stores, and uses energy. Perhaps more importantly, the workshop also developed a set of recommendations to help the Department overcome those challenges. These recommendations provide an action plan for what the Department can do in the coming years to improve the nation’s energy future.

  7. MRI-detectable polymeric micelles incorporating platinum anticancer drugs enhance survival in an advanced hepatocellular carcinoma model

    Directory of Open Access Journals (Sweden)

    Vinh NQ

    2015-06-01

    Full Text Available Nguyen Quoc Vinh,1 Shigeyuki Naka,1 Horacio Cabral,2 Hiroyuki Murayama,1 Sachiko Kaida,1 Kazunori Kataoka,2 Shigehiro Morikawa,3 Tohru Tani4 1Department of Surgery, Shiga University of Medical Science, Shiga, Japan; 2Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan; 3Department of Nursing, Shiga University of Medical Science, Shiga, Japan; 4Biomedical Innovation Center, Shiga University of Medical Science, Shiga, Japan Abstract: Hepatocellular carcinoma (HCC is one of the most intractable and lethal cancers; most cases are diagnosed at advanced stages with underlying liver dysfunction and are frequently resistant to conventional chemotherapy and radiotherapy. The development of tumor-targeting systems may improve treatment outcomes. Nanomedicine platforms are of particular interest for enhancing chemotherapeutic efficiency, and they include polymeric micelles, which enable targeting of multiple drugs to solid tumors, including imaging and therapeutic agents. This allows concurrent diagnosis, targeting strategy validation, and efficacy assessment. We used polymeric micelles containing the T1-weighted magnetic resonance imaging contrast agent gadolinium-diethylenetriaminpentaacetic acid (Gd-DTPA and the parent complex of the anticancer drug oxaliplatin [(1,2-diaminocyclohexaneplatinum(II (DACHPt] for simultaneous imaging and therapy in an orthotopic rat model of HCC. The Gd-DTPA/DACHPt-loaded micelles were injected into the hepatic artery, and magnetic resonance imaging performance and antitumor activity against HCC, as well as adverse drug reactions were assessed. After a single administration, the micelles achieved strong and specific tumor contrast enhancement, induced high levels of tumor apoptosis, and significantly suppressed tumor size and growth. Moreover, the micelles did not induce severe adverse reactions and significantly improved survival outcomes in comparison to oxaliplatin or

  8. Advances in drug therapy for systemic lupus erythematosus

    Directory of Open Access Journals (Sweden)

    Wallace Daniel J

    2010-11-01

    Full Text Available Abstract Systemic lupus erythematosus (SLE is an autoimmune disorder that afflicts 500,000 people in the United States. There has not been a new SLE drug approved in the United States since 1958. However, a guidance document issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numerous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator, met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents targeting a variety of mechanisms of action are currently in development. This minireview highlights the latest therapies under investigation in SLE and gives an overview of the pathways that are specifically being targeted.

  9. Recent advances in combinatorial biosynthesis for drug discovery

    Directory of Open Access Journals (Sweden)

    Sun H

    2015-02-01

    Full Text Available Huihua Sun,1,* Zihe Liu,1,* Huimin Zhao,1,2 Ee Lui Ang1 1Metabolic Engineering Research Laboratory, Institute of Chemical and Engineering Sciences, Agency for Science, Technology and Research, Singapore; 2Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA *These authors contributed equally to this work Abstract: Because of extraordinary structural diversity and broad biological activities, natural products have played a significant role in drug discovery. These therapeutically important secondary metabolites are assembled and modified by dedicated biosynthetic pathways in their host living organisms. Traditionally, chemists have attempted to synthesize natural product analogs that are important sources of new drugs. However, the extraordinary structural complexity of natural products sometimes makes it challenging for traditional chemical synthesis, which usually involves multiple steps, harsh conditions, toxic organic solvents, and byproduct wastes. In contrast, combinatorial biosynthesis exploits substrate promiscuity and employs engineered enzymes and pathways to produce novel “unnatural” natural products, substantially expanding the structural diversity of natural products with potential pharmaceutical value. Thus, combinatorial biosynthesis provides an environmentally friendly way to produce natural product analogs. Efficient expression of the combinatorial biosynthetic pathway in genetically tractable heterologous hosts can increase the titer of the compound, eventually resulting in less expensive drugs. In this review, we will discuss three major strategies for combinatorial biosynthesis: 1 precursor-directed biosynthesis; 2 enzyme-level modification, which includes swapping of the entire domains, modules and subunits, site-specific mutagenesis, and directed evolution; 3 pathway-level recombination. Recent examples of combinatorial biosynthesis employing these

  10. Advanced Systems Biology Methods in Drug Discovery and Translational Biomedicine

    OpenAIRE

    Jun Zou; Ming-Wu Zheng; Gen Li; Zhi-Guang Su

    2013-01-01

    Systems biology is in an exponential development stage in recent years and has been widely utilized in biomedicine to better understand the molecular basis of human disease and the mechanism of drug action. Here, we discuss the fundamental concept of systems biology and its two computational methods that have been commonly used, that is, network analysis and dynamical modeling. The applications of systems biology in elucidating human disease are highlighted, consisting of human disease networ...

  11. Advances in cancer therapeutics and patient access to new drugs.

    Science.gov (United States)

    Dranitsaris, George; Truter, Ilse; Lubbe, Martie S; Amir, Eitan; Evans, William

    2011-03-01

    Globally, there are approximately 7.4 million cancer deaths annually, approximately 13% of deaths from all causes. Cancer is a disease of older people and, as the population ages over the next 10-20 years, we can expect an increase in the cancer incidence. Encouragingly, cancer mortality has stabilized in many countries. Part of this success may be attributed to the development of new cancer agents, collectively called 'targeted therapies', that are more specific to key components of tumour growth. Worldwide, however, one of the main factors that limit patient access to these important new drugs is their cost, which is higher than traditional chemotherapy. In this review, the clinical and pharmacoeconomic data of selected targeted agents are discussed. In the second part of this article, the challenges faced by healthcare systems in making such drugs available to patients is reviewed. Current strategies used by many countries around the world to manage cancer drug budgets are presented, along with a proposed approach using pharmacoeconomic methodology that may increase patient access. PMID:21184619

  12. Recent Advances from the DoD Multidisciplinary University Research Initiative Consortium on Innovative Vacuum Electronics

    International Nuclear Information System (INIS)

    The MURI Innovative Vacuum Electronics Program is administered by Dr. Robert Barker of the Air Force Office of Scientific Research and consists of a collaboration between six premier universities actively engaged in all aspects of multidisciplinary basic research and graduate instruction in innovative microwave vacuum electronics (MIT, Stanford, University of California, Davis, University of Maryland -- College Park, University of Michigan, and University of Wisconsin). The dual goals are to address basic research issues of critical importance to the DoD as well as to train the next generation. A wide range of fast wave amplifier concepts is under investigation at frequencies ranging from 15 GHz to 1 THz. Two representative examples are a TE01 100 kW W-Band gyro-TWT under investigation at UC Davis and a 140 GHz confocal waveguide based gyro-TWT concept developed at MIT. Novel, lightweight 100 kW, W-Band klystrinos suitable for configuration in arrays are under investigation at Stanford using advanced microfabrication techniques. Extensive analytic and numerical analyses are underway at Wisconsin augmented by experimental measurements using a custom-modified well diagnosed test TWT are aimed at an understanding of the complicated physics of multi-toned ultra-wideband traveling wave tubes including details of the beam-wave interaction and the nonlinear time and space evolution of the carrier(s) and inter-modulation products. A significant emphasis of the Maryland activity is on theoretical and experimental studies of various frequency-multiplying gyroamplifier concepts which are both of fundamental interest as well as practical importance because of the relaxation on driver requirements. Finally, the Michigan team is devoting much of its attention to fundamental theoretical and experimental issues associated with crossed-field devices. The latest results from these as well as other activities will be presented

  13. 76 FR 23543 - The Jobs and Innovation Accelerator Challenge; a Coordinated Initiative To Advance Regional...

    Science.gov (United States)

    2011-04-27

    ... Economic Development Administration The Jobs and Innovation Accelerator Challenge; a Coordinated Initiative... Commerce. ACTION: Notice. SUMMARY: The Obama Administration announces the Jobs and Innovation Accelerator...-fueled job creation and economic prosperity through public-private partnerships. The...

  14. The impact of cardiovascular drug innovation on the longevity of elderly residents of Switzerland, 2003-2012

    Directory of Open Access Journals (Sweden)

    Frank R Lichtenberg

    2015-03-01

    Full Text Available Previous investigators have argued that one of the two most important contributors to improved human survival is the treatment of cardiovascular disease. Among Swiss inhabitants age 65 and over, 90% of the 1994-2010 decline in the overall death rate was due to the decline in the rate of deaths from diseases of the circulatory system. Little if any of the decline in cardiovascular mortality is likely to have been due to changes in behavioral risk factors, especially tobacco use and obesity. This study examines the impact of cardiovascular drug innovation on the longevity of elderly residents of Switzerland using cross-sectional patient-level data on about 22 thousand patients insured by a major health insurer (CSS during the period 2003-2011. We investigate the effect of the vintage (world launch year of the cardiovascular drugs used by an individual in 2003 on his or her longevity (time till death, controlling for several demographic characteristics and indicators of health status. We are able to track a patient’s vital status until 12/31/2011: 8 years after the end of the period in which cardiovascular drug use (and other variables are measured. Our estimates indicate that people who used newer cardiovascular drugs in 2003 had longer time till death than people who used older cardiovascular drugs, controlling for the number of 2003 prescriptions and their distribution by main anatomical group, the number of 2003 doctor visits and their distribution by specialty, whether the person was hospitalized in 2003, sex, and age. Our most conservative estimates imply that cardiovascular drug innovation accounted for almost a quarter of the increase in longevity among elderly residents of Switzerland during 2003-2012, and that it increased their longevity by almost 3 months. Other estimates are about twice as large. All of the estimates are consistent with the hypothesis that newer classes of drugs tend to be therapeutically superior to older classes of

  15. Molecularly targeted therapy for advanced hepatocellularcarcinoma - a drug development crisis?

    Institute of Scientific and Technical Information of China (English)

    2016-01-01

    This review summarizes the current status of neoadjuvantradiation approaches in the treatment of pancreatic cancer,including a description of modern radiation techniques,and an overview on the literature regarding neoadjuvantradio- or radiochemotherapeutic strategies both forresectable and irresectable pancreatic cancer. Neoadjuvantchemoradiation for locally-advanced, primarily non- orborderline resectable pancreas cancer results in secondaryresectability in a substantial proportion of patients withconsecutively markedly improved overall prognosisand should be considered as possible alternative inpretreatment multidisciplinary evaluations. In resectablepancreatic cancer, outstanding results in terms ofresponse, local control and overall survival have beenobserved with neoadjuvant radio- or radiochemotherapy inseveral phase Ⅰ/Ⅱ trials, which justify further evaluationof this strategy. Further investigation of neoadjuvantchemoradiation strategies should be performed preferentiallyin randomized trials in order to improvecomparability of the current results with other treatmentmodalities. This should include the evaluation of optimalsequencing with newer and more potent systemicinduction therapy approaches. Advances in patientselection based on new molecular markers might be ofcrucial interest in this context. Finally modern externalbeam radiation techniques (intensity-modulated radiationtherapy, image-guided radiation therapy and stereotacticbody radiation therapy), new radiation qualities (protons,heavy ions) or combinations with alternative boostingtechniques widen the therapeutic window and contributeto the reduction of toxicity.

  16. Assimilation Patterns in the Use of Advanced Manufacturing Technologies in SMEs: Exploring their Effects on Product Innovation Performance

    Directory of Open Access Journals (Sweden)

    Sylvestre Uwizeyemungu

    2015-10-01

    Full Text Available Manufacturing small and medium-sized enterprises (SMEs are more and more adopting advanced manufacturing technologies (AMT aimed at fostering product innovation process, improving product quality, streamlining the production process, and gaining productivity. In this study, we analyze the relationship between AMT proficiency levels in manufacturing SMEs and product innovation performance. Using data from 616 manufacturing SMEs, and considering a wide range of various AMT (20 different types of AMT grouped into 5 categories, we derived three AMT assimilation patterns through a cluster analysis procedure combining hierarchical and non-hierarchical clustering algorithms. The analysis of the relationship between AMT assimilation patterns and product innovation performance shows a rather unexpected picture: in spite of the existence of clearly distinct patterns of AMT assimilation, we find no significant relationship between any pattern and product innovation performance. Instead, we find the organizational and environmental context of SMEs to be more determinant for product innovation performance than any of the AMT assimilation patterns. From a practical point of view, this study indicates that manufacturing SMEs managers interested in fostering their innovation capabilities through AMT assimilation need to be aware of the contingency effects of their organizational size, age, and sector of activity.

  17. Recent advances in CE-MS: Synergy of wet chemistry and instrumentation innovations.

    Science.gov (United States)

    Pantůčková, Pavla; Gebauer, Petr; Boček, Petr; Křivánková, Ludmila

    2011-01-01

    CE with MS detection is a hyphenated technique which greatly improves the ability of CE to deal with real samples, especially with those coming from biology and medicine, where the target analytes are present as trace amounts in very complex matrices. CE-MS is now almost a routine technique performed on commercially available instruments. It faces currently a tremendous development of the technique itself as well as of its wide application area. Great interest in CE-MS is reflected in the scientific literature by many original research articles and also by numerous reviews. The review presented here has a general scope and belongs to a series of regularly published reviews on the topic. It covers the literature from the last 2 years, since January 2008 till June 2010. It brings a critical selection of related literature sorted into groups reflecting the main topics of actual scientific interest: (i) innovations in CE-ESI-MS, (ii) use of alternative interfaces, and (iii) ways to enhance sensitivity. Special attention is paid to novel electrolyte systems amenable to CE-MS including nonvolatile BGEs, to advanced CE separation principles such as MEKC, MEEKC, chiral CE, and to the use of preconcentration techniques. PMID:21171112

  18. Implications of global pricing policies on access to innovative drugs::the case of trastuzumab in seven Latin American countries

    OpenAIRE

    Pichon-Riviere, A; Garay, O.U.; Augustovski, F.; Vallejos, C.; Huayanay, L.; del Pilar Navia Bueno, M.; Rodriguez, A.; Coelho de Andrade, C.J.; Buendía, J.A.; Drummond, M F

    2015-01-01

    Background: Differential pricing, based on countries’ purchasing power, is recommended by the WHO to secure affordable medicines. However, in developing countries innovative drugs often have similar or even higher prices than in high-income countries. We evaluated the potential implications of trastuzumab global pricing policies in terms of cost-effectiveness (CE), coverage and accessibility for patients with breast cancer in Latin America (LA). Methods: A Markov model was designed to estimat...

  19. Innovative Drugs to Treat Depression: Did Animal Models Fail to Be Predictive or Did Clinical Trials Fail to Detect Effects?

    OpenAIRE

    Belzung, Catherine

    2014-01-01

    Over recent decades, encouraging preclinical evidence using rodent models pointed to innovative pharmacological targets to treat major depressive disorder. However, subsequent clinical trials have failed to show convincing results. Two explanations for these rather disappointing results can be put forward, either animal models of psychiatric disorders have failed to predict the clinical effectiveness of treatments or clinical trials have failed to detect the effects of these new drugs. A care...

  20. Energy, economic, and environmental impacts of advanced industrial process innovations, 1976--1996

    International Nuclear Information System (INIS)

    The mission of the Office of Industrial Technologies (OIT), within the Office of Energy Efficiency and Renewable Energy, is to develop and deploy advanced energy efficiency, renewable energy, and pollution-prevention technologies, through partnerships with industry, government, and non-governmental organizations. OIT's objectives have evolved and broadened over nearly two decades, continually responding to a changing energy situation and shifting national priorities. Today, the key focus of the OIT programs is the Industries of the Future approach. This strategy of close collaboration with industry catalyzes and facilitates technology development and transfer efforts in seven manufacturing industries that together account for over 80% of the energy used and over 80% of the wastes produced by the manufacturing sector. In this approach senior level industry groups develop a future vision of their industry and a technology roadmap to attain the vision. DOE helps facilitate this process and partners with industry to identify and pursue an advanced technology R and D portfolio. The seven industries are aluminum, chemicals, forest products, glass, metalcasting, petroleum refining, and steel. In managing all its activities, OIT draws upon program support provided primarily by national Laboratories, universities, and private-sector research organizations throughout the country that have the diverse and specialized expertise needed to develop advanced industrial technologies. Approximately 78 industrial technologies developed with Office of Industrial Technology (OIT) support have successfully entered commercial markets. These technologies have saved a cumulative total of almost 900 trillion Btu, representing a new production cost savings of over $1.8 billion. These dollar savings represent the net total value of all energy saved by technologies developed with OIT support minus the net cost to industry of using the technologies (including capital costs, operating and

  1. Advanced drug delivery systems of curcumin for cancer chemoprevention.

    Science.gov (United States)

    Bansal, Shyam S; Goel, Mehak; Aqil, Farrukh; Vadhanam, Manicka V; Gupta, Ramesh C

    2011-08-01

    Since ancient times, chemopreventive agents have been used to treat/prevent several diseases including cancer. They are found to elicit a spectrum of potent responses including anti-inflammatory, antioxidant, antiproliferative, anticarcinogenic, and antiangiogenic activity in various cell cultures and some animal studies. Research over the past 4 decades has shown that chemopreventives affect a number of proteins involved in various molecular pathways that regulate inflammatory and carcinogenic responses in a cell. Various enzymes, transcription factors, receptors, and adhesion proteins are also affected by chemopreventives. Although, these natural compounds have shown significant efficacy in cell culture studies, they elicited limited efficacy in various clinical studies. Their introduction into the clinical setting is hindered largely by their poor solubility, rapid metabolism, or a combination of both, ultimately resulting in poor bioavailability upon oral administration. Therefore, to circumvent these limitations and to ease their transition to clinics, alternate strategies should be explored. Drug delivery systems such as nanoparticles, liposomes, microemulsions, and polymeric implantable devices are emerging as one of the viable alternatives that have been shown to deliver therapeutic concentrations of various potent chemopreventives such as curcumin, ellagic acid, green tea polyphenols, and resveratrol into the systemic circulation. In this review article, we have attempted to provide a comprehensive outlook for these delivery approaches, using curcumin as a model agent, and discussed future strategies to enable the introduction of these highly potent chemopreventives into a physician's armamentarium. PMID:21546540

  2. Recent Advances in the Discovery of Haem-Targeting Drugs for Malaria and Schistosomiasis

    Directory of Open Access Journals (Sweden)

    Katherine A. de Villiers

    2009-08-01

    Full Text Available Haem is believed to be the target of some of the historically most important antimalarial drugs, most notably chloroquine. This target is almost ideal as haem is host-derived and the process targeted, haemozoin formation, is a physico-chemical process with no equivalent in the host. The result is that the target remains viable despite resistance to current drugs, which arises from mutations in parasite membrane transport proteins. Recent advances in high-throughput screening methods, together with a better understanding of the interaction of existing drugs with this target, have created new prospects for discovering novel haem-targeting chemotypes and for target-based structural design of new drugs. Finally, the discovery that Schistosoma mansoni also produces haemozoin suggests that new drugs of this type may be chemotherapeutic not only for malaria, but also for schistosomiasis. These recent developments in the literature are reviewed.

  3. Conceptual study on a new generation of the high-innovative advanced porous and composite nanostructural functional materials with nanofibers

    OpenAIRE

    L.A. Dobrzański; M. Pawlyta; A. Hudecki

    2011-01-01

    Purpose: The purpose of the paper is to analyse theoretically the possibilities of the development of a new generation of the high-innovative advanced porous and composite nanostructural functional materials with nanofibers and to study into the material science grounds of synthesis and/or production and formulation of such materials’ structure and properties and to characterise and model their structure and properties depending on the compositional, phase and chemical composition and the app...

  4. State of the art: diagnostic tools and innovative therapies for treatment of advanced thymoma and thymic carcinoma.

    Science.gov (United States)

    Ried, Michael; Marx, Alexander; Götz, Andrea; Hamer, Okka; Schalke, Berthold; Hofmann, Hans-Stefan

    2016-06-01

    In this review article, state-of-the-art diagnostic tools and innovative treatments of thymoma and thymic carcinoma (TC) are described with special respect to advanced tumour stages. Complete surgical resection (R0) remains the standard therapeutic approach for almost all a priori resectable mediastinal tumours as defined by preoperative standard computed tomography (CT). If lymphoma or germ-cell tumours are differential diagnostic considerations, biopsy may be indicated. Resection status is the most important prognostic factor in thymoma and TC, followed by tumour stage. Advanced (Masaoka-Koga stage III and IVa) tumours require interdisciplinary therapy decisions based on distinctive findings of preoperative CT scan and ancillary investigations [magnetic resonance imaging (MRI)] to select cases for primary surgery or neoadjuvant strategies with optional secondary resection. In neoadjuvant settings, octreotide scans and histological evaluation of pretherapeutic needle biopsies may help to choose between somatostatin agonist/prednisolone regimens and neoadjuvant chemotherapy as first-line treatment. Finally, a multimodality treatment regime is recommended for advanced and unresectable thymic tumours. In conclusion, advanced stage thymoma and TC should preferably be treated in experienced centres in order to provide all modern diagnostic tools (imaging, histology) and innovative therapy techniques. Systemic and local (hyperthermic intrathoracic chemotherapy) medical treatments together with extended surgical resections have increased the therapeutic options in patients with advanced or recurrent thymoma and TC. PMID:26670806

  5. Innovative Approaches to Development and Ground Testing of Advanced Bimodal Space Power and Propulsion Systems

    International Nuclear Information System (INIS)

    The last major development effort for nuclear power and propulsion systems ended in 1993. Currently, there is not an initiative at either the National Aeronautical and Space Administration (NASA) or the U.S. Department of Energy (DOE) that requires the development of new nuclear power and propulsion systems. Studies continue to show nuclear technology as a strong technical candidate to lead the way toward human exploration of adjacent planets or provide power for deep space missions, particularly a 15,000 lbf bimodal nuclear system with 115 kW power capability. The development of nuclear technology for space applications would require technology development in some areas and a major flight qualification program. The last major ground test facility considered for nuclear propulsion qualification was the U.S. Air Force/DOE Space Nuclear Thermal Propulsion Project. Seven years have passed since that effort, and the questions remain the same, how to qualify nuclear power and propulsion systems for future space flight. It can be reasonably assumed that much of the nuclear testing required to qualify a nuclear system for space application will be performed at DOE facilities as demonstrated by the Nuclear Rocket Engine Reactor Experiment (NERVA) and Space Nuclear Thermal Propulsion (SNTP) programs. The nuclear infrastructure to support testing in this country is aging and getting smaller, though facilities still exist to support many of the technology development needs. By renewing efforts, an innovative approach to qualifying these systems through the use of existing facilities either in the U.S. (DOE's Advance Test Reactor, High Flux Irradiation Facility and the Contained Test Facility) or overseas should be possible

  6. Coordination conjugates of therapeutic proteins with drug carriers: A new approach for versatile advanced drug delivery

    Czech Academy of Sciences Publication Activity Database

    Kejík, Z.; Bříza, T.; Králová, Jarmila; Poučková, P.; Kral, A.; Martásek, P.; Král, V.

    2011-01-01

    Roč. 21, č. 18 (2011), s. 5514-5520. ISSN 0960-894X R&D Projects: GA ČR GA203/09/1311 Grant ostatní: MPO(CZ) FR-TI3/521; AV ČR(CZ) KAN200100801 Institutional research plan: CEZ:AV0Z50520514 Keywords : combined cancer therapy * photodynamic therapy * targeted drug delivery Subject RIV: EB - Genetics ; Molecular Biology Impact factor: 2.554, year: 2011

  7. Recent Advances in Neurogenic Small Molecules as Innovative Treatments for Neurodegenerative Diseases.

    Science.gov (United States)

    Herrera-Arozamena, Clara; Martí-Marí, Olaia; Estrada, Martín; de la Fuente Revenga, Mario; Rodríguez-Franco, María Isabel

    2016-01-01

    The central nervous system of adult mammals has long been considered as a complex static structure unable to undergo any regenerative process to refurbish its dead nodes. This dogma was challenged by Altman in the 1960s and neuron self-renewal has been demonstrated ever since in many species, including humans. Aging, neurodegenerative, and some mental diseases are associated with an exponential decrease in brain neurogenesis. Therefore, the controlled pharmacological stimulation of the endogenous neural stem cells (NSCs) niches might counteract the neuronal loss in Alzheimer's disease (AD) and other pathologies, opening an exciting new therapeutic avenue. In the last years, druggable molecular targets and signalling pathways involved in neurogenic processes have been identified, and as a consequence, different drug types have been developed and tested in neuronal plasticity. This review focuses on recent advances in neurogenic agents acting at serotonin and/or melatonin systems, Wnt/β-catenin pathway, sigma receptors, nicotinamide phosphoribosyltransferase (NAMPT) and nuclear erythroid 2-related factor (Nrf2). PMID:27598108

  8. Innovation surveys

    OpenAIRE

    Tomlinson, Mark

    2010-01-01

    An earlier version of this paper was prepared for the joint OECD/Eurostat workshop on innovation surveys, OECD, Paris, June 30th 1999. The paper addresses some issues about the nature of innovation surveys (particularly the new Community Innovation Surveys) and how they might be improved to take on board several crucial developments in contemporary advanced economies. In particular the following topics are discussed: the increased distribution of innovative activity across firm...

  9. An Innovative Unmanned System for Advanced Environmental Monitoring: Design and Development

    Science.gov (United States)

    Marsella, Ennio; Giordano, Laura; Evangelista, Lorenza; Iengo, Antonio; di Filippo, Alessandro; Coppola, Aniello

    2015-04-01

    The paper summarizes the design and development of a new technology and tools for real-time coordination and control of unmanned vehicles for advanced environmental monitoring. A new Unmanned System has been developed at Institute for Coastal Marine Environmental - National Research Council (Italy), in the framework of two National Operational Programs (PON): Technological Platform for Geophysical and Environmental Marine Survey-PITAM and Integrated Systems and Technologies for Geophysical and Environmental Monitoring in coastal-marine areas-STIGEAC. In particular, the system includes one Unmanned Aerial Vehicle (UAV) and two Unmanned Marine Vehicles (UMV). Major innovations concern the implementation of a new architecture to control each drone and/or to allow the cooperation between heterogeneous vehicles, the integration of distributed sensing techniques and real-time image processing capabilities. Part of the research in these projects involves, therefore, an architecture, where the ground operator can communicate with the Unmanned Vehicles at various levels of abstraction using pointing devices and video viewing. In detail, a Ground Control Station (GCS) has been design and developed to allow the government in security of the drones within a distance up to twenty kilometers for air explorations and within ten nautical miles for marine activities. The Ground Control Station has the following features: 1. hardware / software system for the definition of the mission profiles; 3. autonomous and semi-autonomous control system by remote control (joystick or other) for the UAV and UMVs; 4. integrated control system with comprehensive visualization capabilities, monitoring and archiving of real-time data acquired from scientific payload; 5. open structure to future additions of systems, sensors and / or additional vehicles. In detail, the UAV architecture is a dual-rotor, with an endurance ranging from 55 to 200 minutes, depending on payload weight (maximum 26 kg) and

  10. An Innovative Unmanned System for Advanced Environmental Monitoring: Design and Development

    Science.gov (United States)

    Marsella, Ennio; Giordano, Laura; Evangelista, Lorenza; Iengo, Antonio; di Filippo, Alessandro; Coppola, Aniello

    2015-04-01

    The paper summarizes the design and development of a new technology and tools for real-time coordination and control of unmanned vehicles for advanced environmental monitoring. A new Unmanned System has been developed at Institute for Coastal Marine Environmental - National Research Council (Italy), in the framework of two National Operational Programs (PON): Technological Platform for Geophysical and Environmental Marine Survey-PITAM and Integrated Systems and Technologies for Geophysical and Environmental Monitoring in coastal-marine areas-STIGEAC. In particular, the system includes one Unmanned Aerial Vehicle (UAV) and two Unmanned Marine Vehicles (UMV). Major innovations concern the implementation of a new architecture to control each drone and/or to allow the cooperation between heterogeneous vehicles, the integration of distributed sensing techniques and real-time image processing capabilities. Part of the research in these projects involves, therefore, an architecture, where the ground operator can communicate with the Unmanned Vehicles at various levels of abstraction using pointing devices and video viewing. In detail, a Ground Control Station (GCS) has been design and developed to allow the government in security of the drones within a distance up to twenty kilometers for air explorations and within ten nautical miles for marine activities. The Ground Control Station has the following features: 1. hardware / software system for the definition of the mission profiles; 3. autonomous and semi-autonomous control system by remote control (joystick or other) for the UAV and UMVs; 4. integrated control system with comprehensive visualization capabilities, monitoring and archiving of real-time data acquired from scientific payload; 5. open structure to future additions of systems, sensors and / or additional vehicles. In detail, the UAV architecture is a dual-rotor, with an endurance ranging from 55 to 200 minutes, depending on payload weight (maximum 26 kg) and

  11. Design and evaluation of an innovative floating and bioadhesive multiparticulate drug delivery system based on hollow structure.

    Science.gov (United States)

    Zhang, Chungang; Tang, Jingya; Liu, Dechun; Li, Xuetao; Cheng, Lan; Tang, Xing

    2016-04-30

    In this study a gastric-retentive delivery system was prepared by a novel method which is reported here for the first time. An innovative floating and bioadhesive drug delivery system with a hollow structure was designed and prepared. The floating and bioadhesive drug delivery system was composed of a hollow spherical shell, a waterproof layer (Stearic acid), a drug layer (Ofloxacin), a release retarding film (the novel blended coating materials) and a bioadhesive layer (Carbomer 934P) prepared by using a liquid multi-layering process. A novel blended coating material was designed and investigated to solve the problem of the initial burst release of the formulation and the release mechanism of the novel material was analyzed in this study. The optimized formulation provided the sustained release characteristic and was able to float for 24h. The SEM cross-section images showed that the particulates were hollow with a spherical shell. X-ray images and pharmacokinetic studies (Frel=124.1±28.9%) in vivo showed that the gastric-retentive delivery system can be retained in the stomach for more than 6h. The floating and bioadhesive particulate drug delivery system based on a hollow structure with a dual function presented here is a viable alternative to other for gastroretentive drug delivery system. PMID:26943975

  12. Boceprevir in combination with HIV protease inhibitors in patients with advanced fibrosis-altered drug-drug interactions?

    Directory of Open Access Journals (Sweden)

    C Schwarze-Zander

    2012-11-01

    Full Text Available In HIV/HCV co-infected patients improved treatment outcomes have been reported for the HCV protease inhibitors (PIs boceprevir (BOC and telaprevir (TVR, reaching SVR rates of up to 70% in pilot trials. Due to complex drug-drug-interactions triple therapy is substantially limited in HIV/HCV-coinfected individuals. Co-administration of BOC with the commonly available HIV PIs has been reported not only to decrease the level of BOC but also to lead to relevant decreases in the respective HIV PI. Here, we report on two patients who received BOC-containing HCV triple therapy in combination with a HIV PI. Patient 1 was on darunavir 800 mg/ritonavir 100 mg once-daily mono-therapy. Using FibroScan a liver stiffness of 34 kPa suggested liver cirrhosis prior to start of HCV triple therapy. At week 5 of HCV triple therapy darunavir trough concentration was measured in the reference range with 3777 ng/ml (reference trough concentration 2400–4600 ng/ml. HCV-RNA became negative at week 10 and HIV-RNA was below detection limit (<40 copies/ml at all times. Patient 2 was on a simplified FTC qd and fos-amprenavir 700 mg/ritonavir 100 mg bid regimen. Liver disease had also progressed to liver cirrhosis, confirmed in FibroScan, with a liver stiffness of 32 kPa. At week 8 of HCV triple therapy fos-amprenavir trough level was measured in the normal reference range with 1699 ng/ml (reference trough concentration 750–2500 ng/ml. At week 11 HCV-RNA was <12 IU/ml and HIV viral load was below detection limit of <40 copies/ml at all times. Our clinical data suggest that in patients with advanced liver disease possibly drug levels of HIV PIs which are coadministered with BOC may be within the normal range. In order to better understand the true amount of drug interactions between BOC and commonly used HIV PIs in HIV/HCV-coinfected patients with more advanced liver fibrosis, urgently more PK studies are required to make HCV triple therapy accessible for a wider number of

  13. Recent patents and advances on anti - tuberculosis drug delivery and formulations.

    Science.gov (United States)

    Vora, Chintan; Patadia, Riddhish; Mittal, Karan; Mashru, Rajashree

    2013-08-01

    Tuberculosis has remained, unambiguously, a significant health care problem since long times, particularly in developing countries. The endeavoring battle against multi drug resistant TB, multiple dosing, their prominent side effects and bioavailability hiccups related to fixed dose combinations has undeniably become a Herculean task indicating rigorous research requirement in anti TB drug therapy. In view of the fact that patenting a drug molecule, a drug delivery system or a formulation has been very fruitful for the growth and sustainment of pharmaceutical industry, a meticulous review of recent developments, providing a balanced view on merits/demerits, will facilitate researchers to update themselves, thereby focusing their research in more relevant areas to furnish desired quality traits. This article reviews the present scenario in terms of drug delivery approaches for TB chemotherapy. The review encompasses and summarizes recent patents and advances on variegated facets of dosage forms, together with from conventional solid oral to novel controlled release oral formulations and additionally alternative weapons for anti TB drug delivery. A critical review of multidisciplinary approaches to boost anti TB therapy may facilitate the scientists to resolve existing technological gaps. PMID:23244680

  14. Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells

    Directory of Open Access Journals (Sweden)

    Mohammed Kawser Hossain

    2016-02-01

    Full Text Available Diabetes mellitus (DM is a widespread metabolic disease with a progressive incidence of morbidity and mortality worldwide. Despite extensive research, treatment options for diabetic patients remains limited. Although significant challenges remain, induced pluripotent stem cells (iPSCs have the capacity to differentiate into any cell type, including insulin-secreting pancreatic β cells, highlighting its potential as a treatment option for DM. Several iPSC lines have recently been derived from both diabetic and healthy donors. Using different reprogramming techniques, iPSCs were differentiated into insulin-secreting pancreatic βcells. Furthermore, diabetes patient-derived iPSCs (DiPSCs are increasingly being used as a platform to perform cell-based drug screening in order to develop DiPSC-based cell therapies against DM. Toxicity and teratogenicity assays based on iPSC-derived cells can also provide additional information on safety before advancing drugs to clinical trials. In this review, we summarize recent advances in the development of techniques for differentiation of iPSCs or DiPSCs into insulin-secreting pancreatic β cells, their applications in drug screening, and their role in complementing and replacing animal testing in clinical use. Advances in iPSC technologies will provide new knowledge needed to develop patient-specific iPSC-based diabetic therapies.

  15. Rare Disease Drug Policy and Inheritance and Innovation of Traditional Chinese Medicine

    OpenAIRE

    Baxian Yi; Guangping Wang; Xiaoming Wu

    2014-01-01

    Traditional Chinese medicine is an important component of the health care system in Chinese medical treatment and public health. Rare disease drugs in difficult miscellaneous diseases in traditional Chinese medicine have similar characteristics with the rare disease drugs (orphan drugs) in European and American countries, which both are characterized by individualized medical treatment. The two are different in the development thought. Treatment of difficult miscellaneous diseases in the trad...

  16. Why animal studies are still being used in drug development. An innovation system perspective

    OpenAIRE

    Kooijman, M.

    2013-01-01

    In Europe alone, 3.6 million animals per year are used for drug development. Animal studies are worldwide the gold standard to evaluate the safety, efficacy and quality of drugs before these drugs are tested in humans. Nevertheless the value of animal studies to predict risks for humans has never been extensively established. Nowadays, several studies indicate that the value of animal studies is often limited. Pharmaceutical companies and regulatory authorities as well as the public and gover...

  17. Recent advances in lymphatic targeted drug delivery system for tumor metastasis

    International Nuclear Information System (INIS)

    The lymphatic system has an important defensive role in the human body. The metastasis of most tumors initially spreads through the surrounding lymphatic tissue and eventually forms lymphatic metastatic tumors; the tumor cells may even transfer to other organs to form other types of tumors. Clinically, lymphatic metastatic tumors develop rapidly. Given the limitations of surgical resection and the low effectiveness of radiotherapy and chemotherapy, the treatment of lymphatic metastatic tumors remains a great challenge. Lymph node metastasis may lead to the further spread of tumors and may be predictive of the endpoint event. Under these circumstances, novel and effective lymphatic targeted drug delivery systems have been explored to improve the specificity of anticancer drugs to tumor cells in lymph nodes. In this review, we summarize the principles of lymphatic targeted drug delivery and discuss recent advances in the development of lymphatic targeted carriers

  18. Advances in the integration of drug metabolism into the lead optimization paradigm.

    Science.gov (United States)

    Korfmacher, Walter A

    2009-06-01

    The lead optimization paradigm includes a team of experts that has a multitude of parameters to consider when moving from an initial lead compound through the lead optimization phase to the development phase. While in the past the team may have had only a medicinal chemist and a pharmacologist, the current team would often include experts in the areas of drug metabolism and pharmacokinetics (DMPK) as well as chemical toxicity. This review provides an overview of the some of the recent advances in the areas of DMPK screening plus a discussion of some of the assays that can be used to begin to screen for toxicity issues. The focus of this review is the major potential problem areas: oral bioavailability, half-life, drug-drug interactions and metabolism and toxicity issues. PMID:19519496

  19. Next-Generation Entrepreneurs Ready to Advance Breast Cancer Research Innovations | Poster

    Science.gov (United States)

    By Michele Newton and Thomas Stackhouse, Contributing Writers, and Rosemarie Truman, Guest Writer Editor’s note: In May 2014, the Breast Cancer Start-Up Challenge was named one of six finalists in the HHS Innovates Award Competition. This award celebrates innovations developed by employees of the U.S. Department of Health and Human Services (HHS) to support the mission of HHS. In the final phase of the competition, the public will be invited to help select “The People’s Choice” winner; public voting takes place May 29 through June 6, 2014.

  20. Diffusion of innovations in social interaction systems. An agent-based model for the introduction of new drugs in markets.

    Science.gov (United States)

    Pombo-Romero, Julio; Varela, Luis M; Ricoy, Carlos J

    2013-06-01

    The existence of imitative behavior among consumers is a well-known phenomenon in the field of Economics. This behavior is especially common in markets determined by a high degree of innovation, asymmetric information and/or price-inelastic demand, features that exist in the pharmaceutical market. This paper presents evidence of the existence of imitative behavior among primary care physicians in Galicia (Spain) when choosing treatments for their patients. From this and other evidence, we propose a dynamic model for determining the entry of new drugs into the market. To do this, we introduce the structure of the organization of primary health care centers and the presence of groups of doctors who are specially interrelated, as well as the existence of commercial pressure on doctors. For modeling purposes, physicians are treated as spins connected in an exponentially distributed complex network of the Watts-Strogatz type. The proposed model provides an explanation for the differences observed in the patterns of the introduction of technological innovations in different regions. The main cause of these differences is the different structure of relationships among consumers, where the existence of small groups that show a higher degree of coordination over the average is particularly influential. The evidence presented, together with the proposed model, might be useful for the design of optimal strategies for the introduction of new drugs, as well as for planning policies to manage pharmaceutical expenditure. PMID:22487887

  1. Conference Scene: From innovative polymers to advanced nanomedicine: Key challenges, recent progress and future perspectives

    NARCIS (Netherlands)

    Feijen, J.; Hennink, W.E.; Zhong, Z.

    2013-01-01

    Recent developments in polymer-based controlled delivery systems have made a significant clinical impact. The second Symposium on Innovative Polymers for Controlled Delivery (SIPCD) was held in Suzhou, China to address the key challenges and provide up-to-date progress and future perspectives in the

  2. Careers in Drug and Alcohol Research: AN Innovative Program for Young Appalachian Women

    Science.gov (United States)

    Noland, Melody Powers; Leukefeld, Carl; Reid, Caroline

    Supported by a grant from the National Institute on Drug Abuse, the University of Kentucky's Center on Drug and Alcohol Research developed the Young Women in Science Program to encourage young women from Appalachia to pursue scientific careers гп drug and alcohol research. This 3-year program, which involved 26 young women entering the ninth grade in 13 counties in southeastern Kentucky, included a summer residential program, community educational sessions, and matching students with mentors. When participants' scores prior to and after the 3-week residential program were compared, it was found that participants increased their science knowledge and improved their scores on confidence in science. Other significant changes occurred as well. These preliminary data indicated that some positive changes resulted from the program, even though contact time with the young women has been modest to date. The program shows considerable promise for providing the encouragement and skills needed for these young women to pursue careers in drug and alcohol research.

  3. The industrial research project: “Blu-Archeosys – Innovative Technologies and Advanced Systems as Support in Underwater Archaeology”

    Directory of Open Access Journals (Sweden)

    Salvatore Lorusso

    2003-02-01

    Full Text Available The reasons of the research about new technologies as support in naval and underwater archaeology or, more generally, in waters archaeology are various and described in this work, where the characteristics of the research project “BLU-ARCHEOSYS – Innovative Technologies and Advanced SYStems as Support in Underwater ARCHaeology” are illustrated. This industrial research project faces problems regarding innovative technologies and instruments in waters archaeology and it comprehends synergic steps and joined works among skilled professionals that have the competences to interpret qualitative and/or quantitative data within an artistic – historical and technical – historical study, also with the involvement of various public and private institutions. The BLUARCHEOSYS project has, in fact, the objective to create technologies that have a reply in underwater archaeology and contemporaneously in other sectors. In particular, starting from the methodological way that spans from the discovery in underwater or subaerial environment to the collocation of the objects in museums, the intent is to support the different methodological stages with specific tools and innovative technologies. The education project, presented to the Ministry with the research one, is articulated in the different branches of artistic-historical character, of the management, normative and operative character, and of the technical-diagnostic-material-preservative character. The professionals will have not only theoretical knowledge about standard and consolidated technologies, but they will be also experts about methodologies, in particular the diagnostic ones, that put in field the innovative tools evaluated in the project, with consequent competitive advantage in the working field, more and more demanding specific sector competences.

  4. Potential for Layered Double Hydroxides-Based, Innovative Drug Delivery Systems

    OpenAIRE

    Zhang, Kai; Xu, Zhi Ping; Lu, Ji; Tang, Zhi Yong; Zhao, Hui Jun; Good, David A.; Wei, Ming Qian

    2014-01-01

    Layered Double Hydroxides (LDHs)-based drug delivery systems have, for many years, shown great promises for the delivery of chemical therapeutics and bioactive molecules to mammalian cells in vitro and in vivo. This system offers high efficiency and drug loading density, as well as excellent protection of loaded molecules from undesired degradation. Toxicological studies have also found LDHs to be biocompatible compared with other widely used nanoparticles, such as iron oxide, silica, and sin...

  5. Conceptual study on a new generation of the high-innovative advanced porous and composite nanostructural functional materials with nanofibers

    Directory of Open Access Journals (Sweden)

    L.A. Dobrzański

    2011-12-01

    Full Text Available Purpose: The purpose of the paper is to analyse theoretically the possibilities of the development of a new generation of the high-innovative advanced porous and composite nanostructural functional materials with nanofibers and to study into the material science grounds of synthesis and/or production and formulation of such materials’ structure and properties and to characterise and model their structure and properties depending on the compositional, phase and chemical composition and the applied synthesis and/or production and/or processing processes, without the attitude towards any direct practical application or use, but with confirming the highly probable future application areas, using the unexpected effects of formulating such materials’ functional properties.Design/methodology/approach: In general, the study is of priority cognitive importance as theoretical considerations and the author’s initial analyses related to technology foresight concerning this group of issues as well as sporadical results of research provided in the literature, usually in its incipient phase, indicating a great need to intensify scientific research, to develop the new groups of materials with quite unexpected predictable effects, resulting from the use of nanofibers for fabricating super advanced composite and porous materials.Findings: The description of the state of the art for the subject of the study has been limited to the issues initially selected with an analysis with the method of weighted scores.Practical implications: The outcoming materials may have direct influence on the development of electronics and photonics, medicine and pharmacy, environmental protection, automotive industry, space industry, machine industry, textile and clothing industry, cosmetic industry, agriculture and food sector.Originality/value: The value of this paper lies in the fact that it proposes a new generation of the high-innovative advanced porous and composite

  6. Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury.

    Science.gov (United States)

    Kim, Seung Hyun; Naisbitt, Dean J

    2016-01-01

    Drug-induced liver injury (DILI) is a major concern for public health, as well as for drug development in the pharmaceutical industry, since it can cause liver failure and lead to drug withdrawal from the market and black box warnings. Thus, it is important to identify biomarkers for early prediction to increase our understanding of mechanisms underlying DILI that will ultimately aid in the exploration of novel therapeutic strategies to prevent or manage DILI. DILI can be subdivided into 'intrinsic' and 'idiosyncratic' categories, although the validity of this classification remains controversial. Idiosyncratic DILI occurs in a minority of susceptible individuals with a prolonged latency, while intrinsic DILI results from drug-induced direct hepatotoxicity over the course of a few days. The rare occurrence of idiosyncratic DILI requires multicenter collaborative investigations and phenotype standardization. Recent progress in research on idiosyncratic DILI is based on key developments in 3 areas: (1) newly developed high-throughput genotyping across the whole genome allowing for the identification of genetic susceptibility markers, (2) new mechanistic concepts on the pathogenesis of DILI revealing a key role of drug-responsive T lymphocytes in the immunological response, and (3) broad multidisciplinary approaches using different platform "-omics" technologies that have identified novel biomarkers for the prediction of DILI. An association of a specific human leukocyte antigen (HLA) allele with DILI has been reported for several drugs. HLA-restricted T-cell immune responses have also been investigated using lymphocytes and T-cell clones isolated from patients. A microRNA, miR-122, has been discovered as a promising biomarker for the early prediction of DILI. In this review, we summarize recent advances in research on idiosyncratic DILI with an understanding of the key role of adaptive immune systems. PMID:26540496

  7. Potential for Layered Double Hydroxides-Based, Innovative Drug Delivery Systems

    Directory of Open Access Journals (Sweden)

    Kai Zhang

    2014-04-01

    Full Text Available Layered Double Hydroxides (LDHs-based drug delivery systems have, for many years, shown great promises for the delivery of chemical therapeutics and bioactive molecules to mammalian cells in vitro and in vivo. This system offers high efficiency and drug loading density, as well as excellent protection of loaded molecules from undesired degradation. Toxicological studies have also found LDHs to be biocompatible compared with other widely used nanoparticles, such as iron oxide, silica, and single-walled carbon nanotubes. A plethora of bio-molecules have been reported to either attach to the surface of or intercalate into LDH materials through co-precipitation or anion-exchange reaction, including amino acid and peptides, ATPs, vitamins, and even polysaccharides. Recently, LDHs have been used for gene delivery of small molecular nucleic acids, such as antisense, oligonucleotides, PCR fragments, siRNA molecules or sheared genomic DNA. These nano-medicines have been applied to target cells or organs in gene therapeutic approaches. This review summarizes current progress of the development of LDHs nanoparticle drug carriers for nucleotides, anti-inflammatory, anti-cancer drugs and recent LDH application in medical research. Ground breaking studies will be highlighted and an outlook of the possible future progress proposed. It is hoped that the layered inorganic material will open up new frontier of research, leading to new nano-drugs in clinical applications.

  8. Advanced Condenser Boosts Geothermal Power Plant Output (Fact Sheet), The Spectrum of Clean Energy Innovation

    Energy Technology Data Exchange (ETDEWEB)

    2010-12-01

    When power production at The Geysers geothermal power complex began to falter, the National Renewable Energy Laboratory (NREL) stepped in, developing advanced condensing technology that dramatically boosted production efficiency - and making a major contribution to the effective use of geothermal power. NREL developed advanced direct-contact condenser (ADCC) technology to condense spent steam more effectively, improving power production efficiency in Unit 11 by 5%.

  9. Innovative Asia: Advancing the Knowledge-Based Economy: The Next Policy Agenda

    OpenAIRE

    Asian Development Bank

    2014-01-01

    This study outlines policy actions required in developing countries of Asia to advance as knowledge-based economies. The study uses the four pillars of the Knowledge Economy Index to benchmark the performance of developing economies in Asia against advanced economies of the world. It analyzes opportunities by which Asia’s middle and low income countries can tap new technology trends to move up global value chains and towards high-income levels.

  10. Advances in pulmonary therapy and drug development: Lung tissue engineering to lung-on-a-chip.

    Science.gov (United States)

    Doryab, Ali; Amoabediny, Ghassem; Salehi-Najafabadi, Amir

    2016-01-01

    Lung disease is one of the major causes of death, and the rate of pulmonary diseases has been increasing for decades. Although lung transplantation is the only treatment for majority of patients, this method has been limited due to lack of donors. Therefore, recently, attentions have increased to some new strategies with the aid of tissue engineering and microfluidics techniques not only for the functional analysis, but also for drug screening. In fact, in tissue engineering, the engineered tissue is able to grow by using the patient's own cells without intervention in the immune system. On the other hand, microfluidics devices are applied in order to evaluate drug screenings, function analysis and toxicity. This article reviews new advances in lung tissue engineering and lung-on-a-chip. Furthermore, future directions, difficulties and drawbacks of pulmonary therapy in these areas are discussed. PMID:26875777

  11. AN UPDATED REVIEW ON TECHNICAL ADVANCES TO ENHANCE DISSOLUTION RATE OF HYDROPHOBIC DRUGS

    Directory of Open Access Journals (Sweden)

    Anjan K. Mahapatra

    2012-10-01

    Full Text Available The dissolution behavior of drugs continues to be one of the challenging aspects in formulation development. The advent of combinatorial chemistry and high throughput screening increased the number of hydrophobic compounds significantly. The Biopharmaceutical classification scheme (BCS takes into account three major factors: solubility, intestinal permeability, and dissolution rate and all the three govern the rate and extent of oral absorption and hence bioavailability. Especially for BCS Class II substances the bioavailability of a poorly soluble drug may be enhanced by increasing the solubility and dissolution rate of it in the gastro-intestinal fluids. Drug substances whose highest dose is soluble in less than 250 ml of water over a range of pH from 1.0 to 7.5 are considered as highly soluble. In contrast, the drug compounds with solubility below 1mg mL-1 face significant dissolution or bioavailability problems. With the introduction of advanced technologies it could be possible to overcome the problems. The article provides an overview on the theoretical definitions and technical approaches broadly covering technologies and hydrophilic carriers or excipients used. Further part of the manuscript is committed to the formulation, analytical methods for the characterization of samples, dissolution or release kinetics and model fittings.

  12. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.

    Science.gov (United States)

    Zhan, Peng; Pannecouque, Christophe; De Clercq, Erik; Liu, Xinyong

    2016-04-14

    The early effectiveness of combinatorial antiretroviral therapy (cART) in the treatment of HIV infection has been compromised to some extent by rapid development of multidrug-resistant HIV strains, poor bioavailability, and cumulative toxicities, and so there is a need for alternative strategies of antiretroviral drug discovery and additional therapeutic agents with novel action modes or targets. From this perspective, we first review current strategies of antiretroviral drug discovery and optimization, with the aid of selected examples from the recent literature. We highlight the development of phosphate ester-based prodrugs as a means to improve the aqueous solubility of HIV inhibitors, and the introduction of the substrate envelope hypothesis as a new approach for overcoming HIV drug resistance. Finally, we discuss future directions for research, including opportunities for exploitation of novel antiretroviral targets, and the strategy of activation of latent HIV reservoirs as a means to eradicate the virus. PMID:26509831

  13. A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.

    Science.gov (United States)

    Stern, Andrew M; Schurdak, Mark E; Bahar, Ivet; Berg, Jeremy M; Taylor, D Lansing

    2016-07-01

    Drug candidates exhibiting well-defined pharmacokinetic and pharmacodynamic profiles that are otherwise safe often fail to demonstrate proof-of-concept in phase II and III trials. Innovation in drug discovery and development has been identified as a critical need for improving the efficiency of drug discovery, especially through collaborations between academia, government agencies, and industry. To address the innovation challenge, we describe a comprehensive, unbiased, integrated, and iterative quantitative systems pharmacology (QSP)-driven drug discovery and development strategy and platform that we have implemented at the University of Pittsburgh Drug Discovery Institute. Intrinsic to QSP is its integrated use of multiscale experimental and computational methods to identify mechanisms of disease progression and to test predicted therapeutic strategies likely to achieve clinical validation for appropriate subpopulations of patients. The QSP platform can address biological heterogeneity and anticipate the evolution of resistance mechanisms, which are major challenges for drug development. The implementation of this platform is dedicated to gaining an understanding of mechanism(s) of disease progression to enable the identification of novel therapeutic strategies as well as repurposing drugs. The QSP platform will help promote the paradigm shift from reactive population-based medicine to proactive personalized medicine by focusing on the patient as the starting and the end point. PMID:26962875

  14. The Trial of Drug Discovery using the In-Silico Screening Methods Developed by Pharmaceutical Innovation Value Chain

    Science.gov (United States)

    Inoue, Tsuyoshi; Matsumura, Hiroyoshi; Adachi, Hiroaki; Mori, Yusuke; Takano, Kazufumi; Murakami, Satoshi; Fukunishi, Yoshifumi; Nakamura, Haruki; Kinoshita, Takayoshi; Nakanishi, Isao; Okuno, Yasushi; Minakata, Satoshi; Mikami, Yoshiaki; Sakuma, Toshihiro; Kitajima, Masato; Fukuoka, Yoshitada; Takada, Toshikazu; Sakata, Tsuneaki

    We have recently established Pharmaceutical Innovation Value Chain collaborated by The SOSHO project (http://www.so-sho.jp) and The BioGrid Project (http://www.biogrid.jp/) to accelerate new drug development. The in-silico group calculated the matrices on the interaction between the proteins and chemical compounds, and developed the novel in-silico screening methods, Multiple Target Screening (MTS) and Docking score index (DSI), improving the hit rate of screening a lead compound. We have applied these methods for the two target enzymes; human hematopoietic prostaglandin D synthase (H-PGDS) and orotidine 5’-monophosphate decarboxylase from human malaria parasite plasmodium falciparum (PfOMPDC). The optimizing of HQL-79, one of the known inhibitors for human H-PGDS and the screening of lead compounds for both enzymes are in study.

  15. Implementation of in vitro replacement technologies in regulatory drug testing - An innovation systems perspective

    NARCIS (Netherlands)

    Kooijman, M.; Van Meer, P.J.K.; Moors, E.H.M.; Hekkert, M.P.; Schellekens, H.

    2011-01-01

    The replacement of in vivo methods by in vitro methods in regulatory drug testing is rare. The aim of this research is to identify barriers and drivers of the replacement of in vivo methods by in vitro methods in Europe. We studied two cases. The first case is the Draize eye test. Since 2009, the in

  16. Advancing Innovation Through Collaboration: Implementation of the NASA Space Life Sciences Strategy

    Science.gov (United States)

    Davis, Jeffrey R.; Richard, Elizabeth E.

    2010-01-01

    On October 18, 2010, the NASA Human Health and Performance center (NHHPC) was opened to enable collaboration among government, academic and industry members. Membership rapidly grew to 90 members (http://nhhpc.nasa.gov ) and members began identifying collaborative projects as detailed in this article. In addition, a first workshop in open collaboration and innovation was conducted on January 19, 2011 by the NHHPC resulting in additional challenges and projects for further development. This first workshop was a result of the SLSD successes in running open innovation challenges over the past two years. In 2008, the NASA Johnson Space Center, Space Life Sciences Directorate (SLSD) began pilot projects in open innovation (crowd sourcing) to determine if these new internet-based platforms could indeed find solutions to difficult technical problems. From 2008 to 2010, the SLSD issued 34 challenges, 14 externally and 20 internally. The 14 external challenges were conducted through three different vendors: InnoCentive, Yet2.com and TopCoder. The 20 internal challenges were conducted using the InnoCentive platform, customized to NASA use, and promoted as NASA@Work. The results from the 34 challenges involved not only technical solutions that were reported previously at the 61st IAC, but also the formation of new collaborative relationships. For example, the TopCoder pilot was expanded by the NASA Space Operations Mission Directorate to the NASA Tournament Lab in collaboration with Harvard Business School and TopCoder. Building on these initial successes, the NHHPC workshop in January of 2011, and ongoing NHHPC member discussions, several important collaborations have been developed: (1) Space Act Agreement between NASA and GE for collaborative projects (2) NASA and academia for a Visual Impairment / Intracranial Hypertension summit (February 2011) (3) NASA and the DoD through the Defense Venture Catalyst Initiative (DeVenCI) for a technical needs workshop (June 2011) (4

  17. International Reactor Innovative and Secure (IRIS International Consortium) [Passive Safety Systems in Advanced Small Modular Reactors

    International Nuclear Information System (INIS)

    IRIS is an integral, modular PWR design with a rated power of 335 MW(e). IRIS has been primarily focused on achieving design with innovative safety characteristics. The first line of defence in IRIS is to eliminate event initiators that could potentially lead to core damage. In IRIS, this concept is implemented through the 'safety-by-design' ™ IRIS philosophy, which can be simply described as ‘design the plant in such a way as to eliminate accidents from occurring, rather than coping with their consequences

  18. Innovative experimental particle physics through technological advances: Past, present and future

    Energy Technology Data Exchange (ETDEWEB)

    Cheung, Harry W.K.; /Fermilab

    2005-01-01

    This mini-course gives an introduction to the techniques used in experimental particle physics with an emphasis on the impact of technological advances. The basic detector types and particle accelerator facilities will be briefly covered with examples of their use and with comparisons. The mini-course ends with what can be expected in the near future from current technology advances. The mini-course is intended for graduate students and post-docs and as an introduction to experimental techniques for theorists.

  19. Sudden death related to advanced coronary atherosclerosis in mini-pigs. Influence of some drugs

    Energy Technology Data Exchange (ETDEWEB)

    Jacobsson, L.; Lundholm, L.; Wingren, G. (Department of Pharmacology, Linkoeping University, Linkoeping, Sweden)

    1984-01-01

    Advanced coronary atherosclerosis was produced in 30 mini-pigs by a combination of a hypercholesterolaemic diet and X-irradiation to the precordial region. Within 11-25 weeks after the irradiation, 13 of the 30 animals died a sudden death probably caused by coronary atherosclerosis. The contents of free and ester-bound cholesterol in the right coronary artery were significantly higher in the animals which died spontaneously than in surviving animals. In an untreated group of 12 animals 7 died whereas in a group treated with ..beta..-pyridylcarbinol only 1 out of 5 died. In the coronary arteries, the contents of both free and ester-bound cholesterol were significantly lower in the ..beta..-pyridylcarbinol-treated animals. In a sulfinpyrazontreated group 3 out of 8, and in a metoprolol-treated group 2 out of 5 animals died. None of these drugs reduced the accumulation of cholesterol in the coronary arteries. The rate of sudden death was 26 +- 6% (P<0.05) lower in the combined group of treated animals than in the untreated ones. By regular ECG recordings, signs which could predict the fatal outcome of the experiment were looked for. Although depressed ST segments were present before death in a few animals, this was not a regular phenomenon. It is concluded that advanced coronary atherosclerosis in mini-pigs often leads to sudden death and that this animal model seems suitable for testing the potential therapeutic effects of drugs.

  20. Innovation, Employment and Skills in Advanced and Developing Countries: A Survey of the Literature

    OpenAIRE

    Vivarelli, Marco

    2011-01-01

    This paper critically discusses the theoretical and empirical literature on the quantitative and qualitative employment impact of technological change, compares the relative explanatory power of the competing theories, and explains in detail the macro and micro evidence on the issue, with reference both to the advanced economies and the developing countries (DCs).

  1. The effect of comparative effectiveness research on drug development innovation: a 360° value appraisal

    OpenAIRE

    Doyle JJ

    2011-01-01

    John J DoyleQuintiles, NY, USAAbstract: The drug development process is in dire need of transformation. Even after achieving regulatory approval, pharmaceutical companies are increasingly seeing their products subjected to health technology assessments (HTAs) by public and private payers. The cornerstone of HTA value appraisal, and thus reimbursability, is comparative effectiveness research (CER), a ‘real-world’ comparison of a new product with the existing standard of car...

  2. Fabrication and characterization of anisotropic nanofiber scaffolds for advanced drug delivery systems

    Directory of Open Access Journals (Sweden)

    Jalani G

    2014-05-01

    Full Text Available Ghulam Jalani,* Chan Woo Jung,* Jae Sang Lee, Dong Woo Lim Department of Bionano Engineering, College of Engineering Sciences, Hanyang University, Education Research Industry Cluster at Ansan Campus, Ansan, South Korea*These authors contributed equally to this workAbstract: Stimuli-responsive, polymer-based nanostructures with anisotropic compartments are of great interest as advanced materials because they are capable of switching their shape via environmentally-triggered conformational changes, while maintaining discrete compartments. In this study, a new class of stimuli-responsive, anisotropic nanofiber scaffolds with physically and chemically distinct compartments was prepared via electrohydrodynamic cojetting with side-by-side needle geometry. These nanofibers have a thermally responsive, physically-crosslinked compartment, and a chemically-crosslinked compartment at the nanoscale. The thermally responsive compartment is composed of physically crosslinkable poly(N-isopropylacrylamide poly(NIPAM copolymers, and poly(NIPAM-co-stearyl acrylate poly(NIPAM-co-SA, while the thermally-unresponsive compartment is composed of polyethylene glycol dimethacrylates. The two distinct compartments were physically crosslinked by the hydrophobic interaction of the stearyl chains of poly(NIPAM-co-SA or chemically stabilized via ultraviolet irradiation, and were swollen in physiologically relevant buffers due to their hydrophilic polymer networks. Bicompartmental nanofibers with the physically-crosslinked network of the poly(NIPAM-co-SA compartment showed a thermally-triggered shape change due to thermally-induced aggregation of poly(NIPAM-co-SA. Furthermore, when bovine serum albumin and dexamethasone phosphate were separately loaded into each compartment, the bicompartmental nanofibers with anisotropic actuation exhibited decoupled, controlled release profiles of both drugs in response to a temperature. A new class of multicompartmental nanofibers could be

  3. Impact of recent innovations in the use of mass cytometry in support of drug development

    OpenAIRE

    Nassar, Ala F.; Ogura, Hideki; Wisnewski, Adam V

    2015-01-01

    Cytometry by time-of-flight (CyTOF) is a novel technology for the real-time analysis of single cells. CyTOF is a significant advance in fields including immunology, hematology, and oncology. It resolves multiple metal-conjugated probes per cell with minimal signal overlap, which maximizes the information obtained from each individual sample. CyTOF provides the ability to phenotypically and functionally profile cells from normal and diseased states. Single cell technologies enable researchers ...

  4. Music Therapy Advances in Neuro-disability - Innovations in Research and Practice

    DEFF Research Database (Denmark)

    O'Kelly, Julian; Magee, Wendy L.; Street, Alex;

    2014-01-01

    This article provides a summary of the oral papers presented during a two day international conference, which took place on 7th & 8th June 2013, at the Royal Hospital for Neuro-disability (RHN) in London. The summary texts detail innovative research projects and clinical developments across music...... therapy, music neuroscience and music psychology addressing the needs of those with acquired and degenerative neurological conditions. The diverse and evolving work in this field is reflected in the topics covered, including disorders of consciousness, dementia, stroke, and the use of modern neuro......-imaging methods to measure the effects of music therapy at a cortical level. A discussion of the implications of these converging foci highlights the benefits of the cross-disciplinary dialogue that characterised the conference....

  5. Innovative Bimolecular-Based Advanced Logic Operations: A Prime Discriminator and An Odd Parity Checker.

    Science.gov (United States)

    Zhou, Chunyang; Liu, Dali; Dong, Shaojun

    2016-08-17

    Herein, a novel logic operation of prime discriminator is first performed for the function of identifying the prime numbers from natural numbers less than 10. The prime discriminator logic operation is developed by DNA hybridizations and the conjugation of graphene oxide and single-stranded DNA as a reacting platform. On the basis of the similar reaction principle, an odd parity checker is also developed. The odd parity checker logic operation can identify the even numbers and odd numbers from natural numbers less than 10. Such advanced logic operations with digital recognition ability can provide a new field of vision toward prototypical DNA-based logic operations and promote the development of advanced logic circuits. PMID:27459592

  6. Unlocking the potential of process innovation : A conceptual framework for the exploitation of advanced manufacturing technologies

    OpenAIRE

    Schrettle, Stefan

    2010-01-01

    This paper aims at providing a holistic understanding of the determinants that influence the realization of benefits of new manufacturing technologies. Based on findings from operations management and strategic decision-making literature, we propose a framework that explicitly distinguishes between the phase of decision-making and the phase of implementation of advanced manufacturing technologies. Based on a broad literature review, contingency factors are presented and related to each phase ...

  7. Forensic Bioinformatics: An innovative technological advancement in the field of Forensic Medicine and Diagnosis

    OpenAIRE

    Kumar Ajay; Singh Neetu; Gaurav S.S

    2012-01-01

    Background: The role of Bioinformatics in this modern age of technology advancement can not be over-emphasized. Aim: This study reviews the principle, techniques, and applications of Forensic Bioinformatics. Methods and Materials: Literature searches were done to identify relevant studies. Results: The concepts of sequence annotation and whole genome sequencing were possible due to the assimilation of software based tools which are exclusively responsible for the segregation of bulk genomic d...

  8. Mass cytometry: a highly multiplexed single-cell technology for advancing drug development.

    Science.gov (United States)

    Atkuri, Kondala R; Stevens, Jeffrey C; Neubert, Hendrik

    2015-02-01

    Advanced single-cell analysis technologies (e.g., mass cytometry) that help in multiplexing cellular measurements in limited-volume primary samples are critical in bridging discovery efforts to successful drug approval. Mass cytometry is the state-of-the-art technology in multiparametric single-cell analysis. Mass cytometers (also known as cytometry by time-of-flight or CyTOF) combine the cellular analysis principles of traditional fluorescence-based flow cytometry with the selectivity and quantitative power of inductively coupled plasma-mass spectrometry. Standard flow cytometry is limited in the number of parameters that can be measured owing to the overlap in signal when detecting fluorescently labeled antibodies. Mass cytometry uses antibodies tagged to stable isotopes of rare earth metals, which requires minimal signal compensation between the different metal tags. This unique feature enables researchers to seamlessly multiplex up to 40 independent measurements on single cells. In this overview we first present an overview of mass cytometry and compare it with traditional flow cytometry. We then discuss the emerging and potential applications of CyTOF technology in the pharmaceutical industry, including quantitative and qualitative deep profiling of immune cells and their applications in assessing drug immunogenicity, extensive mapping of signaling networks in single cells, cell surface receptor quantification and multiplexed internalization kinetics, multiplexing sample analysis by barcoding, and establishing cell ontologies on the basis of phenotype and/or function. We end with a discussion of the anticipated impact of this technology on drug development lifecycle with special emphasis on the utility of mass cytometry in deciphering a drug's pharmacokinetics and pharmacodynamics relationship. PMID:25349123

  9. An Innovative Cell Microincubator for Drug Discovery Based on 3D Silicon Structures

    Directory of Open Access Journals (Sweden)

    Francesca Aredia

    2016-01-01

    Full Text Available We recently employed three-dimensional (3D silicon microstructures (SMSs consisting in arrays of 3 μm-thick silicon walls separated by 50 μm-deep, 5 μm-wide gaps, as microincubators for monitoring the biomechanical properties of tumor cells. They were here applied to investigate the in vitro behavior of HT1080 human fibrosarcoma cells driven to apoptosis by the chemotherapeutic drug Bleomycin. Our results, obtained by fluorescence microscopy, demonstrated that HT1080 cells exhibited a great ability to colonize the narrow gaps. Remarkably, HT1080 cells grown on 3D-SMS, when treated with the DNA damaging agent Bleomycin under conditions leading to apoptosis, tended to shrink, reducing their volume and mimicking the normal behavior of apoptotic cells, and were prone to leave the gaps. Finally, we performed label-free detection of cells adherent to the vertical silicon wall, inside the gap of 3D-SMS, by exploiting optical low coherence reflectometry using infrared, low power radiation. This kind of approach may become a new tool for increasing automation in the drug discovery area. Our results open new perspectives in view of future applications of the 3D-SMS as the core element of a lab-on-a-chip suitable for screening the effect of new molecules potentially able to kill tumor cells.

  10. Earth remote sensing as an effective tool for the development of advanced innovative educational technologies

    Science.gov (United States)

    Mayorova, Vera; Mayorov, Kirill

    2009-11-01

    Current educational system is facing a contradiction between the fundamentality of engineering education and the necessity of applied learning extension, which requires new methods of training to combine both academic and practical knowledge in balance. As a result there are a number of innovations being developed and implemented into the process of education aimed at optimizing the quality of the entire educational system. Among a wide range of innovative educational technologies there is an especially important subset of educational technologies which involve learning through hands-on scientific and technical projects. The purpose of this paper is to describe the implementation of educational technologies based on small satellites development as well as the usage of Earth remote sensing data acquired from these satellites. The increase in public attention to the education through Earth remote sensing is based on the concern that although there is a great progress in the development of new methods of Earth imagery and remote sensing data acquisition there is still a big question remaining open on practical applications of this kind of data. It is important to develop the new way of thinking for the new generation of people so they understand that they are the masters of their own planet and they are responsible for its state. They should desire and should be able to use a powerful set of tools based on modern and perspective Earth remote sensing. For example NASA sponsors "Classroom of the Future" project. The Universities Space Research Association in United States provides a mechanism through which US universities can cooperate effectively with one another, with the government, and with other organizations to further space science and technology, and to promote education in these areas. It also aims at understanding the Earth as a system and promoting the role of humankind in the destiny of their own planet. The Association has founded a Journal of Earth System

  11. Advanced Artificial Science. The development of an artificial science and engineering research infrastructure to facilitate innovative computational modeling, analysis, and application to interdisciplinary areas of scientific investigation.

    Energy Technology Data Exchange (ETDEWEB)

    Saffer, Shelley (Sam) I.

    2014-12-01

    This is a final report of the DOE award DE-SC0001132, Advanced Artificial Science. The development of an artificial science and engineering research infrastructure to facilitate innovative computational modeling, analysis, and application to interdisciplinary areas of scientific investigation. This document describes the achievements of the goals, and resulting research made possible by this award.

  12. Innovative Graduate Research Education for Advancement of Implementation Science in Adolescent Behavioral Health.

    Science.gov (United States)

    Burton, Donna L; Levin, Bruce Lubotsky; Massey, Tom; Baldwin, Julie; Williamson, Heather

    2016-04-01

    An innovative approach to research education that integrates the theory and principles of implementation science, participatory research, and service learning in the area of adolescent behavioral health is presented. Qualitative interviews and surveys of program participants have been conducted to assess the program's curricula, service-learning partnerships, student (scholar) satisfaction, and views of community partnerships and academic mentors. The Institute has experienced the successful completion of its first and second cohorts and enrollment of a third cohort of scholars. Community partners are utilizing results of service-learning projects to influence agency operations. Institute scholars have identified research and service learning experiences as key factors in the decision to apply to the Institute graduate certificate program. The availability of tuition support is identified as valuable but not ranked as the most important reason for scholar interest in the program. Academic mentors report positive relationships with community agencies. Future iterations of the program will expand options for distance learning and alternatives to traditional graduate education for community-based scholars. Community partner agency capacity for participation is expected to change over time. Methods are being identified to both sustain existing partnerships and develop new community partnership relationships. PMID:26746638

  13. [Advanced nitrogen removal using innovative denitrification biofilter with sustained-release carbon source material].

    Science.gov (United States)

    Tang, Lei; Li, Peng; Zuo, Jian-e; Yuan, Lin; Li, Zai-xing

    2013-09-01

    An innovative denitrification biofilter was developed with polycaprolactone (PCL) as the carbon source and biofilm carrier. The performance of nitrogen removal was investigated with biologically treated effluent from secondary clarifier, and the results indicated that a maximum TN removal efficiency of 98.9% was achieved under the following conditions: influent total nitrogen (TN) concentration 30.0 mg x L(-1), denitrification load 54.0 mg (L x h)(-1), operating temperature 20. 1-22.0 degrees C, hydraulic retention time 0. 5 h; the total organic carbon (TOC) in effluent was 6.5-8.4 mg x L(-1), which was increased by 2.0-3.0 mg x L(-1) compared with that in the influent; the suspended solids (SS) concentration was less than 4.0 mg x L(-1) during operation; nearly 84.2% of the total released organic carbon which was used as electron donor in the denitrification process, was derived in the presence of microbes. The surface of the PCL pellets was observed by scanning electron microscope (SEM), it was shown that thick biofilm was formed on the surface of pellets, and the main microbial species were Bacillus and Trichobacteria. PMID:24289000

  14. Advanced core physics and thermal hydraulics analysis of boiling water reactors using innovative fuel concepts

    International Nuclear Information System (INIS)

    The economical operation of a boiling water reactor (BWR) is mainly achieved by the axially uniform utilization of the nuclear fuel in the assemblies which is challenging because the neutron spectrum in the active reactor core varies with the axial position. More precisely, the neutron spectrum becomes harder the higher the position is resulting in a decrease of the fuel utilization because the microscopic fission cross section is smaller by several orders of magnitude. In this work, the use of two fuel concepts based on a mixed oxide (MOX) fuel and an innovative thorium-plutonium (ThPu) fuel is investigated by a developed simulation model encompassing thermal hydraulics, neutronics, and fuel burnup. The main feature of these fuel concepts is the axially varying enrichment in plutonium which is, in this work, recycled from spent nuclear fuel and shows a high fission fraction of the absorption cross section for fast incident neutron energies. The potential of balancing the overall fuel utilization by an increase of the fission rate in the upper part of the active height with a combination of the harder spectrum and the higher fission fraction of the absorption cross section in the BWR core is studied. The three particular calculational models for thermal hydraulics, neutronics, and fuel burnup provide results at fuel assembly and/or at core level. In the former case, the main focus lies on the thermal hydraulics analysis, fuel burnup, and activity evolution after unloading from the core and, in the latter case, special attention is paid to reactivity safety coefficients (feedback effects) and the optimization of the operational behavior. At both levels (assembly and core), the isotopic buildup and depletion rates as a function of the active height are analyzed. In addition, a comparison between the use of conventional fuel types with homogeneous enrichments and the use of the innovative fuel types is made. In the framework of the simulations, the ThPu and the MOX

  15. Advances in the application of technology to epilepsy: the CIMIT/NIO Epilepsy Innovation Summit.

    Science.gov (United States)

    Schachter, Steven C; Guttag, John; Schiff, Steven J; Schomer, Donald L

    2009-09-01

    In 2008, a group of clinicians, scientists, engineers, and industry representatives met to discuss advances in the application of engineering technologies to the diagnosis and treatment of patients with epilepsy. The presentations also provided a guide for further technological development, specifically in the evaluation of patients for epilepsy surgery, seizure onset detection and seizure prediction, intracranial treatment systems, and extracranial treatment systems. This article summarizes the discussions and demonstrates that cross-disciplinary interactions can catalyze collaborations between physicians and engineers to address and solve many of the pressing unmet needs in epilepsy. PMID:19780225

  16. WE-D-BRD-01: Innovation in Radiation Therapy Delivery: Advanced Digital Linac Features

    International Nuclear Information System (INIS)

    Last few years has witnessed significant advances in linac technology and therapeutic dose delivery method. Digital linacs equipped with high dose rate FFF beams have been clinically implemented in a number of hospitals. Gated VMAT is becoming increasingly popular in treating tumors affected by respiratory motion. This session is devoted to update the audience with these technical advances and to present our experience in clinically implementing the new linacs and dose delivery methods. Topics to be covered include, technical features of new generation of linacs from different vendors, dosimetric characteristics and clinical need for FFF-beam based IMRT and VMAT, respiration-gated VMAT, the concept and implementation of station parameter optimized radiation therapy (SPORT), beam level imaging and onboard image guidance tools. Emphasis will be on providing fundamental understanding of the new treatment delivery and image guidance strategies, control systems, and the associated dosimetric characteristics. Commissioning and acceptance experience on these new treatment delivery technologies will be reported. Clinical experience and challenges encountered during the process of implementation of the new treatment techniques and future applications of the systems will also be highlighted. Learning Objectives: Present background knowledge of emerging digital linacs and summarize their key geometric and dosimetric features. SPORT as an emerging radiation therapy modality specifically designed to take advantage of digital linacs. Discuss issues related to the acceptance and commissioning of the digital linacs and FFF beams. Describe clinical utility of the new generation of digital linacs and their future applications

  17. WE-D-BRD-01: Innovation in Radiation Therapy Delivery: Advanced Digital Linac Features

    Energy Technology Data Exchange (ETDEWEB)

    Xing, L [Stanford University, Stanford, CA (United States); Wong, J [Johns Hopkins University, Baltimore, MD (United States); Li, R [Stanford University, Palo Alto, CA (United States)

    2014-06-15

    Last few years has witnessed significant advances in linac technology and therapeutic dose delivery method. Digital linacs equipped with high dose rate FFF beams have been clinically implemented in a number of hospitals. Gated VMAT is becoming increasingly popular in treating tumors affected by respiratory motion. This session is devoted to update the audience with these technical advances and to present our experience in clinically implementing the new linacs and dose delivery methods. Topics to be covered include, technical features of new generation of linacs from different vendors, dosimetric characteristics and clinical need for FFF-beam based IMRT and VMAT, respiration-gated VMAT, the concept and implementation of station parameter optimized radiation therapy (SPORT), beam level imaging and onboard image guidance tools. Emphasis will be on providing fundamental understanding of the new treatment delivery and image guidance strategies, control systems, and the associated dosimetric characteristics. Commissioning and acceptance experience on these new treatment delivery technologies will be reported. Clinical experience and challenges encountered during the process of implementation of the new treatment techniques and future applications of the systems will also be highlighted. Learning Objectives: Present background knowledge of emerging digital linacs and summarize their key geometric and dosimetric features. SPORT as an emerging radiation therapy modality specifically designed to take advantage of digital linacs. Discuss issues related to the acceptance and commissioning of the digital linacs and FFF beams. Describe clinical utility of the new generation of digital linacs and their future applications.

  18. Energy systems. Tome 3: advanced cycles, low environmental impact innovative systems

    International Nuclear Information System (INIS)

    This third tome about energy systems completes the two previous ones by showing up advanced thermodynamical cycles, in particular having a low environmental impact, and by dealing with two other questions linked with the study of systems with a changing regime operation: - the time management of energy, with the use of thermal and pneumatic storage systems and time simulation (schedule for instance) of systems (solar energy type in particular); - the technological dimensioning and non-nominal regime operation studies. Because this last topic is particularly complex, new functionalities have been implemented mainly by using the external classes mechanism, which allows the user to freely personalize his models. This tome is illustrated with about 50 examples of cycles modelled with Thermoptim software. Content: foreword; 1 - generic external classes; 2 - advanced gas turbine cycles; 3 - evaporation-concentration, mechanical steam compression, desalination, hot gas drying; 4 - cryogenic cycles; 5 - electrochemical converters; 6 - global warming, CO2 capture and sequestration; 7 - future nuclear reactors (coupled to Hirn and Brayton cycles); 8 - thermodynamic solar cycles; 10 - pneumatic and thermal storage; 11 - calculation of thermodynamic solar facilities; 12 - problem of technological dimensioning and non-nominal regime; 13 - exchangers modeling and parameterizing for the dimensioning and the non-nominal regime; 14 - modeling and parameterizing of volumetric compressors; 15 - modeling and parameterizing of turbo-compressors and turbines; 16 - identification methodology of component parameters; 17 - case studies. (J.S.)

  19. 新药创制的现状与对策%Challenges and strategies of drug innovation

    Institute of Scientific and Technical Information of China (English)

    郭宗儒; 赵红宇

    2013-01-01

    Drug research involves scientific discovery,technological inventions and product development.This multiple dimensional effort embodies both high risk and high reward and is considered one of the most complicated human activities.Prior to the initiation of a program,an in-depth analysis of "what to do" and "how to do it" must be conducted.On the macro level,market prospects,capital required,risk assessment,necessary human resources,etc.need to be evaluated critically.For execution,drug candidates need to be optimized in multiple properties such as potency,selectivity,pharmacokinetics,safety,formulation,etc.,all with the constraint of finite amount of time and resources,to maximize the probability of success in clinical development.Drug discovery is enormously complicated,both in terms of technological innovation and organizing capital and other resources.A deep understanding of the complexity of drug research and our competitive edge is critical for success.Our unique government-enterprise-academia system represents a distinct advantage.As a new player,we have not heavily invested in any particular discovery paradigm,which allows us to select the optimal approach with little organizational burden.Virtue R&D model using CROs has gained momentum lately and China is a global leader in CRO market.Essentially all technological support for drug discovery can be found in China,which greatly enables domestic R&D efforts.The information technology revolution ensures the globalization of drug discovery knowledge,which has bridged much of the gap between China and the developed countries.The blockbuster model and the target-centric drug discovery paradigm have overlooked the research in several important fields such as injectable drugs,orphan drugs,and following high quality therapeutic leads,etc.Prejudice against covalent ligands,prodrugs,nondrug-like ligands can also be taken advantage of to find novel medicines.This article will discuss the current challenges and future

  20. Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs

    Directory of Open Access Journals (Sweden)

    Marilisa Molinaro

    2015-01-01

    Full Text Available Along with the improvement of survival after cancer, cardiotoxicity due to antineoplastic treatments has emerged as a clinically relevant problem. Potential cardiovascular toxicities due to anticancer agents include QT prolongation and arrhythmias, myocardial ischemia and infarction, hypertension and/or thromboembolism, left ventricular (LV dysfunction, and heart failure (HF. The latter is variable in severity, may be reversible or irreversible, and can occur soon after or as a delayed consequence of anticancer treatments. In the last decade recent advances have emerged in clinical and pathophysiological aspects of LV dysfunction induced by the most widely used anticancer drugs. In particular, early, sensitive markers of cardiac dysfunction that can predict this form of cardiomyopathy before ejection fraction (EF is reduced are becoming increasingly important, along with novel therapeutic and cardioprotective strategies, in the attempt of protecting cardiooncologic patients from the development of congestive heart failure.

  1. A review on the advance of experimental assay methods and models in drug screening   %药物筛选模型研究进展

    Institute of Scientific and Technical Information of China (English)

    胡娟娟; 杜冠华

    2001-01-01

    The experimental models for drug screening are very important points in drug discovery. Although the drug screening techniques have been developed, such as high throughput screening (HTS), the screening assay methods (models) still limited drug discovery. In present paper, advanced animal models, cell assays and molecular methodology used for drug discovery were reviewed. The characteristics and requires of the assay methods used for drug discovery in HTS were also discussed.

  2. Innovative grinding wheel design for cost-effective machining of advanced ceramics. Phase I, final report

    Energy Technology Data Exchange (ETDEWEB)

    Licht, R.H.; Ramanath, S.; Simpson, M.; Lilley, E.

    1996-02-01

    Norton Company successfully completed the 16-month Phase I technical effort to define requirements, design, develop, and evaluate a next-generation grinding wheel for cost-effective cylindrical grinding of advanced ceramics. This program was a cooperative effort involving three Norton groups representing a superabrasive grinding wheel manufacturer, a diamond film manufacturing division and a ceramic research center. The program was divided into two technical tasks, Task 1, Analysis of Required Grinding Wheel Characteristics, and Task 2, Design and Prototype Development. In Task 1 we performed a parallel path approach with Superabrasive metal-bond development and the higher technical risk, CVD diamond wheel development. For the Superabrasive approach, Task 1 included bond wear and strength tests to engineer bond-wear characteristics. This task culminated in a small-wheel screening test plunge grinding sialon disks. In Task 2, an improved Superabrasive metal-bond specification for low-cost machining of ceramics in external cylindrical grinding mode was identified. The experimental wheel successfully ground three types of advanced ceramics without the need for wheel dressing. The spindle power consumed by this wheel during test grinding of NC-520 sialon is as much as to 30% lower compared to a standard resin bonded wheel with 100 diamond concentration. The wheel wear with this improved metal bond was an order of magnitude lower than the resin-bonded wheel, which would significantly reduce ceramic grinding costs through fewer wheel changes for retruing and replacements. Evaluation of ceramic specimens from both Tasks 1 and 2 tests for all three ceramic materials did not show evidence of unusual grinding damage. The novel CVD-diamond-wheel approach was incorporated in this program as part of Task 1. The important factors affecting the grinding performance of diamond wheels made by CVD coating preforms were determined.

  3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

    Science.gov (United States)

    Pérez-Herrero, Edgar; Fernández-Medarde, Alberto

    2015-06-01

    mainly deliver chemotherapeutic agents to molecular targets overexpressed on the surface of tumor cells. In particular, we offer a detailed description of different cytotoxic drug carriers, such as liposomes, carbon nanotubes, dendrimers, polymeric micelles, polymeric conjugates and polymeric nanoparticles, in passive and active targeted cancer therapy, by enhancing the permeability and retention or by the functionalization of the surface of the carriers, respectively, emphasizing those that have received FDA approval or are part of the most important clinical studies up to date. These drug carriers not only transport the chemotherapeutic agents to tumors, avoiding normal tissues and reducing toxicity in the rest of the body, but also protect cytotoxic drugs from degradation, increase the half-life, payload and solubility of cytotoxic agents and reduce renal clearance. Despite the many advantages of all the anticancer drug carriers analyzed, only a few of them have reached the FDA approval, in particular, two polymer-protein conjugates, five liposomal formulations and one polymeric nanoparticle are available in the market, in contrast to the sixteen FDA approval of monoclonal antibodies. However, there are numerous clinical trials in progress of polymer-protein and polymer-drug conjugates, liposomal formulations, including immunoliposomes, polymeric micelles and polymeric nanoparticles. Regarding carbon nanotubes or dendrimers, there are no FDA approvals or clinical trials in process up to date due to their unresolved toxicity. Moreover, we analyze in detail the more promising and advanced preclinical studies of the particular case of polymeric nanoparticles as carriers of different cytotoxic agents to active and passive tumor targeting published in the last 5 years, since they have a huge potential in cancer therapy, being one of the most widely studied nano-platforms in this field in the last years. The interest that these formulations have recently achieved is

  4. Recent advances in the pathogenesis and drug actions in periodic paralyses and related channelophaties

    Directory of Open Access Journals (Sweden)

    Domenico eTricarico

    2011-02-01

    Full Text Available The periodic paralysis(PP are rare autosomal-dominant disorders associated to mutations in the skeletal muscle sodium, calcium and potassium channel genes characterized by muscle fiber depolarization with un-excitability, episodes of weakness with variations in serum potassium concentrations. Recent advances in thyrotoxic-PP(TPP and hypokalemic-PP(hypoPP confirm the involvement of the muscle potassium channels in the pathogenesis of the diseases and their role as target of action for drugs of therapeutic interest. The novelty in the gating pore currents theory help to explain the disease symptoms, and open the possibility to more specifically target the disease. It is now known that the fiber depolarization in the hypoPP is due to an unbalance between the novel identified depolarizing gating pore currents(Igp carried by protons or Na+ ions flowing through aberrant alternative pathways of the mutant subunits and repolarizing inwardly rectifying potassium channel(Kir currents which also includes the ATP-sensitive subtype. Abnormal activation of the Igp or deficiency in the Kir channels predispose to fiber depolarization. One pharmacological strategy is based on blocking the Igp without affecting normal channel gating. It remains safe and effective the proposal of targeting the KATP, Kir channels or BK channels by drugs capable to specifically open at nanomolar concentrations the skeletal muscle subtypes with less side effects.

  5. Advances in small animal mesentery models for in vivo flow cytometry, dynamic microscopy, and drug screening

    Institute of Scientific and Technical Information of China (English)

    Ekaterina I Galanzha; Vladimir P Zharov; Philips Classic

    2007-01-01

    Using animal mesentery with intravital optical microscopy is a well-established experimental model for studying blood and lymph microcirculation in vivo.Recent advances in cell biology and optical techniques provide the basis for extending this model for new applications, which should generate significantly improved experimental data. This review summarizes the achievements in this specific area, including in vivo label-free blood and lymph photothermal flow cytometry,super-sensitive fluorescence image cytometry, light scattering and speckle flow cytometry, microvessel dynamic microscopy, infrared (IR) angiography, and high-speed imaging of individual cells in fast flow. The capabilities of these techniques, using the rat mesentery model, were demonstrated in various studies; e.g., realtime quantitative detection of circulating and migrating individual blood and cancer cells, studies on vascular dynamics with a focus on lymphatics under normal conditions and under different interventions (e.g. lasers,drugs, nicotine), assessment of lymphatic disturbances from experimental lymphedema, monitoring cell traffic between blood and lymph systems, and highspeed imaging of cell transient deformability in flow.In particular, the obtained results demonstrated that individual cell transportation in living organisms depends on cell type (e.g., normal blood or leukemic cells), the cell's functional state (e.g., live, apoptotic, or necrotic),and the functional status of the organism. Possible future applications, including in vivo early diagnosis and prevention of disease, monitoring immune response and apoptosis, chemo- and radio-sensitivity tests, and drug screening, are also discussed.

  6. Advanced and innovative reactor concept designs, associated objectives and driving forces

    International Nuclear Information System (INIS)

    Before deployment on an industrial and commercial basis, innovative components features and designs have to be developed and qualified: For the general design, the loop concept is investigated in Japan while other countries focus on the pool concept. Simplification of design will be needed to meet economical objectives. As for the fuel, oxide fuel has more feedback experience, but metal fuel is studied mainly because of its performances with regards to the breeding ratio as well as with regards to possibly simpler manufacturing process. Carbide fuel is also under consideration because of its high density, its high fusion temperature and good thermal conductivity. Fuel development should take into account manufacturing processes (remote handling in case of minor actinide presence), behaviour under irradiation in normal and accidental conditions, and compatibility with treatment processes. Safety, especially behaviour under severe accidental conditions should be a field of major progress. Re-criticality should be well mastered. In support of safety, in service inspection and repair has to be improved to cope with the issues of sodium opacity and temperature of cold shutdown. Energy conversion leads to the study of steam generators more resistant with regards to water-sodium reaction, or to the use of supercritical CO2 enabling higher yields. Treatment and recycling are part of the system; hydro-metallurgical processes have reached an industrial level, and are being further investigated for additional improvements regarding minor actinide separation and non proliferation. Pyro-metallurgical processes are considered for metal fuels. Proliferation resistance, like safety, should offer high guarantee levels in order to meet sustainable development targets. Apart from national R and D programs that support all new projects, there exist international collaboration structures: - The Generation IV International Forum (GIF), which aims at performing R and D on 4th generation

  7. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2009.

    Science.gov (United States)

    Sicherer, Scott H; Leung, Donald Y M

    2010-01-01

    This review highlights some of the research advances in anaphylaxis and hypersensitivity reactions to foods, drugs, and insects, as well as advances in allergic skin disease that were reported in the Journal in 2009. Among key epidemiologic observations, several westernized countries report that more than 1% of children have peanut allergy, and there is some evidence that environmental exposure to peanut is a risk factor. The role of regulatory T cells, complement, platelet-activating factor, and effector cells in the development and expression of food allergy were explored in several murine models and human studies. Delayed anaphylaxis to mammalian meats appears to be related to IgE binding to the carbohydrate moiety galactose-alpha-1,3-galactose, which also has implications for hypersensitivity to murine mAb therapeutics containing this oligosaccharide. Oral immunotherapy studies continue to show promise for the treatment of food allergy, but determining whether the treatment causes tolerance (cure) or temporary desensitization remains to be explored. Increased baseline serum tryptase levels might inform the risk of venom anaphylaxis and might indicate a risk for mast cell disorders in persons who have experienced such episodes. Reduced structural and immune barrier function contribute to local and systemic allergen sensitization in patients with atopic dermatitis, as well as increased propensity of skin infections in these patients. The use of increased doses of nonsedating antihistamines and potential usefulness of omalizumab for chronic urticaria was highlighted. These exciting advances reported in the Journal can improve patient care today and provide insights on how we can improve the diagnosis and treatment of these allergic diseases in the future. PMID:20109740

  8. Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?

    Science.gov (United States)

    Belzung, Catherine

    2014-04-01

    Over recent decades, encouraging preclinical evidence using rodent models pointed to innovative pharmacological targets to treat major depressive disorder. However, subsequent clinical trials have failed to show convincing results. Two explanations for these rather disappointing results can be put forward, either animal models of psychiatric disorders have failed to predict the clinical effectiveness of treatments or clinical trials have failed to detect the effects of these new drugs. A careful analysis of the literature reveals that both statements are true. Indeed, in some cases, clinical efficacy has been predicted on the basis of inappropriate animal models, although the contrary is also true, as some clinical trials have not targeted the appropriate dose or clinical population. On the one hand, refinement of animal models requires using species that have better homological validity, designing models that rely on experimental manipulations inducing pathological features, and trying to model subtypes of depression. On the other hand, clinical research should consider carefully the results from preclinical studies, in order to study these compounds at the correct dose, in the appropriate psychiatric nosological entity or symptomatology, in relevant subpopulations of patients characterized by specific biomarkers. To achieve these goals, translational research has to strengthen the dialogue between basic and clinical science. PMID:24345817

  9. Forensic Bioinformatics: An innovative technological advancement in the field of Forensic Medicine and Diagnosis

    Directory of Open Access Journals (Sweden)

    Kumar Ajay

    2012-01-01

    Full Text Available Background: The role of Bioinformatics in this modern age of technology advancement can not be over-emphasized. Aim: This study reviews the principle, techniques, and applications of Forensic Bioinformatics. Methods and Materials: Literature searches were done to identify relevant studies. Results: The concepts of sequence annotation and whole genome sequencing were possible due to the assimilation of software based tools which are exclusively responsible for the segregation of bulk genomic data. DNA profiling produces profiles which are the encrypted sets of numbers that reflect a person's DNA makeup, which can also be used as the person's identifier. Implementation of automated analysis system coupled with latest computer based software’s making the results easy to comprehend. Major application of forensic Bioinformatics in the field of forensic science includes quick, bulk and precise review of the DNA evidence with the intent of finding and drawing attention to recurring problems so that the testing continues to better and more reliable. Present day, Genetic Counsellors are also used the derived information of Genomic data for creating pedigree in case of genetic disorders. Conclusion: It is important that with the usefulness of Forensic Bioinformatics, a far greater commitment to openness and transparency and a greater availability of documents to public scrutiny is recommended.

  10. Advancing the Frontiers in Nanocatalysis, Biointerfaces, and Renewable Energy Conversion by Innovations of Surface Techniques

    Energy Technology Data Exchange (ETDEWEB)

    Somorjai, G.A.; Frei, H.; Park, J.Y.

    2009-07-23

    The challenge of chemistry in the 21st century is to achieve 100% selectivity of the desired product molecule in multipath reactions ('green chemistry') and develop renewable energy based processes. Surface chemistry and catalysis play key roles in this enterprise. Development of in situ surface techniques such as high-pressure scanning tunneling microscopy, sum frequency generation (SFG) vibrational spectroscopy, time-resolved Fourier transform infrared methods, and ambient pressure X-ray photoelectron spectroscopy enabled the rapid advancement of three fields: nanocatalysts, biointerfaces, and renewable energy conversion chemistry. In materials nanoscience, synthetic methods have been developed to produce monodisperse metal and oxide nanoparticles (NPs) in the 0.8-10 nm range with controlled shape, oxidation states, and composition; these NPs can be used as selective catalysts since chemical selectivity appears to be dependent on all of these experimental parameters. New spectroscopic and microscopic techniques have been developed that operate under reaction conditions and reveal the dynamic change of molecular structure of catalysts and adsorbed molecules as the reactions proceed with changes in reaction intermediates, catalyst composition, and oxidation states. SFG vibrational spectroscopy detects amino acids, peptides, and proteins adsorbed at hydrophobic and hydrophilic interfaces and monitors the change of surface structure and interactions with coadsorbed water. Exothermic reactions and photons generate hot electrons in metal NPs that may be utilized in chemical energy conversion. The photosplitting of water and carbon dioxide, an important research direction in renewable energy conversion, is discussed.

  11. Cost estimates for advanced/innovative wind energy conversion systems /AWECS/

    Science.gov (United States)

    Jacobs, E. W.

    1981-12-01

    Three computer models for determining the economics of advanced wind energy conversion systems (AWECS) in production status are discussed. The SAMICS program, designed for estimating costs of production-line operations, includes details of expenses for a plant in steady-state operation, and yields results in terms of prices, quantities, and a breakdown of cost components. The PRICE model gives cost estimates for electromechanical hardware systems, and comprises design, manufacturing, and subassembly costs. The FAST program derives costs of energy systems in terms of construction and installation. All three models provide production costing, and it is noted that the FAST model can be used as an adjunct to the other two. Small WECS are viewed to become commercially viable at the 10,000 units/yr production level, using a one product job shop mode. Examples for existing 40 kW and 10 kW preproduction model SWECS are provided and a price lowering curve is generated which is similar to a learning curve.

  12. Innovative separation method for advanced spent fuel reprocessing based on tertiary pyridine resin

    International Nuclear Information System (INIS)

    Radiochemical separation experiments have been performed in order to realize a novel reprocessing method based on chromatography techniques using a novel pyridine resin. The newly synthesized tertiary pyridine resin with two functions of ion exchanger and soft-donor was dedicated to the experiments, where highly irradiated mixed oxide fuel from the experimental fast reactor JOYO was used as a reference spent fuel. With a 3-step separation, pure Am and Cm were individually obtained as minor actinide products, and 106Ru group, lanthanides with 137Cs group and Pu group were fractionated, respectively. The decontamination factor of 137Cs and trivalent lanthanides (155Eu, 144Ce) against the Am product exceeded 3.9 x 104 and 1.0 x 105, respectively. The decontamination factor as the mutual separation of 243Cm was larger than 2.2 x 103 against the Am product. Moreover, the content of 137Cs, trivalent lanthanides and 243Cm in Am product did not exceed 2 ppm. The tertiary pyridine resin method is a candidate separation system for an 'advanced ORIENT process', where enhanced separation, transmutation and utilization of actinides, long-lived fission products and rare metal fission product would be oriented. (author)

  13. Advancing the Frontiers in Nanocatalysis, Biointerfaces, and Renewable Energy Conversion by Innovations of Surface Techniques

    International Nuclear Information System (INIS)

    The challenge of chemistry in the 21st century is to achieve 100% selectivity of the desired product molecule in multipath reactions ('green chemistry') and develop renewable energy based processes. Surface chemistry and catalysis play key roles in this enterprise. Development of in situ surface techniques such as high-pressure scanning tunneling microscopy, sum frequency generation (SFG) vibrational spectroscopy, time-resolved Fourier transform infrared methods, and ambient pressure X-ray photoelectron spectroscopy enabled the rapid advancement of three fields: nanocatalysts, biointerfaces, and renewable energy conversion chemistry. In materials nanoscience, synthetic methods have been developed to produce monodisperse metal and oxide nanoparticles (NPs) in the 0.8-10 nm range with controlled shape, oxidation states, and composition; these NPs can be used as selective catalysts since chemical selectivity appears to be dependent on all of these experimental parameters. New spectroscopic and microscopic techniques have been developed that operate under reaction conditions and reveal the dynamic change of molecular structure of catalysts and adsorbed molecules as the reactions proceed with changes in reaction intermediates, catalyst composition, and oxidation states. SFG vibrational spectroscopy detects amino acids, peptides, and proteins adsorbed at hydrophobic and hydrophilic interfaces and monitors the change of surface structure and interactions with coadsorbed water. Exothermic reactions and photons generate hot electrons in metal NPs that may be utilized in chemical energy conversion. The photosplitting of water and carbon dioxide, an important research direction in renewable energy conversion, is discussed.

  14. EPOSAR: an innovative service to provide EPOS community with advanced DInSAR products

    Science.gov (United States)

    Manunta, Michele; De Luca, Claudio; Elefante, Stefano; Lanari, Riccardo; Pepe, Antonio; Zinno, Ivana; Casu, Francesco

    2015-04-01

    The quantitative evaluation of ground deformation is traditionally based on in-situ surveying techniques that, through the intensive use of GPS stations, automatic total stations and levelling benchmarks, can measure up to sub-centimetre displacements. In the last decades, the extensive use of satellite remote sensing data, such as Synthetic Aperture Radar (SAR) images, has represented an important breakthrough in the context of non-invasive ground deformation analyses over large areas, thanks to their large spatial coverage and relatively short revisit time, as well as to their medium-high ground resolution. In such a context, the well-known Differential SAR Interferometry (DInSAR) technique allows us to map and measure deformation phenomena due to both natural and man-made causes with centimetre to millimetre accuracy. The Earth Science community has a wide interest in the use of DInSAR displacement maps both for crisis management and risk mitigation activities, and for surveillance, monitoring and analysis of geophysical phenomena. In areas characterized by high level of hazards the availability of routinely generated advanced DInSAR products would allow a fast analysis of their current status, providing a near real time monitoring. Similarly, an on-demand service would allow the customization of the products by selecting the area of interest, the SAR data to be processed, and other processing parameters to be set by the users to edit/correct/improve the final products. In this work we discuss the Satellite Data Thematic Core Service of EPOS and we present the EPOSAR service. In particular, the EPOSAR service, based on the well-known DInSAR approach referred to as Small Baseline Subset (SBAS), accomplishes a shared and synergic Earth Observation (EO) service aimed at designing, implementing and harmonizing efficient satellite data processing chains capable of ingesting the significantly increased data stream expected from the ESA Sentinel-1 satellites. EPOSAR

  15. Dealing with the challenges of technological innovation in HIV prevention and treatment

    OpenAIRE

    Michael, Mike; Rosengarten, Marsha; Mykhalovskiy, Eric; Imrie, John

    2008-01-01

    The challenges of transferring biomedical advances and non-biomedical technological innovations in HIV prevention and treatment to the field, are a theme of this year's XVII International AIDS Conference. In the HIV field, innovations are often understood in exclusively biomedical or psychosocial terms. Related to these understandings are well-worn disciplinary distinctions. Thus vaccines and drug treatments are typically understood as biotechnological.

  16. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

    Science.gov (United States)

    Mastellos, Dimitrios C; Reis, Edimara S; Yancopoulou, Despina; Hajishengallis, George; Ricklin, Daniel; Lambris, John D

    2016-10-01

    Complement dysregulation is increasingly recognized as an important pathogenic driver in a number of clinical disorders. Complement-triggered pathways intertwine with key inflammatory and tissue destructive processes that can either increase the risk of disease or exacerbate pathology in acute or chronic conditions. The launch of the first complement-targeted drugs in the clinic has undeniably stirred the field of complement therapeutic design, providing new insights into complement's contribution to disease pathogenesis and also helping to leverage a more personalized, comprehensive approach to patient management. In this regard, a rapidly expanding toolbox of complement therapeutics is being developed to address unmet clinical needs in several immune-mediated and inflammatory diseases. Elegant approaches employing both surface-directed and fluid-phase inhibitors have exploited diverse components of the complement cascade as putative points of therapeutic intervention. Targeting C3, the central hub of the system, has proven to be a promising strategy for developing biologics as well as small-molecule inhibitors with clinical potential. Complement modulation at the level of C3 has recently shown promise in preclinical primate models, opening up new avenues for therapeutic intervention in both acute and chronic indications fueled by uncontrolled C3 turnover. This review highlights recent developments in the field of complement therapeutics, focusing on C3-directed inhibitors and alternative pathway (AP) regulator-based approaches. Translational perspectives and considerations are discussed, particularly with regard to the structure-guided drug optimization and clinical advancement of a new generation of C3-targeted peptidic inhibitors. PMID:27353192

  17. Program and Abstracts of the Advanced Research Workshop on Recent Trends and Prospects for Renewable Energy: From Low-Dimensional Functional Materials to Innovation Management

    International Nuclear Information System (INIS)

    The Advanced Research Workshop on Recent Trends and Prospects for Renewable Energy: From Low-Dimensional Functional Materials to Innovation Management was held on October 2-3, 2012 in Tashkent, Uzbekistan. The purpose of the Research Workshop is to discuss recent progress and future trends in the rapidly advancing nanoscience and nanotechnology. The main scientific topics of the workshop: Particle, heat and information transport in low-dimensional nanomaterials; Third generation solar cells on the basis of low-dimensional materials; Hydrogen storage using nanomaterials; Thermoelectricity on nanomaterials; Micro hydropower stations as the effective source for alternative energy; Environmental aspects for renewable energy; Biomass energy conversion; Innovation management in renewable energy; Solar power concentration. (M.K.)

  18. The potential of protein-nanomaterial interaction for advanced drug delivery.

    Science.gov (United States)

    Peng, Qiang; Mu, Huiling

    2016-03-10

    Nanomaterials, like nanoparticles, micelles, nano-sheets, nanotubes and quantum dots, have great potentials in biomedical fields. However, their delivery is highly limited by the formation of protein corona upon interaction with endogenous proteins. This new identity, instead of nanomaterial itself, would be the real substance the organs and cells firstly encounter. Consequently, the behavior of nanomaterials in vivo is uncontrollable and some undesired effects may occur, like rapid clearance from blood stream; risk of capillary blockage; loss of targeting capacity; and potential toxicity. Therefore, protein-nanomaterial interaction is a great challenge for nanomaterial systems and should be inhibited. However, this interaction can also be used to functionalize nanomaterials by forming a selected protein corona. Unlike other decoration using exogenous molecules, nanomaterials functionalized by selected protein corona using endogenous proteins would have greater promise for clinical use. In this review, we aim to provide a comprehensive understanding of protein-nanomaterial interaction. Importantly, a discussion about how to use such interaction is launched and some possible applications of such interaction for advanced drug delivery are presented. PMID:26812004

  19. Approach to the open advanced facilities initiative for innovation (strategic use by industry) at the University of Tsukuba, Tandem Accelerator Complex

    International Nuclear Information System (INIS)

    The University of Tsukuba, Tandem Accelerator Complex (UTTAC) possesses the 12UD Pelletron tandem accelerator and the 1 MV Tandetron accelerator for University's inter-department education research. We have actively advanced collaborative researches with other research institutes and industrial users. Since the Open Advanced Facilities Initiative for Innovation by the Ministry of Education, Culture, Sports, Science and Technology started in 2007, 12 industrial experiments have been carried out at the UTTAC. This report describes efforts by University's accelerator facility to get industrial users. (author)

  20. Boceprevir in combination with HIV protease inhibitors in patients with advanced fibrosis-altered drug-drug interactions?

    OpenAIRE

    Schwarze-Zander, C; C Boesecke; L Dold; J Wasmuth; Rockstroh, J

    2012-01-01

    In HIV/HCV co-infected patients improved treatment outcomes have been reported for the HCV protease inhibitors (PIs) boceprevir (BOC) and telaprevir (TVR), reaching SVR rates of up to 70% in pilot trials. Due to complex drug-drug-interactions triple therapy is substantially limited in HIV/HCV-coinfected individuals. Co-administration of BOC with the commonly available HIV PIs has been reported not only to decrease the level of BOC but also to lead to relevant decreases in the respective HIV P...

  1. Regional Innovation Clusters

    Data.gov (United States)

    Small Business Administration — The Regional Innovation Clusters serve a diverse group of sectors and geographies. Three of the initial pilot clusters, termed Advanced Defense Technology clusters,...

  2. Advances in the Applications of Polyhydroxyalkanoate Nanoparticles for Novel Drug Delivery System

    OpenAIRE

    Young-Rok Kim; Anupama Shrivastav; Hae-Yeong Kim

    2013-01-01

    Drug delivery technology is emerging as an interdisciplinary science aimed at improving human health. The controlled delivery of pharmacologically active agents to the specific site of action at the therapeutically optimal rate and dose regimen has been a major goal in designing drug delivery systems. Over the past few decades, there has been considerable interest in developing biodegradable drug carriers as effective drug delivery systems. Polymeric materials from natural sources play an imp...

  3. Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery

    OpenAIRE

    Das, Surajit; Chaudhury, Anumita

    2010-01-01

    Lipid nanoparticles based on solid matrix have emerged as potential drug carriers to improve gastrointestinal (GI) absorption and oral bioavailability of several drugs, especially lipophilic compounds. These formulations may also be used for sustained drug release. Solid lipid nanoparticle (SLN) and the newer generation lipid nanoparticle, nanostructured lipid carrier (NLC), have been studied for their capability as oral drug carriers. Biodegradable, biocompatible, and physiological lipids ar...

  4. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.

    Science.gov (United States)

    Kostyanev, T; Bonten, M J M; O'Brien, S; Steel, H; Ross, S; François, B; Tacconelli, E; Winterhalter, M; Stavenger, R A; Karlén, A; Harbarth, S; Hackett, J; Jafri, H S; Vuong, C; MacGowan, A; Witschi, A; Angyalosi, G; Elborn, J S; deWinter, R; Goossens, H

    2016-02-01

    Antibiotic resistance (ABR) is a global public health threat. Despite the emergence of highly resistant organisms and the huge medical need for new drugs, the development of antibacterials has slowed to an unacceptable level worldwide. Numerous government and non-government agencies have called for public-private partnerships and innovative funding mechanisms to address this problem. To respond to this public health crisis, the Innovative Medicines Initiative Joint Undertaking programme has invested more than €660 million, with a goal of matched contributions from the European Commission and the European Federation of Pharmaceutical Industries and Associations, in the development of new antibacterial strategies. The New Drugs for Bad Bugs (ND4BB) programme, an Innovative Medicines Initiative, has the ultimate goal to boost the fight against ABR at every level from basic science and drug discovery, through clinical development to new business models and responsible use of antibiotics. Seven projects have been launched within the ND4BB programme to achieve this goal. Four of them will include clinical trials of new anti-infective compounds, as well as epidemiological studies on an unprecedented scale, which will increase our knowledge of ABR and specific pathogens, and improve the designs of the clinical trials with new investigational drugs. The need for rapid concerted action has driven the funding of seven topics, each of which should add significantly to progress in the fight against ABR. ND4BB unites expertise and provides a platform where the commitment and resources required by all parties are streamlined into a joint public-private partnership initiative of unprecedented scale. PMID:26568581

  5. Issues In-Depth: Advancing Understanding of Drug Addiction and Treatment

    Science.gov (United States)

    Miller, Roxanne Greitz

    2009-01-01

    While most school districts utilize a drug abuse resistance curriculum, as science teachers, it is our responsibility to understand the science behind drug addiction in order to most effectively educate our students against drug abuse. In the last two decades, increases in scientific technology have permitted significant discoveries surrounding…

  6. 褪黑素能类药物研究进展%Melatonergic drugs: research advances

    Institute of Scientific and Technical Information of China (English)

    吕志强; 杨建云; 肖炳坤; 甄蓓; 黄荣清

    2013-01-01

    褪黑激素(美乐托宁)是一种专司调节生物节律的神经激素,具有调节免疫系统、抑制肿瘤细胞增殖、保护胃肠道、抗脑损伤和痛觉调制等多种生理作用.褪黑激素主要通过介导两个G蛋白偶联受体MT1和MT2而发挥作用.由于其半衰期短、临床应用受限,多种褪黑激素衍生物和类似物被研究,以获得活性高、药代动力学性质良好的药物.本文主要介绍已上市和处于临床试验的褪黑素能类药物的研究概况.%Melatonin is a hormone responsible for regulating biological rhythms. It has multiple physiological actions such as immune regulation, inhibition of tumor, gastrointestinal tract protection, brain injury prevention and pain regulation, and exerts its actions mainly through two G-protein-coupled receptors MT1 and MT2. To overcome its shortcomings of short half-life and limited clinical application, a variety of melatonin derivatives and analogues have been developed in order to get compounds with high activity and good pharmacokinetic properties. Recent advances in melatonergic drugs which have been listed or in clinical trials are summarized in this review.

  7. Advancements in in vitro hepatic models: application for drug screening and therapeutics.

    Science.gov (United States)

    Damania, Apeksha; Jain, Era; Kumar, Ashok

    2014-01-01

    The liver is one of the most complex organs in the body, performing a multitude of functions. Liver tissue engineering is a combination of various strategies that aim at generating functional liver tissue that can help restore and/or support the ailing liver as it recuperates. Conventionally, in vitro culture has involved growing cells in different media compositions or layering them on matrices largely composed of native ECM components such as collagen or Matrigel. With recent advances in technology, more sophisticated techniques are being devised that are better equipped to capture distinct features of the liver in an in vivo microenvironment. Three-dimensional (3D) cultures of liver cells in 3D scaffolds, as spheroids or cell sheets, allow for a high degree of cell-cell and cell-matrix interaction and an in vivo-like architecture. More recently, decellularized matrices have been used as scaffolds that support ideal cell-matrix interactions. Microfabrication technologies initially used to pattern semiconductors in the integrated circuit industry have grown out of this field and now encompass a variety of methods to etch patterns onto both 2D and 3D scaffolds to allow incorporation of custom-made features resembling the fluid network and organization in native liver. This improvisation permits for enhanced vascularization and oxygen diffusion to the in vitro liver tissue. In this review, we discuss the various configurations that have been implemented in the in vitro culture of liver cells and their application in liver therapeutics in the form of implantable liver tissue constructs and tools for drug screening. PMID:26202404

  8. Chemotherapy combined with target drugs in the treatment of advanced colorectal cancer: A meta-analysis based on Chinese patients

    Directory of Open Access Journals (Sweden)

    Q H Zheng

    2014-01-01

    Full Text Available Background: Colorectal carcinoma is one of most diagnosed solid malignant carcinoma. The chemotherapy combined with target drugs in the treatment of advanced colorectal cancer in not conclusive. Methods: The clinical studies reporting the activity and adverse events between chemotherapy alone versus chemotherapy combined with anti-epidermal growth factor receptor drugs were screened in the databases of Medline, the Cochrane Library, Wanfang and CNKI and included in this meta-analysis. The risk ratio (RR and its 95% confidence interval (CI for treatment response and adverse events were pooled by random or fixed effect model. Results: A total of 10 clinical studies reporting chemotherapy combined with the target in the treatment of advanced colorectal cancer were included in this study. The pooled RR was 3.26 (95% CI: 1.74-6.11, P 0.05, liver function damage (RR = 1.03, 95% CI: 0.74-1.42, myelosuppression (RR = 1.04, 95% CI: 0.83-1.31 and neurotoxicity (RR = 1.12, 95% CI: 0.93-1.35 were not different between the two groups. Conclusion: For Chinese patients with advanced colorectal cancer, chemotherapy combined with target drug can improve the response rate, but also increase the risk of nausea and vomiting.

  9. Recent advances in drug therapy for myopia%近视眼药物治疗研究进展

    Institute of Scientific and Technical Information of China (English)

    许瑶; 曾骏文

    2013-01-01

    本文回顾了最近国内外近视眼药物治疗的相关研究,从常见药物治疗和针对脉络膜新生血管的治疗两方面作了介绍,并为未来的治疗方向提出了一些设想.本文主要介绍了阿托品、哌仑西平、阿扑吗啡、7-甲基黄嘌呤等传统药物的新用法,同时也阐述了光动力疗法、单抗类药物用于近视治疗的最新研究进展.%This article reviews about recent advances of studies on drug therapy for myopia,introducing the common drug therapies and therapies for choroidal neovascularization.This article proposes some ideas of future treatment for myopia.This review introduces the new usage of some traditional drugs including atropine,pirenzepine,apomorphine,7-methylxanthine,and reviews the latest advances in studies on photodynamic therapy and monoclonal antibody drugs therapy for myopia.

  10. Development of advanced strategies for the prediction of toxicity endpoints in drug development

    OpenAIRE

    Carri?? Gaspar, Pau, 1982-

    2015-01-01

    Safety concerns are one of the main causes of drug attrition. In these events, the moment at which the drug toxic effects are discovered changes dramatically the importance of the finding; discarding a valuable candidate at clinical testing stages means wasting years of efforts and huge economicinvestments. Even more dramatic is the discovery of toxic effect at post marketing stages, when the drug could have already produced severe side effects on a number of patients. For these reaso...

  11. Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals?

    Science.gov (United States)

    Bonastre, Julia; Chevalier, Julie; Van der Laan, Chantal; Delibes, Michel; De Pouvourville, Gerard

    2014-06-01

    In DRG-based hospital payment systems, expensive drugs are often funded separately. In France, specific expensive drugs (including a large proportion of anticancer drugs) are fully reimbursed up to national reimbursement tariffs to ensure equity of access. Our objective was to analyse the use of expensive anticancer drugs in public and private hospitals, and between regions. We had access to sales per anticancer drug and per hospital in the year 2008. We used a multilevel model to study the variation in the mean expenditure of expensive anticancer drugs per course of chemotherapy and per hospital. The mean expenditure per course of chemotherapy was €922 [95% CI: 890-954]. At the hospital level, specialisation in chemotherapies for breast cancers was associated with a higher expenditure of anticancer drugs per course for those hospitals with the highest proportion of cancers at this site. There were no differences in the use of expensive drugs between the private and the public hospital sector after controlling for case mix. There were no differences between the mean expenditures per region. The absence of disparities in the use of expensive anticancer drugs between hospitals and regions may indicate that exempting chemotherapies from DRG-based payments and providing additional reimbursement for these drugs has been successful at ensuring equal access to care. PMID:24314625

  12. Advances in material design for regenerative medicine, drug delivery and targeting/imaging

    Science.gov (United States)

    Many of the major breakthroughs and paradigm shifts in medicine to date have occurred due to innovations and materials and/or application/implementation of materials in clinical medicine. Artificial heart valves, implantable cardiac devices, limb prosthesis, cardiovascular stents, orthopedic implan...

  13. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.

    Science.gov (United States)

    Germann, Paul G; Schuhmacher, Alexander; Harrison, Juan; Law, Ronald; Haug, Kevin; Wong, Gordon

    2013-01-01

    The global healthcare industry is undergoing substantial changes and adaptations to the constant decline of approved new medical entities. This decrease in internal research productivity is resulting in a major decline of patent-protected sales (patent cliff) of most of the pharmaceutical companies. Three major global adaptive trends as driving forces to cope with these challenges are evident: cut backs of internal research and development jobs in the western hemisphere (Europe and USA), following the market growth potential of Asia by building up internal or external research and development capabilities there and finally, 'early innovation hunting' with an increased focus on identifying and investing in very early innovation sources within academia and small start-up companies. Early innovation hunting can be done by different approaches: increased corporate funding, establishment of translational institutions to bridge innovation, increasing sponsored collaborations and formation of technology hunting groups for capturing very early scientific ideas and concepts. This emerging trend towards early innovation hunting demands special adaptations from both the pharmaceutical industry and basic researchers in academia to bridge the translation into new medicines which deliver innovative medicines that matters to the patient. This opinion article describes the different modalities of cross-fertilisation between basic university or publicly funded institutional research and the applied research and development activities within the pharmaceutical industry. Two key factors in this important translational bridge can be identified: preparation of both partnering organisations to open up for new and sometime disruptive ideas and creation of truly trust-based relationships between the different groups allowing long-term scientific collaborations while acknowledging that value-creating differences are an essential factor for successful collaboration building. PMID:23496921

  14. Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.

    Science.gov (United States)

    Messori, Andrea

    2016-08-01

    Several cases of expensive drugs designed for large patient populations (e.g. sofosbuvir) have raised a complex question in terms of drug pricing. Even assuming value-based pricing, the treatment with these drugs of all eligible patients would have an immense budgetary impact, which is unsustainable also for the richest countries. This raises the need to reduce the prices of these agents in comparison with those suggested by the value-based approach and to devise new pricing methods that can achieve this goal. The present study discusses in detail the following two methods: (i) The approach based on setting nation-wide budget thresholds for individual innovative agents in which a fixed proportion of the historical pharmaceutical expenditure represents the maximum budget attributable to an innovative treatment; (ii) The approach based on nation-wide price-volume agreements in which drug prices are progressively reduced as more patients receive the treatment. The first approach has been developed in the USA by the Institute for Clinical and Economic Review and has been applied to PCSK9 inhibitors (alirocumab and evolocumab). The second approach has been designed for the Italian market and has found a systematic application to manage the price of ranibizumab, sofosbuvir, and PCSK9 inhibitors. While, in the past, price-volume agreements have been applied only on an empirical basis (i.e. in the absence of any quantitative theoretical rule), more recently some explicit mathematical models have been described. The performance of these models is now being evaluated on the basis of the real-world experiences conducted in some European countries, especially Italy. PMID:27216427

  15. Technological innovation and liberal theories of justice

    OpenAIRE

    Papaioannou, Theo

    2008-01-01

    The acceleration of technological innovation in Western liberal societies has in recent years offered the prospect of applications with crucial impact on social and economic life. For instance, in the area of new life sciences, the successful decoding of human genome and subsequent advances of genomics-based technologies (including biotechnology) have enabled the development of cheaper and safer drugs, the introduction of new gene-based diagnostics and biomedical therapies. However, these new...

  16. Recent Advances in chemistry and pharmacology of 2-methoxyestradiol: An anticancer investigational drug.

    Science.gov (United States)

    Kumar, B Sathish; Raghuvanshi, Dushyant Singh; Hasanain, Mohammad; Alam, Sarfaraz; Sarkar, Jayanta; Mitra, Kalyan; Khan, Feroz; Negi, Arvind S

    2016-06-01

    2-Methoxyestradiol (2ME2), an estrogen hormone metabolite is a potential cancer chemotherapeutic agent. Presently, it is an investigational drug under various phases of clinical trials alone or in combination therapy. Its anticancer activity has been attributed to its antitubulin, antiangiogenic, pro-apoptotic and ROS induction properties. This anticancer drug candidate has been explored extensively in last twenty years for its detailed chemistry and pharmacology. Present review is an update of its chemistry and biological activity. It also extends an assessment of potential of 2ME2 and its analogues as possible anticancer drug in future. PMID:27020471

  17. Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.

    Science.gov (United States)

    Laille, Eric; Patel, Manish; Jones, Suzanne F; Burris, Howard A; Infante, Jeffrey; Lemech, Charlotte; Liu, Liangang; Arkenau, Hendrik-Tobias

    2015-12-01

    Two multicenter, single-arm, single-infusion, open-label studies were conducted to evaluate the effect of ketoconazole (a strong CYP3A inhibitor) or rifampin (a strong CYP3A inducer) daily for 5 days on the pharmacokinetics (PK) and safety of romidepsin (8 mg/m(2) intravenous 4-hour infusion for the ketoconazole study or a 14 mg/m(2) intravenous 4-hour infusion for the rifampin study) in patients with advanced cancer. Romidepsin coadministered with ketoconazole (400 mg) or rifampin (600 mg) was not bioequivalent to romidepsin alone. With ketoconazole, the mean romidepsin AUC and Cmax were increased by approximately 25% and 10%, respectively. With rifampin, the mean romidepsin AUC and Cmax were unexpectedly increased by approximately 80% and 60%, respectively; this is likely because of inhibition of active liver uptake. For both studies, romidepsin clearance and volume of distribution were decreased, terminal half-life was comparable, and median Tmax was similar. Overall, the safety profile of romidepsin was not altered by coadministration with ketoconazole or rifampin, except that a higher incidence and greater severity of thrombocytopenia was observed when romidepsin was given with rifampin. The use of romidepsin with rifampin and strong CYP3A inducers should be avoided. Toxicity related to romidepsin exposure should be monitored when romidepsin is given with strong CYP3A inhibitors. PMID:26053962

  18. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters

    DEFF Research Database (Denmark)

    Andersen, Jacob; Kristensen, Anders Skov; Bang-Andersen, Benny;

    2009-01-01

    The biogenic monoamine transporters are integral membrane proteins that perform active transport of extracellular dopamine, serotonin and norepinephrine into cells. These transporters are targets for therapeutic agents such as antidepressants, as well as addictive substances such as cocaine and...... antidepressant drugs that act on the serotonin and/or the norepinephrine transporters. Specifically, we focus on structure-activity relationships of these drugs with emphasis on relationships between their molecular properties and the current knowledge of transporter structure....

  19. A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human

    International Nuclear Information System (INIS)

    A general toxicity of basic drugs is related to phospholipidosis in tissues. Therefore, it is essential to predict the tissue distribution of basic drugs to facilitate an initial estimate of that toxicity. The objective of the present study was to further assess the original prediction method that consisted of using the binding to red blood cells measured in vitro for the unbound drug (RBCu) as a surrogate for tissue distribution, by correlating it to unbound tissue:plasma partition coefficients (Kpu) of several tissues, and finally to predict volume of distribution at steady-state (Vss) in humans under in vivo conditions. This correlation method demonstrated inaccurate predictions of Vss for particular basic drugs that did not follow the original correlation principle. Therefore, the novelty of this study is to provide clarity on the actual hypotheses to identify i) the impact of pharmacological mode of action on the generic correlation of RBCu-Kpu, ii) additional mechanisms of tissue distribution for the outlier drugs, iii) molecular features and properties that differentiate compounds as outliers in the original correlation analysis in order to facilitate its applicability domain alongside the properties already used so far, and finally iv) to present a novel and refined correlation method that is superior to what has been previously published for the prediction of human Vss of basic drugs. Applying a refined correlation method after identifying outliers would facilitate the prediction of more accurate distribution parameters as key inputs used in physiologically based pharmacokinetic (PBPK) and phospholipidosis models.

  20. Innovative Asia: Advancing the Knowledge-Based Economy: Country Case Studies for the PRC, India, Indonesia, and Kazakhstan

    OpenAIRE

    Asian Development Bank

    2014-01-01

    This report presents the case studies of the People’s Republic of China, India, Indonesia and Kazakhstan in their knowledge-based economy approaches. It identifies a range of policies and initiatives that these economies need to consider to strengthen innovation led growth and make a transition from middle income to high income levels.

  1. Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.

    Science.gov (United States)

    Benet, Marta; Guzmán, Carla; Pisonero-Vaquero, Sandra; García-Mediavilla, M Victoria; Sánchez-Campos, Sonia; Martínez-Chantar, M Luz; Donato, M Teresa; Castell, José Vicente; Jover, Ramiro

    2015-04-01

    The small heterodimer partner (SHP) (NR0B2) is an atypical nuclear receptor that lacks a DNA-binding domain. It interacts with and inhibits many transcription factors, affecting key metabolic processes, including bile acid, cholesterol, fatty acid, and drug metabolism. Our aim was to determine the influence of steatotic drugs and nonalcoholic fatty liver disease (NAFLD) on SHP expression and investigate the potential mechanisms. SHP was found to be repressed by steatotic drugs (valproate, doxycycline, tetracycline, and cyclosporin A) in cultured hepatic cells and the livers of different animal models of NAFLD: iatrogenic (tetracycline-treated rats), genetic (glycine N-methyltransferase-deficient mice), and nutritional (mice fed a methionine- and choline-deficient diet). Among the different transcription factors investigated, CCAAT-enhancer-binding protein α (C/EBPα) showed the strongest dominant-repressive effect on SHP expression in HepG2 and human hepatocytes. Reporter assays revealed that the inhibitory effect of C/EBPα and steatotic drugs colocalize between -340 and -509 base pair of the SHP promoter, and mutation of a predicted C/EBPα response element at -473 base pair abolished SHP repression by both C/EBPα and drugs. Moreover, inhibition of major stress signaling pathways demonstrated that the mitogen-activated protein kinase kinase 1/2 pathway activates, while the phosphatidylinositol 3 kinase pathway represses SHP in a C/EBP-dependent manner. We conclude that SHP is downregulated by several steatotic drugs and in advanced NAFLD. These conditions can activate signals that target C/EBPα and consequently repress SHP, thus favoring the progression and severity of NAFLD. PMID:25576488

  2. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations

    Directory of Open Access Journals (Sweden)

    Ali Khan A

    2013-07-01

    Full Text Available Arshad Ali Khan, Jahanzeb Mudassir, Noratiqah Mohtar, Yusrida Darwis School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia Abstract: The delivery of drugs and bioactive compounds via the lymphatic system is complex and dependent on the physiological uniqueness of the system. The lymphatic route plays an important role in transporting extracellular fluid to maintain homeostasis and in transferring immune cells to injury sites, and is able to avoid first-pass metabolism, thus acting as a bypass route for compounds with lower bioavailability, ie, those undergoing more hepatic metabolism. The lymphatic route also provides an option for the delivery of therapeutic molecules, such as drugs to treat cancer and human immunodeficiency virus, which can travel through the lymphatic system. Lymphatic imaging is useful in evaluating disease states and treatment plans for progressive diseases of the lymph system. Novel lipid-based nanoformulations, such as solid lipid nanoparticles and nanostructured lipid carriers, have unique characteristics that make them promising candidates for lymphatic delivery. These formulations are superior to colloidal carrier systems because they have controlled release properties and provide better chemical stability for drug molecules. However, multiple factors regulate the lymphatic delivery of drugs. Prior to lymphatic uptake, lipid-based nanoformulations are required to undergo interstitial hindrance that modulates drug delivery. Therefore, uptake and distribution of lipid-based nanoformulations by the lymphatic system depends on factors such as particle size, surface charge, molecular weight, and hydrophobicity. Types of lipid and concentration of the emulsifier are also important factors affecting drug delivery via the lymphatic system. All of these factors can cause changes in intermolecular interactions between the lipid nanoparticle matrix and the incorporated drug, which in turn affects

  3. Recent advances in novel heterocyclic scaffolds for the treatment of drug-resistant malaria.

    Science.gov (United States)

    Kumar, Sahil; Singh, Rajesh K; Patial, Babita; Goyal, Sachin; Bhardwaj, T R

    2016-01-01

    Malaria is a major public health problem all over the world, particularly in tropical and subtropical countries due to the development of resistance and most deadly infection is caused by Plasmodium falciparum. There is a direct need for the discovery of new drugs with unique structures and mechanism of action to treat sensitive and drug-resistant strains of various plasmodia for radical cure of this disease. Traditional compounds such as quinine and related derivatives represent a major source for the development of new drugs. This review presents recent modifications of 4-aminoquinoline and 8-aminoquinolone rings as leads to novel active molecules which are under clinical trials. The review also encompasses the other heterocyclic compounds emerged as potential antimalarial agents with promising results such as acridinediones and acridinone analogues, pyridines and quinolones as antimalarials. Miscellaneous heterocyclics such as tetroxane derivatives, indole derivatives, imidazolopiperazine derivatives, biscationic choline-based compounds and polymer-linked combined antimalarial drugs are also discussed. At last brief introduction to heterocyclics in natural products is also reviewed. Most of them have been under clinical trials and found to be promising in the treatment of drug-resistant strains of Plasmodium and others can be explored for the same purpose. PMID:25775094

  4. Importation and Innovation

    OpenAIRE

    Frank R Lichtenberg

    2006-01-01

    Importation of drugs into the U.S. would result in a decline in U.S. drug prices. The purpose of this paper is to assess the consequences of importation for new drug development. A simple theoretical model of drug development suggests that the elasticity of innovation with respect to the expected price of drugs should be at least as great as the elasticity of innovation with respect to expected market size (disease incidence). I examine the cross-sectional relationship between pharmaceutical ...

  5. 3D scanning and 3D printing as innovative technologies for fabricating personalized topical drug delivery systems.

    Science.gov (United States)

    Goyanes, Alvaro; Det-Amornrat, Usanee; Wang, Jie; Basit, Abdul W; Gaisford, Simon

    2016-07-28

    Acne is a multifactorial inflammatory skin disease with high prevalence. In this work, the potential of 3D printing to produce flexible personalised-shape anti-acne drug (salicylic acid) loaded devices was demonstrated by two different 3D printing (3DP) technologies: Fused Deposition Modelling (FDM) and stereolithography (SLA). 3D scanning technology was used to obtain a 3D model of a nose adapted to the morphology of an individual. In FDM 3DP, commercially produced Flex EcoPLA™ (FPLA) and polycaprolactone (PCL) filaments were loaded with salicylic acid by hot melt extrusion (HME) (theoretical drug loading - 2% w/w) and used as feedstock material for 3D printing. Drug loading in the FPLA-salicylic acid and PCL-salicylic acid 3D printed patches was 0.4% w/w and 1.2% w/w respectively, indicating significant thermal degradation of drug during HME and 3D printing. Diffusion testing in Franz cells using a synthetic membrane revealed that the drug loaded printed samples released <187μg/cm(2) within 3h. FPLA-salicylic acid filament was successfully printed as a nose-shape mask by FDM 3DP, but the PCL-salicylic acid filament was not. In the SLA printing process, the drug was dissolved in different mixtures of poly(ethylene glycol) diacrylate (PEGDA) and poly(ethylene glycol) (PEG) that were solidified by the action of a laser beam. SLA printing led to 3D printed devices (nose-shape) with higher resolution and higher drug loading (1.9% w/w) than FDM, with no drug degradation. The results of drug diffusion tests revealed that drug diffusion was faster than with the FDM devices, 229 and 291μg/cm(2) within 3h for the two formulations evaluated. In this study, SLA printing was the more appropriate 3D printing technology to manufacture anti-acne devices with salicylic acid. The combination of 3D scanning and 3D printing has the potential to offer solutions to produce personalised drug loaded devices, adapted in shape and size to individual patients. PMID:27189134

  6. Drug Formulation Advances in Extended-Release Medications for Pain Control.

    Science.gov (United States)

    Jones, Mark R; Carney, Martin J; Kaye, Rachel J; Prabhakar, Amit; Kaye, Alan D

    2016-05-01

    Prescription opioid abusers frequently tamper with opioid tablets in order to either accelerate the delivery of the euphoria-inducing agent or to alter the route of delivery, such that it may be delivered intranasally or intravenously. As one strategy to combat the opioid epidemic in the USA, drug manufacturers have begun to explore formulations which resist such tampering by abusers. Techniques to prevent tampering consist of physical barriers to crushing, chewing, and drug extraction, or aversive or antagonistic agents, incorporated within the formulation itself. Recent years have seen the development of numerous extended-release opioid agents, which are described in this review. This article provides a comprehensive summary of the pharmacology, benefits, risks, and processes behind the development of currently available extended-release opioid drugs, as well as a glimpse into promising future formulations. PMID:27084375

  7. Fast track: The practice of drug development and regulatory innovation in the late Twentieth Century U.S

    OpenAIRE

    Messner, Donna A.

    2008-01-01

    This thesis examines the laws and regulations created in the 1980s and 1990s in the U.S. to hasten development, evaluation, and approval of drugs to treat serious and lifethreatening diseases, and to allow access of seriously ill patients to investigational drugs on a pre-market approval basis. Using detailed historical exposition in tandem with the social-theoretic tools of the sociology of scientific knowledge (SSK), and particularly Barnes’s account of meaning finitism, this...

  8. Behaviour of pharmaceuticals and psychotic drugs in conventional and advanced wastewater treatments

    International Nuclear Information System (INIS)

    The occurrence of various pharmaceuticals and psychotic drugs in wastewater and their removal rates in a conventional wastewater treatment plant has been investigated. The psychoactive drugs are poorly removed in the biological step. However, most pharmaceuticals except of carbamazepine, are significantly biodegraded depending the removal degree on the type of compound and on the sludge retention time of the biological treatment. Also, the removal efficiency of conventional tertiary treatments and ultrafiltration and nano filtration membranes using two pilot plants was examined. the effects of retaining pharmaceuticals with ultrafiltration and nano filtration membranes do not greatly differ despite the difference in their pore size. (Author) 25 refs.

  9. Policy Entrepreneurship in an Emergent Domain: Advancing Innovation in Non-Cognitive Factors From the Federal Level

    OpenAIRE

    Saxena, Suchitra

    2015-01-01

    I served as the Raikes Foundation Fellow on Non-Cognitive Factors and Learning within the U.S. Department of Education’s Office of Innovation and Improvement during the 2014-2015 academic year. So called non-cognitive factors are the intrapersonal and interpersonal skills and attitudes which, in combination with cognitive skills, enable students to successfully navigate the learning tasks of school and the unpredictable, multilayered challenges of life beyond school. The Department seeks to d...

  10. Webinar as the innovative marketing tool: its place and a role in system of advancement of educational services

    Directory of Open Access Journals (Sweden)

    Matuhina Tatiana Vasilevna

    2011-04-01

    Full Text Available Marketing of webinar represents research which is carried out by seminar carrying out in a network the Internet, by means of virtual conference. Webinar as the innovative marketing tool allows the buyer to investigate a product or service, and to the supplier to investigate requirements and interests of the consumers by means of decrease in expenses for marketing since the technology of webinar-marketing is much more economic traditional than means of marketing, advertising, polls, seminars and conferences.

  11. Webinar as the innovative marketing tool: its place and a role in system of advancement of educational services

    OpenAIRE

    Matuhina Tatiana Vasilevna

    2011-01-01

    Marketing of webinar represents research which is carried out by seminar carrying out in a network the Internet, by means of virtual conference. Webinar as the innovative marketing tool allows the buyer to investigate a product or service, and to the supplier to investigate requirements and interests of the consumers by means of decrease in expenses for marketing since the technology of webinar-marketing is much more economic traditional than means of marketing, advertising, polls, seminars a...

  12. Network based elucidation of drug response: from modulators to targets

    OpenAIRE

    Iorio, Francesco; Saez-Rodriguez, Julio; Bernardo, Diego di

    2013-01-01

    Network-based drug discovery aims at harnessing the power of networks to investigate the mechanism of action of existing drugs, or new molecules, in order to identify innovative therapeutic treatments. In this review, we describe some of the most recent advances in the field of network pharmacology, starting with approaches relying on computational models of transcriptional networks, then moving to protein and signaling network models and concluding with “drug networks”. These networks are de...

  13. Combination of click chemistry and controlled radical polymerization for synthesis of advanced polymer drug delivery systems

    Czech Academy of Sciences Publication Activity Database

    Pechar, Michal; Pola, Robert; Braunová, Alena; Laga, Richard; Ulbrich, Karel

    2013-01-01

    Roč. 9, č. 1 (2013), s. 106-107 /3P10/. ISSN 1336-7242. [Zjazd chemikov /65./. 09.09.2013-13.09.2013, Tatranské Matliare] R&D Projects: GA ČR GCP207/12/J030 Institutional support: RVO:61389013 Keywords : polymer conjugates * controlled drug delivery * diagnostics of tumors Subject RIV: CD - Macromolecular Chemistry

  14. The eTOX data-sharing project to advance in silico drug-induced toxicity prediction.

    Science.gov (United States)

    Cases, Montserrat; Briggs, Katharine; Steger-Hartmann, Thomas; Pognan, François; Marc, Philippe; Kleinöder, Thomas; Schwab, Christof H; Pastor, Manuel; Wichard, Jörg; Sanz, Ferran

    2014-01-01

    The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug development, which follows numerous strict guidelines, are mostly not available in the public domain. These safety data are sometimes published as a condensed summary for the few compounds that reach the market, but the majority of studies are never made public and are often difficult to access in an automated way, even sometimes within the owning company itself. It is evident from many academic and industrial examples, that useful data mining and model development requires large and representative data sets and careful curation of the collected data. In 2010, under the auspices of the Innovative Medicines Initiative, the eTOX project started with the objective of extracting and sharing preclinical study data from paper or pdf archives of toxicology departments of the 13 participating pharmaceutical companies and using such data for establishing a detailed, well-curated database, which could then serve as source for read-across approaches (early assessment of the potential toxicity of a drug candidate by comparison of similar structure and/or effects) and training of predictive models. The paper describes the efforts undertaken to allow effective data sharing intellectual property (IP) protection and set up of adequate controlled vocabularies) and to establish the database (currently with over 4000 studies contributed by the pharma companies corresponding to more than 1400 compounds). In addition, the status of predictive models building and some specific features of the eTOX predictive system (eTOXsys) are presented as decision support knowledge-based tools for drug development process at an early stage. PMID:25405742

  15. The eTOX Data-Sharing Project to Advance in Silico Drug-Induced Toxicity Prediction

    Directory of Open Access Journals (Sweden)

    Montserrat Cases

    2014-11-01

    Full Text Available The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug development, which follows numerous strict guidelines, are mostly not available in the public domain. These safety data are sometimes published as a condensed summary for the few compounds that reach the market, but the majority of studies are never made public and are often difficult to access in an automated way, even sometimes within the owning company itself. It is evident from many academic and industrial examples, that useful data mining and model development requires large and representative data sets and careful curation of the collected data. In 2010, under the auspices of the Innovative Medicines Initiative, the eTOX project started with the objective of extracting and sharing preclinical study data from paper or pdf archives of toxicology departments of the 13 participating pharmaceutical companies and using such data for establishing a detailed, well-curated database, which could then serve as source for read-across approaches (early assessment of the potential toxicity of a drug candidate by comparison of similar structure and/or effects and training of predictive models. The paper describes the efforts undertaken to allow effective data sharing intellectual property (IP protection and set up of adequate controlled vocabularies and to establish the database (currently with over 4000 studies contributed by the pharma companies corresponding to more than 1400 compounds. In addition, the status of predictive models building and some specific features of the eTOX predictive system (eTOXsys are presented as decision support knowledge-based tools for drug development process at an early stage.

  16. The weak-ties in advanced business services as a major force of innovation and diffusion; Las Eak-Ties en los servicios avanzados a empresas como factor relevante de la innovacion y su difusion

    Energy Technology Data Exchange (ETDEWEB)

    Almenar i Llongo, V.; Hernandez Sancho, F.; Solar i Marco, V.

    2012-07-01

    This paper tries to expose the role of weak-ties of advanced business services in both mechanisms which generate innovation as well as allow technological diffusion and transfer of innovations (spillovers). Assuming that the latest information generally flows to agents through weak ties, the Weak-Ties Hypothesis (WTH) is an approach that helps to explain the importance of the relations with the environment in the process of innovation and generation of new knowledge and its implementation and dissemination, evaluating the synergy's resulting from cooperation between agents. (Author) 21 refs.

  17. Parent Engagement in Youth Drug Prevention in Chinese Families: Advancement in Program Development and Evaluation

    Directory of Open Access Journals (Sweden)

    Sandra K. M. Tsang

    2011-01-01

    Full Text Available The escalating youth drug abuse problem in Hong Kong has attracted intense attention from the government, schools, and youth service professionals. Most preventive efforts have focused directly on positive youth development, very often through school programs delivered to secondary school students. There have been limited efforts to engage parents even though it is obvious that the family is actually the primary context of children and youth development. This paper will assert the importance of parental engagement in youth drug-prevention work, discuss some barriers in such parental involvement, present some promising local attempts and their strengths and limitations, and propose that sustained efforts are needed to build up theory-driven and evidence-based resources for Chinese communities on the subject.

  18. Recent advances in ceramic implants as drug delivery systems for biomedical applications

    OpenAIRE

    Vallet-Regi, Maria; Colilla, Montserrat; Manzano, Miguel

    2008-01-01

    Montserrat Colilla, Miguel Manzano, María Vallet-RegíDepartamento de Química Inorgánica y Bioinorgánica, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, SpainAbstract: Research in the development of new bioceramics with local drug delivery capability for bone regeneration technologies i...

  19. AN UPDATED REVIEW ON TECHNICAL ADVANCES TO ENHANCE DISSOLUTION RATE OF HYDROPHOBIC DRUGS

    OpenAIRE

    Anjan K. Mahapatra; P. Narasimha Murthy; E. Radha Rani; S. Pallavi Soujanya; Ruchita Kumari Patra

    2012-01-01

    The dissolution behavior of drugs continues to be one of the challenging aspects in formulation development. The advent of combinatorial chemistry and high throughput screening increased the number of hydrophobic compounds significantly. The Biopharmaceutical classification scheme (BCS) takes into account three major factors: solubility, intestinal permeability, and dissolution rate and all the three govern the rate and extent of oral absorption and hence bioavailability. Especially for BCS C...

  20. Grafting polyacrylates from carbohydrates by ATRP and formation of nanoparticles for advanced drug delivery

    OpenAIRE

    Hirosue, Masayuki

    2010-01-01

    The present thesis describes synthesis and characterization of graft copolymers from carbohydrates and formulation of nanoparticles(NP)s for drug carrier application. Side chains were produced grafting from carbohydrate based macroinitiators via Atom Transfer Radical Polymerization (ATRP). Firstly, hydrophobic homo-, random- and block-copolymer side chains were grafted from a beta-Cyclodextrin core, followed by starch as a core. Monomer conversions up to 80% were achieved in most cases and we...

  1. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations

    OpenAIRE

    Ali Khan A; Mudassir J; Mohtar N; Darwis Y

    2013-01-01

    Arshad Ali Khan, Jahanzeb Mudassir, Noratiqah Mohtar, Yusrida Darwis School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia Abstract: The delivery of drugs and bioactive compounds via the lymphatic system is complex and dependent on the physiological uniqueness of the system. The lymphatic route plays an important role in transporting extracellular fluid to maintain homeostasis and in transferring immune cells to injury sites, and is able to avoid first-pass me...

  2. Polymer-Based Sustained-Release Dosage Forms for Protein Drugs, Challenges, and Recent Advances

    OpenAIRE

    Wu, Fei; Jin, Tuo

    2008-01-01

    While the concept of using polymer-based sustained-release delivery systems to maintain therapeutic concentration of protein drugs for extended periods of time has been well accepted for decades, there has not been a single product in this category successfully commercialized to date despite clinical and market demands. To achieve successful systems, technical difficulties ranging from protein denaturing during formulation process and the course of prolonged in vivo release, burst release, an...

  3. Twitter K-H networks in action: Advancing biomedical literature for drug search.

    Science.gov (United States)

    Hamed, Ahmed Abdeen; Wu, Xindong; Erickson, Robert; Fandy, Tamer

    2015-08-01

    The importance of searching biomedical literature for drug interaction and side-effects is apparent. Current digital libraries (e.g., PubMed) suffer infrequent tagging and metadata annotation updates. Such limitations cause absence of linking literature to new scientific evidence. This demonstrates a great deal of challenges that stand in the way of scientists when searching biomedical repositories. In this paper, we present a network mining approach that provides a bridge for linking and searching drug-related literature. Our contributions here are two fold: (1) an efficient algorithm called HashPairMiner to address the run-time complexity issues demonstrated in its predecessor algorithm: HashnetMiner, and (2) a database of discoveries hosted on the web to facilitate literature search using the results produced by HashPairMiner. Though the K-H network model and the HashPairMiner algorithm are fairly young, their outcome is evidence of the considerable promise they offer to the biomedical science community in general and the drug research community in particular. PMID:26065982

  4. Challenges, Applications, and Recent Advances of Protein-Ligand Docking in Structure-Based Drug Design

    Directory of Open Access Journals (Sweden)

    Sam Z. Grinter

    2014-07-01

    Full Text Available The docking methods used in structure-based virtual database screening offer the ability to quickly and cheaply estimate the affinity and binding mode of a ligand for the protein receptor of interest, such as a drug target. These methods can be used to enrich a database of compounds, so that more compounds that are subsequently experimentally tested are found to be pharmaceutically interesting. In addition, like all virtual screening methods used for drug design, structure-based virtual screening can focus on curated libraries of synthesizable compounds, helping to reduce the expense of subsequent experimental verification. In this review, we introduce the protein-ligand docking methods used for structure-based drug design and other biological applications. We discuss the fundamental challenges facing these methods and some of the current methodological topics of interest. We also discuss the main approaches for applying protein-ligand docking methods. We end with a discussion of the challenging aspects of evaluating or benchmarking the accuracy of docking methods for their improvement, and discuss future directions.

  5. Innovative methods to study human intestinal drug metabolism in vitro : Precision-cut slices compared with Ussing chamber preparations

    NARCIS (Netherlands)

    van de Kerkhof, Esther G.; Ungell, Anna-Lena B.; Sjoberg, Asa K.; de Jager, Marina H.; Hilgendorf, Constanze; de Graaf, Inge A. M.; Groothuis, Geny M. M.

    2006-01-01

    Predictive in vitro methods to investigate drug metabolism in the human intestine using intact tissue are of high importance. Therefore, we studied the metabolic activity of human small intestinal and colon slices and compared it with the metabolic activity of the same human intestinal segments usin

  6. Providing the Basis for Innovative Improvements in Advanced LWR Reactor Passive Safety Systems Design: An Educational R and D Project

    International Nuclear Information System (INIS)

    This project characterizes typical two-phase stratified flow conditions in advanced water reactor horizontal pipe sections, following activation of passive cooling systems. It provides (1) a means to educate nuclear engineering students regarding the importance of two-phase stratified flow in passive cooling systems to the safety of advanced reactor systems and (2) describes the experimental apparatus and process to measure key parameters essential to consider when designing passive emergency core cooling flow paths that may encounter this flow regime. Based on data collected, the state of analysis capabilities can be determined regarding stratified flow in advanced reactor systems and the best paths forward can be identified to ensure that the nuclear industry can properly characterize two-phase stratified flow in passive emergency core cooling systems

  7. Advanced systems for the rapid detection of anthelmintic drugs in food

    OpenAIRE

    Keegan, Jemma Louise

    2011-01-01

    Several surface plasmon resonance (SPR) biosensor assays were developed and validated for the detection of anthelmintic veterinary drugs in liver tissue and milk using a QuEChERS (Quick, Easy, Cheap, Effective, Rugged and Safe) extraction procedure. The first screening assay was developed to detect 11 benzimidazole carbamates in milk and liver. In bovine milk the assay showed a limit of detection (LOD) of 2.7 μg kg-1 and a detection capability (CCβ) of 5 μg kg-1. Analyte recovery was in th...

  8. Advancing the vesosome, a multifunctional drug delivery platform, toward applied in vivo testing

    Science.gov (United States)

    Wong, Benjamin J.

    An optimal drug delivery vehicle should circulate long enough to reach the site of illness or disease, possess a large drug loading capacity, retain its contents over the course of treatment, and be able deliver its contents at a rate appropriate for maximum therapeutic benefit at the site of interest. The vesosome, a large lipid bilayer enclosing multiple, smaller liposomes, is our solution to addressing these needs. The external lipid bilayer offers a second barrier of protection for interior components and can also serve as the anchor for active targeting components. Furthermore, internal compartmentalization permits customization of separate environments for multiple therapeutics and release triggers. Previous work established the ability of the vesosome to retain its contents in vitro an order of magnitude longer than liposomes. To be viable in vivo, the vesosome must be functionalized for biocompatibility and tracking, and its synthetic procedure must be repeatable, reliable and result in a purified product. The vesosome was functionalized by introducing biocompatible polymers, such as poly(ethylene glycol) (PEG), and fluorescent dyes in their lipid-bound forms into the external membrane of the vesosome. The external vesosomal membrane is formed from large, flat lipid sheets in the interdigitated (L betaI) phase which, when heated, are used to encapsulate smaller drug-containing vesicles. Through X-Ray diffraction (XRD) and freeze-fracture transmission electron microscopy (FF-TEM), we established that the molar amounts of functionalized lipid required to label the vesosome for tracking and biocompatibility (˜5--7mol% total) did not prevent the formation of the interdigitated phase. Thus, functionalization of the external vesosome membrane can be achieved through functionalization of interdigitated sheets. For in vivo testing, functionalized vesosomes must be separated from unencapsulated vesicles and purification was performed using size exclusion

  9. "Is there nothing more practical than a good theory?": Why innovations and advances in health behavior change will arise if interventions are used to test and refine theory

    Directory of Open Access Journals (Sweden)

    Rothman Alexander J

    2004-07-01

    Full Text Available Abstract Theoretical and practical innovations are needed if we are to advance efforts to persuade and enable people to make healthy changes in their behavior. In this paper, I propose that progress in our understanding of and ability to promote health behavior change depends upon greater interdependence in the research activities undertaken by basic and applied behavioral scientists. In particular, both theorists and interventionists need to treat a theory as a dynamic entity whose form and value rests upon it being rigorously applied, tested and refined in both the laboratory and the field. To this end, greater advantage needs to be taken of the opportunities that interventions afford for theory-testing and, moreover, the data generated by these activities need to stimulate and inform efforts to revise, refine, or reject theoretical principles.

  10. The categorization of the impacts of the results of scientific and technological innovation in the Agency of Nuclear energy and advanced technologies (AENTA)

    International Nuclear Information System (INIS)

    Science and technology are essential to the development of contemporary societies, however, there are different concepts and methodologies internationally to assess the economic and social impact of science and technology. In our country he has worked intensely with this aim and has established a national nomenclature of impact of science, technology and innovation. The Agency of Nuclear energy and advanced technologies (AEN-TA) is intended to improve the management of the programmes and projects management system framed within the system of science and technological innovation of the Republic of Cuba (SCIT) and one of the aspects of your special attention is the proper selection and follow-up (ex - before and during) projects to ensure that they contribute to improving the level of economic and social of our country one of his fundamental premises. This work has aims to show how the bases of the categorization of the impacts of the projects were established in the AEN-Mt management programs, as a management tool for the selection and monitoring of them, and which are characterized by a flexibility that keeping their identity do not differ from the established in the country. (author)

  11. Evaluation of innovative stationary phase ligand chemistries and analytical conditions for the analysis of basic drugs by supercritical fluid chromatography.

    Science.gov (United States)

    Desfontaine, Vincent; Veuthey, Jean-Luc; Guillarme, Davy

    2016-03-18

    Similar to reversed phase liquid chromatography, basic compounds can be highly challenging to analyze by supercritical fluid chromatography (SFC), as they tend to exhibit poor peak shape, especially those with high pKa values. In this study, three new stationary phase ligand chemistries available in sub -2μm particle sizes, namely 2-picolylamine (2-PIC), 1-aminoanthracene (1-AA) and diethylamine (DEA), were tested in SFC conditions for the analysis of basic drugs. Due to the basic properties of these ligands, it is expected that the repulsive forces may improve peak shape of basic substances, similarly to the widely used 2-ethypyridine (2-EP) phase. However, among the 38 tested basic drugs, less of 10% displayed Gaussian peaks (asymmetry between 0.8 and 1.4) using pure CO2/methanol on these phases. The addition of 10mM ammonium formate as mobile phase additive, drastically improved peak shapes and increased this proportion to 67% on 2-PIC. Introducing the additive in the injection solvent rather than in the organic modifier, gave acceptable results for 2-PIC only, with 31% of Gaussian peaks with an average asymmetry of 1.89 for the 38 selected basic drugs. These columns were also compared to hybrid silica (BEH), DIOL and 2-EP stationary phases, commonly employed in SFC. These phases commonly exhibit alternative retention and selectivity. In the end, the two most interesting ligands used as complementary columns were 2-PIC and BEH, as they provided suitable peak shapes for the basic drugs and almost orthogonal selectivities. PMID:26895829

  12. The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development

    OpenAIRE

    Heslop, Emma; Csimma, Cristina; Straub, Volker; McCall, John; Nagaraju, Kanneboyina; Wagner, Kathryn R.; Caizergues, Didier; Korinthenberg, Rudolf; Flanigan, Kevin M.; Kaufmann, Petra; McNeil, Elizabeth; Mendell, Jerry; Hesterlee, Sharon; Wells, Dominic J.; BUSHBY, Kate

    2015-01-01

    Despite multiple publications on potential therapies for neuromuscular diseases (NMD) in cell and animal models only a handful reach clinical trials. The ability to prioritise drug development according to objective criteria is particularly critical in rare diseases with large unmet needs and a limited numbers of patients who can be enrolled into clinical trials. TREAT-NMD Advisory Committee for Therapeutics (TACT) was established to provide independent and objective guidance on the preclinic...

  13. Newer insights in drugs inhibiting formation and accumulation of advanced glycation end products.

    Directory of Open Access Journals (Sweden)

    Sana Alam

    2013-07-01

    Full Text Available It is now well established that non enzymatic glycation leads to formation of Amadori products which over course of time leads to formation of advanced glycation end products (AGEs. Accumulation of AGEs is very toxic and can have direct and indirect effects in the pathogenesis of various diseases including diabetes, alzheimer’s disease, rheumatoid arthritis etc. Hence, to curb these harmful effects, a number of natural and synthetic compounds are being investigated so as to reduce clinically the impact of AGEs. Here, various AGE inhibitors and breakers published till date are being reviewed. Also, potential novel therapies are also being explored.

  14. Display innovations through glass

    Science.gov (United States)

    Hamilton, Lori L.

    2016-03-01

    Prevailing trends in thin, lightweight, high-resolution, and added functionality, such as touch sensing, continue to drive innovation in the display market. While display volumes grow, so do consumers’ need for portability, enhanced optical performance, and mechanical reliability. Technical advancements in glass design and process have enabled display innovations in these areas while supporting industry growth. Opportunities for further innovation remain open for glass manufacturers to drive new applications, enhanced functionality, and increased demand.

  15. Innovation and employment

    OpenAIRE

    Vivarelli, Marco

    2015-01-01

    Studies find that technological change has contributed to the decline in manufacturing and to persistent unemployment in many advanced economies. While process innovation can be job-destroying, product innovation can imply the emergence of new firms, new sectors, and thus new jobs. But even for process innovation, the final impact on labor demand is shaped by market mechanisms that can compensate for the direct job-destroying impact if market and institutional rigidities do not impede them. P...

  16. Innovation and employment

    OpenAIRE

    Marco Vivarelli

    2015-01-01

    Studies find that technological change has contributed 
to the decline in manufacturing and to persistent unemployment in many advanced economies. While 
process innovation can be job-destroying, product innovation can imply the emergence of new firms, new sectors, and thus new jobs. But even for process innovation, the final impact on labor demand is shaped by market mechanisms that can compensate for the direct job-destroying impact if market and institutional rigidities do not impede them....

  17. Innovation networks

    CERN Document Server

    Ahrweiler, Petra

    2013-01-01

    This paper advances a framework for modeling the component interactions between cognitive and social aspects of scientific creativity and technological innovation. Specifically, it aims to characterize Innovation Networks; those networks that involve the interplay of people, ideas and organizations to create new, technologically feasible, commercially-realizable products, processes and organizational structures. The tri-partite framework captures networks of ideas (Concept Level), people (Individual Level) and social structures (Social-Organizational Level) and the interactions between these levels. At the concept level, new ideas are the nodes that are created and linked, kept open for further investigation or closed if solved by actors at the individual or organizational levels. At the individual level, the nodes are actors linked by shared worldviews (based on shared professional, educational, experiential backgrounds) who are the builders of the concept level. At the social-organizational level, the nodes...

  18. Irinotecan drug eluting beads used as a treatment of advanced intra hepatic cholangiocarcinoma.

    Science.gov (United States)

    Roch, Jean Amede; Palma-Gutierrez, John; Lapalus, Marie Georges; Paillet, Carole; Pilleul, Frank

    2008-01-01

    This report describes a 74-year-old male with unresectable intrahepatic cholangiocarcinoma (ICC). However surgical procedure is the only curative treatment, it often seems to be ineffective because of the aggressive behaviour of the disease. The role of systemic chemotherapy in the ICC is undefined with a median survival between 6.43 to 12.17 months obtained by using the combination chemotherapy of gemcitabine with cisplatin. In the present case, we performed a targeted treatment using drug eluting beads (DEB) with irinotecan (IRI) administered as transarterial-chemoembolization (TACE). After one session, the tumour vascularity decreased significantly at the one month evaluation on computed tomography (CT) scan of the liver. This case report suggested that minimally invasive transcatheter DEB embolization could be a promising, safe and effective treatment for selective patients with unresectable ICC. PMID:22470601

  19. Irinotecan drug eluting beads used as a treatment of advanced intra hepatic cholangiocarcinoma

    Directory of Open Access Journals (Sweden)

    Jean Amede Roch

    2008-10-01

    Full Text Available

    This report describes a 74-year-old male with unresectable intrahepatic cholangiocarcinoma (ICC. However surgical procedure is the only curative treatment, it often seems to be ineffective because of the aggressive behaviour of the disease. The role of systemic chemotherapy in the ICC is undefined with a median survival between 6.43 to 12.17 months obtained by using the combination chemotherapy of gemcitabine with cisplatin. In the present case, we performed a targeted treatment using drug eluting beads (DEB with irinotecan (IRI administered as transarterial-chemoembolization (TACE. After one session, the tumour vascularity decreased significantly at the one month evaluation on computed tomography (CT scan of the liver.  This case report suggested that minimally invasive transcatheter DEB embolization could be a promising, safe and effective treatment for selective patients with unresectable ICC.

  20. Erythropoiesis-stimulating agents for the management of anemia of chronic kidney disease: past advancements and current innovations.

    Science.gov (United States)

    Dutka, Paula

    2012-01-01

    Over the last century, remarkable advances have been made in the care of patients with end stage renal disease (ESRD), resulting in improved prognosis. However, for decades after the advent of dialysis, anemia-associated symptoms continued to adversely affect patients' daily lives. The identification, isolation, and eventual cloning of erythropoietin and its receptor led to development of erythropoiesis stimulating agents, revolutionizing anemia management. Continued advancements have paved the way for the discovery of novel erythropoiesis stimulating agents with enhanced properties. This article charts the history of anemia management in patients with ESRD, including the discovery of erythropoietin, and briefly reviews the development, mechanism of action, and select attributes of erythropoiesis-stimulating agents. PMID:23469411

  1. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

    Science.gov (United States)

    Godman, Brian; Haycox, Alan; Schwabe, Ulrich; Joppi, Roberta; Garattini, Silvio

    2008-01-01

    There are insufficient resources in the UK to fund all new technologies and new indications approved by the National Institute for Health and Clinical Excellence (NICE). Diverting funding from existing sources will have a detrimental effect on the provision of other priority services. The UK Office of Fair Trading (OFT) recently suggested a value-based pricing approach that appears workable but has generated considerable debate. Their proposal of a 25% premium for the originator product once generics are available is more generous than seen in a number of other European countries, where typically only the lowest priced product is reimbursed. The OFT proposal for a maximum 50% premium for patent-protected products, versus the prices of generics in a class or related classes, is also more generous than the proposed reforms for the pricing of proton pump inhibitors in Sweden or current reforms in Germany. In our opinion, the OFT proposals are persuasive and in accordance with the reforms seen in other European countries, and therefore should be adopted. The alternatives to fully funding new drugs or new indications as approved by NICE are either tightening the cost per QALY threshold, giving NICE an annual national budget to fund its advice alongside suggested areas for disinvestment, proactively switching patients from high-cost brand-name drugs to generics, or further delaying funding for new drugs and new indications approved by NICE. The majority of these suggestions are not in the best interests of patients or innovative pharmaceutical companies seeking to reap the rewards of their efforts. PMID:18198930

  2. Passive Safety Systems in Advanced Water Cooled Reactors (AWCRS). Case Studies. A Report of the International Project on Innovative Nuclear Reactors and Fuel Cycles (INPRO)

    International Nuclear Information System (INIS)

    This report presents the results from the International Project on Innovative Nuclear Reactors and Fuel Cycles (INPRO) collaborative project (CP) on Advanced Water Cooled Reactor Case Studies in Support of Passive Safety Systems (AWCR), undertaken under the INPRO Programme Area C. INPRO was launched in 2000 - on the basis of a resolution of the IAEA General Conference (GC(44)/RES/21) - to ensure that nuclear energy is available in the 21st century in a sustainable manner, and it seeks to bring together all interested Member States to consider actions to achieve innovation. An important objective of nuclear energy system assessments is to identify 'gaps' in the various technologies and corresponding research and development (R and D) needs. This programme area fosters collaboration among INPRO Member States on selected innovative nuclear technologies to bridge technology gaps. Public concern about nuclear reactor safety has increased after the Fukushima Daiichi nuclear power plant accident caused by the loss of power to pump water for removing residual heat in the core. As a consequence, there has been an increasing interest in designing safety systems for new and advanced reactors that are passive in nature. Compared to active systems, passive safety features do not require operator intervention, active controls, or an external energy source. Passive systems rely only on physical phenomena such as natural circulation, thermal convection, gravity and self-pressurization. Passive safety features, therefore, are increasingly recognized as an essential component of the next-generation advanced reactors. A high level of safety and improved competitiveness are common goals for designing advanced nuclear power plants. Many of these systems incorporate several passive design concepts aimed at improving safety and reliability. The advantages of passive safety systems include simplicity, and avoidance of human intervention, external power or signals. For these reasons, most

  3. Non-Oral Drug Delivery Strategies: From Early Diagnosis to Advanced Treatments

    Directory of Open Access Journals (Sweden)

    Claudia Trenkwalder

    2015-08-01

    Full Text Available This educational symposium, sponsored by Britannia Pharmaceuticals Limited, was held during the 1st Congress of the European Academy of Neurology (EAN, which took place from 20th-23rd June 2015 in Berlin, Germany. The symposium reviewed the role of non-oral drug delivery strategies in patients with Parkinson’s disease (PD and how they can overcome problems that occur with the gastrointestinal (GI route of administration in many patients. GI dysfunction is recognised as a common problem in PD and may in fact be a preclinical marker of the disease. It can affect the absorption of oral medication resulting in OFF periods and unreliable control of motor symptoms, which in turn can have a negative impact on quality of life (QoL. Delayed time-to-ON (TTO after an oral levodopa dose and dose failures are known to be significant contributors to total OFF time. Results of the recently completed AM-IMPAKT trial in patients with morning akinesia due to a delay in the onset of oral levodopa effect demonstrate that apomorphine intermittent injection (penject is able to provide rapid and effective resolution of such complications, restoring patients to the ON state quickly and allowing them to get on with their daily activities.

  4. Advanced topical drug delivery system for the management of vaginal candidiasis.

    Science.gov (United States)

    Johal, Himmat Singh; Garg, Tarun; Rath, Goutam; Goyal, Amit Kumar

    2016-01-01

    Vaginal candidiasis or vulvovaginal candidiasis (VC) is a common mucosal infection of vagina, mainly caused by Candida species. The major symptoms of VC are dyspareunia, pruritis, itching, soreness, vagina as well as vulvar erythema and edema. Most common risk factors that lead to the imbalance in the vaginal micro biota are the use of antibiotics, pregnancy, diabetes mellitus, immuno suppression as in AIDS or HIV patients, frequent sexual intercourse, spermicide and intra-uterine devices and vaginal douching. Various anti-fungal drugs are available for effective treatment of VC. Different conventional vaginal formulations (creams, gels, suppositories, powder, ointment, etc.) for VC are available today but have limited efficacy because of lesser residence time on vaginal epithelium due to self-cleansing action of vagina. So to overcome this problem, an extended and intimate contact with vaginal mucosa is desired; which can be accomplished by utilizing mucoadhesive polymers. Mucoadhesive polymers have an excellent binding capacity to mucosal tissues for considerable period of time. This unique property of these polymers significantly enhances retention time of different formulations on mucosal tissues. Currently, various novel formulations such as liposomes, nano- and microparticles, micro-emulsions, bio-adhesive gel and tablets are used to control and treat VC. In this review, we focused on current status of vaginal candidiasis, conventional and nanotechnology inspired formulation approaches. PMID:24959937

  5. Innovative Training Experience for Advancing Entry Level, Mid-Skilled and Professional Level URM Participation in the Geosciences Workforce

    Science.gov (United States)

    Okoro, M. H.; Johnson, A.

    2015-12-01

    The representation of URMs in the U.S. Geosciences workforce remains proportionally low compared to their representation in the general population (Bureau of Labor Sta.s.cs, 2014). Employment in this and related industries is projected to grow 32% by 2030 for minority workers (Gillula and Fullenbaum, 2014), corresponding to an additional 48,000 jobs expected to be filled by minorities (National Research Council, 2014). However, there is a shortage of employees with proper training in the hard sciences (Holeywell, 2014; Ganzglass, 2011), as well as craft skills (Hoover and Duncan, 2013), both important for middle skill employment. Industry recognizes the need for developing and retaining a diverse workforce, therefore we hightlight a program to serve as a potential vanguard initative for developing an innovative training experience for URM and underserved middle skilled workers with essential knowledge, experience and skills necessary to meet the demands of the Geosciences industry's growing need for a safe, productive and diverse workforce. Objectives are for participants to achieve the following: understanding of geosciences workforce trends and associated available opportunities; mastery of key environmental, health and safety topics; improvements in decision making skills and preparedness for responding to potential environmental, health and safety related situations; and engagement in one-on-one coaching sessions focused on resume writing, job interviewing and key "soft skills" (including conflict resolution, problem solving and critical observation, representing 3 major skills that entry- level workers typically lack.

  6. Innovation on Energy Power Technology (15)Great Advances in Power System Stabilizing Technology triggered by the Wide-area Outage

    Science.gov (United States)

    Egawa, Masanao

    On July 23, 1987, a very hot day, the largest wide-area power outage occurred in Kanto-Area, Japan. The cause was a voltage collapse on the bulk power network of Tokyo Electric Power Company, due to the abnormal rate of demand rising following resume after lunch break. Aggressive studies on voltage collapse throughout industry and university have led to great advances in power system stability. This essay describes the detail record of the outage, the applied countermeasures, and the inside story when the multiple voltage solutions of power flow on actual power system were found out for the first time.

  7. Update on celiac disease – etiology, differential diagnosis, drug targets, and management advances

    Directory of Open Access Journals (Sweden)

    Scanlon SA

    2011-12-01

    Full Text Available Samantha A Scanlon1, Joseph A Murray1,21Department of Internal Medicine, 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USAAbstract: Celiac disease (CD is an immune-mediated enteropathy triggered by exposure to wheat gluten and similar proteins found in rye and barley that affects genetically susceptible persons. This immune-mediated enteropathy is characterized by villous atrophy, intraepithelial lymphocytosis, and crypt hyperplasia. Once thought a disease that largely presented with malnourished children, the wide spectrum of disease activity is now better recognized and this has resulted in a shift in the presenting symptoms of most patients with CD. New advances in testing, both serologic and endoscopic, have dramatically increased the detection and diagnosis of CD. While the gluten-free diet is still the only treatment for CD, recent investigations have explored alternative approaches, including the use of altered nonimmunogenic wheat variants, enzymatic degradation of gluten, tissue transglutaminase inhibitors, induction of tolerance, and peptides to restore integrity to intestinal tight junctions.Keywords: immune-mediated enteropathy, gliadin, gluten, epidemiology, CD diagnosis, therapy

  8. Advances of new antidiabetic drugs%新型抗糖尿病药物的研究进展

    Institute of Scientific and Technical Information of China (English)

    徐斯盛; 张惠斌; 周金培; 黄建军

    2011-01-01

    Diabetes mellitus, an epidemic metabolic disorder characterized by high blood glucose level associated with various microvascular complications, is one of the main causes of human suffering across the globe.With the advance of the pathogenesis of diabetic research, the study of anti-diabetic drugs has transformed from the traditional drugs to the current products with new targets and new mechanism.Some of these drugs are already marketed or still in clinical trials, e.g.GLP-1 activator, DPP4 inhibitor, C.PR119 activator, SGLT-2 inhibitor, 11βHSDl inhibitor, PTPIB inhibitor and so on.In this article, the new antidiabetic drugs mentioned above are reviewed with regard to the therapeutic targets and mechanism.%糖尿病是一种慢性代谢性疾病,其主要表现为高血糖及微血管并发症,是影响人类生活的重大疾病之一.随着对糖尿病发病机制的深入研究,糖尿病药物研究也从对传统机制的药物研究过渡到对具有新作用靶点和新作用机制的药物研究.其中一些药物已经上市或正处于临床研究阶段,如胰高血糖素样肽.1受体激动剂、二肽基肽酶4抑制剂、G蛋白偶联受体119激动剂、钠一葡萄糖同向转运体-2抑制剂、11β-羟基固醇脱氢酶1抑制剂以及蛋白质酪氨酸磷酸酶抑制剂等.本文按作用靶点和机制分类对上述新型抗糖尿病药物进行了综述.

  9. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.

    Science.gov (United States)

    Man, Shan; Munoz, Raquel; Kerbel, Robert S

    2007-12-01

    disease development is illustrated. Metastases that eventually stop responding to a particular therapy can be removed as a source of variant cell lines which have both 'refractory' and highly metastatic phenotypes. Such models may provide a more accurate picture of the potential responsiveness to an experimental therapy so that a high degree of responsiveness observed could be a factor in deciding whether to move a particular therapy forward into phase I/phase II clinical trial evaluation. An example of this is illustrated using doublet metronomic low-dose chemotherapy for the treatment of advanced metastatic breast cancer, using two conventional chemotherapy drugs, namely, cyclophosphamide and UFT, a 5-FU oral prodrug. PMID:17846863

  10. Euler Technology Assessment - SPLITFLOW Code Applications for Stability and Control Analysis on an Advanced Fighter Model Employing Innovative Control Concepts

    Science.gov (United States)

    Jordan, Keith J.

    1998-01-01

    This report documents results from the NASA-Langley sponsored Euler Technology Assessment Study conducted by Lockheed-Martin Tactical Aircraft Systems (LMTAS). The purpose of the study was to evaluate the ability of the SPLITFLOW code using viscous and inviscid flow models to predict aerodynamic stability and control of an advanced fighter model. The inviscid flow model was found to perform well at incidence angles below approximately 15 deg, but not as well at higher angles of attack. The results using a turbulent, viscous flow model matched the trends of the wind tunnel data, but did not show significant improvement over the Euler solutions. Overall, the predictions were found to be useful for stability and control design purposes.

  11. The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases.

    Science.gov (United States)

    Sachs-Barrable, Kristina; Conway, Jocelyn; Gershkovich, Pavel; Ibrahim, Fady; Wasan, Kishor M

    2014-11-01

    Neglected tropical diseases (NTDs) are infections which are endemic in poor populations in lower- and middle-income countries (LMIC). Approximately one billion people have now or are at risk of getting an NTD and yet less than 5% of research dollars are focused on providing treatments and prevention of these highly debilitating and deadly conditions. The United States Food and Drug Administration (FDA) Orphan Drug Designation program (ODDP) provides orphan status to drugs and biologics, defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases and/or disorders that affect fewer than 200 000 people in the United States, or that affect more than 200 000 persons but are not expected to recover the costs of developing and marketing a treatment drug. These regulations have led to the translation of rare disease knowledge into innovative rare disease therapies. The FDA Guidance for Industry on developing drugs for the treatment and prevention of NTDs describes the following regulatory strategies: Orphan Product Designation, Fast Track Designation, Priority Review Designation, Accelerated Approval and Tropical Disease Priority Review Voucher. This paper will discuss how these regulations and especially the ODDP can improve the clinical development and accessibility of drug products for NTDs. PMID:24512098

  12. Helical tomotherapy: an innovative radiotherapy technique for the treatment of locally advanced oropharynx and inoperable oral cavity carcinoma

    International Nuclear Information System (INIS)

    To report our initial clinical experience of helical tomotherapy (HT) in the treatment of locally advanced oropharynx and inoperable oral cavity cancer. Between February 2008 and January 2011, 24 consecutive patients, 15 with oropharyngeal cancer and 9 with oral cavity cancer were treated with exclusive radiotherapy or concomitant chemoradiotherapy. Simultaneous integrated boost (SIB) in 30 fractions scheme was prescribed to all patients, using Helical Tomotherapy. Doses administered to primary tumor, oropharynx/oral cavity and positive lymph-nodes and negative lymph-nodes were 66–67.5 Gy, 60–63 Gy and 54 Gy, respectively. Complete response rate for the oropharynx and the oral cavity group was 86.7% and 77.8%, respectively. The 1 and 2-year Overall Survival (OS) and Disease Free Survival (DFS) rate for the oropharynx group was 92.9%, 85.1%, 92.9% and 77.4% respectively. For the oral cavity group, 1 and 2-year OS and DFS rates were 55.6%, 55.6%, 75% and 75%, respectively. No patient developed grade ≥3 mucositis, dysphagia or dermatitis. The maximum late-toxicity grade observed was 2, for all the variables examined. HT appears to achieve encouraging clinical outcomes in terms of response, survival and toxicity rates

  13. Innovation surveys: A researcher's perspective

    OpenAIRE

    Mark Tomlinson

    2000-01-01

    An earlier version of this paper was prepared for the joint OECD/Eurostat workshop on innovation surveys, OECD, Paris, June 30th 1999. The paper addresses some issues about the nature of innovation surveys (particularly the new Community Innovation Surveys) and how they might be improved to take on board several crucial developments in contemporary advanced economies. In particular the following topics are discussed: the increased distribution of innovative activity across firms and networks;...

  14. Advanced deep reactive-ion etching technology for hollow microneedles for transdermal blood sampling and drug delivery.

    Science.gov (United States)

    Liu, Yufei; Eng, Pay F; Guy, Owen J; Roberts, Kerry; Ashraf, Huma; Knight, Nick

    2013-06-01

    Using an SPTS Technologies Ltd. Pegasus deep reactive-ion etching (DRIE) system, an advanced two-step etching process has been developed for hollow microneedles in applications of transdermal blood sampling and drug delivery. Because of the different etching requirements of both narrow deep hollow and large open cavity, hollow etch and cavity etch steps have been achieved separately. This novel two-step etching process is assisted with a bi-layer etching mask. Results show that the etch rate of silicon during this hollow etch step was about 7.5 microm/min and the etch rate of silicon during this cavity etch step was about 8-10 microm/min, using the coil plasma etching power between 2.0 and 2.8 kW. Especially for the microneedle bores etch, the deeper it etched, the slower the etch rate was. The microneedle bores have successfully been obtained 75-150 microm in inner diametre and 700-1000 microm long with high aspect ratio DRIE, meanwhile, the vertical sidewall structures have been achieved with the high etch load exposed area over 70% for the cavity etch step. PMID:24046906

  15. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.

    Science.gov (United States)

    Singh, Jagdeep; Garg, Tarun; Rath, Goutam; Goyal, Amit K

    2016-06-01

    From the early sixteenth and seventeenth centuries to the present day of life, tuberculosis (TB) still is a global health threat with some new emergence of resistance. This type of emergence poses a vital challenge to control TB cases across the world. Mortality and morbidity rates are high due to this new face of TB. The newer nanotechnology-based drug-delivery approaches involving micro-metric and nano-metric carriers are much needed at this stage. These delivery systems would provide more advantages over conventional systems of treatment by producing enhanced therapeutic efficacy, uniform distribution of drug molecule to the target site, sustained and controlled release of drug molecules and lesser side effects. The main aim to develop these novel drug-delivery systems is to improve the patient compliance and reduce therapy time. This article reviews and elaborates the new concepts and drug-delivery approaches for the treatment of TB involving solid-lipid particulate drug-delivery systems (solid-lipid micro- and nanoparticles, nanostructured lipid carriers), vesicular drug-delivery systems (liposomes, niosomes and liposphere), emulsion-based drug-delivery systems (micro and nanoemulsion) and some other novel drug-delivery systems for the effective treatment of tuberculosis and role of immunomodulators as an adjuvant therapy for management of MDR-TB and XDR-TB. PMID:26289212

  16. Smokeless Cook stove an Advancement of the Combustion Technology and Innovative Approach towards Eco-Efficiency and Low Emissions in Rural Areas

    Directory of Open Access Journals (Sweden)

    Manoj Kumar Sharma

    2015-05-01

    Full Text Available In rural India many women spending several hours a day cooking over an indoor open stove is a normal practice. What these women fail to realize is that there is an invisible killer in their kitchen of burning biomass fuels causes almost 500,000 deaths every year in India alone. A design initiative can use its design expertise to help these women continue with their traditional culture, while empowering them to select a way of cooking that does not endanger their lives. It describes the brief and the open-innovation process used in creating the ‘Chulha’ (Stove – a low-smoke stove that prevents sickness and death from indoor air pollution due to cooking activities with biomass fuels in rural low-income communities. Evaluation included a certification of stove’s thermal performance, fuel consumption and carbon monoxide emissions. Stoves under testing used bio-organic waste. The firewood used as fuel was free from any potential pollutants. The design brief challenged team has to come up with a low-smoke solution for healthy and safe cooking able to fit the local socio-cultural and infrastructural conditions of rural and semi-urban areas. More specifically, objectives were to design, develop and test a solution, which able to reduce indoor pollution and therefore health-related diseases with respect to local culinary habits and cooking behaviors. With the advancement of the combustion technology and innovative approach towards applying the known principle of cook stove designing. The cook stove technology has gain the boost and now fourfold improvement in the overall thermal efficiency as compare to the traditional tri-stone cook stove. Apart from the type and quality of the fuel used, design of the cook stove chamber is the deciding factor for the associated emission causing by the fuel combustion. . TIDE has put up an effort to train more entrepreneurs. But finding the right candidate for training is a limiting factor to overcome.

  17. Innovation af innovation

    DEFF Research Database (Denmark)

    Harste, Gorm

    2009-01-01

    , at innovation af innovationen forsøges gennemført på en måde, hvor tiden kræves at forholde sig til sin egen tidslighed i form af fremtid, nutid, fortid og ikke mindst i form af samtidighed. I tiden skal vi iagttage, hvordan vi iagttager tiden. Vi dobbelt-koder tiden på samme måde, som forskning forsker i...... organisationssystemerne. De to typer systemer kan noget helt bestemt med fænomenet tid. De kan synkronisere. Analyseres organisationssystemer ser vi, imidlertid at innovation kræver ro. Stærkt innovative systemer er militærsystemet og kunstsystemet, der også inddrages, og hvor vi ser paradokset mellem innovation og...... involution. Tid er med et medium og ikke et lufttomt rum. Tid er end ikke en gasart, men udgør et solidt fluidum, som samfundet bader i og flyder i, konstant i bevægelse. Reformer forudsætter former, og innovation forudsætter involution. Kun sådan muliggøres evolution....

  18. Open Innovation

    OpenAIRE

    Аникина, К. Ю.; Таланкина, Н. Г.

    2006-01-01

    In the past 10 years, numerous interesting articles, book chapters, and books have been written on open innovation strategies in mainly large companies. While closed innovation models have resulted in important breakthrough innovations, many large companies have abandoned vertical integration strategies in recent years and have moved toward a combination of both closed and open innovation models that are used for reaching different sets of innovative goals. The definition of open innovation a...

  19. Attitudes about Advances in Sweat Patch Testing in Drug Courts: Insights from a Case Study in Southern California

    Science.gov (United States)

    Polzer, Katherine

    2010-01-01

    Drug courts are reinventing the drug testing framework by experimenting with new methods, including use of the sweat patch. The sweat patch is a band-aid like strip used to monitor drug court participants. The validity and reliability of the sweat patch as an effective testing method was examined, as well as the effectiveness, meaning how likely…

  20. Compulsive drug use and its neural substrates.

    Science.gov (United States)

    Lesscher, Heidi M B; Vanderschuren, Louk J M J

    2012-01-01

    Drug addiction is a chronic relapsing brain disease, characterized by compulsive drug use. Despite the fact that drug addiction affects millions of people worldwide, treatments for this disorder are limited in number and efficacy. In our opinion, understanding the neural underpinnings of drug addiction would open new avenues for the development of innovative treatments for this disorder. Based on an awareness that drug use and drug reward do not equal drug addiction, there has been increasing interest in developing animal models of addiction that mimick the loss of control over drug use more closely than existing models aimed at studying drug reward. The present review provides an overview of animal studies of compulsive drug use and the neural mechanisms involved. First, the employed models are summarized, with a particular emphasis on models of escalation of drug use and resistance to punishment. Next, we discuss mechanisms within the (ventral and dorsal) striatum and (central) amygdala that have recently been implicated in the compulsive seeking and taking of alcohol and cocaine. The studies discussed here provide a promising line of research that will advance our knowledge of the neural circuits involved in the self-destructive behavior that characterizes drug addiction. PMID:23079511

  1. Innovation Gains More Strengths

    Institute of Scientific and Technical Information of China (English)

    Wang Ting

    2007-01-01

    @@ Innovation ,is a hot word in 2007 for the Chinese textile industry.Encountering the export drawback, RMB appreciation, trade barrier,energy-saving and social compliance, Chinese textile industry find outthat the innovation, along with the advancing of production technology,branding strategy and scientific management,could improve its competitiveness in domestic and overseas markets. The China Textile Innovation Conference, held in Nov.2007, could be defined as an annual general summary, for the textile enterprises in China as well as the whole industry, to acknowledge what they have achieved,and to know what to do in the future.

  2. Advancement on pharmacogenomics of partial antitumor drugs%部分抗肿瘤药物基因组学研究进展

    Institute of Scientific and Technical Information of China (English)

    华之卉; 侯颖; 宋洪涛

    2009-01-01

    Recently, diverse effects and side effects of antitumor drugs induced by individual difference have received considerable attention. Studies on pharmacogenomics show that genomic polymorphism is closely associated with individual difference and side effects of antitumor drugs. The paper summarizes the advancement on pharmacogenomics of partial antitumor drugs.%近年来,由于个体差异引起抗肿瘤药物疗效和毒副作用的不同受到越来越多的重视.药物基因组学的研究结果表明基因多态性与抗肿瘤药物个体间作用多样性及毒副作用之间的关系密切.本文就部分抗肿瘤药物基因组学的研究进展加以综述.

  3. Early Purchaser Involvement in Open Innovation- the case of an advanced purchasing function triggering the absorption of external knowledge in the French automotive industry

    OpenAIRE

    Servajean-Hilst, Romaric; Picaud, Katia

    2014-01-01

    International audience This paper investigates the mechanisms that trigger the absorption of external knowledge in an innovative French automotive firm. An ethnographic-inspired study conducted by an academic embedded within the Innovation Purchasing Department has enable us to present a rare and new function of Purchasing that plays an important role between potential new suppliers and Research and Development personnel.

  4. Mindful innovation

    DEFF Research Database (Denmark)

    Olsen, Poul Bitsch

    2008-01-01

    Mindful innovation is an approach to innovation that pays attention to people's experience in an organization rather than to formal organization or social role.......Mindful innovation is an approach to innovation that pays attention to people's experience in an organization rather than to formal organization or social role....

  5. Innovative didaktik

    DEFF Research Database (Denmark)

    Lund, Birthe

    Innovative didaktik. This deals with innovative didaktik from at methodological point of view in three ways - how to define the concept, how to develop it and how analyse it. Issues analysed: How to create innovative students? How to create innovative learning envoriments? These are core questions...

  6. Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method

    OpenAIRE

    Schuitenmaker Martin S; Boom Frits A; Swart Eleonora L; van Leeuwen Roelof WF; Hugtenburg Jacqueline G

    2010-01-01

    Abstract Background The pharmacotherapeutic treatment of patients with cancer is generally associated with multiple side-effects. Drug interactions and duplicate prescriptions between anti-cancer drugs or interactions with medication to treat comorbidity can reinforce or intensify side-effects. The aim of the present study is to gain more insight into the prevalence of drug interactions and duplicate prescriptions among patients being treated in the outpatient day care departments for oncolog...

  7. Exploring the fit between CSR and innovation

    OpenAIRE

    Steven P. MacGregor; Fontrodona, Joan

    2008-01-01

    An exploration of the fit or space between CSR and innovation is presented, based on the RESPONSE project, a 15-month study involving 60 SMEs throughout Europe. The main practical output of the project was the Social Innovation model, yet a conceptual understanding of CSR and innovation is best advanced through the three hypotheses that constitute the conclusions of the project: H1) The diffusion of CSR should be modelled on the diffusion of innovation; H2) CSR implementation and innovation c...

  8. Innovation in nuclear technology

    International Nuclear Information System (INIS)

    Innovation has been a driving force for the success of nuclear energy and remains essential for its future. For the continued safe and economically effective operation and maintenance of existing nuclear systems, and to meet the goals set out by projects aiming at designing and implementing advanced systems for the future, efficient innovation systems are needed. Consequently, analysing innovation systems is essential to understand their characteristics and enhance their performance in the nuclear sector. Lessons learnt from innovation programmes that have already been completed can help enhance the effectiveness of future programmes. The analysis of past experience provides a means for identifying causes of failure as well as best practices. Although national and local conditions are important factors, the main drivers for the success of innovative endeavors are common to all countries. Cooperation and coordination among the various actors are major elements promoting success. All interested stakeholders, including research organisations, industrial actors, regulators and civil society, have a role to play in supporting the success of innovation, but governments are an essential trigger, especially for projects with long durations and very ambitious objectives. Governments have a major role to play in promoting innovation because they are responsible for the overall national energy policy which sets the stage for the eventual deployment of innovative products and processes. Moreover, only governments can create the stable legal and regulatory framework favourable to the undertaking and successful completion of innovation programmes. International organisations such as the NEA may help enhance the effectiveness of national policies and innovation programmes by providing a forum for exchanging information, facilitating multilateral collaboration and joint endeavors, and offering technical support for the management of innovative programmes

  9. Drug Elucidation: Invertebrate Genetics Sheds New Light on the Molecular Targets of CNS Drugs

    Directory of Open Access Journals (Sweden)

    Donard S. Dwyer

    2014-07-01

    Full Text Available Many important drugs approved to treat common human diseases were discovered by serendipity, without a firm understanding of their modes of action. As a result, the side effects and interactions of these medications are often unpredictable, and there is limited guidance for improving the design of next-generation drugs. Here, we review the innovative use of simple model organisms, especially Caenorhabditis elegans, to gain fresh insights into the complex biological effects of approved CNS medications. Whereas drug discovery involves the identification of new drug targets and lead compounds/biologics, and drug development spans preclinical testing to FDA approval, drug elucidation refers to the process of understanding the mechanisms of action of marketed drugs by studying their novel effects in model organisms. Drug elucidation studies have revealed new pathways affected by antipsychotic drugs, e.g., the insulin signaling pathway, a trace amine receptor and a nicotinic acetylcholine receptor. Similarly, novel targets of antidepressant drugs and lithium have been identified in C. elegans, including lipid-binding/transport proteins and the SGK-1 signaling pathway, respectively. Elucidation of the mode of action of anesthetic agents has shown that anesthesia can involve mitochondrial targets, leak currents and gap junctions. The general approach reviewed in this article has advanced our knowledge about important drugs for CNS disorders and can guide future drug discovery efforts.

  10. Collaborative innovation

    DEFF Research Database (Denmark)

    Torfing, Jacob; Sørensen, Eva; Hartley, Jean

    2013-01-01

    There are growing pressures for the public sector to be more innovative but considerable disagreement about how to achieve it. This article uses institutional and organizational analysis to compare three major public innovation strategies. The article confronts the myth that the market......-driven private sector is more innovative than the public sector by showing that both sectors have a number of drivers of as well as barriers to innovation, some of which are similar, while others are sector specific. The article then systematically analyzes three strategies for innovation: New Public Management...... for enhancing public innovation is contingent rather than absolute. Some contingencies for each strategy are outlined....

  11. The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives.

    Science.gov (United States)

    Martorana, Annamaria; Perricone, Ugo; Lauria, Antonino

    2016-01-01

    Have you a compound in your lab, which was not successful against the designed target, or a drug that is no more attractive? The drug repurposing represents the right way to reconsider them. It can be defined as the modern and rationale approach of the traditional methods adopted in drug discovery, based on the knowledge, insight and luck, alias known as serendipity. This repurposing approach can be applied both in silico and in wet. In this review we report the molecular modeling facilities that can be of huge support in the repurposing of drugs and/or unsuccessful lead compounds. In the last decades, different methods were proposed to help the scientists in drug design and in drug repurposing. The steps strongly depend on the approach applied. It could be a ligand or a structure based method, correlated to the use of specific means. These processes, starting from a compound with potential therapeutic properties and a sizeable number of toxicity passed tests, can successfully speed up the very slow development of a molecule from bench to market. Herein, we discuss the facilities available to date, classifying them by methods and types. We have reported a series of databases, ligand and structure stand-alone software, and of web-based tools, which are free accessible to scientific community. This review does not claim to be exhaustive, but can be of interest to help in drug repurposing through in silico methods, as a valuable tool for the medicinal chemistry community. PMID:26881716

  12. A Typology of Reverse Innovation

    DEFF Research Database (Denmark)

    von Zedtwitz, Max; Corsi, Simone; Søberg, Peder Veng;

    2015-01-01

    Reverse innovation commonly refers to an innovation initially launched in a developing country and later introduced to an advanced country. Adopting a linear innovation model with the four sequential phases of concept ideation, product development, primary target market introduction, and subsequent...... secondary market introduction, this study expands the espoused definition of reverse innovation beyond its market-introduction focus with reversals in the flow of innovation in the ideation and product development phases. Recognizing that each phase can take place in different geographical locations, the...... taking place in an emerging country. This analytical framework allows recasting of current research at the intersection between innovation and international business. Of the 10 reverse innovation flows, six are new and have not been covered in the literature to date. The study addresses questions of...

  13. MRI-detectable polymeric micelles incorporating platinum anticancer drugs enhance survival in an advanced hepatocellular carcinoma model

    OpenAIRE

    Vinh NQ; Naka S; Cabral H; Murayama H.; Kaida S.; Kataoka K; Morikawa S; Tani T

    2015-01-01

    Nguyen Quoc Vinh,1 Shigeyuki Naka,1 Horacio Cabral,2 Hiroyuki Murayama,1 Sachiko Kaida,1 Kazunori Kataoka,2 Shigehiro Morikawa,3 Tohru Tani4 1Department of Surgery, Shiga University of Medical Science, Shiga, Japan; 2Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan; 3Department of Nursing, Shiga University of Medical Science, Shiga, Japan; 4Biomedical Innovation Center, Shiga University of Medical Science, Shiga, Japan Abstract: Hepatocellu...

  14. Measuring Innovation

    OpenAIRE

    Cobbe, Brian

    2011-01-01

    The aim of this thesis is to conduct an on-site survey of IKEA Of Sweden, Älmhult (IKEA 2010b), with the aim to determine if IKEA Of Sweden, as an empirical case, innovates within its organization. Measuring innovation is achieved by investigating the level of alignment of the daily operational activities employed by the IKEA Of Sweden organization, with key, modern managerial theorists in the field of innovation and organizational structure; namely, Henry Chesbrough’s Open Innovation paradig...

  15. Brugerdreven innovation

    DEFF Research Database (Denmark)

    Helms, Niels Henrik; Larsen, Lasse Juel

    2007-01-01

    På et generelt plan er vores afsæt et opgør med traditionelle modeller for kreativitet og innovation. Artiklen mener, at brugerdreven innovation ikke bare en god idé, men en beskrivelse af, hvordan innovation finder sted. Vores afsæt er interaktionsdesign, hvor vi bygger på den antagelse...

  16. Organising Innovation

    NARCIS (Netherlands)

    J.C.M. van den Ende (Jan)

    2008-01-01

    textabstractInnovation offers many opportunities for corporations. That is beyond dispute. The only question is how to make the most of them. In this lecture, I show what the process of innovation entails; I give examples of successful and failed innovations and I discuss the current issues and tren

  17. 扁平苔藓药物治疗进展%Advances in the drug treatment of lichen planus

    Institute of Scientific and Technical Information of China (English)

    周勐; 简晓清

    2013-01-01

    Lichen planus ( LP ) is a chronic or subacute inflammatory dermatosis of the mucocutaneous surfaces that can present with a variety of clinical manifestations. The pathogenesis of LP is unknown and LP is difficult to cure. A variety of drugs are used to treat LP, in addition to commonly used drugs such as steroid hormones, retinoic acid, immunosuppressant, etc. There are sul-fasalazine, levamisole, biological agents and other drugs. In this paper, the latest research on the LP drug therapy are reviewed, in order to provide drug information and treatment guidance for the correct treatment of LP.%扁平苔藓(lichen planus,LP)是慢性或亚急性炎症性疾病,病因未明,治疗较困难.现在有多种药物用于治疗LP,除类固醇激素、维甲酸类、免疫抑制剂等常用药物外,还有柳氮磺吡啶、左旋咪唑、生物制剂等药物.文中就近年来治疗LP的药物研究进展做一综述,为正确治疗LP提供药物信息和指导.

  18. High-content live cell imaging with RNA probes: advancements in high-throughput antimalarial drug discovery

    Science.gov (United States)

    Cervantes, Serena; Prudhomme, Jacques; Carter, David; Gopi, Krishna G; Li, Qian; Chang, Young-Tae; Le Roch, Karine G

    2009-01-01

    Background Malaria, a major public health issue in developing nations, is responsible for more than one million deaths a year. The most lethal species, Plasmodium falciparum, causes up to 90% of fatalities. Drug resistant strains to common therapies have emerged worldwide and recent artemisinin-based combination therapy failures hasten the need for new antimalarial drugs. Discovering novel compounds to be used as antimalarials is expedited by the use of a high-throughput screen (HTS) to detect parasite growth and proliferation. Fluorescent dyes that bind to DNA have replaced expensive traditional radioisotope incorporation for HTS growth assays, but do not give additional information regarding the parasite stage affected by the drug and a better indication of the drug's mode of action. Live cell imaging with RNA dyes, which correlates with cell growth and proliferation, has been limited by the availability of successful commercial dyes. Results After screening a library of newly synthesized stryrl dyes, we discovered three RNA binding dyes that provide morphological details of live parasites. Utilizing an inverted confocal imaging platform, live cell imaging of parasites increases parasite detection, improves the spatial and temporal resolution of the parasite under drug treatments, and can resolve morphological changes in individual cells. Conclusion This simple one-step technique is suitable for automation in a microplate format for novel antimalarial compound HTS. We have developed a new P. falciparum RNA high-content imaging growth inhibition assay that is robust with time and energy efficiency. PMID:19515257

  19. HIMSS Venture+ Forum and HX360 Provide Industry View of Health Technology Innovation, Startup and Investment Activity; Advancing the New Model of Care.

    Science.gov (United States)

    Burde, Howard A; Scarfo, Richard

    2015-01-01

    Presented by HIMSS, the Venture+ Forum program and pitch competition provides a 360-degree view on health technology investing and today's top innovative companies. It features exciting 3-minute pitch presentations from emerging and growth-stage companies, investor panels and a networking reception. Recent Venture+ Forum winners include TowerView Health, Prima-Temp, ActuaiMeds and M3 Clinician. As an industry catalyst for health IT innovation and business-building resource for growing companies and emerging technology solutions, HIMSS has co-developed with A VIA, a new initiative that addresses how emerging technologies, health system business model changes and investment will transform the delivery of care. HX360 engages senior healthcare leaders, innovation teams, investors and entrepreneurs around the vision of transforming healthcare delivery by leveraging technology, process and structure. PMID:26571634

  20. 纳米药物设计与负责任创新:建构论视角的解释%The Design of Nano -drug and Responsible Innovation:The Interpretation from Constructivism Perspective

    Institute of Scientific and Technical Information of China (English)

    赵迎欢; Bärbel Dorbeck -Jung

    2016-01-01

    The design of drug is the initial stage of life cycle of a drug,and it is also a key link to control the risk of drug. The design of Nano -drug will be to realize the risk control of the “origin”governance.The method of value sensitive de-sign (value embedded)used to design process showed the consciousness of responsible innovation of designers.The re-sponsibility of designers objectively caused by the structure effect and size effect of nano -preparation not only includes the responsibility of the technical assessment (TA)related to risk of nano -drug,and but also needs to study a system of con-structive technology assessment (CTA)linking with risk from the constructivism perspective.The theory basis for construc-ting risk assessment of Nano -drug is the humanism theory of Marxism and stakeholder theory.The designers of Nano -drug implement the path of responsible innovation which should pay attention to the four dimensions of promotion of knowl-edge,codes of ethics,legal constraints and policy orientation.%药物设计是药品生命周期的起始阶段,也是控制药品风险的关键环节。纳米药物设计是实现风险控制的“源头”治理,设计过程采用的价值敏感设计(价值嵌入)方法是设计者负责任创新意识的展现。由纳米制剂的结构效应和尺寸效应客观决定的纳米药物设计者责任,不仅表现为对纳米药物风险的技术评估(TA)的责任,而且需要从建构论视角探索纳米药物风险的建构性技术评估(CTA)体系。建构性纳米药物风险评估的理论基础是马克思主义的“人本”理论和利益相关者理论。纳米药物设计者实施负责任创新的路径应关注知识提升、道德规范、法律制约及政策导向4个维度。

  1. 某地药品安全监管信息化建设现状分析及创新策略%Situation and Innovation Strategy of Construction of Drug Safety Administration Information in A City

    Institute of Scientific and Technical Information of China (English)

    罗莉; 陈晓隽; 陈勇

    2016-01-01

    Objective To strengthen and innovate the construction of drug safety administration information in a city. Methods To in-vestigate the construction situation of the drug safety administration in one food and drug administration,and to analyze the current situ-ation and deficiency of the drug safety administration system. Results and Conclusion The countermeasure and suggestion of the con-struction of the drug safety administration were put forward on the basis of big data:to establish the big data thinking,innovative drug regulatory mode;build big data centers,perfect the drug safety administration model divined by information,construct the 3 big basic da-ta bases of pharmaceutical information,pharmaceutical enterprise subject information,pharmaceutical enterprise behavior,and consolidate the basis of information interconnection and intercommunication.%目的:促进药品安全监管信息化建设的加强和创新。方法对某地食品药品监管部门药品安全监管信息化建设情况进行调研,对其药品安全监管信息系统的运行现状及存在的不足进行分析。结果与结论基于大数据思维提出了药品安全监管信息化建设的对策与建议,即建立“大数据思维”,创新药品安全监管模式;构建大数据中心,完善信息驱动下的药品安全监管模式;建设药品信息、医药企业主体信息、医药企业行为三大基础数据库,夯实信息互联互通基础。

  2. An implantable and controlled drug-release silk fibroin nanofibrous matrix to advance the treatment of solid tumour cancers.

    Science.gov (United States)

    Xie, Maobin; Fan, Dejun; Chen, Yufeng; Zhao, Zheng; He, Xiaowen; Li, Gang; Chen, Aizheng; Wu, Xiaojian; Li, Jiashen; Li, Zhi; Hunt, John A; Li, Yi; Lan, Ping

    2016-10-01

    The development of more effective cancer therapeutic strategies are still critically required. The maximization of the therapeutic effect in combination with avoiding the severe side effects on normal tissues when using chemotherapy drugs is still an urgent problem that requires improvements urgently. Here we provide implantable and controllable drug-release that utilises silk fibroin (SF) as a nanofibrous drug delivery system (DDS) for cancer treatment. A nanofibrous structure with controllable fibre diameter (curcumin (CM)-SF nanofibrous matrix had a superior anti-cancer potential when the concentration was >5 μg/mL. The mechanism could be explained by the cell cycle being held in the S phase. The toxic effect on normal cells (NCM460) was minimized by using a treatment concentration range (5-20 μg/mL). Implantation of this DDS into the tumour site inhibited the growth of solid tumour; this offers an alternative approach for novel cancer therapy. PMID:27376557

  3. Innovation hubs

    DEFF Research Database (Denmark)

    O´Hara, J.; Hansen, Poul H. Kyvsgård; Turner, N.;

    2008-01-01

    "Whilst ‘incremental innovation' is an imperative for the short-to-medium term success of a company, there is also a need for companies to engage in innovation activity that goes beyond the incremental in order to guarantee long-term success. However, such ‘radical innovation' (RI) poses new...... challenges and requires new competencies, some of which may conflict with existing best-practices for incremental innovations. ‘Innovation hubs' are a type of organisational structure dedicated to RI projects that have been used by companies to manage these conflicts by maintaining a certain degree...... of separation from the culture and routines of the mainstream organisation. Unfortunately, it would appear that many attempts to set-up innovation hubs have ended in failure within a few years; not before considerable time, effort and resource has been expended. This paper reports on a study of six innovation...

  4. Controlled drug delivery systems towards new frontiers in patient care

    CERN Document Server

    Rossi, Filippo; Masi, Maurizio

    2016-01-01

    This book offers a state-of-the-art overview of controlled drug delivery systems, covering the most important innovative applications. The principles of controlled drug release and the mechanisms involved in controlled release are clearly explained. The various existing polymeric drug delivery systems are reviewed, and new frontiers in material design are examined in detail, covering a wide range of polymer modification techniques. The concluding chapter is a case study focusing on use of a drug-eluting stent. The book is designed to provide the reader with a complete understanding of the mechanisms and design of controlled drug delivery systems, and to this end includes numerous step-by-step tutorials. It illustrates how chemical engineers can advance medical care by designing polymeric delivery systems that achieve either temporal or spatial control of drug delivery and thus ensure more effective therapy that eliminates the potential for both under-and overdosing.

  5. Veblen, Bataille and Financial Innovation

    DEFF Research Database (Denmark)

    Gammon, Earl; Wigan, Duncan

    2015-01-01

    This article advances towards the reconceptualization of financial innovation. It examines the calamitous role of financial innovation in the global financial crisis, developing a non-rational theorization of finance within the social economy that factors in the role of affect. Outlining the...... financial innovation premised on pecuniary expedients and aspirations of market completion. As we argue, in a broader affective economy, contemporary financial innovation serves invidious ends, providing a means of attaining social distinction, constituting a medium for violent expenditure and bestowing...... access to sovereign expression on its purveyors. Highlighting the non-rational dimension of financial markets prompts a reconsideration of the nature of crisis and the means of its redress....

  6. Induced Innovation and Energy Prices

    OpenAIRE

    David Popp

    2001-01-01

    I use U.S. patent data from 1970 to 1994 to estimate the effect of energy prices on energy-efficient innovations. Using patent citations to construct a measure of the usefulness of the existing base of scientific knowledge, I consider the effect of both demand-side factors, which spur innovative activity by increasing the value of new innovations, and supply-side factors, such as scientific advancements that make new innovations possible. I find that both energy prices and the quality of exis...

  7. Evaluating Innovation and Moral Hazard in Pharmaceuticals

    OpenAIRE

    Paris Cleanthous

    2011-01-01

    This paper formulates an empirical methodology that evaluates pharmaceutical innovation in the American antidepressant market by quantifying patient welfare benefits from innovation. While evaluating pharmaceutical innovation in antidepressants, I uncover and address the moral hazard issue that arises due to the existence of prescription drug insurance coverage. A combination of market-level data, drug and patient characteristics are used to estimate demand for all antidepressants between 198...

  8. DUAL-MODE PROPULSION SYSTEM ENABLING CUBESAT EXPLORATION OF THE SOLAR SYSTEM NASA Innovative Advanced Concepts (NIAC) Phase I Final Report

    Energy Technology Data Exchange (ETDEWEB)

    Nathan Jerred; Troy Howe; Adarsh Rajguru; Dr. Steven Howe

    2014-06-01

    -based systems. The second scenario allows for the production of electrical power, which is then available for electric-based propulsion. Additionally, once at location the production of electrical power can be dedicated to the payload’s communication system for data transfer. Ultimately, the proposed dual-mode propulsion platform capitalizes on the benefits of two types of propulsion methods – the thrust of thermal propulsion ideal for quick orbital maneuvers and the specific impulse of electric propulsion ideal for efficient inter-planetary travel. Previous versions of this RTR-based concept have been studied for various applications [NETS 1-3]. The current version of this concept is being matured through a NASA Innovative Advanced Concepts (NIAC) Phase I grant, awarded for FY 2014. In this study the RTR concept is being developed to deliver a 6U CubeSat payload to the orbit of the Saturnian moon - Enceladus. Additionally, this study will develop an entire mission architecture for Enceladus targeting a total allowable launch mass of 1,000 kg.

  9. Recent advances in traditional plant drugs and orchids%传统植物药和兰花的最新进展

    Institute of Scientific and Technical Information of China (English)

    KONG Jin-Ming; GOH Ngoh-Khang; CHIA Lian-Sai; CHLA Tet-Fatt

    2003-01-01

    The main objective of this paper is to review recent advances in plant drug research and developments in orchid study, in an attempt to provide useful references for plant drag studies. Plants have been used as medicine for millennia. Out of estimated 250 000 to 350 000 plant species identified so far, about 35 000 are used worldwide for medicinal purposes. It has been confirmed by WHO that herbal medicines serve the health needs of about 80 percent of the world's population; especially for millions of people in the vast rural areas of developing countries.Meanwhile, consumers in developed countries are becoming disillusioned with modem healthcare and are seeking alternatives. The recent resurgence of plant remedies results from several factors: 1) the effectiveness of plant medicines; 2) the side effect of most modem drugs; and 3) the development of science and technology. It has been estimated that in the mid-1990s over 200 companies and research organizations worldwide are screening plant and animal compounds for medicinal properties. Actually, several important drugs used in modern medicine have come from medicinal plant studies, eg, taxol/paclitaxel, vinblastine, vincristine, topotecan, irinotecan, etoposide, teniposide,etc. As for drugs derived from orchids, some novel discoveries, both in phytochemical and pharmacological properties, were reported by some universities. However, studies on plants are very limited. Only about a third of the million or so species of higher plants have been identified and named by scientists. Of those named, only a tiny fraction has been studied. Nowadays the linking of the indigenous knowledge of medicinal plants to modem research activities provides a new approach, which makes the rate of discovery of drugs much more effective than with random collection.

  10. Recent Advances in Delivery Systems and Therapeutics of Cinnarizine: A Poorly Water Soluble Drug with Absorption Window in Stomach

    Directory of Open Access Journals (Sweden)

    Smita Raghuvanshi

    2014-01-01

    Full Text Available Low solubility causing low dissolution in gastrointestinal tract is the major problem for drugs meant for systemic action after oral administration, like cinnarizine. Pharmaceutical products of cinnarizine are commercialized globally as immediate release preparations presenting low absorption with low and erratic bioavailability. Approaches to enhance bioavailability are widely cited in the literature. An attempt has been made to review the bioavailability complications and clinical therapeutics of poorly water soluble drug: cinnarizine. The interest of writing this paper is to summarize the pharmacokinetic limitations of drug with special focus on strategies to improvise bioavailability along with effectiveness of novel dosage forms to circumvent the obstacle. The paper provides insight to the approaches to overcome low and erratic bioavailability of cinnarizine by cyclodextrin complexes and novel dosage forms: self-nanoemulsifying systems and buoyant microparticulates. Nanoformulations need to systematically explored in future, for their new clinical role in prophylaxis of migraine attacks in children. Clinical reports have affirmed the role of cinnarizine in migraine prophylaxis. Research needs to be dedicated to develop dosage forms for efficacious bioavailability and drug directly to brain.

  11. Diffusion of innovation I: Formulary acceptance rates of new drugs in teaching and non-teaching British Columbia hospitals--a hospital pharmacy perspective.

    Science.gov (United States)

    D'Sa, M M; Hill, D S; Stratton, T P

    1994-12-01

    Lag times in the diffusion of new drugs in the hospital setting have both patient care and pharmaceutical industry implications. This two-part series uses diffusion theory to examine differences in the adoption rates of new drugs in British Columbia teaching and non-teaching hospitals. Formulary addition of a new drug by a hospital's Pharmacy and Therapeutics Committee was considered the adoption indicator. Time for adoption was defined as the difference between a drug's Canadian market approval date and the date of formulary addition. Surveys were mailed in September 1990 to 41 hospital pharmacies (response rate = 88%), asking respondents to provide formulary inclusion dates of 29 drugs marketed between July 1987 and March 1990. A significant difference (Mann-Whitney U Test, p < 0.0358) in median adoption time was observed between the six teaching and 25 non-teaching study hospitals, with the former adopting a new drug in 7.5 months versus the latter adopting a new drug in 12.1 months. PMID:10139270

  12. Tokamak concept innovations

    International Nuclear Information System (INIS)

    This document contains the results of the IAEA Specialists' Meeting on Tokamak Concept Innovations held 13-17 January 1986 in Vienna. Although it is the most advanced fusion reactor concept the tokamak is not without its problems. Most of these problems should be solved within the ongoing R and D studies for the next generation of tokamaks. Emphasis for this meeting was placed on innovations that would lead to substantial improvements in a tokamak reactor, even if they involved a radical departure from present thinking

  13. 水飞蓟素纳米传递系统的研究进展%Advances in the nanoparticle drug delivery systems of silymarin

    Institute of Scientific and Technical Information of China (English)

    陈美婉; 谭雯; 王胜鹏; 钟章锋; 王一涛

    2011-01-01

    The recent advances in nanoscience and nanotechnology have greatly facilitated the development of nanoparticle drug delivery system.A nanoparticle drug delivery system of silymarin will improve its poor solubility in water and oil,thus enhancing its bioavailability.A variety of nanoparticle formulations of silymarin such as solid lipid nanoparticles,microemulsion and self-emulsifying drug delivery system,and liposomes have been extensively investigated.This paper reviews the advances of these formulations on their preparation and characterization,absorption and bioavailability,as well as in vivo and in vitro studies,in order to provide an assessment of current research for further pharmaceutical studies of silymarin.%纳米科学和纳米技术在纳米药物传递系统中具有很大的潜力.水飞蓟素纳米药物传递系统的研究和开发将改善其水溶性和脂溶性,并提高生物利用度.固体脂质纳米粒、微乳、自微乳和脂质体等一系列水飞蓟素纳米处方的研究已越来越受到关注.本文综述了水飞蓟素纳米制剂的制备表征,性能评价,吸收、生物利用度等体内外研究,为其制剂的进一步研究提供科学基础.

  14. People, Politics, and Innovation: A Process Perspective

    OpenAIRE

    Alexander, Lameez

    2014-01-01

    markdownabstract__Abstract__ Innovation is often considered the Holy Grail of competitive advantage and growth in modern organizations. Organizing for innovation can therefore be seen as the cornerstone of organizational success. In this dissertation, I aimed to advance a more complex and dynamic understanding of innovation that places people – what they do and how they do it – at the centre of the process. The two studies in this dissertation both advance novel theoretical concepts and model...

  15. SOCIAL SCIENCE KNOWLEDGE AND INSTITUTIONAL INNOVATION

    OpenAIRE

    Ruttan, Vernon W.

    2002-01-01

    In this paper I advance a model in which institutional innovation is induced by changes in resource endowments, cultural endowments and technical change. I also introduce the role of advances in social science knowledge as a source of institutional innovation. The sources of institutional innovation are illustrated by changes in land tenure and labor relations in Philippine agriculture and by the transition from command and control to market based systems of resource management in the United ...

  16. DEVELOPMENT AND INNOVATION IN CARDIOVASCULAR MEDICINE

    OpenAIRE

    DESMOND SHERIDAN

    2007-01-01

    The last century has witnessed groundbreaking advances in clinical medicine across the entire diagnostic and therapeutic range, but inequities in access to these advances and innovations continue to be a major challenge to our societies.Innovations are often initiated by "eureka" moments of discovery, but realising their full potential depend on a process of continuous incremental innovation and interaction involving complex networks. When developing systems that reward, encourage, and sustai...

  17. A novel application of maleimide for advanced drug delivery: in vitro and in vivo evaluation of maleimide-modified pH-sensitive liposomes

    Directory of Open Access Journals (Sweden)

    Li T

    2013-10-01

    Full Text Available Tianshu Li, Shinji TakeokaDepartment of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University (TWIns, Shinjuku-ku, Tokyo, JapanAbstract: Maleimide is a stable and easy-to-handle moiety that rapidly and covalently conjugates thiol groups of cysteine residues in proteins or peptides. Herein, we use maleimide to modify the surface of liposomes in order to obtain an advanced drug delivery system. Employing a small amount (0.3 mol% of maleimide-polyethylene glycol (PEG to modify the surface of the liposomes M-GGLG-liposomes, composed of 1,5-dihexadecyl N,N-diglutamyl-lysyl-L-glutamate (GGLG/cholesterol/poly(ethylene glycol 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (PEG5000-DSPE/maleimide-PEG5000-Glu2C18 at a molar ratio of 5:5:0.03:0.03, drug delivery efficiency was remarkably improved both in vitro and in vivo compared to unmodified liposomes (GGLG-liposomes, composed of GGLG/cholesterol/PEG5000-DSPE/PEG5000-Glu2C18 at a molar ratio of 5:5:0.03:0.03. Moreover, this modification did not elicit any detectable increase in cytotoxicity. The maleimide-modification did not alter the physical characteristics of the liposomes such as size, zeta potential, pH sensitivity, dispersibility and drug encapsulation efficiency. However, M-GGLG-liposomes were more rapidly (≥2-fold internalized into HeLa, HCC1954, and MDA-MB-468 cells compared to GGLG-liposomes. In vivo, M-GGLG-liposomes encapsulating doxorubicin (M-GGLG-DOX-liposomes also showed a more potent antitumor effect than GGLG-DOX-liposomes and the widely used 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC-DOX-liposomes after two subcutaneous injections around breast cancer tissue in mice. The biodistribution of liposomes in this model was observed using an in vivo imaging system, which showed that M-GGLG-liposomes were present for significantly longer at the injection site compared to GGLG-liposomes. The outstanding biological functions of

  18. Online Innovation

    DEFF Research Database (Denmark)

    Vujovic, Sladjana; Ulhøi, John Parm

    2008-01-01

      Purpose - The aim of this paper is to investigate the role of online networking during the innovation process, including its role(s) in communication, cooperation and coordination. The paper neither implicitly assumes that online computer-based networking is a prerequisite for the innovation...... process nor denies the possibility that innovation can emerge and successfully survive without it. It merely presupposes that, in cases of innovation where information and communication technologies play a substantial role, non-proprietarity may offer an interesting alternative to innovations based...... on proprietary knowledge. Design/methodology/approach - The paper borrows from the theory of communities-of-practice, which takes into account social relations, contacts, and the transfer and incorporation of knowledge. Open source innovation is not the exclusive preserve of computer nerds, but also has...

  19. Sensitive innovation

    DEFF Research Database (Denmark)

    Søndergaard, Katia Dupret

    Present paper discusses sources of innovation as heterogenic and at times intangible processes. Arguing for heterogeneity and intangibility as sources of innovation originates from a theoretical reading in STS and ANT studies (e.g. Callon 1986, Latour 1996, Mol 2002, Pols 2005) and from field work...... in the area of mental health (Dupret Søndergaard 2009, 2010). The concept of sensitive innovation is developed to capture and conceptualise exactly those heterogenic and intangible processes. Sensitive innovation is therefore primarily a way to understand innovative sources that can be......, but are not necessarily, recognized and acknowledged as such in the outer organisational culture or by management. The added value that qualifies these processes to be defined as “innovative” are thus argued for along different lines than in more traditional innovation studies (e.g. studies that build on the classic...

  20. The Determinants of National Innovative Capacity

    OpenAIRE

    Scott Stern; Porter, Michael E.; Jeffrey L. Furman

    2000-01-01

    Motivated by differences in R&D productivity across advanced economies, this paper presents an empirical examination of the determinants of country-level production of international patents. We introduce a novel framework based on the concept of national innovative capacity. National innovative capacity is the ability of a country to produce and commercialize a flow of innovative technology over the long term. National innovative capacity depends on the strength of a nation's common innovatio...

  1. Innovation in care services for the elderly

    OpenAIRE

    Djellal, Faridah; Gallouj, FaÏz; Gallouj, Karim

    2004-01-01

    Ageing and innovation are usually considered to be contradictory phenomena. This article on innovation in care services for the elderly seeks to counter this established view. Taking as its starting point a definition of care services for the elderly that draws on the economics of services, the article advances a simple framework for analysing innovation in terms of 'targets'. These targets, which make it possible to circumvent the usual economic categories (product and process innovation), a...

  2. Using Selection to Advance Drug Discovery%基于筛选的新型药物开发方法

    Institute of Scientific and Technical Information of China (English)

    K. John MORROW, Jr

    2011-01-01

    近年来,遗传化学和系统生物学的原理都已经关注于药物开发的过程,例如各公司在寻找作为潜在药物的来源以及其他感兴趣的商品化的化合物。本文介绍了一种新型的基于Darwinian筛选原理的平台。%In recent years, the principles of genetic chemistry and systems biology have been brought to bear on the process of drug discovery, as companies seek to develop sources of drug candidates and other commercially interesting compounds. This article discuss

  3. The eTOX data-sharing project to advance in Silico drug-induced toxicity prediction

    OpenAIRE

    Montserrat Cases; Katharine Briggs; Thomas Steger-Hartmann; François Pognan; Philippe Marc; Thomas Kleinöder; Schwab, Christof H; Manuel Pastor; Jörg Wichard; Ferran Sanz

    2014-01-01

    The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug development, which follows numerous strict guidelines, are mostly not available in the public domain. These safety data are sometimes published as a condensed summary for the few compounds that reach the market, but the majority of studies are never made public and are often difficult to access in an automated way, even sometimes within the owning company itself. It is evident from many academ...

  4. PARTICIPATORY INNOVATION

    OpenAIRE

    JACOB BUUR; BEN MATTHEWS

    2008-01-01

    An increasing number of corporations engage with users in co-innovation of products and services. But there are a number of competing perspectives on how best to integrate these understandings into existing corporate innovation development processes. This paper maps out three of the dominant approaches, compares them in terms of goals, methods and basic philosophy, and shows how they may beneficially enrich one another. We will present an industrial innovation case that has been instrumental ...

  5. Projecting future drug expenditures--2003.

    Science.gov (United States)

    Shah, Nilay D; Hoffman, James M; Vermeulen, Lee C; Hunkler, Robert J; Hontz, Karrie M

    2003-01-15

    Drug expenditure projections for 2003 and factors likely to influence drug costs are discussed. The United States continues to face the challenge of increased growth in health expenditures, and drug expenditures are continuing to increase faster than the growth in total health care expenditures. These increases can be largely attributed to an increase in the average age of the U.S. population and technological advancement. On the basis of price inflation and non-price inflationary factors, including increases in volume, shifts in patient and therapeutic intensity, and expected approval of new drugs, a 10-12% increase in drug expenditures in 2003 for the inpatient setting and a 13.5-15.5% increase for ambulatory care settings are forecasted. While few new drugs are expected to greatly influence expenditures in 2003, the continued diffusion of recently approved drugs such as drotrecogin alfa and nesiritide will have a dramatic impact on total drug expenditures and must be carefully considered in the budgeting process. An agent likely to have a significant impact on HIV treatment is enfuvirtide, the first in a new class of antiretrovirals (fusion inhibitors), but its high cost ($10,000-$15,000 per year) may limit patients' access to this medication. An expanded user's guide is provided to assist the reader in appropriate application of this information in the drug budgeting process. Technological, demographic, and market-based changes and changes in public policy will continue to influence pharmaceutical expenditures in the coming year. An understanding of the overall drivers of medication expenditures and vigilance in monitoring pharmaceutical innovation are critical in the effective management of these resources. PMID:12561658

  6. Innovation @ NASA

    Science.gov (United States)

    Roman, Juan A.

    2014-01-01

    This presentation provides an overview of the activities National Aeronautics and Space Administration (NASA) is doing to encourage innovation across the agency. All information provided is available publicly.

  7. 乳腺癌内分泌药物治疗的研究进展%Research advances in new endocrine therapy drugs of breast cancer

    Institute of Scientific and Technical Information of China (English)

    蒋维平

    2013-01-01

    Breast cancer is one of malignant tumors that seriously impact women's physical and mental health and even cause death. The traditional endocrine therapy drugs of breast cancer are estrogen receptor modulators and aromatase inhibitors that act on metabolic pathway of endogenous estrogenic steroids. The objective of the research on this class of drugs is to find new aromatase inhibitors with tissue selectivity, high efficacy and low toxic-ity. Novel steroid sulfatase inhibitors are effective hormone dependent breast cancer (HDBC) treatment drugs. Sul-famate moiety is confirmed to be the pharmacophore of these drugs. This article reviews research advances in aromatase inhibitors and steroid sulfatase inhibitors.%乳腺癌是严重影响妇女身心健康甚至危及生命的恶性肿瘤之一.传统的乳腺癌内分泌治疗药物是作用于雌激素环节的雌激素受体调节剂、芳香化酶抑制剂,但芳香化酶抑制剂的选择性较差,有中度的治疗相关毒性,如高血脂、骨丢失、肝脂肪化等,因此需要开发具有组织选择性、高效低毒的芳香化酶抑制剂.此外,新型的甾体硫酸酯酶抑制剂也已成为有效的激素依赖性乳腺癌(HDBC)治疗药物,氨基磺酸酯基团被证实是这类药物中的药效团.本文综述了芳香化酶抑制剂和硫酸酯酶抑制剂的研究进展.

  8. Innovating the capacity to innovate

    OpenAIRE

    Ingerslev, Karen; Bjørn, Kasper; Johansen, Jørgen

    2012-01-01

    This paper addresses the potential clash between the “non-failure” culture of the hospital and the “fail-fast-forward” approach of innovation by sharing and analysing narratives from a field study of innovation processes. The case is a large university hospital in Scandinavia and the health care sector in general is outlined as context of the challenges addressed by the innovation processes. The narratives fall into three overlapping categories; the product, the process and the...

  9. Market Access Advancements and Challenges in “Drug-Companion Diagnostic Test” Co-Development in Europe

    Directory of Open Access Journals (Sweden)

    Ildar Akhmetov

    2015-06-01

    Full Text Available The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders. This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution. Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

  10. Creating Innovative Opportunities

    DEFF Research Database (Denmark)

    Ljungberg, Daniel; McKelvey, Maureen; Lassen, Astrid Heidemann

    2012-01-01

    illustrations of the processes, and the 86 case studies in knowledge intensive entrepreneurship in Europe. These case studies were developed during the European Union research project AEGIS (Advancing Knowledge-Intensive Entrepreneurship and Innovation for Economic Growth and Well-being in Europe). The case......This paper develops lessons about how and why the founders and ventures involved in knowledge intensive entrepreneurship (KIE) manage the process of venture creation. The meta-analysis of the 86 case studies is based upon as conceptual model (from a systemic literature review), linked to...... studies do demonstrate how the individual KIE ventures are dependent upon variables and processes in the surrounding innovation systems. The overall analysis of the cases provides insight into how KIE processes link the KIE venture and the innovation system, thereby highlighting e.g. the importance of...

  11. Responsive Innovation

    DEFF Research Database (Denmark)

    Pedersen, Carsten

    Although the importance of stakeholder networks has been recognized in recent years, a non-teleological model that incorporates their collective sensing into innovation processes has so far not been developed. Hence, this paper argues that traditional linear and sequential innovation models...

  12. Innovation process

    DEFF Research Database (Denmark)

    Kolodovski, A.

    2006-01-01

    Purpose of this report: This report was prepared for RISO team involved in design of the innovation system Report provides innovation methodology to establish common understanding of the process concepts and related terminology The report does not includeRISO- or Denmark-specific cultural, economic...

  13. Responsible innovation

    CERN Document Server

    De Woot, Philippe

    2015-01-01

    Economic development is rooted in disruption, not in equilibrium. And a powerful engine of economic development is innovation; but is this innovation always for the common good? The dark side of the extraordinary dynamism of innovation lies precisely in its destructive power. If simply left to market forces, it could lead to social chaos and great human suffering. To face the challenges of our time, we must create the proper climate and culture to develop strong entrepreneurial drive. But, more than ever, we must give this entrepreneurial drive its ethical and societal dimensions. Responsible innovation means a more voluntary orientation towards the great problems of the 21st century, e.g. depletion of the planet's resources, rising inequality, and new scientific developments potentially threatening freedom, democracy and human integrity. We need to transform our ceaseless creativity into real progress for humankind. In this respect, the rapid development of social innovation opens the door for new methods an...

  14. Accidental Innovation

    DEFF Research Database (Denmark)

    Austin, Robert D.; Devin, Lee; Sullivan, Erin E.

    2012-01-01

    Historical accounts of human achievement suggest that accidents can play an important role in innovation. In this paper, we seek to contribute to an understanding of how digital systems might support valuable unpredictability in innovation processes by examining how innovators who obtain value from...... they incorporate accidents into their deliberate processes and arranged surroundings. By comparing makers working in varied conditions, we identify specific factors (e.g., technologies, characteristics of technologies) that appear to support accidental innovation. We show that makers in certain specified...... conditions not only remain open to accident but also intentionally design their processes and surroundings to invite and exploit valuable accidents. Based on these findings, we offer advice for the design of digital systems to support innovation processes that can access valuable unpredictability....

  15. Everyday Innovation

    DEFF Research Database (Denmark)

    Lippke, Lena; Wegener, Charlotte

    2014-01-01

    Purpose – The purpose of this paper is to explore how vocational teachers’ everyday practices can constitute innovative learning spaces that help students to experience engagement and commitment towards education and thus increase their possibilities for completing their studies despite notable...... difficulties. Design/methodology/approach – Based on two ethnographic field studies, we analyse vocational teaching situations in which teachers and students engage in daily remaking of the vocational educational training practice. It is argued that these everyday situations can be understood as innovative...... transformation of participation and practice. Findings – The exploration of teachers’ practicing new learning spaces sheds light on innovation potential embedded in everyday educational practices. The paper thus challenges the celebration of radical innovation and argues that innovation emerges from everyday...

  16. MAPPING INNOVATION

    DEFF Research Database (Denmark)

    Thuesen, Christian Langhoff; Koch, Christian

    2011-01-01

    By adopting a theoretical framework from strategic niche management research (SNM) this paper presents an analysis of the innovation system of the Danish Construction industry. Theories within SNM look upon innovation in a sector as a socio-technical phenomenon and identifies three levels of socio......-technical interaction within which sectorial innovation can be explained. The analysis shows a multifaceted landscape of innovation around an existing regime, built in the existing ways of working and developing over generations. The regime is challenged from various niches and the sociotechnical landscape through...... trends as globalization. Three niches (Lean Construction, BIM and System Deliveries) are subject to a detailed analysis showing partly incompatible rationales and various degrees of innovation potential. The paper further discusses how existing policymaking operates in a number of tensions one being...

  17. Participatory Innovation

    DEFF Research Database (Denmark)

    Buur, Jacob; Matthews, Ben

    2008-01-01

    An increasing number of corporations engage with users in co-innovation of products and services. But there are a number of competing perspectives on how best to integrate these understandings into existing corporate innovation development processes. This paper maps out three of the dominant...... approaches, compares them in terms of goals, methods and basic philosophy, and shows how they may beneficially enrich one another. We will present an industrial innovation case that has been instrumental to the development of what we have termed ‘Participatory Innovation’. Based on this we will list...... the challenges such an approach sets to innovation management, and discuss research directions we see as fundamental to the development of the field of user-driven innovation. Udgivelsesdato: September...

  18. 线粒体毒性评价及其在创新药物安全性评价中的意义%Significance of mitochondrial toxicity testing in the safety evaluation of innovative drugs

    Institute of Scientific and Technical Information of China (English)

    郭家彬; 彭辉; 王以美; 彭双清

    2012-01-01

    Mitochondria are the major sources of cellular energy and reactive oxygen species (ROS) , playing fundamental roles in regulation of cell survival and death under pathological conditions. Mitochondria are important targets of drug toxicity. A variety of drugs, eg. antivirals, anti-cancer drugs, and antibiotics, have been shown to significantly induce mitochondrial toxicity in targeted organs such as liver and heart. Drug-induced mitochondrial injury may involve multiple pathways and mechanisms. Recently, it has been suggested that mitochondrial toxicity is the main cause leading to the failure of drug development, and many post-market drugs that have been withdrawn or received Black Box warnings from the FDA are characterized by mitochondrial toxicity. Thus, assessment of mitochondrial toxicity is of great significance in the research and development of innovative drugs.%线粒体是细胞内能量和活性氧自由基(ROS)的主要来源,在病理条件下对细胞的存活与死亡具有十分重要的调控作用.线粒体是药物毒性作用的重要靶标.一些抗病毒药物、抗肿瘤药物和抗生素等可显著诱导肝脏和心脏等靶器官线粒体损伤.药物诱导的线粒体损伤可能涉及多条途径和多种机制.近年来研究表明,线粒体毒性可能是多种已上市药物被迫撤市或受到美国FDA“黑框”警告以及候选药物研发失败的重要原因.因此,在创新药物研发过程中,开展线粒体毒性评价具有十分重要的意义.

  19. The innovative use of a large-scale industry biomedical consortium to research the genetic basis of drug induced serious adverse events.

    Science.gov (United States)

    Holden, Arthur L

    2007-01-01

    The International Serious Adverse Event Consortium (SAEC) is a pharmaceutical industry and FDA led international (501 c3 non-profit) consortium, focused on identifying and validating DNA-variants useful in predicting the risk of drug induced, rare serious adverse events (SAEs). As such, it functions with the explicit purpose of enhancing the 'public good'. Its members are (i) organizations engaged principally in the business of discovering, developing and marketing pharmaceutical products, or (ii) a charitable, governmental, or other non-profit organization with an interest in researching the molecular basis of drug response.Drug-induced, rare SAEs present significant health issues for patients; and pose challenges for the safe use of approved drugs and the development of new drugs. Examples of drug-induced, rare SAEs include hepatotoxicity, QT prolongation, rhabdomyolosis, serious skin rashes (e.g. SJS), edema, acute renal failure, acute hypersensitivity, anemias/neutropenias, excessive weigh gain, retinopathy, vasculitis, among others. The rarity of such drug induced SAEs and the absence of effective government surveillance/research networks, makes it extremely difficult for any one company or research entity to accrue enough SAE cases and controls to conduct effective whole genome studies. Central to the notion of the SAEC is industry, government and health care providers can join forces to make use of a variety of sample and data resources in researching the genetic basis of these events.The purpose of the SAEC is threefold:•To carry out research directed toward the discovery of DNA-variants clinically useful in understanding and predicting the risk of drug induced serious adverse events and similar scientific research.•To ensure the widespread availability of the results of such research to the scientific research community and the public at large for no charge through publication and web-based methods; and•To educate the scientific research and medical

  20. Accelerating advanced-materials commercialization

    Science.gov (United States)

    Maine, Elicia; Seegopaul, Purnesh

    2016-05-01

    Long commercialization times, high capital costs and sustained uncertainty deter investment in innovation for advanced materials. With appropriate strategies, technology and market uncertainties can be reduced, and the commercialization of advanced materials accelerated.

  1. The tuberculosis drug discovery and development pipeline and emerging drug targets.

    Science.gov (United States)

    Mdluli, Khisimuzi; Kaneko, Takushi; Upton, Anna

    2015-06-01

    The recent accelerated approval for use in extensively drug-resistant and multidrug-resistant-tuberculosis (MDR-TB) of two first-in-class TB drugs, bedaquiline and delamanid, has reinvigorated the TB drug discovery and development field. However, although several promising clinical development programs are ongoing to evaluate new TB drugs and regimens, the number of novel series represented is few. The global early-development pipeline is also woefully thin. To have a chance of achieving the goal of better, shorter, safer TB drug regimens with utility against drug-sensitive and drug-resistant disease, a robust and diverse global TB drug discovery pipeline is key, including innovative approaches that make use of recently acquired knowledge on the biology of TB. Fortunately, drug discovery for TB has resurged in recent years, generating compounds with varying potential for progression into developable leads. In parallel, advances have been made in understanding TB pathogenesis. It is now possible to apply the lessons learned from recent TB hit generation efforts and newly validated TB drug targets to generate the next wave of TB drug leads. Use of currently underexploited sources of chemical matter and lead-optimization strategies may also improve the efficiency of future TB drug discovery. Novel TB drug regimens with shorter treatment durations must target all subpopulations of Mycobacterium tuberculosis existing in an infection, including those responsible for the protracted TB treatment duration. This review summarizes the current TB drug development pipeline and proposes strategies for generating improved hits and leads in the discovery phase that could help achieve this goal. PMID:25635061

  2. Counting on natural products for drug design

    Science.gov (United States)

    Rodrigues, Tiago; Reker, Daniel; Schneider, Petra; Schneider, Gisbert

    2016-06-01

    Natural products and their molecular frameworks have a long tradition as valuable starting points for medicinal chemistry and drug discovery. Recently, there has been a revitalization of interest in the inclusion of these chemotypes in compound collections for screening and achieving selective target modulation. Here we discuss natural-product-inspired drug discovery with a focus on recent advances in the design of synthetically tractable small molecules that mimic nature's chemistry. We highlight the potential of innovative computational tools in processing structurally complex natural products to predict their macromolecular targets and attempt to forecast the role that natural-product-derived fragments and fragment-like natural products will play in next-generation drug discovery.

  3. Technological Innovations in Forensic Genetics

    DEFF Research Database (Denmark)

    Wienroth, Matthias; Morling, Niels; Williams, Robin

    2014-01-01

    This paper discusses the nature of four waves of technological innovations in forensic genetics alongside the social, legal and ethical aspect of these innovations. It emphasises the way in which technological advances and their socio-legal frameworks are co-produced, shaping technology expectati......This paper discusses the nature of four waves of technological innovations in forensic genetics alongside the social, legal and ethical aspect of these innovations. It emphasises the way in which technological advances and their socio-legal frameworks are co-produced, shaping technology...... expectations, social identities, and legal institutions. It also considers how imagined and actual uses of forensic genetic technologies are entangled with assertions about social order, affirmations of common values and civil rights, and promises about security and justice. Our comments seek to encourage...... the participation of scientific actors in the development of anticipatory governance deliberations concerning the widening application of forensic genetics in an increasing number of criminal and civil jurisdictions....

  4. Advances in drug therapy for gastroesophageal reflux disease%胃食管反流病药物治疗进展

    Institute of Scientific and Technical Information of China (English)

    王河; 汪安江; 朱萱

    2011-01-01

    我国胃食管反流病(GERD)发病率逐年升高.GERD可能引起反流性食管炎、慢性咳嗽、哮喘、Barrett’s食管和食管腺癌等并发症,并且严重影响人们的生活质量.质子泵抑制剂(PPIs)的应用,使多数患者症状得到了缓解.但近年来发现PPIs对部分GERD患者无效,且长期使用会出现间质性肾炎、骨折和小肠细菌增生过多等并发症.近年来,一些新型药物逐渐应用于临床.本文就GERD药物治疗进展作一综述.%The incidence of gastroesophageal reflux disease (GERD) is increasing drastically in China. GERD could probably cause reflux esophagitis, chronic cough, asthma, Barrett's esophagus and adeno-carcinoma, and frequently affects health-related quality of life. The use of proton pump inhibitors (PPIs) provides effective symptomatic relief in most patients; however, some patients appear refractory to the treatment with PPIs. The long term use of PPIs might also cause adverse effects, such as interstitial nephritis, fracture and small intestinal bacterial overgrowth. Many new drugs for GERD have emerged recently. This article reviews the advances in drug therapy for GERD.

  5. 聚酮合酶与药物筛选的研究进展%Advances in polyketide synthases and drug screening

    Institute of Scientific and Technical Information of China (English)

    陈路劼; 赵薇; 连云阳

    2012-01-01

    由于结构多样化和生物活性多样性,聚酮化合物已经成为新药的重要来源.聚酮合酶(polyketide synthase,PKS)是合成聚酮类物质的酶复合体.本文介绍了聚酮合酶的分类、作用机制及相关药物筛选的研究进展.并对通过宏基因组技术,从自然环境中获得新聚酮化合物的基因筛选方法的研究进展进行了总结.%Polyketide with the diversity in chemical structure and biological activity is one of the most important source of novel drugs. Polyketide synthase catalyses the syntheses of polyketides. In this paper, the type, the mechanism and the research advance of drug screening of polyketide synthases were summarized. In addition, the gene screening method that acquiring new polyketides from natural environment via metagenome library technique was introduced.

  6. Responsive Innovation

    DEFF Research Database (Denmark)

    Pedersen, Carsten

    of the firm’s daily operations. Yet, they are rarely asked to provide updated information about critical issues. The present paper seeks to conceptually develop the notion of responsive innovation, by drawing on literary streams concerning collective sensing, strategic issue diagnosis and integra......-tive strategy within a micro foundations perspective. It is posited that companies should root their innovation processes in the collective sensing of frontline-employees and customers that operate around the organizational periphery. This frames the con-cept of responsive innovation, where individuals engaged...

  7. Participatory Innovation

    DEFF Research Database (Denmark)

    Buur, Jacob; Matthews, Ben

    In this paper we discuss the potential for Participatory Design (PD) to make a fundamental contribution to the business-oriented field of user-driven innovation, taking note of where we find PD can best benefit from interaction with this other field. We examine some of the challenges that must...... be addressed if PD is to contribute to innovation processes in companies. We conclude by presenting a research agenda comprising of six promising topics to shape a new discipline of Participatory Innovation....

  8. Design & Innovation

    DEFF Research Database (Denmark)

    Boelskifte, Per; Jørgensen, Ulrik

    2005-01-01

    and design oriented engineers in industry and society has turned out to challenge a number of the standard – and often taken for granted – concepts in engineering education still dominated world wide by rather strict norms and concepts of learning that do not challenge the students creativity and innovative......The new design and innovation programme at DTU is challenging some of the standard concepts dominating most engineering educations. The programme, its background, context and basic educational ideas are presented and discussed in this paper. To build competences that match the need for innovative...

  9. Recent advances in vacuum sciences and applications

    International Nuclear Information System (INIS)

    Recent advances in vacuum sciences and applications are reviewed. Novel optical interferometer cavity devices enable pressure measurements with ppm accuracy. The innovative dynamic vacuum standard allows for pressure measurements with temporal resolution of 2 ms. Vacuum issues in the construction of huge ultra-high vacuum devices worldwide are reviewed. Recent advances in surface science and thin films include new phenomena observed in electron transport near solid surfaces as well as novel results on the properties of carbon nanomaterials. Precise techniques for surface and thin-film characterization have been applied in the conservation technology of cultural heritage objects and recent advances in the characterization of biointerfaces are presented. The combination of various vacuum and atmospheric-pressure techniques enables an insight into the complex phenomena of protein and other biomolecule conformations on solid surfaces. Studying these phenomena at solid–liquid interfaces is regarded as the main issue in the development of alternative techniques for drug delivery, tissue engineering and thus the development of innovative techniques for curing cancer and cardiovascular diseases. A review on recent advances in plasma medicine is presented as well as novel hypotheses on cell apoptosis upon treatment with gaseous plasma. Finally, recent advances in plasma nanoscience are illustrated with several examples and a roadmap for future activities is presented. (topical review)

  10. Recent advances in vacuum sciences and applications

    Science.gov (United States)

    Mozetič, M.; Ostrikov, K.; Ruzic, D. N.; Curreli, D.; Cvelbar, U.; Vesel, A.; Primc, G.; Leisch, M.; Jousten, K.; Malyshev, O. B.; Hendricks, J. H.; Kövér, L.; Tagliaferro, A.; Conde, O.; Silvestre, A. J.; Giapintzakis, J.; Buljan, M.; Radić, N.; Dražić, G.; Bernstorff, S.; Biederman, H.; Kylián, O.; Hanuš, J.; Miloševič, S.; Galtayries, A.; Dietrich, P.; Unger, W.; Lehocky, M.; Sedlarik, V.; Stana-Kleinschek, K.; Drmota-Petrič, A.; Pireaux, J. J.; Rogers, J. W.; Anderle, M.

    2014-04-01

    Recent advances in vacuum sciences and applications are reviewed. Novel optical interferometer cavity devices enable pressure measurements with ppm accuracy. The innovative dynamic vacuum standard allows for pressure measurements with temporal resolution of 2 ms. Vacuum issues in the construction of huge ultra-high vacuum devices worldwide are reviewed. Recent advances in surface science and thin films include new phenomena observed in electron transport near solid surfaces as well as novel results on the properties of carbon nanomaterials. Precise techniques for surface and thin-film characterization have been applied in the conservation technology of cultural heritage objects and recent advances in the characterization of biointerfaces are presented. The combination of various vacuum and atmospheric-pressure techniques enables an insight into the complex phenomena of protein and other biomolecule conformations on solid surfaces. Studying these phenomena at solid-liquid interfaces is regarded as the main issue in the development of alternative techniques for drug delivery, tissue engineering and thus the development of innovative techniques for curing cancer and cardiovascular diseases. A review on recent advances in plasma medicine is presented as well as novel hypotheses on cell apoptosis upon treatment with gaseous plasma. Finally, recent advances in plasma nanoscience are illustrated with several examples and a roadmap for future activities is presented.

  11. Efficacy analysis of two drugs consisting platinum combined with first-line chemotherapeutics regimens on 117 elderly patients with advanced non-small cell lung carcinoma

    Directory of Open Access Journals (Sweden)

    Li-li ZHANG

    2013-09-01

    Full Text Available Objective To investigate the therapeutic effects of Gemcitabine(GEM, Vinorelbine(NVB,Paclitaxel(TAX and other first-line chemotherapeutics plus platinum containing drugs on the elderly patients with advanced non-small cell lung cancer(NSCLC who had undergone surgery, and analyze the clinicopathological factors influencing the prognosis. Methods One hundred and seventeen advanced NSCLC patients aged 60 or over were treated with GP(GEM+platinum, or NP(NVB+platinum, or TP(TAX+platinum, or other first-line chemotherapeutics plus platinum(OCP after surgery, and their clinical data were then retrospectively studied to look for the relationship of patients' prognosis to clinicopathological factors(gender, operation methods, pathologicaltypes, differentiation, clinical stages.The survival curve was plotted with Kaplan-Meier method, hypothesis test was performed by log-rank, and the independent prognostic factors were screened with Cox proportional hazards regression model. Results Theone-, three- and five-year survival rates of the 117 patients were 47.23%,17.52% and 8.05%, respectively. The progression free survival(PFS of GP, NP, TP and OCP groups were 6.0, 5.2, 6.1 and5.5 months(P>0.05, respectively. The median progression free survival was 5.7 months. Univariate and multivariate analysis showed that the differentiated degrees and clinical stages of elderly NSCLC patients were the independent prognostic factors. Conclusions Clinicopathological factors(differentiated degree andclinical stages are closely related to one-, three- and five-year survival rates of advanced NSCLC in elderly patients who received treatment of first-line chemotherapeutics plus platinum. However, the efficacy ofGP, NP, TP or OCP shows no significant difference.

  12. Outcomes research and drug development

    Directory of Open Access Journals (Sweden)

    Sandeep Duttagupta

    2010-01-01

    Full Text Available With increasing health care cost, focus needs to be given towards value-for-money, especially in the context of innovative drugs. A multi-disciplinary approach towards drug development is important in order to demonstrate the value of innovation to physicians and patients. Input into the drug development process at various stages of clinical trials must incorporate patient-focused endpoints and analyses. Demonstrating value of drugs will help ensure that innovative therapies should be seen as health care investment and not expense.

  13. MAPPING INNOVATION

    DEFF Research Database (Denmark)

    Thuesen, Christian Langhoff; Koch, Christian

    2011-01-01

    By adopting a theoretical framework from strategic niche management research (SNM) this paper presents an analysis of the innovation system of the Danish Construction industry. The analysis shows a multifaceted landscape of innovation around an existing regime, built around existing ways of working...... and developed over generations. The regime is challenged from various niches and the socio-technical landscape through trends as globalization. Three niches (Lean Construction, BIM and System Deliveries) are subject to a detailed analysis showing partly incompatible rationales and various degrees of innovation...... potential. The paper further discusses how existing policymaking operates in a number of tensions one being between government and governance. Based on the concepts from SNM the paper introduces an innovation map in order to support the development of meta-governance policymaking. By mapping some...

  14. Reconsidering Innovation

    DEFF Research Database (Denmark)

    Vaaben, Nana Katrine

    2014-01-01

    Innovation and reforms seem to be on the agenda everywhere, not least in political attempts to reorganize the public sector in ways that are supposed to enable our welfare societies to survive economic turmoil and sinister future prognosis. This paper examines how classical anthropological theories...... and debates about change, myths, and othering can help us rethink theoretical approaches to innovation in organizational studies, and the concern is especially to consider the implications that our “innovation myths” can have for public employees and the valuation their work. The argument in the paper...... is that innovation is better understood as a perspective (a prism) than as a product or a process, and that this perspective tends to “other” people who’s work is not visible as a positive asset in a budget, but may be visible as a positive contribution in people’s lives. The way in which that point is made...

  15. Ensuring safe access to medication for palliative care while preventing prescription drug abuse: innovations for American inner cities, rural areas, and communities overwhelmed by addiction

    Directory of Open Access Journals (Sweden)

    Francoeur RB

    2011-09-01

    Full Text Available Richard B FrancoeurSchool of Social Work, Adelphi University, Garden City, NY, USA; Center for the Psychosocial Study of Health and Illness, Columbia University, New York, NY, USAAbstract: This article proposes and develops novel components of community-oriented programs for creating and affording access to safe medication dispensing centers in existing retail pharmacies and in permanent or travelling pharmacy clinics that are guarded by assigned or off-duty police officers. Pharmacists at these centers would work with police, medical providers, social workers, hospital administrators, and other professionals in: planning and overseeing the safe storage of controlled substance medications in off-site community safe-deposit boxes; strengthening communication and cooperation with the prescribing medical provider; assisting the prescribing medical provider in patient monitoring (checking the state prescription registry, providing pill counts and urine samples; expanding access to lower-cost, and in some cases, abuse-resistant formulations of controlled substance medications; improving transportation access for underserved patients and caregivers to obtain prescriptions; and integrating community agencies and social networks as resources for patient support and monitoring. Novel components of two related community-oriented programs, which may be hosted outside of safe medication dispensing centers, are also suggested and described: (1 developing medication purchasing cooperatives (ie, to help patients, families, and health institutions afford the costs of medications, including tamper- or abuse-resistant/deterrent drug formulations; and (2 expanding the role of inner-city methadone maintenance treatment programs in palliative care (ie, to provide additional patient monitoring from a second treatment team focusing on narcotics addiction, and potentially, to serve as an untapped source of opioid medication for pain that is less subject to abuse

  16. Innovation in wind turbine design

    CERN Document Server

    Jamieson, Peter

    2011-01-01

    Innovation in Wind Turbine Design addresses the fundamentals of design, the reasons behind design choices, and describes the methodology for evaluating innovative systems and components. Always referencing a state of the art system for comparison, Jamieson discusses the basics of wind turbine theory and design, as well as how to apply existing engineering knowledge to further advance the technology, enabling the reader to gain a thorough understanding of current technology before assessing where it can go in the future. Innovation in Wind Turbine Design is divided into four mai

  17. Extreme Innovation

    OpenAIRE

    Sandmeier, Patricia; Gassmann, Oliver

    2006-01-01

    The article focuses on a study which examined the application of extreme programming methods to product innovation and development. Extreme programming is a process used in software engineering which deals with the fast changing customer requirements. The methodology used in the study is described. The study explored the challenges associated with product innovation structuring and management. The implications of the study findings for companies are highlighted.

  18. Innovation process

    OpenAIRE

    Kolodovski, A.

    2006-01-01

    Purpose of this report: This report was prepared for RISO team involved in design of the innovation system Report provides innovation methodology to establish common understanding of the process concepts and related terminology The report does not includeRISO- or Denmark-specific cultural, economic, and political challenges, which will be considered in a separate report on implementation The report was written in February 2005.

  19. Music Therapy Advances in Neuro-disability - Innovations in Research and Practice: Summary Report and Reflections on a Two-Day International Conference

    Directory of Open Access Journals (Sweden)

    Julian Winn O'Kelly

    2014-03-01

    Full Text Available This article provides a summary of the oral papers presented during a two day international conference, which took place on 7th & 8th June 2013, at the Royal Hospital for Neuro-disability (RHN in London. The summary texts detail innovative research projects and clinical developments across music therapy, music neuroscience and music psychology addressing the needs of those with acquired and degenerative neurological conditions. The diverse and evolving work in this field is reflected in the topics covered, including disorders of consciousness, dementia, stroke, and the use of modern neuro-imaging methods to measure the effects of music therapy at a cortical level. A discussion of the implications of these converging foci highlights the benefits of the cross-disciplinary dialogue that characterised the conference.

  20. 支气管哮喘防治药物的进展%The Advances of Clinical Research and Application of Drugs for Prevention and Treatment of Bronchial Asthma

    Institute of Scientific and Technical Information of China (English)

    杨玉

    2001-01-01

    文章系统地介绍了支气管哮喘防治药物的进展,内容包括β2-激动药、茶碱、抗胆碱药物、糖皮质激素、肥大细胞稳定药、抗组胺药、抗白三烯类药物、新型抗炎药、免疫抑制药及免疫疗法的进展等,可供大家参考。%In This paper, the advances of clinical research and application of the drugs for preventing and treating bronchial asthma were reviewed, with a detailed reference to such drugs as β2-adrenoceptor agonist, theophylline, anticholinergic drugs, glucocorticoids, mast cell membrane stabilizers, antihistamines, leukotriene receptor antogonists, new anti-inflammatory drugs and immunosuppressive drugs as well as immunotherapy.

  1. Challenges Related to the Use of Liquid Metal and Molten Salt Coolants in Advanced Reactors. Report of the collaborative project COOL of the International Project on Innovative Nuclear Reactors and Fuel Cycles (INPRO)

    International Nuclear Information System (INIS)

    The International Project on Innovative Nuclear Reactors and Fuel Cycles (INPRO) was launched in 2000, based on a resolution by the IAEA General Conference (GC(44)/RES/21). INPRO aims at helping to ensure that nuclear energy is available in the twenty-first century in a sustainable manner, and seeks to bring together all interested Member States, both technology holders and technology users, to jointly consider actions to achieve desired innovations. INPRO is taking care of the specific needs of developing countries. One of the aims of INPRO is to develop options for enhanced sustainability through promotion of technical and institutional innovations in nuclear energy technology through collaborative projects among IAEA Member States. Collaboration among INPRO members is fostered on selected innovative nuclear technologies to bridge technology gaps. Collaborative projects have been selected so that they complement other national and international R and D activities. The INPRO Collaborative Project COOL on Investigation of Technological Challenges Related to the Removal of Heat by Liquid Metal and Molten Salt Coolants from Reactor Cores Operating at High Temperatures investigated the technological challenges of cooling reactor cores that operate at high temperatures in advanced fast reactors, high temperature reactors and accelerator driven systems by using liquid metals and molten salts as coolants. The project was initiated in 2008 and was led by India; experts from Brazil, China, Germany, India, Italy and the Republic of Korea participated and provided chapters of this report. The INPRO Collaborative Project COOL addressed the following fields of research regarding liquid metal and molten salt coolants: (i) survey of thermophysical properties; (ii) experimental investigations and computational fluid dynamics studies on thermohydraulics, specifically pressure drop and heat transfer under different operating conditions; (iii) monitoring and control of coolant

  2. Policy Innovation in Innovation Policy

    DEFF Research Database (Denmark)

    Borras, Susana

    During the past two decades Europe has experienced important changes and transformations in the way in which governments approach the issue of science, technology and innovation, and their relation to economic growth and competitiveness. This has to do with the European Union level as well...... as with national and sub-national governments in Europe, all of them introducing interesting novelties in their innovation policy. These changes refer to different aspects of policy, mainly the content of policy initiatives towards science, technology and innovation; the instruments governments are using...... at the EU level, and mentions similar trends taking place at national and sub-national levels. The questions that guide the contents here are essentially three, namely, what are the main traits of innovation policies in Europe since the 1990s and how have the EU and different national governments approached...

  3. Social innovation as institutional innovation

    OpenAIRE

    Edwards Schachter, Mónica E.; Benneworth, Paul; Amanatidou, Effie; Gulbrandsen, Magnus

    2015-01-01

    Trabajo presentado a la Annual Conference of the EU-SPRI Forum: "Innovation policies for economic and social transitions: Developing strategies for knowledge, practices and organizations" celebrada en Helsinki (Finlandia) del 9 al 12 de junio de 2015.

  4. Academic Drug Discovery Centres

    DEFF Research Database (Denmark)

    Kirkegaard, Henriette Schultz; Valentin, Finn

    2014-01-01

    Academic drug discovery centres (ADDCs) are seen as one of the solutions to fill the innovation gap in early drug discovery, which has proven challenging for previous organisational models. Prior studies of ADDCs have identified the need to analyse them from the angle of their economic...

  5. Social Innovation and Service Innovation

    OpenAIRE

    Djellal, Faridah; Gallouj, FaÏz

    2011-01-01

    International audience Social innovation and service innovation issues have developed separately over the last two decades, with too rare intersections between them. Both issues share many points in common, however, and sometimes even describe the same socio-economic reality. This paper aims to help establish dialogue between these two still marginal but promising fields of economic theory and the social sciences in general. It briefly describes each of these two fields, puts them into per...

  6. The Effects of Innovation on Performance of Korean Firms

    OpenAIRE

    Heshmati, Almas; Kim, Yee-Kyoung; Kim, Hyesung

    2006-01-01

    This study empirically examines the relationship between knowledge capital and performance heterogeneity at the firm level. The model is based on a knowledge production function comprising of four interdependent equations linking innovativeness to innovation input, innovation output and productivity. The empirical part is based on Korean firm level innovation data. The model is estimated using advanced econometric methods. We investigate whether innovation is a significant and contributing de...

  7. Theoretical approaches to social innovation – A critical literature review

    OpenAIRE

    Butzin, A.; Davis, A.; Domanski, D.; Dhondt, S.; Howaldt, J.; Kaletka, C.; Kesselring, A.; Kopp, R.; Millard, J; Oeij, P.; Rehfeld, D.; Schaper-Rinkel, P.; Schwartz, M.; Scoppetta, A.; Wagner-Luptacik, P.

    2014-01-01

    The SI-DRIVE report “Theoretical approaches to Social Innovation – A Critical Literature Review” delivers a comprehensive overview on the state of the art of theoretically relevant building blocks for advancing a theoretical understanding of social innovation. It collects different theoretical approaches which are conducive to a deeper understanding of social innovation. The chapters, focusing on (1) Theories of Social Change, (2) Social Innovation Studies and (3) Innovation and Management St...

  8. Innovative Clean Coal Technology (ICCT): 500 MW demonstration of advanced wall-fired combustion techniques for the reduction of nitrogen oxide (NO sub x ) emissions from coal-fired boilers

    Energy Technology Data Exchange (ETDEWEB)

    1992-04-21

    This quarterly report discusses the technical progress of an Innovative Clean Coal Technology (ICCT) demonstration of advanced wall-fired combustion techniques for the reduction of nitrogen oxide (NO{sub x}) emissions from coal-fired boilers. The project is being conducted at Georgia Power Company's Plant Hammond Unit 4 located near Rome, Georgia. The primary goal of this project is the characterization of the low NO{sub x} combustion equipment through the collection and analysis of long-term emissions data. A target of achieving fifty percent NO{sub x} reduction using combustion modifications has been established for the project. The project provides a stepwise retrofit of an advanced overfire air (AOFA) system followed by low NO{sub x} burners (LNB). During each test phase of the project, diagnostic, performance, long-term, and verification testing will be performed. These tests are used to quantify the NO{sub x} reductions of each technology and evaluate the effects of those reductions on other combustion parameters such as parameters such as particulate characteristics and boiler efficiency.

  9. Innovative Clean Coal Technology (ICCT): 500 MW demonstration of advanced wall-fired combustion techniques for the reduction of nitrogen oxide (NO{sub x}) emissions from coal-fired boilers. Technical progress report, fourth quarter 1991

    Energy Technology Data Exchange (ETDEWEB)

    1992-04-21

    This quarterly report discusses the technical progress of an Innovative Clean Coal Technology (ICCT) demonstration of advanced wall-fired combustion techniques for the reduction of nitrogen oxide (NO{sub x}) emissions from coal-fired boilers. The project is being conducted at Georgia Power Company`s Plant Hammond Unit 4 located near Rome, Georgia. The primary goal of this project is the characterization of the low NO{sub x} combustion equipment through the collection and analysis of long-term emissions data. A target of achieving fifty percent NO{sub x} reduction using combustion modifications has been established for the project. The project provides a stepwise retrofit of an advanced overfire air (AOFA) system followed by low NO{sub x} burners (LNB). During each test phase of the project, diagnostic, performance, long-term, and verification testing will be performed. These tests are used to quantify the NO{sub x} reductions of each technology and evaluate the effects of those reductions on other combustion parameters such as parameters such as particulate characteristics and boiler efficiency.

  10. Collaborative innovation

    DEFF Research Database (Denmark)

    Timenes Laugen, Bjørge; Lassen, Astrid Heidemann

    2011-01-01

    Industry and academia alike are increasingly becoming aware of the fact that innovation does not take place in isolated cells or functions within the firm. Although the idea of involving internal and external actors in the new product development (NPD) process is not new, the knowledge about...... the benefits and pitfalls is still limited. This paper aims to contribute to refining the concept of open innovation, by investigating how strategic priorities influence the degree of external and internal involvement in the NPD process, moderated by contextual factors. The results indicate that suppliers...... are heavily involved in the NPD process in firms in B2C markets aiming at increasing the innovation volume. For B2B companies the reverse picture emerges. However, when the aim is to increase the radicality of new products, suppliers and customers are heavily involved for firms in B2B markets....

  11. Reconsidering Innovation

    DEFF Research Database (Denmark)

    Vaaben, Nana Katrine

    2014-01-01

    Innovation og reformer er på dagsordenen allevegne, ikke mindst i politiske forsøg på at reorganisere den offentlige sektor for at få velfærdssamfundet til at kunne overleve økonomisk tumult og dystre fremtidsprognoser. Dette papir undersøger, hvordan klassiske antropologiske teorier og debatter om...... forandring og myter kan hjælpe os med at genoverveje teoretiske forståelser af innovation i organisatoriske studier. I særlig grad sættes der fokus på de implikationer som vores "innovationsmyte" kan have for offentligt ansatte og værdsættelsen af deres arbejde. Analysens argument er, at innovation ikke skal...

  12. Innovative clean coal technology: 500 MW demonstration of advanced wall-fired combustion techniques for the reduction of nitrogen oxide (NOx) emissions from coal-fired boilers. Final report, Phases 1 - 3B

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1998-01-01

    This report presents the results of a U.S. Department of Energy (DOE) Innovative Clean Coal Technology (ICCT) project demonstrating advanced wall-fired combustion techniques for the reduction of nitrogen oxide (NOx) emissions from coal-fired boilers. The project was conducted at Georgia Power Company`s Plant Hammond Unit 4 located near Rome, Georgia. The technologies demonstrated at this site include Foster Wheeler Energy Corporation`s advanced overfire air system and Controlled Flow/Split Flame low NOx burner. The primary objective of the demonstration at Hammond Unit 4 was to determine the long-term effects of commercially available wall-fired low NOx combustion technologies on NOx emissions and boiler performance. Short-term tests of each technology were also performed to provide engineering information about emissions and performance trends. A target of achieving fifty percent NOx reduction using combustion modifications was established for the project. Short-term and long-term baseline testing was conducted in an {open_quotes}as-found{close_quotes} condition from November 1989 through March 1990. Following retrofit of the AOFA system during a four-week outage in spring 1990, the AOFA configuration was tested from August 1990 through March 1991. The FWEC CF/SF low NOx burners were then installed during a seven-week outage starting on March 8, 1991 and continuing to May 5, 1991. Following optimization of the LNBs and ancillary combustion equipment by FWEC personnel, LNB testing commenced during July 1991 and continued until January 1992. Testing in the LNB+AOFA configuration was completed during August 1993. This report provides documentation on the design criteria used in the performance of this project as it pertains to the scope involved with the low NOx burners and advanced overfire systems.

  13. A Systems Biology Approach to Infectious Disease Research: Innovating the Pathogen-Host Research Paradigm

    Energy Technology Data Exchange (ETDEWEB)

    Aderem, Alan; Adkins, Joshua N.; Ansong, Charles; Galagan, James; Kaiser, Shari; Korth, Marcus J.; Law, G. L.; McDermott, Jason E.; Proll, Sean; Rosenberger, Carrie; Schoolnik, Gary; Katze, Michael G.

    2011-02-01

    The 20th century was marked by extraordinary advances in our understanding of microbes and infectious disease, but pandemics remain, food and water borne illnesses are frequent, multi-drug resistant microbes are on the rise, and the needed drugs and vaccines have not been developed. The scientific approaches of the past—including the intense focus on individual genes and proteins typical of molecular biology—have not been sufficient to address these challenges. The first decade of the 21st century has seen remarkable innovations in technology and computational methods. These new tools provide nearly comprehensive views of complex biological systems and can provide a correspondingly deeper understanding of pathogen-host interactions. To take full advantage of these innovations, the National Institute of Allergy and Infectious Diseases recently initiated the Systems Biology Program for Infectious Disease Research. As participants of the Systems Biology Program we think that the time is at hand to redefine the pathogen-host research paradigm.

  14. Software Innovation

    DEFF Research Database (Denmark)

    Rose, Jeremy

      Innovation is the forgotten key to modern systems development - the element that defines the enterprising engineer, the thriving software firm and the cutting edge software application.  Traditional forms of technical education pay little attention to creativity - often encouraging overly...... rationalistic ways of thinking which stifle the ability to innovate. Professional software developers are often drowned in commercial drudgery and overwhelmed by work pressure and deadlines. The topic that will both ensure success in the market and revitalize their work lives is never addressed. This book sets...

  15. Effektiv innovation

    DEFF Research Database (Denmark)

    Søndergaard, Katia Dupret; Brandi, Ulrik

    2011-01-01

    Er det vækst og udvikling eller åbenhed, videnudvikling, netværk, leg og innovation? Eller er det prisregulering, tilpasning og stærk styring, som skal gøre universiteterne til førende drivkræfter for dansk vækst?......Er det vækst og udvikling eller åbenhed, videnudvikling, netværk, leg og innovation? Eller er det prisregulering, tilpasning og stærk styring, som skal gøre universiteterne til førende drivkræfter for dansk vækst?...

  16. Microfluidic cell chips for high-throughput drug screening.

    Science.gov (United States)

    Chi, Chun-Wei; Ahmed, Ah Rezwanuddin; Dereli-Korkut, Zeynep; Wang, Sihong

    2016-05-01

    The current state of screening methods for drug discovery is still riddled with several inefficiencies. Although some widely used high-throughput screening platforms may enhance the drug screening process, their cost and oversimplification of cell-drug interactions pose a translational difficulty. Microfluidic cell-chips resolve many issues found in conventional HTS technology, providing benefits such as reduced sample quantity and integration of 3D cell culture physically more representative of the physiological/pathological microenvironment. In this review, we introduce the advantages of microfluidic devices in drug screening, and outline the critical factors which influence device design, highlighting recent innovations and advances in the field including a summary of commercialization efforts on microfluidic cell chips. Future perspectives of microfluidic cell devices are also provided based on considerations of present technological limitations and translational barriers. PMID:27071838

  17. A concise review on smart polymers for controlled drug release.

    Science.gov (United States)

    Aghabegi Moghanjoughi, Arezou; Khoshnevis, Dorna; Zarrabi, Ali

    2016-06-01

    Design and synthesis of efficient drug delivery systems are of critical importance in health care management. Innovations in materials chemistry especially in polymer field allows introduction of advanced drug delivery systems since polymers could provide controlled release of drugs in predetermined doses over long periods, cyclic and tunable dosages. To this end, researchers have taken advantages of smart polymers since they can undergo large reversible, chemical, or physical fluctuations as responses to small changes in environmental conditions, for instance, in pH, temperature, light, and phase transition. The present review aims to highlight various kinds of smart polymers, which are used in controlled drug delivery systems as well as mechanisms of action and their applications. PMID:26744179

  18. Towards open innovation practices in aerospace industry

    OpenAIRE

    Parida, Vinit; Larsson, Tobias; Isaksson, Ola; Oghazi, Pejvak

    2011-01-01

    Across industrial settings and environmental conditions, innovation is viewed as a source of advancing firms’ competitive position. Recently, a shift has been witnessed from the traditional innovation model, which mainly focused on internal research and development (R&D) towards open innovation. In this study, we have attempted to study if this approach is suitable for the regular, more mature industry by focusing the context of aerospace industry. The study involves a single case company...

  19. Innovation in care services for the elderly

    OpenAIRE

    Djellal, Faridah; Gallouj, FaÏz

    2006-01-01

    International audience Ageing and innovation are usually considered to be contradictory phenomena. This article on innovation in care services for the elderly seeks to counter this established view. Taking as its starting point a definition of care services for the elderly that draws on the economics of services, the article advances a simple framework for analysing innovation in terms of 'targets'. These targets, which make it possible to circumvent the usual economic categories (product ...

  20. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?

    Science.gov (United States)

    Arnold, Denis G; Troyer, Jennifer L

    2016-04-01

    The pharmaceutical industry has been criticized for developing and aggressively marketing drugs that do not provide significant health benefits relative to existing drugs but retain the benefits of patent protection. Critics argue that drug marketing increases health care expenditures and provides a disincentive for pioneering drug innovation. However, evidence that marketing expenditures have any relationship to new drug approvals has been anecdotal. We hypothesized that, at publicly traded pharmaceutical firms, increased marketing expenditures will result in a reduced volume of pioneering new drugs in comparison to less innovative new drugs. We also hypothesized that additional research and development spending will result in an increased volume of pioneering new drugs in comparison to less innovative drugs. Results confirm our hypotheses. Specific policy recommendations for altering firms' incentives for the development of pioneering drugs are provided. PMID:26732315

  1. The challenges of technological innovation in HIV

    OpenAIRE

    Rosengarten, Marsha

    2008-01-01

    The challenges of transferring biomedical advances and non-biomedical technological innovations in HIV prevention and treatment to the field, are a theme of this year’s XVII International AIDS Conference.

  2. Antiretroviral drugs.

    Science.gov (United States)

    De Clercq, Erik

    2010-10-01

    In October 2010, it will be exactly 25 years ago that the first antiretroviral drug, AZT (zidovudine, 3'-azido-2',3'-dideoxythymidine), was described. It was the first of 25 antiretroviral drugs that in the past 25 years have been formally licensed for clinical use. These antiretroviral drugs fall into seven categories [nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), co-receptor inhibitors (CRIs) and integrase inhibitors (INIs). The INIs (i.e. raltegravir) represent the most recent advance in the search for effective and selective anti-HIV agents. Combination of several anti-HIV drugs [often referred to as highly active antiretroviral therapy (HAART)] has drastically altered AIDS from an almost uniformly fatal disease to a chronic manageable one. PMID:20471318

  3. People, Politics, and Innovation: A Process Perspective

    NARCIS (Netherlands)

    L. Alexander (Lameez)

    2014-01-01

    markdownabstract__Abstract__ Innovation is often considered the Holy Grail of competitive advantage and growth in modern organizations. Organizing for innovation can therefore be seen as the cornerstone of organizational success. In this dissertation, I aimed to advance a more complex and dynamic

  4. The Path to Enduring Innovation in Schools

    Science.gov (United States)

    Hall, Catherine J.

    2016-01-01

    It is difficult, if not impossible, for a school proud of its reputation for excellence not to feel the need to claim to have a firm grip on "innovation." Leading in innovation suggests many things that the school is--such as being technologically advanced, current in pedagogy and practice, and generally ahead of the curve. Yet, in…

  5. Advanced Manufacturing Technologies

    Science.gov (United States)

    Fikes, John

    2016-01-01

    Advanced Manufacturing Technologies (AMT) is developing and maturing innovative and advanced manufacturing technologies that will enable more capable and lower-cost spacecraft, launch vehicles and infrastructure to enable exploration missions. The technologies will utilize cutting edge materials and emerging capabilities including metallic processes, additive manufacturing, composites, and digital manufacturing. The AMT project supports the National Manufacturing Initiative involving collaboration with other government agencies.

  6. Financing Innovation

    OpenAIRE

    Yoo, JaeHoon

    2007-01-01

    More than 24 countries operate separate boards and exchanges aimed at small and medium-size enterprises (SMEs). Equity markets play a critical role in fostering economic productivity by financing innovation. But only a few SME exchanges function properly, providing coveted fresh capital and liquidity. What steps are key to building an efficient exchange to provide risk capital for SMEs? Cr...

  7. HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions

    Directory of Open Access Journals (Sweden)

    Francesca Esposito

    2012-01-01

    Full Text Available During the retrotranscription process, characteristic of all retroviruses, the viral ssRNA genome is converted into integration-competent dsDNA. This process is accomplished by the virus-coded reverse transcriptase (RT protein, which is a primary target in the current treatments for HIV-1 infection. In particular, in the approved therapeutic regimens two classes of drugs target RT, namely, nucleoside RT inhibitors (NRTIs and nonnucleoside RT inhibitors (NNRTIs. Both classes inhibit the RT-associated polymerase activity: the NRTIs compete with the natural dNTP substrate and act as chain terminators, while the NNRTIs bind to an allosteric pocket and inhibit polymerization noncompetitively. In addition to these two classes, other RT inhibitors (RTIs that target RT by distinct mechanisms have been identified and are currently under development. These include translocation-defective RTIs, delayed chain terminators RTIs, lethal mutagenesis RTIs, dinucleotide tetraphosphates, nucleotide-competing RTIs, pyrophosphate analogs, RT-associated RNase H function inhibitors, and dual activities inhibitors. This paper describes the HIV-1 RT function and molecular structure, illustrates the currently approved RTIs, and focuses on the mechanisms of action of the newer classes of RTIs.

  8. INNOVATION IN THE CONSTRUCTION INDUSTRY

    Directory of Open Access Journals (Sweden)

    David Arditi

    2000-01-01

    Full Text Available In this paper%2C existing innovation models are reviewed. The influence of technology and market-driven schools of thought on the creation and diffusion of innovation is examined. Incremental vs. radical models and autonomous vs. systemic models are considered in the context of the construction industry. The concept of %93technology adoption life cycle%94 is investigated to understand better the acceptance of new technology by key parties. A new model of innovation is proposed. In this model%2C the transformation process of invention into adoption flows through a cyclical mechanism encompassing six phases%3A 1%29 need%2C 2%29 creation%2C 3%29 invention%2C 4%29 innovation%2C 5%29 diffusion%2C and 6%29 adoption. This model clearly shows the interaction of the three most influential domains%3A users%2C changes%2C and the environment. The model also takes into consideration the influence of technology and market-driven forces on the creation and diffusion of innovation. As a consequence of their particular function in the construction activity%2C construction management firms should perform as catalysts in the generation and diffusion of technological advances in the Abstract in Bahasa Indonesia : Innovation%2C+invention%2C+innovation+models%2C+technology+adoption+life+cycle%2C+construction+management.+

  9. Rethinking Open Innovation Beyond the Innovation Funnel

    OpenAIRE

    Wim Vanhaverbeke

    2013-01-01

    In his article, I first argue that open innovation can be applied in situations where companies do not themselves develop new products or services. As a consequence, open innovation becomes relevant for a much larger group of organizations than previously considered. Second, I argue that open-innovation scholars have insufficiently differentiated open-innovation initiatives in terms of their impact on companies’ growth: some open-innovation initiatives lead to incremental innovations in an ex...

  10. Rethinking Open Innovation Beyond the Innovation Funnel

    Directory of Open Access Journals (Sweden)

    Wim Vanhaverbeke

    2013-04-01

    Full Text Available In his article, I first argue that open innovation can be applied in situations where companies do not themselves develop new products or services. As a consequence, open innovation becomes relevant for a much larger group of organizations than previously considered. Second, I argue that open-innovation scholars have insufficiently differentiated open-innovation initiatives in terms of their impact on companies’ growth: some open-innovation initiatives lead to incremental innovations in an existing business while, in other cases, open-innovation initiatives are used to establish completely new businesses. Both arguments illustrate the need to integrate open-innovation initiatives into the strategy of the firm.

  11. Innovations in urban agriculture

    NARCIS (Netherlands)

    Schans, van der J.W.; Renting, Henk; Veenhuizen, Van René

    2014-01-01

    This issuehighlights innovations in urban agriculture. Innovation and the various forms of innovations are of particular importance because urban agriculture is adapted to specific urban challenges and opportunities. Innovation is taking place continuously, exploring the multiple fundions of urban a

  12. Computational Science and Innovation

    International Nuclear Information System (INIS)

    Simulations - utilizing computers to solve complicated science and engineering problems - are a key ingredient of modern science. The U.S. Department of Energy (DOE) is a world leader in the development of high-performance computing (HPC), the development of applied math and algorithms that utilize the full potential of HPC platforms, and the application of computing to science and engineering problems. An interesting general question is whether the DOE can strategically utilize its capability in simulations to advance innovation more broadly. In this article, I will argue that this is certainly possible.

  13. Methodology and tools of enterprise innovativeness evaluation

    Directory of Open Access Journals (Sweden)

    L.O. Ligonenko

    2015-09-01

    base for the innovativeness internal indicator calculation. It helps to make conclusions more profound and develope appropriate management decisions. The author proposed a comprehensive system of enterprise innovativeness public evaluation. It is based on the current Ukrainian statistical reporting and comprises of two subsystems (determinants: preconditions and results (manifestations of innovativeness. It is proposed to evaluate preconditions of innovativeness in such areas as: intellectual property rights formation; cooperation with educational, scientific, and entrepreneurial sectors; information and personnel readiness for innovations implementation; financial and investment support of innovative enterprise activity; state (regional promotion of enterprise innovativeness. It is proposed to evaluate the results of innovativeness in the context of such directions as innovative enterprise activity; market launch of innovative products; introduction of new technique and advanced technologies; introduction of new information and communication technologies; participation in technological transfers. It is also proposed to summarize analytical indicators into an integral indicator of innovativeness according to the principles of additive weighted average clotting. A specially formed group of experts should assess coefficients of significance of individual valuation indicators. Interpretation of innovative level can be based on quantitative assessment (close to one or according to 5-interval scale of linguistic interpretation of Harrington. This integral indicator of innovation can further be used for dynamic and comparative analysis (comparison with the corresponding indicator of other enterprises or average values in the industry. To determine the reference value one can use the average or maximum value in the aggregate researched. Conclusions and directions for future research. This methodology of innovativeness evaluation may interest different groups of enterprise

  14. Relationship between the Genetic Polymorphisms of Phase I and II Drug-metabolizing Enzymes, as well as the Outcome of Chemotherapy in Advanced Non-small Cell Lung Cancer

    Directory of Open Access Journals (Sweden)

    Weiying LI

    2011-11-01

    Full Text Available Background and objective Currently available studies on the polymorphisms of drug-metabolizing enzymes and their chemotherapeutic effects in non-small cell lung cancer are not consistent. In the present study, the relationship of the gene polymorphisms of cytochrome P450 1A1 (CYP1A1, cytochrome P450 2E1 (CYP2E1, cytochrome P450 2D6 (CYP2D6, and glutathione S-transferase M1 (GSTM1 enzymes with chemotherapeutic effects were investigated. The effects of these relationships on the survival of advanced non-small cell lung cancer patients were also examined. Methods Four drug metabolism enzymes were genotyped in lung cancer patients by polymerase chain reaction (PCR and PCR-restriction fragment length polymorphism. These patients were followed for five years. Results The chemotherapeutic effect on patients carrying B-type CYP1A1 and null-type GSTM1 was better than on those carrying other types (P<0.001. The chemotherapeutic effect on patients carrying A-type CYP1A1 was better than on those carrying the B and C types when non-platinum drugs were administered (P=0.041. The chemotherapeutic effect on patients carrying null-type GSTM1 was better than on those carrying the functional type when platinum drugs were administered (P=0.011. The four enzymes did not affect the overall survival (OS of advanced non-small cell lung cancer patients (P>0.05. Conclusion The chemotherapeutic effect on patients carrying A-type CYP1A1 was better than on those carrying the B and C types when non-platinum drugs were administered. The chemotherapeutic effect on patients carrying null-type GSTM1 was better than on those carrying the functional type when platinum drugs were administered. The four enzymes did not affect the OS of advanced non-small cell lung cancer patients.

  15. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment

    Directory of Open Access Journals (Sweden)

    Ju Jin

    2015-01-01

    Conclusion: MAGE-A3 expression in EGFR-TKIs target therapy in NSCLC patient suggests that there might be EGFR-TKIs drug resistance, and the higher the level of expression, the shorter the time of acquired drug resistance.

  16. Editorial: Advanced learning technologies

    OpenAIRE

    Yu-Ju Lan; Gang-Shan Fu; Stephen J.H. Yang; Jeff J.S. Huang

    2012-01-01

    Recent rapid development of advanced information technology brings high expectations of its potential to improvement and innovations in learning. This special issue is devoted to using some of the emerging technologies issues related to the topic of education and knowledge sharing, involving several cutting edge research outcomes from recent advancement of learning technologies. Advanced learning technologies are the composition of various related technologies and concepts such as mobile tech...

  17. Innovative Clean Coal Technology (ICCT): 500 MW demonstration of advanced wall-fired combustion techniques for the reduction of nitrogen oxide (NO{sub x}) emissions from coal-fired boilers. Technical progress report: First quarter 1993

    Energy Technology Data Exchange (ETDEWEB)

    1993-12-31

    This quarterly report discusses the technical progress of an Innovative Clean Coal Technology (ICCT) demonstration being conducted at Georgia Power Company`s Plant Hammond Unit 4 located near Rome, Georgia. The primary goal of this project is the characterization of the low NO{sub x} combustion equipment through the collection and analysis of long-term emissions data. A target of achieving fifty percent NO{sub x} reduction using combustion modifications has been established for the project. The project provides a stepwise retrofit of an advanced overfire air (AOFA) system followed by low NO{sub x} burners (LNB). During each test phase of the project, diagnostic, performance, long-term, and verification testing will be performed. These tests are used to quantify the NO{sub x} reductions of each technology and evaluate the effects of those reductions on other combustion parameters such as particulate characteristics and boiler efficiency. During this quarter, long-term testing of the LNB + AOFA configuration continued and no parametric testing was performed. Further full-load optimization of the LNB + AOFA system began on March 30, 1993. Following completion of this optimization, comprehensive testing in this configuration will be performed including diagnostic, performance, verification, long-term, and chemical emissions testing. These tests are scheduled to start in May 1993 and continue through August 1993. Preliminary engineering and procurement are progressing on the Advanced Low NOx Digital Controls scope addition to the wall-fired project. The primary activities during this quarter include (1) refinement of the input/output lists, (2) procurement of the distributed digital control system, (3) configuration training, and (4) revision of schedule to accommodate project approval cycle and change in unit outage dates.

  18. Global Health Innovation Technology Models

    Directory of Open Access Journals (Sweden)

    Kimberly Harding

    2016-04-01

    Full Text Available Chronic technology and business process disparities between High Income, Low Middle Income and Low Income (HIC, LMIC, LIC research collaborators directly prevent the growth of sustainable Global Health innova‐ tion for infectious and rare diseases. There is a need for an Open Source-Open Science Architecture Framework to bridge this divide. We are proposing such a framework for consideration by the Global Health community, by utiliz‐ ing a hybrid approach of integrating agnostic Open Source technology and healthcare interoperability standards and Total Quality Management principles. We will validate this architecture framework through our programme called Project Orchid. Project Orchid is a conceptual Clinical Intelligence Exchange and Virtual Innovation platform utilizing this approach to support clinical innovation efforts for multi-national collaboration that can be locally sustainable for LIC and LMIC research cohorts. The goal is to enable LIC and LMIC research organizations to acceler‐ ate their clinical trial process maturity in the field of drug discovery, population health innovation initiatives and public domain knowledge networks. When sponsored, this concept will be tested by 12 confirmed clinical research and public health organizations in six countries. The potential impact of this platform is reduced drug discovery and public health innovation lag time and improved clinical trial interventions, due to reliable clinical intelligence and bio-surveillance across all phases of the clinical innovation process.

  19. Ecological Innovation

    OpenAIRE

    Blok, Vincent; Gremmen, Bart

    2016-01-01

    In this article, we critically reflect on the concept of biomimicry. On the basis of an analysis of the concept of biomimicry in the literature and its philosophical origin, we distinguish between a strong and a weaker concept of biomimicry. The strength of the strong concept of biomimicry is that nature is seen as a measure by which to judge the ethical rightness of our technological innovations, but its weakness is found in questionable presuppositions. These presuppositions are addressed b...

  20. Innovative solutions

    OpenAIRE

    2014-01-01

    The 2013 11th annual Global Conference on Sustainable Manufacturing (GCSM) sponsored by the International Academy for Production Engineering (CIRP) taking place in Technische Universität Berlin and Fraunhofer Production Technology Center is committed to exploiting the potentials of innovative technologies in economic, environmental and social dimensions for global value creation. If the lifestyles of upcoming and also developed communities will be shaped in the future by the existing, actuall...

  1. Cooperative Innovation

    OpenAIRE

    Mingzhuan, Huang

    2013-01-01

    The current companies increasingly expect to involve more external sources to achieve more open innovation for value-added. However, the cooperation problem between internal organization and external parties still challenges the top management. This paper aims to find out the solution. The fast spring up Chinese IT market impacts the world market, especially mobile Internet. Therefore, this paper employ the fast growing Chinese Mobile Internet company--- Xiao Mi as the study case. By applying...

  2. User Driven Innovation in the Building Process

    DEFF Research Database (Denmark)

    Christiansson, Per; Sørensen, Kristian Birch; Rødtness, Mette;

    2008-01-01

    Innovation in Construction (VIC) project. One important driving force for change is the opportunity for users to develop and articulate real needs concerning for example different functionalities of a building and its parts, but also on artifacts supporting the actual needs capture and requirements...... to introduction of advanced information and communication technology (ICT). The paper focuses on creative changes of the building process powered by user driven innovation activities. An overview of existing user driven innovation methodologies is given as well experiences from the ongoing Virtual...... formulation during building design. A general methodological framework and meta ontology for Virtual Innovation in Construction is presented as well as findings from implementation of the method....

  3. Advanced information society (12)

    Science.gov (United States)

    Komatsuzaki, Seisuke

    In this paper, the original Japanese idea of "advanced information society" was reviewed at the first step. Thus, advancement of information/communication technology, advancement of information/communication needs and tendency of industrialization of information" were examined. Next, by comparing studies on advanced information society in various countries, the Japanese characteristics of consensus building was reviewed. Finally, in pursuit of prospect and tasks for the society, advancement of innovation and convergence information/communication technology, information/communication needs, institutional environment for utilization of information/communication and countermeasures against information pollution. Matching of information/communication technology and needs, besides with countermeasures against information pollution were discussed.

  4. 线粒体靶向递药系统的研究进展%Research Advance in Mitochondrial Targeting Drug Delivery System

    Institute of Scientific and Technical Information of China (English)

    徐焕春; 宋彦峰; 赵先; 白娟; 廖悠悠; 封小娜; 文爱东

    2014-01-01

    线粒体控制着细胞凋亡的激活系统。肿瘤细胞的多种特征,包括无限的增殖能力、对抑制生长信号的不敏感、受损的细胞凋亡机制等都与线粒体的机能丧失有关。研究发现,肥胖、糖尿病等疾病的发生发展过程中均存在线粒体功能的紊乱,并且多种疾病的发生与线粒体DNA的变异有关。因此,为了防止或修复线粒体功能的损伤,寻找靶向线粒体的递药系统越来越重要。针对线粒体的结构特征,该文综述了国内外不同线粒体靶向策略的研究进展。%Mitochondria controls the activation system of apoptosis, a variety of characteristics of tumor cells, including unlimited prolifera-tion ability, unsensitive to the signals of growth inhibition and the damaged apoptosis mechanism, are related to the function loss of mi-tochondria. Some researches found that the mitochondrial function disorder exists in the occurrence and development of some diseases, such as obesity and diabetes, and the occurrences of many diseases have a relationship with the DNA mutation of mitochondria. Therefore, in order to prevent or repair the damaged function of mitochondrion, looking for the drug delivery systems targeting mitochon-dria is more and more important. Aiming at the mitochondrial structure characteristics, this paper reviews the research advances in differ-ent mitochondrial targeting strategies at home and abroad.

  5. Impact of Metronomic UFT/Cyclophosphamide Chemotherapy and Antiangiogenic Drug Assessed in a New Preclinical Model of Locally Advanced Orthotopic Hepatocellular Carcinoma

    Directory of Open Access Journals (Sweden)

    Terence C. Tang

    2010-03-01

    Full Text Available Hepatocellular carcinoma (HCC is an intrinsically chemotherapy refractory malignancy. Development of effective therapeutic regimens would be facilitated by improved preclinical HCC models. Currently, most models consist of subcutaneous human tumor transplants in immunodeficient mice; however, these do not reproduce the extensive liver disease associated with HCC or metastasize. To address this deficiency, we developed an orthotopic model. Human HCC cells were transfected with the gene encoding secretable β-subunit human choriogonadotropin (β-hCG, which was used as a surrogate marker of tumor burden. The HCC cells were implanted into the left liver lobe of severe combined immunodeficient (SCID mice, after which the efficacy of different therapies was evaluated on established, but liver-confined human Hep3B cell line HCC. Treatments included sorafenib or metronomic chemotherapy using cyclophosphamide (CTX, UFT, an oral 5-fluorouracil prodrug, or doxorubicin either alone or in various combinations, with or without an antiangiogenic agent, DC101, an anti-vascular endothelial growth factor receptor-2 antibody. Sorafenib inhibited tumor growth in a dose-dependent manner but caused severe weight loss in SCID mice, thus necessitating use of DC101 in subsequent experiments. Although less toxicity was observed using either single or doublet metronomic chemotherapy without any added antiangiogenic agent, none, provided survival benefit. In contrast, significantly improved overall survival was observed using various combinations of metronomic chemotherapy regimens such as UFT + CTX with DC101. In conclusion, using this model of liver-confined but advanced HCC suggests that the efficacy of a targeted antiangiogenic drug or metronomic chemotherapy can be mutually enhanced by concurrent combination treatment.

  6. Development and Testing of the Advanced CHP System Utilizing the Off-Gas from the Innovative Green Coke Calcining Process in Fluidized Bed

    Energy Technology Data Exchange (ETDEWEB)

    Chudnovsky, Yaroslav; Kozlov, Aleksandr

    2013-08-15

    petroleum coke calcination process. - Increase the opportunity of heat (chemical and physical) utilization from process off-gases and solid product. - Develop a design of advanced CHP system utilizing off-gases as an “opportunity fuel” for petroleum coke calcinations and sensible heat of calcined coke. A successful accomplishment of the aforementioned objectives will contribute toward the following U.S. DOE programmatic goals: - Drive a 25% reduction in U. S. industrial energy intensity by 2017 in support of EPAct 2005; - Contribute to an 18% reduction in U.S. carbon intensity by 2012 as established by the Administration’s “National Goal to Reduce Emissions Intensity.” 8

  7. European Innovation Policy Concepts and the Governance of Innovation: Slovenia and the Struggle for Organizational Readiness at the National Level

    Science.gov (United States)

    Gebhardt, Christiane; Stanovnik, Peter

    2016-01-01

    This paper examines the interdependency of European Policy and governance of innovation. The authors elaborate on the policy implementation context of Slovenia, a small and less advanced European member state in a transition process. The literature on innovation policy, governance and existing innovation concepts aiming to accelerate economic…

  8. Service Innovations

    DEFF Research Database (Denmark)

    Sørensen, Lene Tolstrup; Nicolajsen, Hanne Westh

    2010-01-01

    This article discusses the challenges in relation to an ongoing project named converged advanced mobile media platform (CAMMP), where all the different stakeholders need to have a saying in the service development for the upcoming rich, mobile broadcasting services....

  9. Scenarios and innovative systems

    International Nuclear Information System (INIS)

    The purpose of this workshop is to present to the GEDEON community the scenarios for the deployment of innovative nuclear solutions. Both steady state situations and possible transitions from the present to new reactors and fuel cycles are considered. Innovative systems that satisfy improved natural resource utilization and waste minimization criteria will be described as well as the R and D orientations of various partners. This document brings together the transparencies of 17 communications given at this workshop: general policy for transmutation and partitioning; Amster: a molten salt reactor (MSR) concept; MSR capabilities; potentials and capabilities of accelerator driven systems (ADS); ADS demonstrator interest as an experimental facility; innovative systems: gas coolant technologies; Pu management in EPR; scenarios with thorium fuel; scenarios at the equilibrium state; scenarios for transition; partitioning and specific conditioning; management of separated radio-toxic elements; European programs; DOE/AAA (Advanced Accelerator Applications) program; OECD scenario studies; CEA research programs and orientations; partitioning and transmutation: an industrial point of view. (J.S.)

  10. German innovation initiative for nanotechnology

    International Nuclear Information System (INIS)

    In many areas of nanotechnology, Germany can count on a good knowledge basis due to its diverse activities in nanosciences. This knowledge basis, when paired with the production and sales structures needed for implementation and the internationally renowned German talent for system integration, should consequently lead to success in the marketplace. And this is exactly the field of application for the innovation initiative 'Nanotechnologie erobert Maerkte' (nanotechnology conquers markets) and for the new BMBF strategy in support of nanotechnology. Until now, aspects of nanotechnology have been advanced within the confines of their respective technical subject areas. However, the primary aim of incorporating them into an overall national strategy is to build on Germany's well-developed and internationally competitive research in science and technology to tap the potential of Germany's important industrial sectors for the application of nanotechnology through joint research projects (leading-edge innovations) that strategically target the value-added chain. This development is to be supported by government education policy to remedy a threatening shortage of skilled professionals. To realize that goal, forward-looking political policymaking must become oriented to a uniform concept of innovation, one that takes into consideration all facets of new technological advances that can contribute to a new culture of innovation in Germany. And that includes education and research policy as well as a climate that encourages and supports innovation in science, business and society

  11. Workplace innovation, social innovation and social quality

    NARCIS (Netherlands)

    Oeij, P.R.A.; Dhondt, S.; Korver, T.

    2011-01-01

    Social innovation is becoming a core value of the EU flagship initiative Innovation Union, but it is not clearly demarcated as it covers a wide field of topics. To understand social innovation within European policymaking a brief outline is given of EC policy developments on innovation and on workpl

  12. Disruptive Innovation in Numerical Hydrodynamics

    Energy Technology Data Exchange (ETDEWEB)

    Waltz, Jacob I. [Los Alamos National Laboratory

    2012-09-06

    We propose the research and development of a high-fidelity hydrodynamic algorithm for tetrahedral meshes that will lead to a disruptive innovation in the numerical modeling of Laboratory problems. Our proposed innovation has the potential to reduce turnaround time by orders of magnitude relative to Advanced Simulation and Computing (ASC) codes; reduce simulation setup costs by millions of dollars per year; and effectively leverage Graphics Processing Unit (GPU) and future Exascale computing hardware. If successful, this work will lead to a dramatic leap forward in the Laboratory's quest for a predictive simulation capability.

  13. Problem framing in new innovation spaces

    DEFF Research Database (Denmark)

    Lema, Rasmus

    2015-01-01

    This paper is concerned with the global distribution of innovation activity. It uses the case of the software industry to show that there is considerable scope for innovation as an incremental extension of routine outsourcing low-cost countries. To show this, the paper develops a new vocabulary for...... outsourcing to developing countries fails to recognize that innovation tasks, even advanced ones, are becoming increasingly mobile. It also explains why innovative software activities including problem framing activities are likely to follow the relocation of routine ‘software production’ activities to the...... the analysis of innovation outsourcing in global value chains. It then draws on qualitative case study research focused on outsourcing from firms in OECD countries to firms in Bangalore, India. Some buyers are willing to farm out ‘advanced’ activities to firms of the new innovation spaces. But such...

  14. Fast reactor technology innovation and visualization

    International Nuclear Information System (INIS)

    Innovations in safety, operations, and maintenance for improving the availability, reliability, and capital cost of the sodium fast reactor are described. Concerning safety these innovations deal with on-line limiting safety settings, inherent core protection, detection of subassembly coolant mis-allocation. Concerning reactor operations these innovations deal with advanced energy conversion, adapting non-base load nuclear plants and on-line diagnostics. Other innovations concern inspection, servicing, refueling. The development of these innovations rely on visualization technology for their use and for demonstration of improvements achievable. A visualization platform for running these innovations and the nuclear plant thermal-hydraulic, structure, and process codes that underlie them are described. The platform hardware consists of a large-scale tiled display and a haptic hand-controller and in the future will grow to include a high-speed network and multiple graphics-client systems

  15. `Me-Too' Innovation in Pharmaceutical Markets

    OpenAIRE

    Jena Anupam B.; Calfee John E.; Mansley Edward C; Philipson Tomas J.

    2009-01-01

    Critics of me-too innovation often argue that follow-on drugs offer little incremental clinical value over existing pioneer products, while at the same time increasing health care costs. We examine whether consumers view follow-on and pioneer drugs as close substitutes or distinct clinical therapies. For five major classes of drugs, we find that large reductions in the price of pioneer molecules after patent expirationwhich would typically lead to decreased consumption of strong substitutesha...

  16. Approaching Service Innovation Patterns

    OpenAIRE

    Nagy, Andrea

    2013-01-01

    The present paper aims at analyzing the types of innovation in the field of services. First, the concept of innovation is defined and second, field literature is reviewed from the perspective of service innovation. The main types of innovation are identified based on several attempts at defining innovation, the most notable being Schumpeter’s. Thus, it is possible to approach concepts such as product and process innovation, incremental and radical innovation. Another aim has been to regard se...

  17. Benefits of different drug formulations in psychopharmacology

    NARCIS (Netherlands)

    Frijlink, Henderik W

    2003-01-01

    Adequate dosage forms are essential for achieving successful pharmacotherapy. Innovative dosage forms or delivery systems may direct a drug to its specific site of action, optimize the timing of the drug release, or increase comfort or convenience for the patient. Thus, such innovations may improve

  18. Characterization of Innovation Situation in a Remote Rural Region

    OpenAIRE

    Minna Sarkkinen; Tuomo Kässi

    2013-01-01

    Innovation debates dealing with regional economic development have generally focused on densely populated, technologically advanced areas and areas around university cities, undervaluing rural regions and their integration in national innovation systems. However, some statistics indicate that remote and rural regions may also have good innovation potential. This study examines more closely the innovation situation of the firms located in a remote rural region in Finland. The...

  19. Advancing Concentrating Solar Power Research (Fact Sheet)

    Energy Technology Data Exchange (ETDEWEB)

    2014-02-01

    Researchers at the National Renewable Energy Laboratory (NREL) provide scientific, engineering, and analytical expertise to help advance innovation in concentrating solar power (CSP). This fact sheet summarizes how NREL is advancing CSP research.

  20. Nanotechnology Innovations

    Science.gov (United States)

    Malroy, Eric

    2010-01-01

    Nanotechnology is rapidly affecting all engineering disciplines as new products and applications are being found and brought to market. This session will present an overview of nanotechnology and let you learn about the advances in the field and how it could impact you. Some of the areas touched upon will be nanomaterials with their multifunctional capabilities, nanotechnology impact on energy systems, nanobiotechnology including nanomedicine, and nanotechnology relevant to space systems with a focus on ECLSS. Also, some important advances related to thermal systems will be presented as well as future predictions on nanotechnology.

  1. Organising for innovation. A case study of innovation teams and team leadership in a large, R&D intensive firm

    OpenAIRE

    Robbins, Peter

    2012-01-01

    Successful innovation is vital for firm survival and success (Dougherty, 2004). Leaders of established companies acknowledge that radical innovation, in particular, is critical to their growth and renewal (Leifer et al, 2000). This is especially true for the research and development sector (Eisenbeiß and Boerner, 2010). New product development, while not the only form of innovation, remains the most advanced, the most widely studied, and the most significant type of firm-level innovation (Gar...

  2. Chitosan-based formulations of drugs, imaging agents and biotherapeutics

    NARCIS (Netherlands)

    Amidi, M.; Hennink, W.E.

    2010-01-01

    This preface is part of the Advanced Drug Delivery Reviews theme issue on “Chitosan-Based Formulations of Drugs, Imaging Agents and Biotherapeutics”. This special Advanced Drug Delivery Reviews issue summarizes recent progress and different applications of chitosanbased formulations.

  3. Supporting radical front end innovation

    DEFF Research Database (Denmark)

    Aagaard, Annabeth; Gertsen, Frank

    2011-01-01

    An organization benefits substantially by improving front end innovation (FEI) actively and may thereby enhance the chances of developing innovations, as emphasized by several authors e.g. Reinertsen (1999), Dahl & Moreau (2002), Boeddrich (2004), Williams et al. (2007) and Vernorn et al. (2008......). Pharmaceutical innovation is unique, as it opposed to most other industries’ product development is science-driven and not customer-driven. In addition, the pharmaceutical FEI, as represented by research, lasts up to 5 years and the entire R&D process constitutes a period of 10-12 years, which is highly...... regulated by external authorities, e.g. The American Food and Drug Administration (FDA). The research aim of this paper is: to contribute to the field of FEI by studying how FEI can be actively supported within the industry specific context of the pharmaceutical industry, and through a conceptual discussion...

  4. The Innovative Directions in Agriculture of Kazakhstan

    Directory of Open Access Journals (Sweden)

    Dinar Abdrakhmanova

    2014-09-01

    Full Text Available In this article ways of increase of competitiveness of agrarian production, on the basis of introduction of the innovative directions in agriculture are considered. For a sustainable development of agriculture the innovative policy which basis there is an increase of efficiency of use of scientific and technical achievements has defining value. Becomes obvious that without harmonious, scientifically reasonable and balanced innovative policy, the system principle of its realization it is impossible to solve a problem of increase of profitability of agricultural production with scientific, resource, organizational and information support. Innovative process is connected with creation, development and distribution of innovations. It is process within which producers of innovations for receiving profit create and advance innovations to their consumers. The organization of innovative activity for the purpose of innovation finishing to the end user accepts huge value. Activization of innovative activity is the main condition in system of the factors providing development and increase of efficiency of agrarian production in market economy.

  5. Designing collaborative policy innovation

    DEFF Research Database (Denmark)

    Agger, Annika; Sørensen, Eva

    2014-01-01

    Recent approaches to enhancing public innovation suffer from two shortcomings: They overemphasize competition as a driver of innovation and overlook the fact that public sector innovation involves policy innovation as well as service innovation. Drawing on governance research and innovation theory......, the chapter investigates the extent to which and how collaboration between politicians and relevant stakeholders can spur the formulation, implementation and diffusion of new innovative policies. A case study of a process of collaborative policy innovation in a Danish municipality shows that...... collaborative policy arenas do contribute to policy innovation but also that the degree to which they do so depends on the institutional design of these arenas....

  6. Approaching Service Innovation Patterns

    Directory of Open Access Journals (Sweden)

    Andrea NAGY

    2013-06-01

    Full Text Available The present paper aims at analyzing the types of innovation in the field of services. First, the concept of innovation is defined and second, field literature is reviewed from the perspective of service innovation. The main types of innovation are identified based on several attempts at defining innovation, the most notable being Schumpeter’s. Thus, it is possible to approach concepts such as product and process innovation, incremental and radical innovation. Another aim has been to regard service innovation as a standout type of innovation.

  7. Advanced Cathode Electrolyzer (ACE) Project

    Data.gov (United States)

    National Aeronautics and Space Administration — The proposed innovation is a static, cathode-fed, 2000 psi, balanced-pressure Advanced Cathode Electrolyzer (ACE) based on PEM electrolysis technology. It...

  8. Innovation: a necessary luxury

    OpenAIRE

    Van der Duin, P.A.

    2015-01-01

    Innovate, innovate, innovate, it has become the mantra of any modern company. But how much stands of these ambitions after the business case is completed. And what does it take to truly innovate as a company. Patrick van der Duin sheds light on the subject from a corporate as well as an academic perspective to make recommendations for understanding and implementing innovation

  9. Drug Facts

    Medline Plus

    Full Text Available ... Why Is It So Hard to Quit Drugs? Effects of Drugs Drug Abuse Hurts Other People Drug Abuse Hurts Families Drug Abuse Hurts Kids Drug Abuse Hurts Unborn Children Drug Abuse Hurts Your Health Drug Abuse Hurts Bodies Drug Abuse Hurts Brains Drug Abuse and Mental ...

  10. Firm technological innovation persistence: Organizational innovation matters

    OpenAIRE

    Haned, Naciba; Le Bas, Christian; Mothe, Caroline,; Nguyen, Uyen

    2012-01-01

    Les innovations organisationnelles favorisent les innovations technologiques mais influencent-elles la persistance à l'innovation technologique ? Cet article analyse empiriquement un modèle de persistance de l'innovation et teste sur des données de panel l'impact potentiel des innovations d'organisation. La base de données est issue de trois vagues d'enquêtes communautaires sur l'innovation réalisées sur un échantillon d'entreprises françaises. Les résultats montrent un impact positif de plus...

  11. Innovation in the ‘Public Sector’

    DEFF Research Database (Denmark)

    Perry, Kevin

    Governments around the world advance innovation as a significant means to improving public services (Walker, 2006:311). Within this discussion the word innovation seems to be used habitually by policy makers where there are high expectations in relation to reviving, boosting and renewing the flag...... reviewing the literature concerning innovation theory and the more recent literature on innovation in the public sector this paper compares and contrasts both definitions and classifications of innovation in an effort to shed more light on this complex area.......Governments around the world advance innovation as a significant means to improving public services (Walker, 2006:311). Within this discussion the word innovation seems to be used habitually by policy makers where there are high expectations in relation to reviving, boosting and renewing the...... flagging economies and the public sector services. Within this context, innovation in the public sector is recognized as a vital factor in meeting the challenges of globalization and demographic changes, and simultaneously sustaining a high level of public services to citizens and businesses. However...

  12. Funding innovation

    CERN Multimedia

    Marina Giampietro

    2012-01-01

    For the first time, six knowledge and technology transfer activities are set to benefit from a dedicated fund made available by the Knowledge Transfer group. This initiative cements CERN’s commitment to sharing its technological knowledge and expertise with society.   GEM detectors for flame detection and early earthquake prediction, radio-frequency absorbers for energy recovery, and exotic radioisotopes for medical applications are among the projects funded by the recently introduced KT Fund. “CERN’s scientific programme generates a considerable amount of intellectual property, a natural driver for innovation,” explains Giovanni Anelli, Head of the Knowledge Transfer Group. “Very often, though, financial support is needed to bring the newly-born technologies a step further and make them ready for transfer to other research institutes or to companies.” This is where the KT fund comes into play. It provides vital support in the early sta...

  13. Drug Plan Coverage Rules

    Science.gov (United States)

    ... gov Medicare forms Advance directives & long-term care Electronic prescribing Electronic Health Records (EHRs) Download claims with Medicare’s Blue ... or needed a prescription drug and this created waste and unnecessary additional costs for people with Medicare ...

  14. The changing environment for technological innovation in health care.

    Science.gov (United States)

    Goodman, C S; Gelijns, A C

    1996-01-01

    A distinguishing feature of American health care is its emphasis on advanced technology. Yet today's changing health care environment is overhauling the engine of technological innovation. The rate and direction of technological innovation are affected by a complex of supply- and demandside factors, including biomedical research, education, patent law, regulation, health care payment, tort law, and more. Some distinguishing features of technological innovation in health care are now at increased risk. Regulatory requirements and rising payment hurdles are especially challenging to small technology companies. Closer management of health care delivery and payment, particularly the standardization that may derive from practice guidelines and clamping down on payment for investigational technologies, curtails opportunities for innovation. Levels and distribution of biomedical research funding in government and industry are changing. Financial constraints are limiting the traditional roles of academic health centers in fostering innovation. Despite notable steps in recent years to lower regulatory barriers and speed approvals, especially for products for life-threatening conditions, the Food and Drug Administration is under great pressure from Congress, industry, and patients to do more. Technology gatekeeping is shifting from hundreds of thousands of physicians acting on behalf of their patients to fewer, yet more powerful, managed care organizations and health care networks. Beyond its direct effects on adoption, payment, and use of technologies, the extraordinary buying leverage of these large providers is cutting technology profit margins and heightening competition among technology companies. It is contributing to unprecedented restructuring of the pharmaceutical and medical device industries, leading to unprecedented alliances with generic product companies, health care providers, utilization review companies, and other agents. These industry changes are already

  15. Rocket Engine Innovations Advance Clean Energy

    Science.gov (United States)

    2012-01-01

    During launch countdown, at approximately T-7 seconds, the Space Shuttle Main Engines (SSMEs) roar to life. When the controllers indicate normal operation, the solid rocket boosters ignite and the shuttle blasts off. Initially, the SSMEs throttle down to reduce stress during the period of maximum dynamic pressure, but soon after, they throttle up to propel the orbiter to 17,500 miles per hour. In just under 9 minutes, the three SSMEs burn over 1.6 million pounds of propellant, and temperatures inside the main combustion chamber reach 6,000 F. To cool the engines, liquid hydrogen circulates through miles of tubing at -423 F. From 1981to 2011, the Space Shuttle fleet carried crew and cargo into orbit to perform a myriad of unprecedented tasks. After 30 years and 135 missions, the feat of engineering known as the SSME boasted a 100-percent flight success rate.

  16. Innovative approach to advanced modulated waterjet technology

    Czech Academy of Sciences Publication Activity Database

    Kušnerová, M.; Foldyna, Josef; Sitek, Libor; Valíček, Jan; Hloch, S.; Harničárová, M.; Kadnár, M.

    2012-01-01

    Roč. 19, č. 3 (2012), s. 475-480. ISSN 1330-3651 R&D Projects: GA MŠk ED2.1.00/03.0082; GA MŠk(CZ) ED1.1.00/02.0070 Grant ostatní: GA MŠk(CZ) ED0040/01/01 Institutional support: RVO:68145535 Keywords : modulated waterjet * analytical model * resonance chamber Subject RIV: JQ - Machines ; Tools Impact factor: 0.601, year: 2012 http://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=129051

  17. Modeling Innovations Advance Wind Energy Industry

    Science.gov (United States)

    2009-01-01

    In 1981, Glenn Research Center scientist Dr. Larry Viterna developed a model that predicted certain elements of wind turbine performance with far greater accuracy than previous methods. The model was met with derision from others in the wind energy industry, but years later, Viterna discovered it had become the most widely used method of its kind, enabling significant wind energy technologies-like the fixed pitch turbines produced by manufacturers like Aerostar Inc. of Westport, Massachusetts-that are providing sustainable, climate friendly energy sources today.

  18. Drug Facts

    Medline Plus

    Full Text Available ... Drug Abuse Hurts Kids Drug Abuse Hurts Unborn Children Drug Abuse Hurts Your Health Drug Abuse Hurts ... and Family Can Help Prevent Drug Abuse Help Children and Teens Stay Drug-Free Talking to Kids ...

  19. Drug Facts

    Medline Plus

    Full Text Available ... People Drug Abuse Hurts Families Drug Abuse Hurts Kids Drug Abuse Hurts Unborn Children Drug Abuse Hurts ... Children and Teens Stay Drug-Free Talking to Kids About Drugs: What To Say if You Were ...

  20. Want Drugs? Use Python

    OpenAIRE

    Nowotka, Michał; Papadatos, George; Davies, Mark; Dedman, Nathan; Hersey, Anne

    2016-01-01

    We describe how Python can be leveraged to streamline the curation, modelling and dissemination of drug discovery data as well as the development of innovative, freely available tools for the related scientific community. We look at various examples, such as chemistry toolkits, machine-learning applications and web frameworks and show how Python can glue it all together to create efficient data science pipelines.

  1. Innovative Separations Technologies

    Energy Technology Data Exchange (ETDEWEB)

    J. Tripp; N. Soelberg; R. Wigeland

    2011-05-01

    Reprocessing used nuclear fuel (UNF) is a multi-faceted problem involving chemistry, material properties, and engineering. Technology options are available to meet a variety of processing goals. A decision about which reprocessing method is best depends significantly on the process attributes considered to be a priority. New methods of reprocessing that could provide advantages over the aqueous Plutonium Uranium Reduction Extraction (PUREX) and Uranium Extraction + (UREX+) processes, electrochemical, and other approaches are under investigation in the Fuel Cycle Research and Development (FCR&D) Separations Campaign. In an attempt to develop a revolutionary approach to UNF recycle that may have more favorable characteristics than existing technologies, five innovative separations projects have been initiated. These include: (1) Nitrogen Trifluoride for UNF Processing; (2) Reactive Fluoride Gas (SF6) for UNF Processing; (3) Dry Head-end Nitration Processing; (4) Chlorination Processing of UNF; and (5) Enhanced Oxidation/Chlorination Processing of UNF. This report provides a description of the proposed processes, explores how they fit into the Modified Open Cycle (MOC) and Full Recycle (FR) fuel cycles, and identifies performance differences when compared to 'reference' advanced aqueous and fluoride volatility separations cases. To be able to highlight the key changes to the reference case, general background on advanced aqueous solvent extraction, advanced oxidative processes (e.g., volumetric oxidation, or 'voloxidation,' which is high temperature reaction of oxide UNF with oxygen, or modified using other oxidizing and reducing gases), and fluorination and chlorination processes is provided.

  2. ENTREPRENEURS’ CONFIDENCE IN INNOVATION AND THEIR INNOVATIVENESS

    Directory of Open Access Journals (Sweden)

    Nastooh Nochian

    2012-05-01

    Full Text Available This article tests the hypothesis that entrepreneurs’ confidence in innovation has a positive effect on their innovativeness. The sample is 550 owner managers sampled from the population of owner managers in Iran in 2010, surveyed in the Global Entrepreneurship Monitor, GEM. An organizational innovation confidence index is constructed from three questions asking whether the organization that they work in is likely to buy products or services that are new, use new technologies in their daily work, and use new products and services that will improve their working life. Innovation is measured by two questions asking if customers consider the product or service new and unfamiliar, if the technologies or procedures required for the product or service are new. Using structural equations modeling, we conclude that there is a positive effect of organizational innovation confidence on innovation. Therefore, the Iranian owner managers who have more confidence in innovation act more innovatively.

  3. [Medical doctors driving technological innovation: questions about and innovation management approaches to incentive structures for lead users].

    Science.gov (United States)

    Bohnet-Joschko, Sabine; Kientzler, Fionn

    2010-01-01

    Management science defines user-generated innovations as open innovation and lead user innovation. The medical technology industry finds user-generated innovations profitable and even indispensable. Innovative medical doctors as lead users need medical technology innovations in order to improve patient care. Their motivation to innovate is mostly intrinsic. But innovations may also involve extrinsic motivators such as gain in reputation or monetary incentives. Medical doctors' innovative activities often take place in hospitals and are thus embedded into the hospital's organisational setting. Hospitals find it difficult to gain short-term profits from in-house generated innovations and sometimes hesitate to support them. Strategic investment in medical doctors' innovative activities may be profitable for hospitals in the long run if innovations provide first-mover competitive advantages. Industry co-operations with innovative medical doctors offer chances but also bear potential risks. Innovative ideas generated by expert users may result in even higher complexity of medical devices; this could cause mistakes when applied by less specialised users and thus affect patient safety. Innovations that yield benefits for patients, medical doctors, hospitals and the medical technology industry can be advanced by offering adequate support for knowledge transfer and co-operation models. PMID:21147434

  4. Innovation and Collective Entrepreneurship

    OpenAIRE

    Spear, Roger

    2012-01-01

    This paper examines different forms of innovation including social innovation, and why innovation and social innovation have become important themes in public policy in a context of the increasing and diverse demands on welfare regimes, and in an era of constrained budgets. It will review different perspectives on innovation and social innovation and the dynamic interaction through collective entrepreneurship in the social and solidarity economy; bringing out process and outcome dimensions of...

  5. Systematic Implementation of Innovation Best Practices:Thota Framework for Innovation

    Institute of Scientific and Technical Information of China (English)

    Hamsa; Thota

    2011-01-01

    The Product Development and Management Association(PDMA)comparative performance assessment studies(CPAS)teach us that the new product development(NPD)and innovation management practices continue to evolve.However,advances in the practice of NPD and innovation did not yield significant increases in new product success rates.However,the PDMA 2003 CPAS reported a significant difference in the success rates for top performing businesses versus the"rest".This paper summarizes innovation practices of top performing businesses from CPAS and compares them with the practices of PDMA Outstanding Corporate Innovator(OCI)Award winning companies.The paper verifies that what the top performers say they do in research surveys is actually what the outstanding corporate innovators do in practice.The paper then raises the question of how underperforming companies can implement key learnings from the best to improve their own innovation performance.The development of Thota framework for innovation as a systematic framework to help underperformers implement the best practices is discussed.As a case study,the implementation of the Thota framework for innovation is illustrated with BMW,an OCI award winning company.The Thota Framework for Innovation is based on three organizing principles and eight actions.Underperforming businesses can improve their innovation performance by internalizing the three organizing principles and rigorously implementing eight actions specified in the Thota framework for innovation.

  6. Services in innovation - Innovation in services

    OpenAIRE

    Hauknes, Johan

    1998-01-01

    There has been a considerable gap between efforts to understand innovation and other change processes, and ongoing structural changes in national economies. The SI4S project has aimed at developing concepts, empirical evidence and proposals for practical action concerning the role of services in European innovation systems. The general objectives were to map, understand and analyse the changing role of services and service innovations as users, carriers, shapers and sources of innovations in ...

  7. Innovation Management and Knowledge Economics

    Institute of Scientific and Technical Information of China (English)

    2002-01-01

    This paper includes three parts: (1) The main characteristics of knowledge economics in new era; (2) Innovation management is an inevitable trend; (3) Corporate culture lead literary excellence. With the advance of science technique and development of productive force , huma nity entered on knowledge economics era.It is a new social economic pattern that occupy and coordinate intellectual resources and causes some essential changes of produce method. Investment pattern, industrial construction, throug...

  8. Unionization Structure, Licensing and Innovation

    OpenAIRE

    Mukherjee, Arijit; Pennings, Enrico

    2005-01-01

    This discussion paper led to a publication in the 'International Journal of Industrial Organization', 29(2), 232-41.Taking technological differences between firms as given, we show that the technologically advanced firm has a stronger incentive for technology licensing under a decentralized unionization structure than with centralized wage setting. Furthermore, We show that, in presence of licensing, the incentive for innovation may also be stronger under decentralized unions. Unions have a c...

  9. Innovative Concepts in Microwave Photonics

    OpenAIRE

    Capmany Francoy, José; Sales Maicas, Salvador; Gasulla Mestre, Ivana; Mora Almerich, José; Lloret Soler, Juan Antonio; Sancho Durá, Juan

    2012-01-01

    This paper reports the work carried by ITEAM researchers on novel concepts in the field of Microwave Photonics (MWP). It includes activities related to the general modelling of MWP systems, the use of novel multicore fibers and recent advances in the emergent and hot topic of integrated microwave photonics. Capmany Francoy, J.; Sales Maicas, S.; Gasulla Mestre, I.; Mora Almerich, J.; Lloret Soler, JA.; Sancho Durá, J. (2012). Innovative Concepts in Microwave Photonics. Waves...

  10. Small Business Innovations (Fiber Optics)

    Science.gov (United States)

    1991-01-01

    Foster-Miller, Inc. Waltham, MA developed the In-Situ Fiber Optic Polymer Reaction Monitor which could lead to higher yields and lower costs in complex composite manufacturing. The monitor, developed under a Small Business Innovation Research (SBIR) contract with Langley Research Center, uses an infrared, fiber optic sensor to track the molecular vibrational characteristics of a composite part while it is being cured. It is the first analytical system capable of directly measuring the chemistry of advanced composite materials.

  11. Challenging the Innovation Paradigm

    CERN Document Server

    Sveiby, Karl Erik; Segercrantz, Beata

    2012-01-01

    Innovation is almost always seen as a "good thing". Challenging the Innovation Paradigm is a critical analysis of the innovation frenzy and contemporary innovation research. The one-sided focus on desirable effects of innovation misses many opportunities to reduce the undesirable consequences. Authors in this book show how systemic effects outside the innovating firms reduce the net benefits of innovation for individual employees, customers, as well as for society as a whole - also the innovators' own organizations. This book analyzes the dominant discourses that construct and recons

  12. Um caso de inovação “acidental” em matéria de penas: a lei brasileira de drogas An accidental innovation case on punishment: the brazilian drug law

    Directory of Open Access Journals (Sweden)

    Alvaro P. Pires

    2011-06-01

    Full Text Available Este trabalho é uma reflexão sobre alternativas à prisão e, de forma mais geral, sobre as complexas relações entre os conceitos de punição e de inovação. Nesse sentido, discutiremos um exemplo concreto extraído da legislação criminal brasileira - um dispositivo da nova lei de drogas (2006 - com a finalidade de enfatizar tanto o interesse teórico quanto as questões éticas que o conceito de inovação penal pode suscitar. introduzindo uma modificação extremamente improvável relativa às penas, essa lei brasileira nos possibilitará desenvolver aqui nossa argumentação em sete etapas: 1 descrever a modificação legislativa que servirá como pano de fundo para nossos propósitos; 2 apresentar as ferramentas conceituais necessárias à descrição que pretendemos fazer dessa modificação legislativa; 3 invocar o status que a teoria dos sistemas autorreferenciais outorga à produção legislativa; 4 chamar a atenção para duas maneiras historicamente marginais de conceitualizar a punição; 5 indicar alguns marcos históricos sobre o conceito dominante ou "normal" de pena; e finalmente 7 voltar, a título de conclusão, aos conceitos centrais tratados em nossa discussão.This paper is a reflection on alternatives to imprisonment and, more generally, on the complex relationships between the concepts of punishment and innovation. for this purpose, we will discuss a concrete example taken from the Brazilian criminal legislation, a new drug law disposition (2006, in order to emphasize the theoretical interest as well as the ethical stakes which the concept of penal innovation can underscore. this legislation introduces a hyper-improbable modification of the concept of punishment and it will therefore enable us to develop our arguments along seven points: 1 to describe the legislative modification which will serve as the backdrop to our discussion; 2 to introduce the conceptual tools needed to describe this legislative modification

  13. The Contribution of Innovation Strategy Development and Implementation in Active Facilitation of Pharmaceutical Front End Innovation

    DEFF Research Database (Denmark)

    Aagaard, Annabeth

    2012-01-01

    research and FEI to produce more valid candidates and faster for drug development. This paper explores how pharmaceutical front end innovation can be actively supported through the development and implementation of an innovation strategy. The empirical field and applied methodology is an action......, Steven & Burly, 2003, and Vernorn et al., 2008) and that innovation strategies play a central role in optimization of innovation (Clark & Wheelwright, 1995; Cottam et al., 2001; Morgan & Berthon, 2008). Innovation strategies are suggested in literature (e.g. Page, 1993; Oke, 2002; Adams et al., 2006......; Igartua, 2010) as a facilitator of innovation and may therefore also be targeted at FEI support. The pharmaceutical industry has experienced a worldwide decline in the number of applications for new molecular entities to regulatory agencies since 1997. Therefore high pressures are put on pharmaceutical...

  14. Compulsory licensing and access to drugs

    OpenAIRE

    Stavropoulou, C; Valletti, T.

    2015-01-01

    Compulsory licensing allows the use of a patented invention without the owner's consent, with the aim of improving access to essential drugs. The pharmaceutical sector argues that, if broadly used, it can be detrimental to innovation. We model the interaction between a company in the North that holds the patent for a certain drug and a government in the South that needs to purchase it. We show that both access to drugs and pharmaceutical innovation depend largely on the Southern country's abi...

  15. Firm persistence in technological innovation: the relevance of organizational innovation

    OpenAIRE

    Naciba Haned; Caroline Mothe; Nguyen-Thi Thuc Uyen

    2014-01-01

    Organizational innovation favors technological innovation, but does it also influence persistence in technological innovation? This article empirically investigates the pattern of technological innovation persistence and tests the potential impact of organizational innovation using firm-level data from three waves of French Community Innovation Surveys. The evidence indicates a positive effect of organizational innovation on persistence in technological innovation, according to various measur...

  16. 78 FR 34346 - Proposed Information Collection; Comment Request; NIST MEP Advanced Manufacturing Jobs and...

    Science.gov (United States)

    2013-06-07

    ... Advanced Manufacturing Jobs and Innovation Accelerator Challenge (AMJIAC) Client Impact Survey AGENCY... information collection. The purpose of the Advanced Manufacturing Jobs and Innovation Accelerator Challenge... to support job creation, encourage economic development, and enhance the competitiveness of...

  17. Advances in Searching for Anticoccidial Drugs Target%抗球虫药物靶标筛选的研究进展

    Institute of Scientific and Technical Information of China (English)

    周变华; 王宏伟; 赵振升

    2011-01-01

    At present,coccidiosis is still mainly controlled by the use of chemotherapeutic agents; thus. New drugs are urgently needed due to the rising problem of drug-resistant strains of Eimeria. To discover and select suitable drug target was the precondition of drug development as well as the key point of drug screening and oriented synthesis. This article reviews the progress in research of the drug target screening.%目前,药物防治仍然是防治球虫病的主要手段,随着抗球虫药物的使用,耐药性的产生越来越严重,迫切需要抗球虫新药的研发,发现和选择合适的药物靶点是药物开发的前提,也是药物筛选及药物定向合成的关键因素.文章就近年来抗球虫药物靶标筛选的研究进展作一简单回顾.

  18. Geothermal innovative technologies catalog

    Energy Technology Data Exchange (ETDEWEB)

    Kenkeremath, D. (ed.)

    1988-09-01

    The technology items in this report were selected on the basis of technological readiness and applicability to current technology transfer thrusts. The items include technologies that are considered to be within 2 to 3 years of being transferred. While the catalog does not profess to be entirely complete, it does represent an initial attempt at archiving innovative geothermal technologies with ample room for additions as they occur. The catalog itself is divided into five major functional areas: Exploration; Drilling, Well Completion, and Reservoir Production; Materials and Brine Chemistry; Direct Use; and Economics. Within these major divisions are sub-categories identifying specific types of technological advances: Hardware; Software; Data Base; Process/Procedure; Test Facility; and Handbook.

  19. Innovation Concepts in Healthcare

    CERN Document Server

    CERN. Geneva

    2010-01-01

    AbstractDemographic change and advances in medical science pose increased challenges to healthcare systems globally: The economic basis is aging and thus health is becoming more and more a productivity factor. At the same time, with today’s new communication possibilities the demand and expectations of effective medical treatment have been increased. This presentation will illustrate the need for the “industrialization” of healthcare in order to achieve highest results at limited budgets. Thereby, industrialization is not meaning the medical treatment based on the assembly line approach. Rather it is to recognize the cost of medical care as an investment with respective expectations on the return of the investment. Innovations in imaging and pharmaceutical products as well as in processes - that lead to similar medical results, but with lower efforts - are keys in such scenarios.BiographyProf. Dr. Hermann Requardt, 54, is a member of the Managing Board of Siemens AG and Chief Executive Officer of the He...

  20. Biomaterials innovation bundling technologies and life

    CERN Document Server

    Styhre, A

    2014-01-01

    Rapid advances in the life sciences means that there is now a far more detailed understanding of biological systems on the cellular, molecular and genetic levels. Sited at the intersection between the life sciences, the engineering sciences and the design sciences, innovations in the biomaterials industry are expected to garner increasing attention and play a key role in future development. This book examines the biomaterials innovations taking place in corporations and in academic research settings today.

  1. Lead markets in age-based innovations

    OpenAIRE

    Levsen, Nils; Herstatt, Cornelius

    2014-01-01

    The trend of population aging is affecting an increasing number of countries around the world, especially advanced economies. One consequence of a growing population share of aged persons is a shift in consumer needs, reflected by a rising number of products and services designed particularly for elderly users. Thus, population aging is a catalyst for new markets and a driver of innovation. A common objective of such age-based innovations is the delay of an age-associated decline in individua...

  2. Employment protection legislation, multinational firms and innovation

    OpenAIRE

    Griffith, Rachel; Macartney, Gareth

    2010-01-01

    The theoretical effects of labour regulations such as employment protection legislation (EPL) on innovation is ambiguous, and empirical evidence has thus far been inconclusive. EPL increases job security and the greater enforceability of job contracts may increase worker investment in innovative activity. On the other hand EPL increases adjustment costs faced by firms, and this may lead to under-investment in activities that are likely to require adjustment, including technologically advanced...

  3. 7th ICT Innovations 2015 Conference

    CERN Document Server

    Koceski, Saso

    2016-01-01

    This book offers a collection of selected papers presented at the Seventh International Conference on ICT Innovations held in October 2015, in Ohrid, Macedonia, with main topic Emerging Technologies for Better Living. The conference gathered academics, professionals and industrial practitioners that work on developing the emerging technologies, systems, applications in the industrial and business arena especially innovative commercial implementations, novel application of technology, and experience in applying recent ICT research advances to practical solutions.

  4. Recent advances in novel topical drug delivery systems for cutaneous mycosis%皮肤真菌病新型局部给药系统研究进展

    Institute of Scientific and Technical Information of China (English)

    范云周; 杨美燕; 刘庆晓; 高春生

    2011-01-01

    Cutaneous mycosis is a common and frequent kind of dermatosis, seriously affecting the quality of patients' life.With advantages of easy application and good patient compliance, topical drug delivery systems are the first choice to treat cutaneous mycosis, which act on the target sites directly.New drug delivery systems (NDDS) such as liposomes, ethosomes, microemulsions and lipid nanoparticle could increase the drug permeation,reduce the drug transdermal transport and result in accumulation of drug within skin.As a result, the NDDS could enhance the therapeutic effect, shorten therapy periods and reduce side effects.All these show a great application prospects in the topical treatment of cutaneous mycosis.According to related publications, recent advances in novel topical drug delivery systems for cutaneous mycosis were reviewed.%皮肤真菌病是易发病、易传染、易复发的疾病,严重影响患者生活质量.局部给药制剂直接作用于病变部位,使用方便,患者顺应性好,是皮肤真菌病临床治疗的首选.以脂质体、醇质体、微乳和脂质纳米粒等为代表的新型给药系统,可以提高药物的渗透性,减小药物透过,使其在皮肤局部蓄积,从而能够增强疗效、缩短疗程和减少不良反应,使皮肤真菌病的局部治疗更具有应用前景.本文综述了近年来国内外皮肤真菌病新型局部给药系统的研究进展.

  5. Bridging conflicting innovation spheres of tourism innovation

    DEFF Research Database (Denmark)

    Fuglsang, Lars; Sørensen, Flemming; Nordli, Anne Jørgensen

    2016-01-01

    competition which may inhibit networked and open innovation. Tourist destinations are examples of such localized systems. In this paper we present two extreme cases of tourist destinations in which collaborative innovation processes were established in spite of fierce disagreements between actors. We argue...... that in tourist destinations actors belong to conflicting innovation spheres but can be brought together in innovation processes when a diplomat enable compromises and when innovation spheres change from personalized to more generalized forms of activity during interaction. The findings are relevant...

  6. Technological advances transforming rheumatology

    OpenAIRE

    Robinson, William H.; Mao, Rong

    2015-01-01

    Technological advances over the past decade have revolutionized many areas of rheumatology, ranging from diagnosis, prognosis and therapeutic development to the mechanistic understanding of rheumatic diseases. This overview highlights key technological innovations and discusses the major impact that these developments are having on research and clinical practice.

  7. 失眠症的非药物治疗进展①%Advance in Non-drug Therapy of Insomnia (review)

    Institute of Scientific and Technical Information of China (English)

    2013-01-01

    At present, insomnia treatments mainly contain drug therapy and non-drug therapy. The non-drug therapy included sleep hy-giene instruction, cognitive behavioral therapy, psychological therapy, physical therapy, relaxation therapy, and music therapy, etc. The non-drug therapy is a safe and effective treatment, and it plays a good effect whether using with drug or alone.%  目前关于失眠症的治疗方法主要有药物治疗和非药物治疗。非药物治疗有睡眠卫生指导、认知行为治疗、心理疗法、物理疗法、松弛疗法、音乐疗法等。非药物治疗具有安全有效的优势,无论是与药物联合还是单独运用均起到较好的效果。

  8. Recent advances in candidate-gene and whole-genome approaches to the discovery of anthelmintic resistance markers and the description of drug/receptor interactions

    Directory of Open Access Journals (Sweden)

    Andrew C. Kotze

    2014-12-01

    Full Text Available Anthelmintic resistance has a great impact on livestock production systems worldwide, is an emerging concern in companion animal medicine, and represents a threat to our ongoing ability to control human soil-transmitted helminths. The Consortium for Anthelmintic Resistance and Susceptibility (CARS provides a forum for scientists to meet and discuss the latest developments in the search for molecular markers of anthelmintic resistance. Such markers are important for detecting drug resistant worm populations, and indicating the likely impact of the resistance on drug efficacy. The molecular basis of resistance is also important for understanding how anthelmintics work, and how drug resistant populations arise. Changes to target receptors, drug efflux and other biological processes can be involved. This paper reports on the CARS group meeting held in August 2013 in Perth, Australia. The latest knowledge on the development of molecular markers for resistance to each of the principal classes of anthelmintics is reviewed. The molecular basis of resistance is best understood for the benzimidazole group of compounds, and we examine recent work to translate this knowledge into useful diagnostics for field use. We examine recent candidate-gene and whole-genome approaches to understanding anthelmintic resistance and identify markers. We also look at drug transporters in terms of providing both useful markers for resistance, as well as opportunities to overcome resistance through the targeting of the transporters themselves with inhibitors. Finally, we describe the tools available for the application of the newest high-throughput sequencing technologies to the study of anthelmintic resistance.

  9. Recent advances in candidate-gene and whole-genome approaches to the discovery of anthelmintic resistance markers and the description of drug/receptor interactions

    Science.gov (United States)

    Kotze, Andrew C.; Hunt, Peter W.; Skuce, Philip; von Samson-Himmelstjerna, Georg; Martin, Richard J.; Sager, Heinz; Krücken, Jürgen; Hodgkinson, Jane; Lespine, Anne; Jex, Aaron R.; Gilleard, John S.; Beech, Robin N.; Wolstenholme, Adrian J.; Demeler, Janina; Robertson, Alan P.; Charvet, Claude L.; Neveu, Cedric; Kaminsky, Ronald; Rufener, Lucien; Alberich, Melanie; Menez, Cecile; Prichard, Roger K.

    2014-01-01

    Anthelmintic resistance has a great impact on livestock production systems worldwide, is an emerging concern in companion animal medicine, and represents a threat to our ongoing ability to control human soil-transmitted helminths. The Consortium for Anthelmintic Resistance and Susceptibility (CARS) provides a forum for scientists to meet and discuss the latest developments in the search for molecular markers of anthelmintic resistance. Such markers are important for detecting drug resistant worm populations, and indicating the likely impact of the resistance on drug efficacy. The molecular basis of resistance is also important for understanding how anthelmintics work, and how drug resistant populations arise. Changes to target receptors, drug efflux and other biological processes can be involved. This paper reports on the CARS group meeting held in August 2013 in Perth, Australia. The latest knowledge on the development of molecular markers for resistance to each of the principal classes of anthelmintics is reviewed. The molecular basis of resistance is best understood for the benzimidazole group of compounds, and we examine recent work to translate this knowledge into useful diagnostics for field use. We examine recent candidate-gene and whole-genome approaches to understanding anthelmintic resistance and identify markers. We also look at drug transporters in terms of providing both useful markers for resistance, as well as opportunities to overcome resistance through the targeting of the transporters themselves with inhibitors. Finally, we describe the tools available for the application of the newest high-throughput sequencing technologies to the study of anthelmintic resistance. PMID:25516826

  10. User Innovation Management

    DEFF Research Database (Denmark)

    Kanstrup, Anne Marie; Bertelsen, Pernille

    User Innovation Management (UIM) is a method for fo-opereation with users in innovation projects. The UIM method emphasizes the practice of a participatorty attitude.......User Innovation Management (UIM) is a method for fo-opereation with users in innovation projects. The UIM method emphasizes the practice of a participatorty attitude....

  11. Radical Financial Innovation

    OpenAIRE

    Robert J. Shiller

    2004-01-01

    Radical financial innovation is the development of new institutions and methods that permit risk management to be extended far beyond its former realm, covering important new classes of risks. This paper compares past such innovation with potential future innovation, looking at the process that produced past success and the possibilities for future financial innovation.

  12. Entrepreneurship, Innovation and Institutions

    NARCIS (Netherlands)

    Stam, E.; Nooteboom, B.

    2011-01-01

    This paper discusses the nature of entrepreneurship and its relation to innovation along a cycle in which exploration and exploration follow upon each other. We place the roles of entrepreneurship in innovation policy within this cycle of innovation. Different types of innovation along the cycle of

  13. Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm

    Directory of Open Access Journals (Sweden)

    Liliana Civalleri

    2012-09-01

    Full Text Available Aim: the aim of this study was to assess the innovative quality of a medicine based on agomelatine, authorized by the European Commission through a centralized procedure on 19th February 2009 and distributed in Italy under the brands Valdoxan® and Thymanax®.Methodology: the degree of innovation of agomelatine was determined through the Innovation Assessment Algorithm (IAA, which considers the innovative quality of a medicine as a combination of multiple properties. The algorithm may be represented as a decision tree, with each branch corresponding to a property connected with innovation and having a fixed numerical value. The sum of these values establishes the degree of innovation of the medicine. The IAA is articulated in two phases: the first assesses the efficacy of the drug based on the clinical trials presented in support of the registration application (IAA-efficacy; the second reconsiders the degree of innovation on the basis of the efficacy and safety data resulting from clinical practice once the drug has been placed on the market (IAA-effectiveness.Results and conclusions: the score obtained for agomelatine was 592.73 in the efficacy phase and 291.3 in the effectiveness phase. The total score for the two phases was 884, which is equivalent to a good degree of innovation for the molecule

  14. Innovative times

    International Nuclear Information System (INIS)

    This article discusses technology and market developments in the wind energy components industry, such as gearboxes, main shafts and generators. At two of the wind industry's most important events in April and May 2006 many large companies, including among others Vestas, Enercon, Fuhrlander, Suzlon and EU Energy attended. For Vestas, the global wind turbine market leader, the main focus was consolidation. This is in line with Vestas' new company slogan 'The Will to Win'. The Group's technology division has won the race for lower kWh prices, but the complexity of wind turbines has increased dramatically in recent years. Vestas still intends to be among the front-runners in the race for technological advancement. Many of the other companies described their latest developments in several different countries including Spain, Sweden, Japan, USA, Germany, and the Netherlands

  15. RESEARCH ADVANCEMENT OF MICROEMULSIONS IN DRUG FlELD%微乳液在药物领域中的研究进展

    Institute of Scientific and Technical Information of China (English)

    刁兆玉; 李玲; 王仲妮

    2011-01-01

    In this paper, the structure and characteristics as drug carriers of microemulsion are described,and the recent progress on microemulsions as drug carders in different routes of administration have been reviewed and discussed. The broad prospects of research and development of microemulsions in the fields of drug have been expected.%作者介绍了微乳液的结构和作为药物载体的特点,综述了微乳液近年来作为药物载体在不同给药途径中的应用,并指出微乳在药品领域的研究和发展会有广阔的前景.

  16. 76 FR 22404 - Analgesic Clinical Trials Innovation, Opportunities, and Networks (ACTION) Initiative

    Science.gov (United States)

    2011-04-21

    ... Networks (ACTION) Initiative AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food... Analgesic Clinical Trials Innovation, Opportunities, and Networks (ACTION) Initiative. The goal of...

  17. Socio-Ecological Innovation

    DEFF Research Database (Denmark)

    Edgeman, Rick; Eskildsen, Jacob Kjær

    Socio‐Ecological Innovation or SEI is innovation resulting from strategic integration of sustainable innovation and innovation for sustainability. In particular SEI is regarded as critical to organizations intent on progressing toward Sustainable Enterprise Excellence (SEE) and, indeed, progressing...... toward the asymptotic goal of becoming a continuously relevant and responsible organization (CR2O). Sustainable Innovation is something that is attained only when innovation in an enterprise is regular, systematic, and systemic to the endeavors of the enterprise itself – that is – Sustainable Innovation...... is part of the enterprise cultural fabric, is foundational to enterprise strategy, and contributes to the financial security of the enterprise. Innovation for Sustainability is innovation that is specifically targeted to address ecological and / or societal considerations. That is, Innovation...

  18. Drug Facts

    Medline Plus

    Full Text Available ... Abuse Hurts Unborn Children Drug Abuse Hurts Your Health Drug Abuse Hurts Bodies Drug Abuse Hurts Brains Drug Abuse and Mental Health Problems Often Happen Together The Link Between Drug ...

  19. Drug Facts

    Medline Plus

    Full Text Available ... Addiction? Addiction Risk Factors Does Addiction Run in Families? Why Is It So Hard to Quit Drugs? ... Drug Abuse Hurts Other People Drug Abuse Hurts Families Drug Abuse Hurts Kids Drug Abuse Hurts Unborn ...

  20. Behaviour of pharmaceuticals and psychotic drugs in conventional and advanced wastewater treatments; Comportamiento de medicamentos y psicofarmacos en tratamaientos de depuracion convencionales y terciarios

    Energy Technology Data Exchange (ETDEWEB)

    Cortacans Torre, J. A.; Castillo Gonzalez, I. del; Hernandez Lehmann, A.; Hernandez Munoz, A.; Rodriguez Barrera, X.

    2009-07-01

    The occurrence of various pharmaceuticals and psychotic drugs in wastewater and their removal rates in a conventional wastewater treatment plant has been investigated. The psychoactive drugs are poorly removed in the biological step. However, most pharmaceuticals except of carbamazepine, are significantly biodegraded depending the removal degree on the type of compound and on the sludge retention time of the biological treatment. Also, the removal efficiency of conventional tertiary treatments and ultrafiltration and nano filtration membranes using two pilot plants was examined. the effects of retaining pharmaceuticals with ultrafiltration and nano filtration membranes do not greatly differ despite the difference in their pore size. (Author) 25 refs.